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Abstract 
Heavy menstrual bleeding (HMB) affects 30% of women of reproductive age, 
accounting for two-thirds of all hysterectomies. 50% HMB cases are 
unexplained and current treatment options often compromise fertility. 
Understanding the mechanisms underlying HMB is therefore critical to delineate 
potential pathways for therapeutic intervention. Previous studies suggested 
structural and functional roles for endometrial blood vessels in the pathogenesis 
of HMB. Endothelial cells (ECs) are associated with growth and formation of 
blood vessels; extracellular matrix (ECM) provides the framework for 
maintaining vascular structure, while vascular smooth muscle cell (VSMC) 
differentiation regulates blood flow and pressure. Altered endometrial vascular 
maturation is seen in recurrent miscarriage in association with increased uterine 
natural killer (uNK) cell number and variation in endometrial angiogenic growth 
factor (AGF) expression, but these processes have not been extensively 
studied in HMB. This study aimed to assess vascular maturation and AGF 
expression in HMB and investigate some of their effects in vitro. 
A study of VSMC differentiation revealed reduced endometrial calponin 
expression, suggesting a dysfunctional vascular contraction mechanism in 
HMB. This was associated with increased osteopontin expression, supporting 
previous evidence of regulation of vascular calponin expression by osteopontin. 
Endometrial collagen IV expression was lower in HMB, reflecting weaker 
vascular structure and definition. An altered pattern of uNK cell density in HMB 
may reflect altered in situ differentiation and or proliferation, which could impact 
vascular development and/or endometrial preparation for menstruation. VSMCs 
showed decreased endometrial expression of PDGFRα and TGFβRI, 
highlighting altered state of VSMC differentiation and potentially dysregulated 
endometrial vascular development in HMB. Furthermore, preliminary results 
indicated that PDGFBB helped to maintain EC ‘honeycomb’ structures, while 
anti-PDGFBB or TGFβ1 treatment decreased their numbers in vitro. 
Collectively, this study has highlighted key alterations in blood vessels in HMB, 
and established an in vitro model for future functional studies of blood vessel 
development. 
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1 INTRODUCTION 
Procreation is central to all living organisms and is indispensible to the 
continuation of a species and its evolution. In many organisms, including 
humans, the main purpose of the male reproductive system may be simplified 
as the mechanism of delivery of the paternal genetic material into the female 
reproductive tract, while that of the female reproductive system is much more 
complicated. In mammals, the female bears an enormous reproductive burden 
since she is not only responsible for producing an egg carrying the maternal 
genetic content (ovulation), but also has to provide a suitable environment for 
the journey of the sperm towards the egg, fertilization of the egg, sustaining 
pregnancy via implantation, accommodating the subsequent growth of the 
embryo and fetus during the nine months of gestation, successful delivery of the 
child and finally lactation for healthy maintenance of the new-born (Figure 1.1). 
Most of these early stages of development are accommodated in the uterus of 
the mother. Uterine anomalies can therefore have diverse effects and may lead 
to developmental inaccuracies, infertility and even death during pregnancy or 
childbirth. In humans, abnormal uterine-tract formation is estimated to occur in 
0.1-4.0% of live births (Gidwani, 1999; Grimbizis et al., 2001). Although the 
percentage may vary depending on population and diagnostic technique, 
uterine anomalies are associated with adverse reproductive outcomes and thus 
pose a significant concern (Venetis et al., 2014). Understanding the underlying 
mechanisms of development and normal function of the uterus becomes 
essential, since it not only enhances our understanding of basic reproductive 
biology but also more importantly opens the door for practical applications 
including new less invasive and more effective treatments, regenerative 
medicine and infertility treatment through in vitro fertilisation (IVF).  
1.1 THE UTERUS 
The uterus, which sustains the very beginning of life, forms the central part of 
the female reproductive system. It is a hormone-responsive reproductive organ, 
present in most mammals, including humans. The uterus originates from a pair 
of paramesonephric ducts, first observed in 1825, by the German physiologist, 
Johannes Müller (Figure 1.2). Before sexual differentiation, 
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Figure 1.1: Early stages of development in the female reproductive tract. (A) The 
journey of the sperm through the uterus; (B) Fertilisation, stages of early embryonic 
development and implantation; and (C) Fetus in utero. Diagrams A and B are drawn by 
the author. Diagram C has been modified from birthinjuryjustice.org. 
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Figure 1.2: The origin of the male and female reproductive systems. The Müllerian duct 
is formed during early fetal development. In males, Müllerian-inhibiting substance (MIS) 
leads to the regression of these ducts, while in the absence of this hormone in females 
the ducts give rise to the oviduct and the uterus. Diagram adapted from Kobayashi and 
Behringer (2003). 
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embryo possesses both the Wolffian duct (mesonephric) and the Müllerian duct 
(paramesonephric). However, during differentiation, in males the presence of 
Müllerian-inhibiting substance (MIS) or anti-Müllerian Hormone (AMH) leads to 
regression of the Müllerian duct along with formation of the male reproductive 
tract. In the female the Wolffian duct degenerates and the Müllerian duct 
differentiates anteriorly into the oviducts, the uterus and posteriorly into the 
neck of the uterus called the cervix, which opens into the vagina (Aplin et al., 
2008). The uterus broadly consists of two layers; the myometrium is made up of 
layers of smooth muscle, while the uterine mucosa or the endometrium forms 
the innermost layer lining the uterine cavity and is made up of glands lined by 
columnar epithelium and a supporting stroma. The endometrium forms the site 
of implantation and therefore accommodates the development of the 
fetoplacental unit. 
1.1.1 Types of uteri 
Across the vast mammalian species uteri can be divided into four types 
depending on the extent of lateral fusion of the two paramesonephric ducts 
(Figure 1.3).  A duplex uterus is defined by two entirely separate uteri with one 
fallopian tube each as found in kangaroos, mice and rabbits, a bipartite uterus 
consists of two uteri which share a single cervix as seen in cats, dogs and pigs. 
Cows and horses have a bicornuate uterus, which consist of two uterine horns; 
one cervix and the lower part remaining fused forming a larger uterine body. 
Higher primates including human and chimpanzee have a simplex uterus with a 
single uterine body and cervix, which is formed as a result of complete fusion of 
the paramesonephric ducts in the uterine segment (Aplin et al., 2008). 
1.1.2 Uterine vasculature 
The uterine arteries form the main blood supply to the uterus and also supply 
branches to the cervix and the vagina. This blood supply to the uterus forms a 
branched structure with a gradual decrease in vessel diameter during the 
course of its journey through the myometrium and endometrium. The arcuate 
arteries originating from the uterine and ovarian arteries, supply blood to the 
myometrium. They give rise to the radial arteries, which in turn branch into 
basal and spiral arteries. While basal arteries supply the basal layer, spiral 
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Figure 1.3: Types of uteri amongst different mammalian species. Basic anatomical 
features of the female reproductive tract (a) and amongst different mammalian species 
(b-g). Diagram adapted from Kobayashi and Behringer (2003). US-urogential sinus 
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arteries supply the functional layer of the endometrium and the decidua during 
pregnancy (Figure 1.4). During pregnancy the spiral arteries undergo 
substantial remodelling and are transformed from high-resistance, low-flow 
vessels into large dilated vessels with increased blood flow velocity and 
reduced pressure (Burton et al., 2009; Whitley and Cartwright, 2010). In the 
absence of fertilisation the spiral arteries regress and are eventually lost during 
menstrual shedding of the endometrium. 
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Figure 1.4: Uterine vasculature. Arcuate arteries form the radial arteries, which in turn 
branch into basal and spiral arteries. While basal arteries supply the basal layer, spiral 
arteries supply the functional layer of the endometrium. 
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1.2 THE ENDOMETRIUM 
The endometrium, which is one of the fastest growing tissues in the human, 
forms the inner lining of the uterus. This complex mucosal lining consists of two 
major layers: a germinal layer or stratum basalis, which persists from one 
menstrual cycle to the next and the transient superficial layer, the stratum 
functionalis. It is the germinal basal layer, which regenerates the stratum 
functionalis after menstruation (Figure 1.5). While the former is not hormone-
responsive, the stratum functionalis undergoes dynamic cyclical changes such 
as proliferation, maintenance, differentiation and loss in response to specific 
hormonal signalling (Heller, 1994; Jabbour et al., 2006). While in humans the 
endometrium goes through the complete cycle of proliferation through to 
decidualisation or shedding in the absence of pregnancy, in rodents 
decidualisation occurs only in the presence of a blastocyst (Finn, 1974). Normal 
functioning of the endometrium is integral to reproductive health, with 
endometrial pathologies ranging from abnormal uterine bleeding, pregnancy 
related anomalies such as infertility and recurrent miscarriage (RM). Study of 
the underlying physiological and molecular mechanisms therefore remains of 
utmost importance and requires our understanding of the structural and 
temporal framework of the endometrium. 
The cellular structure of the endometrium broadly comprises of a lining surface 
or luminal epithelium, associated glands and glandular epithelium, a connective 
tissue bed termed stroma, blood vasculature and extracellular matrix (ECM) 
(Figure 1.5). The glands and stroma, along with the endometrial vasculature in 
the stratum functionalis undergo dramatic morphological changes during the 
menstrual cycle. 
1.2.1 The menstrual cycle  
The human menstrual cycle encompasses structural and functional remodelling 
of the endometrium and its blood vasculature under the dynamic influence of 
the hormones oestrogen and progesterone. The menstrual cycle is divided into 
three phases: menstrual (days 1-4), proliferative (or follicular, days 5-14) and 
secretory (or luteal, days 14-28) phases.  
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Figure 1.5: Structure of the endometrium. (A) The blood supply to the endometrium 
through the spiral arteries and capillary bed. (B) The cellular components of the 
stratum functionalis and stratum basalis of the endometrium.  
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The standard menstrual cycle length is 28 days; the first day of menstrual 
bleeding is day 1 and ovulation occurs approximately on day 14 under the 
surge of luteinizing hormone (LH) (Figure 1.6). However, there is variability 
between women from different regional, ethnic and socioeconomic backgrounds 
(Harlow, 2000), mainly due to variability in length of the follicular phase (Waller 
et al., 1998; Mihm et al., 2011). The menstrual phase involves breakdown and 
shedding of the stratum functionalis and initiation of re-epithelialisation (Ludwig 
and Spornitz, 1991). In the proliferative phase oestrogen leads to an increased 
proliferation of all cell types. This post-menstrual re-epithelialisation together 
with growth of stroma and glands leads to an increase in endometrial thickness 
from 1mm to 3-4mm at ovulation.  
Ovulation in mid-cycle marks the switch of hormonal control to progesterone 
produced by the corpus luteum, which regulates endometrial functional 
differentiation to accommodate implantation. In the absence of pregnancy, a 
reduction in levels of oestrogen and progesterone leads to endometrial 
regression, exposing open blood vessels and glands and resulting in menstrual 
bleeding (Aplin et al., 2008). This event is associated with local presence of 
proinflammatory cells such as neutrophils, macrophages and uterine natural 
killer cells, vasoactive mediators such as prostaglandins (PGs) and matrix 
metalloproteinases (MMPs) such as MMP-2, MMP-9 (King et al., 1998a; 
Salamonsen and Woolley, 1999). Although this decrease in levels of oestrogen 
and progesterone is common to all mammals, it is only in humans, some old-
world primates and bats that menstrual bleeding occurs. Figure 1.7 outlines the 
probable mechanisms of ECM breakdown leading to tissue destruction at 
menstruation. The histological changes in the endometrium during the 
menstrual cycle are summarised in Table 1.1.  
Thrombin production in the basal layer allows for homeostasis, while 
regeneration from the basal stumps appears in the superficial layer, and 
extends through the entire stratum functionalis (Ludwig and Spornitz, 1991; 
Jabbour et al., 2006). This remodelling is essential since the endometrium 
irreversibly differentiates during the menstrual cycle and therefore needs to be 
discarded in order to re-proliferate and maintain its reproductive function (Finn, 
1998). Interestingly a stem cell population located in the stratum basalis of the  
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Figure 1.6: Hormonal control of the menstrual cycle with relation to ovulation and the 
changes in the endometrium. Diagram compiled and modified by the author from 
lpch.org; SBayram. GnRH-gonadotropin releasing hormone; LH-luteinising hormone; 
FSH-follicle stimulating hormone. 
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Figure 1.7: Tissue destruction at menstruation. Progesterone withdrawal affects 
epithelial cells to stimulate chemokine production, which activates leucocytes. 
Leucocytes produce cytokines, which stimulate production of latent (pro) matrix 
metalloproteinases (MMPs), chemokines and other mediators. Leucocytes also 
produce proteases that start the activation cascade of MMPs. Activation of pro-MMPs 
can also be triggered by other proteases or by the plasmin system (uPA/tPA) released 
either by stromal cells or by inflammatory cells. An increase in MMPs leads to an 
imbalance between the activators and inhibitors of tissue breakdown, leading to 
breakdown of extracellular matrix (ECM).  
  
14
Table 1.1: Histological differences and leukocyte population in the human endometrium during the menstrual cycle 
MENSTRUAL 
PHASE 
PROLIFERATIVE 
PHASE 
EARLY SECRETORY 
PHASE 
MID SECRETORY 
PHASE 
LATE SECRETORY 
PHASE 
• Loss of epithelium and 
underlying tissue. 
 
• Loss of stratum 
functionalis containing 
blood clots, fragments of 
disintegrated stroma, 
uterine glands. 
 
• The uterine glands in the 
functionalis layer are 
infiltrated by blood. 
 
• Stratum basalis remains 
unaffected and contains 
intact bases of the uterine 
glands. 
 
• The distal parts of the 
coiled spiral arteries 
become necrotic, while 
the deeper parts remain 
intact. 
 
• The stroma contains 
erythrocytes (extruded 
from disintegrating blood 
vessels), moderate 
numbers of lymphocytes 
and neutrophils. 
• The endometrium is lined 
by columnar epithelium, 
which extends down to 
the stroma to form 
numerous long, straight, 
tubular uterine glands. 
 
• Cellular proliferation and 
differentiation occur, 
marked by the presence of 
mitotic figures in the 
glandular epithelium and 
stroma. 
 
• Angiogenesis occurs and 
the arteries remain 
relatively straight. 
 
• Extracellular remodelling 
occurs in the stroma. 
 
• Stroma is infiltrated with 
low to moderate numbers 
of macrophages, mast 
cells and T-lymphocytes. 
B-lymphocytes are very 
few in number in stratum 
functionalis but more in 
stratum basalis. 
• The endometrium 
thickens due to increased 
glandular secretions and 
stromal oedema, resulting 
from accumulation of 
tissue fluid. 
 
• The uterine glands 
become tortuous. 
 
• The glandular epithelial 
cells stop dividing; hence 
mitotic figures are absent. 
 
• The presence of vacuoles 
and the upward 
movement of nuclei mark 
the glandular epithelial 
cells. 
 
• The arteries in the stratum 
functionalis become 
increasingly coiled and 
termed as spiral arteries. 
• The endometrium 
thickens further. 
 
• Glands are increasingly 
tortuous and their 
secretions are elevated.  
 
• Stromal oedema persists 
and the cells undergo 
differentiation. 
 
• Nuclei travel 
downwards in the 
glandular epithelial cells 
and the subnuclear 
vacuoles are lost. 
 
• Stroma is infiltrated 
with moderate to high 
numbers of 
macrophages and uNK 
cells. 
• The endometrium 
remains thickened. 
 
• Glands remain tortuous. 
 
• Stromal oedema 
persists, but there are 
signs of apoptosis and 
extracellular matrix 
degradation. 
 
• Stroma is infiltrated 
with moderate to high 
numbers of 
macrophages, uNK 
cells, mast cells and T-
lymphocytes. 
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endometrium may play a role in the self-renewal of the human endometrium 
(Prianishnikov, 1978; Schwab et al., 2005; Gargett, 2007). 
1.2.2 The stroma 
The stroma of the endometrium is a dynamic connective tissue comprised of 
specific cells and an ECM. The cells of the stroma include fibroblast-like 
reticular cells, lymphocytes, macrophages and uterine natural killer (uNK) cells. 
The reticular cells of the stroma produce most of the components of the ECM. 
These cells are dynamic in nature with a changing morphology, which leads to 
‘decidualisation’ during pregnancy (Aplin et al., 2008). In the early proliferative 
phase endometrial stromal cells are more like undifferentiated fibroblast cells 
with mesenchymal features. Their morphology begins to change around 
ovulation. The mid secretory phase is marked by stromal cell oedema, with an 
increase in nuclear diameter and rounding up of nucleoli, suggesting increased 
transcriptional activity. In the late secretory phase, the stromal cells undergo 
irreversible differentiation or decidualisation, critical for preparation of 
menstruation or pregnancy. The initial stages of menstruation are mediated by 
progesterone expressing stromal cells, which also involve prostaglandin E2 and 
F2α synthesis, growth factor expression and influx of leukocytes. However, 
later, in the progesterone-independent stage, menstruation is mediated by 
leukocytes secreting MMPs, which allow endometrial ECM breakdown (Irwin et 
al., 1996).  
The stromal cells are involved in ECM remodelling during the menstrual cycle 
(More et al., 1974). The endometrium contains both stromal interstitial matrix as 
well as basal lamina underlying endometrial glands and vasculature (Evans and 
Salamonsen, 2012). The ECM provides a structural framework for the stroma; it 
contains cytokines and growth factors and interacts with the stromal cells via 
various receptors such as integrins. The stromal matrix is composed of 
microfibrils, which may be made up of bundles of collagens and fibrillin. Fibulin 
1, an ECM protein, interacts with elastic fibres of blood vessels containing 
elastin. Other factors in the stroma include dermatopontin, which control 
collagen fibrillogenesis, tenacin, which associates with smooth muscle cells of 
the spiral arteries and thrombospondin (Tsp-1), which has an inhibitory effect on 
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angiogenesis (Iruela-Arispe et al., 1996; Haendler et al., 2004; Aplin et al., 
2008). MMPs and tissue inhibitors of MMPs (TIMPs), play a critical role in ECM 
breakdown during menstruation. In addition to endometrial stromal or epithelial 
cells, which release MMPs (in particular MMP1, MMP3, MMP8, MMP9-11), 
leukocytes such as neutrophils when activated may also release MMP8, MMP9 
(Evans and Salamonsen, 2012; Gaide Chevronnay et al., 2012). 
1.2.3 Endometrial leukocytes 
Menstruation, although triggered by down regulation of hormones, is considered 
to be an inflammatory process (Finn, 1986) maintained by the presence of 
proinflammatory cells such as neutrophils, macrophages and uNK cells 
(Salamonsen and Woolley, 1999; R. L. Jones et al., 2004; Berbic and Fraser, 
2013). The endometrial immune cell populations undergo dynamic changes 
during the different phases of the menstrual cycle, depending on the underlying 
need to provide protection to the uterine mucosal layer, facilitate endometrial 
remodelling and the process of menstruation. Human endometrial leukocyte 
populations have been widely studied (Bulmer and Sunderland, 1984; Bulmer 
and Johnson, 1985; Morris et al., 1985; Bulmer et al., 1987; Kamat and 
Isaacson, 1987; Bulmer et al., 1988; Marshall and Jones, 1988; King et al., 
1998a; Salamonsen et al., 2002; Evans and Salamonsen, 2012; Berbic and 
Fraser, 2013) (Table 1.1). Depending on their state of activation, these cells 
exhibit phenotypic differences and function differently. Cytolytic activity of CD3+ 
T cells is present during the proliferative phase (White et al., 1997), while 
increased numbers of macrophages, mast cells and T cells are reported in the 
late secretory phase (Poropatich et al., 1987; Salamonsen and Woolley, 1999; 
Berbic and Fraser, 2013). While uNK cells are scarce in proliferative 
endometrium, their numbers increase in the mid and late secretory phase of the 
menstrual cycle (Bulmer et al., 1991). Finally, in the menstrual phase of the 
cycle there is increased activity of mast cells, matrix metalloproteinases (Zhang 
and Salamonsen, 2002) and antigen presenting cells such as macrophages and 
dendritic cells, suggesting a role in tissue breakdown and clearance (Schulke et 
al., 2008; Berbic et al., 2009; Berbic et al., 2010). The endometrial immune 
response during the cyclic shedding, tissue remodelling and angiogenesis helps 
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in maintaining a healthy functioning endometrium, which may otherwise be 
linked with abnormal uterine bleeding disorders such as menorrhagia. 
1.2.3.1 uNK cells 
During the progesterone dominated mid and late secretory phases of the 
menstrual cycle in non-pregnant endometrium (in the stratum functionalis, 
around arteries and arterioles) and in the first trimester of pregnancy, uNK cells 
are the most prevalent leukocyte population in the endometrial stroma, although 
they are present in low numbers in proliferative endometrium (Hamperl and 
Hellweg, 1958; King et al., 1989; Pace et al., 1989; Bulmer et al., 1991). It has 
been suggested that the PR expressing endometrial stromal cells promote uNK 
proliferation and differentiation via secretion of the cytokine interleukin-15 (IL-
15) and the differentiated uNK cells modify medial VSMC resulting in vascular 
stability (Wilkens et al., 2013). uNK cells have been implicated in a wide range 
of functions; cytokine and growth factor secretion, immune function, regulation 
of trophoblast invasion in early pregnancy and also in the initial stages of spiral 
artery remodelling (Hiby et al., 2004; Bulmer and Lash, 2005; Hanna et al., 
2006; De Oliveira et al., 2010; Lash et al., 2011b; Robson et al., 2012). They 
secrete angiogenic growth factors including angiopoietin-1 (Ang1), Ang2, 
vascular endothelial growth factor C (VEGF-C), placenta growth factor (PIGF) 
and transforming growth factor β1 (TGF-β1) (Li et al., 2001; Lash et al., 2006). 
uNK cells assist trophoblast invasion and tissue and spiral artery remodelling by 
secreting proteolytic enzymes such as MMP2, MMP9, and TIMP1, TIMP2, 
TIMP3, which help in the breakdown of the ECM (Smith et al., 2009). uNK cells 
have been implicated in various female reproductive disorders (reviewed by 
Zhang and Tian, 2007; Lash and Bulmer, 2011). Previous studies in the 
laboratory have reported a positive association between uNK cell density and 
vascular maturation in women with RM and recurrent implantation failure 
(Quenby et al., 2009). However, their role in the non-pregnant cycling 
endometrium remains unclear. Therefore, given their possible role in 
endometrial vascular maturation (Wilkens et al., 2013), it is important to 
understand how they affect the normal as well as pathological states of 
menstrual bleeding.  
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1.2.3.2 Eosinophils 
Eosinophils, detected by the eosinophil cationic proteins (ECP1 and ECP2), are 
present in aggregates in the endometrium immediately before the onset of 
menstruation (Jeziorska et al., 1995; Evans and Salamonsen, 2012). Although 
IL-5 is known to primarily stimulate development and function of eosinophils, it 
has not been examined in premenstrual endometrium. Some endometrial 
eosinophils secrete MMP9 and therefore may play a role in tissue breakdown 
and menstruation (Jeziorska et al., 1995; Evans and Salamonsen, 2012). 
However, due to overlapping functions, elucidating their specific roles in the 
endometrium remains challenging. 
1.2.3.3 Macrophages 
Amongst the diverse population of immune cells in the endometrium are the 
macrophages (Bulmer et al., 1988), which have been suggested to play a 
critical role in endometrial decidualisation and receptivity for the implanting 
blastocyst (Lea and Clark, 1991; Kats et al., 2005; Thiruchelvam et al., 2013). 
Following differentiation of peripheral blood monocytes or in situ proliferation 
into tissue specific macrophages, these cells may perform a wide variety of 
functions including phagocytosis, maintaining tissue homeostasis, regulation of 
wound healing or other immune cell populations, depending on the requirement 
of their tissue microenvironment (Thiruchelvam et al., 2013). Hence 
macrophages may perform different roles in the endometrium depending on the 
menstrual cycle phase. In the proliferative phase, macrophages make up 1-2% 
of endometrial cells and have been suggested to be involved in the proliferation 
and regeneration of stratum functionalis, since they express adhesion and 
activation markers such as CD71, CD69 and CD54 (Salamonsen et al., 2002; 
Eidukaite and Tamosiunas, 2004). During the secretory phase macrophage 
numbers rise making up 3-5% of all endometrial cells and their role is thought to 
become more focused on maintaining a receptive endometrium and regulating 
fertility (Salamonsen et al., 2002; Aghajanova, 2004; Kats et al., 2005; 
Thiruchelvam et al., 2013). Moreover, endometrial macrophages express a 
variety of chemoattractants during the secretory phase (Jones et al., 2004). 
Endometrial macrophage numbers reach their maximum in the menstrual phase 
  
 
1.2 THE ENDOMETRIUM 
 
  
19
when they make up 6-15% of endometrial cells and they express various MMPs 
(latent MMP9, MMP12, MMP14) and other molecules that regulate MMPs 
suggesting their role in breakdown of the stratum functionalis marking the 
initiation of menstruation (Zhang et al., 2000; Salamonsen et al., 2002). 
Endometrial macrophages secrete AGFs such as VEGF-A, which is reduced in 
women suffering from heavy menstrual bleeding (Malik et al., 2006; Berbic et 
al., 2014). They also act as potent vasodilators (Hickey and Fraser, 2000) and 
unscheduled endometrial bleeding in women using Levonorgestrel (LNG) 
contraceptive has been shown to correlate with the increase in endometrial 
macrophages and cytokines (Clark et al., 1996) suggesting a critical role for 
macrophages in abnormal menstrual bleeding. 
1.2.3.4 Neutrophils 
The observation that decidualisation and chemokine secretion in the 
endometrium occurs first around the endometrial vessels led to a belief that 
neutrophils transmigrate from peripheral blood into the endometrium via the 
spiral arterioles (Jones et al., 2004). The function of neutrophils is specific for 
their tissue microenvironment and they interact with both the endometrial vessel 
walls as well as the tissue ECM (Soehnlein et al., 2009). They secrete MMPs 
and other degradative enzymes supporting their role in the menstrual phase. In 
a mouse model their numbers increased during repair, and depletion of 
neutrophils delayed endometrial repair (Kaitu'u-Lino et al., 2007). However, 
whether they play a role in endometrial repair as well as menstrual breakdown 
in human remains to be investigated. 
1.2.3.5 Dendritic cells 
Dendritic cells (DCs) are a unique population of leukocytes, which play a critical 
role in initiation and modulation of immune responses in the entire body, as well 
as serving as a link between innate and adaptive immunity. DCs communicate 
with other immune cell populations such as NK cells, macrophages, T-
lymphocytes and B-lymphocytes (Banchereau and Steinman, 1998). Moreover, 
several chemokines and cytokines secreted by DCs have been implicated in 
angiogenesis, tissue repair, menstruation and blastocyst implantation (Kayisli et 
al., 2002; Barrientos et al., 2009). Compared with macrophages and uNK cells, 
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the dendritic cell population in the cyclic endometrium is much lower. Moreover, 
studies using early DC markers showed few to no DCs in the endometrium 
(Kamat and Isaacson, 1987; Bulmer et al., 1988), while a more recent study 
using a combination of immature (CD1a) and mature DC (CD83) marker 
reported an increase in CD1a+ DCs in stratum basalis and a relatively unaltered 
mature CD83+ DCs throughout the menstrual cycle (Schulke et al., 2008). This 
may suggest that although influx of DCs into the uterus may be hormonally 
regulated, their maturation is not. The specific role of DCs in the menstrual 
cycle remains unknown. However DCs produce MMPs, cytokines and 
chemokines, which may directly influence the uterine microenvironment or 
regulate other immune cell populations and their functions (Kayisli et al., 2002; 
Schulke et al., 2008).  
1.2.3.6 T-lymphocytes 
T lymphocytes play critical roles in adaptive immune responses and account for 
45% of endometrial leukocytes in the proliferative phase their proportion 
decreasing gradually in the secretory phase (Vassiliadou and Bulmer, 1996). 
Two-thirds of this leukocyte population are CD8+ cytotoxic T cells (Yeaman et 
al., 2001). They target foreign antigens by release of cytotoxins. Moreover, they 
retain information about the invading antigen, such that of any subsequent 
invasion by the same antigen, an appropriate immune response is more actively 
available (Berbic et al., 2014). Others include CD4+ T cells which can either be 
T helper 1(Th1) and Th2 depending on their respective cytokine production 
(Vassiliadou and Bulmer, 1996); and forkhead box transcription factor, FOXP3+ 
regulatory T cells (Tregs), which supress T cell proliferation and activation, 
macrophage, B lymphocyte, dendritic cell and NK cell function and thus may 
play a role in immunological tolerance during pregnancy (Campbell and Koch, 
2011; Nevers et al., 2011; Berbic et al., 2014). Decidual and circulating Tregs 
peak in the first trimester of pregnancy (Somerset et al., 2004) coinciding with 
high levels of vascular development and maturation, trophoblast invasion and 
spiral artery remodelling, suggesting a possible role in vascular development. In 
the cyclic non-pregnant endometrium, Tregs increase in number during the 
proliferative phase peaking before ovulation, but decrease again in the luteal 
phase (Arruvito et al., 2007). Although important for immune tolerance and 
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vascular remodelling homeostasis (via IL-10 in pregnancy) (Nevers et al., 
2011), the specific roles of Tregs in non-pregnant endometrium are unclear, 
especially in regulation of menstrual bleeding. 
1.2.3.7 Mast cells 
Mast cell (MC) populations do not alter during the menstrual cycle, but become 
highly active immediately before and during the menstrual phase (Jeziorska et 
al., 1995). On maturation, mast cells (MC) differentiate into two populations; 
MCt expressing the protease tryptase (t) and mainly seen in the stratum 
functionalis and MCtc expressing chymase (c) found in stratum basalis only 
(Rogers et al., 1993; Evans and Salamonsen, 2012). On activation MCs release 
proteases, which regulate cytokine activity and activate other MMPs. MCs also 
secrete MMP9, which may reflect their potential role in tissue breakdown and 
menstruation (Salamonsen and Lathbury, 2000; Baram et al., 2001). However, 
specific molecular events leading to endometrial MC activation remain unclear. 
 
Alterations in leukocytes populations in particular macrophages, uNK cells, 
dendritic cells, Tregs and T cells in the endometrium may be reflective of altered 
vascular development leading to menstrual disturbances, infertility or other 
endometrial pathologies; therefore inviting further research in both normal and 
pathological states of the endometrium 
1.2.4 Endometrial blood vessel development 
The endometrial vasculature primarily consists of the basal arteries supplying 
the stratum basalis and the spiral arteries supplying the functionalis layer. The 
coiled shape of the spiral arteries helps to reduce blood pressure and rate of 
flow along its length, maintaining a steady blood flow to the non-pregnant 
stratum functionalis and the pregnant decidua. Additionally, the spiral arteries 
give rise to capillaries forming the sub-epithelial plexus, which empty into the 
venous plexus and subsequently drain into the inner myometrium (Aplin et al., 
2008). In humans, this endometrial vasculature goes through cycles of growth, 
disruption, remodelling and repair under the universal control of the ovarian 
steroid hormones oestrogen and progesterone, during the monthly menstrual 
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cycle. Understanding the menstrual cycle (section 1.2.1) requires knowledge of 
the structure of blood vessels and the process of angiogenesis including 
elongation, muscularisation and expansion of the capillary network required for 
growth and maintenance of the blood supply.  
1.2.4.1 Angiogenesis 
The structure of a blood vessel broadly consists of the innermost endothelial 
cell (EC) layer, basement membrane or vascular ECM and an outer covering 
composed of pericytes or vascular smooth muscle cells (VSMCs). Angiogenesis 
is the process of development of new vessels from pre-existing capillary 
network. It broadly consists of an activation phase involving EC activation and 
degradation of vascular ECM, followed by a resolution phase involving EC 
proliferation and migration, tube formation and stabilisation. Four different 
processes underlie angiogenesis: sprouting, intussusception, 
elongation/widening and incorporation of circulating endothelial progenitor cells 
(EPC) into growing vessels (Figure 1.8). Sprouting is a multistep process 
involving EC activation, degradation of vascular ECM, EC proliferation and 
migration, tube formation and stabilisation (Risau, 1997). Intussusception 
occurs by virtue of proliferation of ECs and ECM formation, internally dividing 
the vessel into two. This results in a network of smaller interlocking vessels, 
which may remodel or enlarge during the formation of a capillary plexus (Peirce 
and Skalak, 2003). Elongation or widening does not involve formation of 
additional vascular junctions and occurs by lengthways growth of a vessel. 
Finally, incorporation of EPCs into the development of a new growing vessel 
may be another means of angiogenesis (Asahara et al., 1999; Khakoo and 
Finkel, 2005). However, the timing and role of circulating EPCs in angiogenesis 
remains to be elucidated. Thus angiogenesis results in formation of new 
capillary networks, which are primarily EC tubes lacking wall structure including 
VSMCs. Following this, these vessels undergo arteriogenesis involving 
enlargement of collateral vessels (Peirce and Skalak, 2003). During this 
process the capillaries gain a layer of VSMCs and become capable of blood 
flow regulation by means of rapid internal diameter alteration (Figure 1.8). 
VSMCs and pericytes belong to the same cell lineage; while VSMCs coat 
venules and arterioles, pericytes support  
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Figure 1.8: Mechanisms of angiogenesis and arteriogenesis. While angiogenesis 
involves sprouting, intussusception or elongation, arteriogenesis involves de-novo 
arteriole formation from new or pre-existing capillaries by recruitment of pericytes or 
vascular smooth muscle cells (mural cells) and by collateral enlargement. Elongative 
angiogenesis occurs in the mid-late proliferative phase while branching angiogenesis is 
common in the early-mid secretory phase of the menstrual cycle. Diagram re-drawn by 
author with reference to Aplin et al. (2008a). 
  
 
1.2 THE ENDOMETRIUM 
 
  
24
capillaries (Jain, 2003). In this study the process of blood vessel development 
and functional maturation will be termed vascular maturation. The primate 
endometrium comprises two different types of arteries: the straight and spiral 
arteries, both of which originate from the radial arteries. The spiral arteries 
develop during the progesterone influenced secretory phase and are unique to 
menstruating primates (Kaiserman-Abramof and Padykula, 1989). While the 
straight arteries are seen both in the stratum functionalis and stratum basalis, 
the spiral arteries are almost exclusive to the stratum functionalis. Their heavily 
coiled structure, larger VSMCs and in human, absence of internal elastic 
lamina, make them distinct from the straight arterioles (Rogers and Abberton, 
2003). The spiral arteries are vital for normal menstruation, implantation and 
formation of the placenta. 
In the menstrual cycle (section 1.2.1) vascular development and maturation 
occurs in all three phases: during menstruation when repair of vascular bed 
occurs, during the proliferative phase, marked by rapid endometrial growth and 
also during the secretory phase with growth and coiling of spiral arteries. While 
intussusception is the major mechanism underlying angiogenesis in the early-
mid proliferative phase, it is vessel elongation or widening that prevails during 
the oestrogen driven mid-late proliferative phase (Gambino et al., 2002). During 
the early secretory phase, the increase in endometrial thickness results in 
increased vessel density and vessel segment length. In the early-mid secretory 
phase vessel lengths remain elevated, but an increase in vessel junctions leads 
to a decreased segment length. Finally, in the late secretory phase vascular 
length density falls to the levels during proliferative phase suggesting vascular 
regression prior to menstruation. Therefore, branching is key to secretory phase 
angiogenesis (Gambino et al., 2002).   
Angiogenesis is principally regulated by a network of hormones, growth factors 
and cytokines, along with adhesion, cytoskeletal and extracellular proteins 
(Figure 1.9). In the endometrium, oestrogen and progesterone are the primary 
hormonal regulators of angiogenesis. While oestrogen receptor α (ERα) is only 
present in the VSMCs, oestrogen receptor β (ERβ) is expressed in both ECs 
and VSMCs (Critchley et al., 2001; Lecce et al., 2001; Hapangama et al., 2015). 
Oestrogen has been implicated as a proangiogenic factor by several studies in  
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Figure 1.9: Major pathways involved in angiogenesis and arteriogenesis. Angiogenic 
factors bind to their receptors and activate the endothelial cells (ECs). EC activation 
releases proteases, which dissolve basement membrane and start the process of EC 
assembly via proliferation and migration. While the VEGF receptors maintain normal 
vasculature, platelet derived growth factor (PDGF) helps to recruit smooth muscle cells 
(SMCs). Following this transforming growth factor (TGF-β) mediates proliferation and 
migration of VSMCs to form layers around the EC tube. Once a vessel is mature, a 
network is formed via destabilization, EC proliferation and migration under actions of 
VEGF, matrix metalloproteinases (MMPs), and adhesion molecules.  
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both humans and other primates. Studies have also suggested that increased 
vascular permeability, dilation of vessels and increased blood flow may be due 
to the opening of tight junctions between ECs (Albrecht et al., 2003; Kayisli et 
al., 2004). The role of progesterone in regulation of angiogenesis remains 
inconsistent and controversial. While some studies have reported the presence 
of progesterone receptors (PRs) in human and non-human ECs and VSMCs, 
others have suggested their presence only in some arteries (Press et al., 1988; 
Rogers et al., 1996). Moreover, several studies showed an inhibitory effect of 
PR on endometrial angiogenesis (Iruela-Arispe et al., 1999); these were mostly 
in vitro studies and progesterone has been observed to increase in vivo 
angiogenesis in primates without causing vasodilation (Gambino et al., 2002). 
To summarise, under the action of oestrogen, rapid tissue growth and 
elongation of vessels occurs during the proliferative phase. In the secretory 
phase progesterone induces growth and coiling of spiral arteries. Following this, 
in the late secretory phase a decrease in levels of oestrogen and progesterone 
leads to regression and breakdown of endometrium. The action of oestrogen 
and progesterone on endometrial angiogenesis and vascular maturation is 
mediated by various growth factors such as TGFβ, epidermal growth factor 
(EGF) and VEGF (Figure 1.9).  
1.2.4.2 Vascular smooth muscle cells, endothelial cells and extracellular 
matrix 
Role of VSMCs: VSMC proliferation and differentiation is key to vascular 
maturation during the menstrual cycle. Alpha smooth muscle actin (αSMA), a 
contractile cytoskeletal protein is the earliest marker of VSMC differentiation 
and is located in both small and large vessels. During differentiation VSMCs 
express a series of markers including αSMA, calponin, H-caldesmon (H-cal), 
myosin heavy chain (MyHC), desmin and smoothelin amongst others. Changes 
in the state of VSMC differentiation have been implicated in vascular diseases, 
while the co-operative signal transduction pathways underlying VSMC 
differentiation and proliferation have been widely studied (Owens, 1995; Owens 
et al., 2004; Kawai-Kowase and Owens, 2007). Mature VSMCs have the 
capacity to de-differentiate in order to fulfil immediate needs for growth and 
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remodelling throughout the menstrual cycle. Mature VSMCs may therefore 
alternate between a contractile state expressing a high level of contractile 
proteins and a secretory state, which involves proliferation and secretion of 
basement membrane proteins (Owens, 1995; Rogers and Abberton, 2003). 
Following recruitment and differentiation, proliferation of VSMCs forms the key 
to maturation of an arteriole. Studies using proliferating cell nuclear antigen 
(PCNA) have shown that VSMC proliferation in spiral arteries remained 
consistently low during the early menstrual cycle and increased during the mid-
late secretory phase, explaining the growth and coiling of spiral arteries. In 
contrast, VSMC proliferation remained constant for straight arterioles (Abberton 
et al., 1999b). In women with heavy menstrual bleeding (HMB; menorrhagia) 
VSMC proliferation was significantly reduced in the mid and late secretory 
phase in both the spiral and straight arterioles (Abberton et al., 1999b). This 
suggests that the spiral arterioles have an altered growth pattern in HMB, since 
it is in the secretory phase that spiral arterioles grow and gain their distinctive 
coiled structure. Interestingly, the total number of VSMCs in spiral arterioles 
was similar between control and menorrhagic tissue and consequently absolute 
wall thickness and αSMA actin staining pattern was similar. In addition, staining 
of MyHC, a late marker of VSMC differentiation was lower in the early secretory 
phase in women with HMB, suggesting that VSMCs mature at different rates in 
the spiral arterioles in HMB compared with control endometrium (Abberton et 
al., 1999b). 
Role of ECs: Endometrial ECs play a central role in the menstrual cycle; they 
regulate cyclic blood vessel maturation in association with VSMC recruitment 
under the action of angiogenic growth factors (AGFs). Vascular EC-VSMC 
signalling is key to maintaining normal blood flow by regulation of vascular tone 
(Feletou, 2011). ECs are also associated with degradation of vascular and 
stromal ECM by protease production, thereby allowing co-ordinated EC 
migration and proliferation (Findlay, 1986; Zetter, 1988; Goodger and Rogers, 
1994). Moreover, in a study which used EC proliferation as a measure of 
angiogenesis, patients with HMB had high endometrial EC proliferation 
compared with controls, indicating altered blood vessel development (Kooy et 
al., 1996). During the menstrual cycle, angiogenesis is spatially and temporally 
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regulated: in the menstrual phase there is vascular repair in the stratum basalis; 
in the stratum functionalis angiogenesis in the proliferative phase supports 
endometrial growth, while in the secretory phase there is growth and coiling of 
the spiral arterioles (Gargett and Rogers, 2001). Thus vascular EC 
differentiation/maturation may also be spatio-temporally regulated during the 
menstrual cycle and dysregulation of this process may in turn reflect altered 
vascular function/development, contributing to bleeding disorders such as HMB. 
Vascular ECs express a number of molecules, including Factor VIII related 
antigen (F8RA), CD34 and CD31 and EC specific glycoproteins, which 
selectively bind the lectin Ulex Europaeus-Agglutinin I (UEA-1). F8RA and 
CD34 are glycosylated transmembrane proteins, whereas CD31 is an 
endothelial cell adhesion glycoprotein molecule present at intercellular 
junctions. During studies of vessel development in secretory phase of the 
endometrium from women suffering recurrent reproductive failure, 
heterogeneous staining of different EC markers was noted (Quenby et al., 
2009). While there have been several studies of expression of different EC 
markers in endometrium and myometrium during the menstrual cycle (Rees et 
al., 1993; Rogers et al., 1993; Tawia et al., 1993; Nikitenko et al., 2000; Zhang 
et al., 2002), a detailed analysis of ECs in the different layers of the 
endometrium (luminal region, stratum functionalis, stratum basalis) and 
superficial myometrium throughout the menstrual cycle and in endometrial 
bleeding disorders such as HMB has not been reported.  
Role of ECM: As a major component of blood vasculature, the ECM is integral 
to angiogenesis, tissue stability, regulation of cell growth and differentiation and 
provides mechanical properties maintaining vascular tone. Moreover, ECs and 
synthetic VSMCs are capable of synthesizing most of the ECM constitutent 
proteins. Vascular ECM (Paulsson, 1992; Timpl, 1996; Timpl and Brown, 1996) 
consist of anchoring fibrils and proteins, including type IV collagen (Paulsson, 
1992; Schmidt et al., 1992; Poschl et al., 2004), fibronectin (Clark et al., 1982; 
Risau and Lemmon, 1988; Francis et al., 2002; Astrof et al., 2007; Hynes, 2007; 
Astrof and Hynes, 2009), laminin (Cheng et al., 1997; Miner et al., 1998; Thyboll 
et al., 2002; Miner and Yurchenco, 2004; Scheele et al., 2007; Yurchenco and 
Patton, 2009) and osteopontin (Chen et al., 1992; Denhardt and Guo, 1993; 
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Giachelli et al., 1993; Liaw et al., 1994; Giachelli et al., 1995; Apparao et al., 
2001; Kang et al., 2014). The ECM is located radially outward from the EC 
layer. The main constituents of the human endometrial vascular ECM have 
been identified (Faber et al., 1986; Aplin et al., 1988) and shown to be 
expressed even during the menstrual phase (Kelly et al., 1995). Since the 
pattern of vascular growth and development differs between the layers and 
phases of the menstrual cycle, this may also accompany an altered spatio-
temporal pattern of ECM expression. Although staining of the ECM components 
have been studied to some extent in the menstrual cycle (Aplin et al., 1988; 
Kelly et al., 1995; Oefner et al., 2015), osteopontin, laminin, collagen IV and 
fibronectin have not been studied in detail in endometrial vasculature and in the 
context of endometrial bleeding disorders such as HMB.  
1.2.4.3 Angiogenic growth factors 
Angiogenesis involves various molecular pathways involving growth factors 
such as PDGF-B and its receptor PDGFR-β. PDGF-B, secreted by ECs 
probably in response to VEGF-A, is important in recruiting VSMCs and 
pericytes (Jain, 2003) (Figure 1.9). In vitro studies have shown that PDGF-BB is 
capable of inducing tube formation, sprouting and proliferation by stimulating 
ECs. PDGF-BB also acts as a mitogen for VSMCs and pericytes leading to cell 
proliferation (Battegay et al., 1994). Another growth factor, TGF-β1 is involved 
in a plethora of events including proliferation of ECs, ECM stimulation and 
production of proteases, and differentiation of ECs and VSMCs (Distler et al., 
2003). TGF-β1 performs a dual role; acting both as an angiostatic and as an 
angiogenic factor. In vitro studies have shown that while low doses of TGF-β1 
induce EC proliferation and tube formation, higher doses have a negative effect. 
Alongside its roles in angiogenesis, TGF-β1 is also involved in ECM 
degradation (Pepper, 1997). Tyrosine kinase receptor Tie-2 and its ligands, 
Ang1 and Ang2 also play a role. Ang1, which is present throughout the 
menstrual cycle but in reduced levels in the endometrial stromal fibroblasts, 
regulates vessel maturation through VSMC recruitment and EC-VSMC 
structural association (Jain, 2003). Ang2 is mostly present in the secretory 
phase in the luminal epithelial and is detected in uNK cells around VSMCs. In 
contrast to the role of Ang1, Ang2 takes part in vessel degradation and 
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remodelling, destabilising vessels via apoptosis of ECs, which in the absence of 
VEGF degenerate (Jain, 2003; Rogers and Abberton, 2003).  
It is important to note that the development of the endometrial vascular bed 
results from a strict balance between inducers and inhibitors. Inhibition of vessel 
formation can occur via various mechanisms: blocked production, 
downregulation or neutralization of an inducer or its receptor, direct inhibition of 
migration or proliferation of ECs or VSMCs. Inhibitors of angiogenesis include 
endostatin, tumstatin, angiostatin, Tsp-1 and tissue inhibitor of MMP-2 (TIMP-
2). As an example, Tsp-1 produced by the endometrial stromal cells inhibits 
angiogenesis via downregulation of platelet endothelial cell adhesion molecule 
1 (PECAM1) and by binding to FGF2 and endothelial cell glycoprotein CD36. It 
also promotes apoptosis of ECs either by upregulating the proapoptotic factor 
BAX or by downregulating the antiapoptotic factor BCL2 (Smith, 2001). It is 
clear that the mechanism of endometrial blood vessel development involves a 
complex network of interactions between several AGFs, the understanding of 
which requires further knowledge of the key AGFs involved. 
1.2.5 The TGFβ family 
The evolutionarily conserved TGFβ superfamily, the largest family of secreted 
cytokines or growth factors in mammals, play key roles in a number of diverse 
physiological and pathological process (Massague et al., 2000; Chang et al., 
2002; Juengel and McNatty, 2005; Padua and Massague, 2009; Ikushima and 
Miyazono, 2010) from embryo development to tissue homeostasis (Knight and 
Glister, 2006; Gordon and Blobe, 2008; Wu and Hill, 2009). TGFβs are secreted 
in latent forms, and their bioavailability is a strictly regulated multistep process 
including secretion, storage and interaction with ECM components, release from 
ECM and finally activation prior to receptor binding (ten Dijke and Arthur, 2007). 
The inactive TGFβ peptide consists of a TGFβ dimer covalently bound to its 
latency-associated peptide (LAP) forming the small latent complex (SLC), which 
can subsequently covalently attach to the large latent TGFβ-binding protein 
(LTBP) to form the large latent complex (LLC) (Kanzaki et al., 1990;  Saharinen 
et al., 1996; Maroni and Davis, 2011). The LLC binds to microfibrils and ECM 
via the LTBP. The degradation of these microfibrils via inflammatory proteolytic 
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enzymes like elastase displaces the LLC from ECM, prior to TGFβ activation 
(Chaudhry et al., 2007; ten Dijke and Arthur, 2007). Following displacement 
from ECM, the mature TGFβ dimer is released from the LAP and activated by 
proteases, thrombospondin-1 (THBS1) or integrins in a cell-specific manner 
(Figure 1.10A), prior to binding to their signalling receptors (Crawford et al., 
1998; Annes et al., 2003; Sheppard, 2005; ten Dijke and Arthur, 2007). Active 
TGFβ dimer signalling is mediated via two pairs of transmembrane receptor 
serine/threonine kinases knows as the TGFβ type I (TGFβRI) and TGFβ type II 
(TGFβRII) and/or accessory receptors TGFβRIII (betaglycan) and endoglin (on 
ECs). One TGFβRII and two distinct TGFβRI receptors; endothelium restricted 
activin receptor-like kinase (ALK)1 and widely expressed ALK5 are indicated in 
the TGFβ signalling. Active TGFβ binds to TGFβRII, which recruits, 
phosphorylates and activates TGFβRI (ALK5), which in turn phosphorylates 
SMAD transcription factors SMAD 2 and 3. Subsequently, SMAD2 and SMAD3 
proteins interact either with SMAD4 to regulate targeted gene expression or 
with inhibitory SMAD7 resulting in inhibition of this cascade (ten Dijke and 
Arthur, 2007; Massague, 2008).  
TGFβ exists in three isoforms; TGFβ1, TGFβ2 and TGFβ3, which show some 
overlap as well as distinct functions (Lebrin et al., 2005). While active TGFβ2 
binds to TGFβRIII, on ECs TGFβ1 and TGFβ3 bind to endoglin (Omwandho et 
al., 2010). TGFβ1 is expressed in ECs during embryogenesis (Akhurst et al., 
1990). Mice lacking Tgfb1 either present with abnormal angiogenesis and die at 
embryonic day (E)10.5 or develop a normal cardiovascular system but die 
neonatally from an uncontrolled autoimmune disorder (Goumans and 
Mummery, 2000). In contrast, mice lacking either Tgfb2 or Tgfb3 show relatively 
normal angiogenesis (Kaartinen et al., 1995; Bartram et al., 2001). These 
studies suggest that TGFβ1 is more important than TGFβ2 and TGFβ3 for 
angiogenesis (ten Dijke and Arthur, 2007). 
1.2.5.1 TGFβ1 and vascular development 
The TGFβ1 signalling pathway is critical for angiogenesis (Figure 1.10B). In the 
activation phase it regulates cell proliferation, adhesion, differentiation and 
migration through the TGFβ/ALK1 pathway (Goumans et al., 2002). However, in  
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Figure 1.10: The TGFβ regulatory pathway. (A) Regulation of TGFβ bioavailability and 
(B) the TGFβ signal transduction pathway. Diagram adapted from ten Dijke and Arthur 
(2007). 
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the resolution phase, it inhibits EC migration and proliferation through the 
TGFβ/ALK5 pathway (Goumans et al., 2002), imparts stability to the blood 
vessels (Pardali and ten Dijke, 2009) through recruitment and differentiation of 
VSMCs as well as by facilitating changes in the ECM (Hanahan and Folkman, 
1996; Massague, 1998; Smith, 1998; Lebrin et al., 2005). Not surprisingly, 
various cardiovascular diseases in humans result from dysregulated TGFβ 
signalling (Gordon and Blobe, 2008). Moreover, mice deficient in Tgfb1 die in 
utero due to abnormal vasculogenesis (Dickson et al., 1995). 
Depending on the experimental setup, TGFβ1 can either stimulate or inhibit 
angiogenesis in vivo and in vitro (Goumans et al., 2009). This variation in action 
is due to three fundamental features of the TGFβ signalling pathway; pleiotropy 
(based on a large set of transcription factors), co-ordination (due to the 
presence of a common enhancer element) and context dependence (due to cell 
or environment dependant SMAD expression) (Massague, 2008). In vitro 
studies have shown that while TGFβ1 disrupts growth in microvascular EC in 
bovine corpus luteum (Maroni and Davis, 2011), induces apoptosis in bovine 
aortic ECs (Pollman et al., 1999b) and rat pulmonary microvascular ECs (Lu et 
al., 2009), it also protects against EC apoptosis induced by serum deprivation in 
rat pulmonary arteries (Q. Lu, 2008). In comparison, in vivo, TGFβ1 induced 
angiogenesis via VEGF mediated EC apoptosis, followed by increased EC 
proliferation (Ferrari et al., 2009). However, it is important to remember that, 
VEGF mediated apoptosis of ECs via TGFβ1 is essential during angiogenesis 
and its inhibition results in abnormal vessels (Pollman et al., 1999a; Pollman et 
al., 1999b; Ferrari et al., 2009). 
Both VEGF and TGFβ1 have also been shown to increase EC differentiation 
(Ferrari et al., 2009), although some discrepancy exists in the context of their 
collaborative role (Mallet et al., 2006). Interaction between ECs and ECM is 
crucial for angiogenesis, vascular stabilisation, storage and presentation of a 
variety of growth factors and cytokines which regulate vascular remodelling 
(Davis and Senger, 2008). One set of molecules key to mediating this 
interaction is the integrins; ECs interact with ECM components such as 
collagen, laminin and fibronectin through integrins (Weis, 2007). TGFβ1 also 
regulates the expression of various integrin molecules in ECs (Margadant and 
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Sonnenberg, 2010), thus allowing EC-ECM interactions thereby co-ordinating 
vascular stabilisation and development. Once vascular stability is achieved, 
ECs induce paracrine TGFβ1 signalling on neighbouring mesenchymal cells to 
promote pericyte or VSMC differentiation (Hirschi et al., 1998; Mao et al., 2012; 
Shi and Chen, 2014; Shi et al., 2014). Consequently, these cells cover the new 
vessels achieving muscularisation and vascular maturation (ten Dijke and 
Arthur, 2007). The importance of TGFβ1 signalling in VSMCs is further 
highlighted by the study, which showed that loss of TGFβ receptors TGFβRII or 
ALK5 in VSMCs results in vascular defects and embryonic lethality (Jiao et al., 
2006). The fact that TGFβ1 signalling critically affects ECs prior to vascular 
maturation as well as VSMCs signifies its critical role in both early and late 
stages of angiogenesis.  
1.2.5.2 TGFβ1 in endometrium 
Amongst other reproductive events, the TGFβ1 signalling pathway has been 
implicated in uterine decidualisation and embryo implantation in mice (Roelen et 
al., 1994; Lee et al., 2007). Although understanding the specific functions of this 
pathway in vivo remains poorly understood due to receptor redundancy and/or 
embryonic lethality of Tgfb null mice, Li et al. (2011) showed the importance of 
Tgfbr1 in the function of the female reproductive tract by developing a 
conditional knockout (cKO) Tgfbr1 mouse model; these cKO female mice were 
sterile, had abnormal embryo development and defective SMC development in 
the uteri. In the endometrium TGFβ1 is expressed abundantly and is secreted 
by several different cell types including stromal cells, glandular epithelium, ECs, 
VSMCs and the immune cell population (Omwandho et al., 2010; Lash et al., 
2012). Since TGFβ1 is involved in wound repair, it is also expressed by 
neutrophils, macrophages, NK cells and fibroblasts (Margadant and 
Sonnenberg, 2010). TGFβ1 is known to play a role in tumour promotion and 
even initial steps of endometrial carcinoma invasion (Muinelo-Romay et al., 
2011). Again, transcriptional downregulation of TGFβ1 has been found to 
correlate with transformation of the endometrium in malignancy (Soufla et al., 
2013). Interestingly, TGFβ1 transcript levels correlate with those of VEGF in 
endometrial tissue (Soufla et al., 2013) and TGFβ1 has been shown to regulate 
VEGF production in breast cancer cell models (Donovan et al., 1997). Although, 
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the presence of TGFβ1 and its receptors TGFβRI and TGFβRII in normal 
human endometrium, endometrial cancer and RM have been reported 
(Abberton et al., 1999b; von Wolff et al., 2000; Piestrzeniewicz-Ulanska et al., 
2002; Omwandho et al., 2010; Lash et al., 2012), to the best of our knowledge 
their presence in the context of heavy menstrual bleeding remains unknown.  
1.2.6 The PDGF family 
PDGF, discovered in the 1970s, is a serum growth factor, which stimulates 
growth and migration in glial cells (Westermark and Wasteson, 1976), 
fibroblasts (Kohler and Lipton, 1974) and vascular smooth muscle cells (Ross et 
al., 1974). This highly conserved heparin-binding family is structurally and 
functionally related to the VEGF family of growth factors and can even stimulate 
VEGF secretion (Paez-Ribes et al., 2009). The PDGF family consists of five 
disulphide bonded homo or heterodimer compositions; PDGF-AA, PDGF-BB, 
PDGF-AB resulting from PDGF-A and PDGF-B genes and the more recently 
described PDGF-CC and PDGF-DD, encoded by PDGF-C and PDGF-D genes 
respectively (Heldin and Westermark, 1999; Li et al., 2000; Bergsten et al., 
2001; Fredriksson et al., 2004). The A- and B- precursors are synthesised 
intracellularly as cleaved polypeptide chains, while the C- and D- precursors are 
not processed intracellularly and contain an N-terminal CUB domain, cleavage 
of which by tissue-type plasminogen activator (tPA) or plasmin for PDGF-C, or 
by urokinase-type PA (uPA) or matriptase (MT-Sp1) for PDGF-D, is essential 
for activation and receptor binding (Heldin, 2014). Spatial diffusion of the 
PDGFs in the tissue is also regulated by ECM binding or cleavage and release 
from the ECM by endogenous proteases (Figure 1.11A). Although such 
endogenous proteases are yet to be identified, Kelly et al. (1993) identified 
thrombin as a potential candidate (Kelly et al., 1993; Andrae et al., 2008). Once 
cleaved from ECM, the PDGFs can bind to their respective receptors for 
downstream signal transduction (Fredriksson et al., 2004; Ustach and Kim, 
2005; Ustach et al., 2010). 
The PDGFs act via two receptor tyrosine kinases (RTKs), PDGFRα and 
PDGFRβ. PDGFRα binds to all PDGF isoforms except PDGF-DD, while 
PDGFRβ binds to PDGF-BB and PDGF-DD. Additionally a heterodimeric  
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Figure 1.11: The PDGF regulatory pathway. (A) Regulation of PDGF bioavailability and 
(B) the PDGF signal transduction pathway. Diagrams (A, B) adapted from Demoulin 
and Essaghir (2014), Heldin (2014) respectively. 
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PDGFRαβ receptor exists which binds to PDGF-AB, BB and possibly even to 
PDGF-CC and DD (Demoulin and Essaghir, 2014). Ligand binding leads to 
autophosphorylation of the receptor, which activates its tyrosine kinase activity, 
which in turn allows docking sites for downstream signalling molecules 
containing Src homology 2 (SH2) domains. Subsequently, activation of the 
PDGFR and downstream signalling results in cell proliferation, survival, actin re-
organisation and cell migration (Andrae et al., 2008; Heldin, 2014), which may 
be enhanced by the interaction of PDGFR with integrins (Frisch and Ruoslahti, 
1997). Factors that have been shown to induce PDGFR expression, include 
TGFβ, FGF-2 and oestrogen (Heldin and Westermark, 1999). 
The PDGF signalling pathway is critical to normal embryo development since 
mice lacking PDGF ligands and receptors die shortly after birth. Importantly, 
mice lacking PDGFRα showed severe multi-organ defects, which included 
those observed in mice deficient in PDGF-A and –C (Soriano, 1997; Ding et al., 
2004), while those lacking PDGF-B and PDGFRβ were deficient in VSMCs and 
died at birth. Although PDGFRβ also binds PDGF-D, further studies did not 
indicate any major role for PDGF-D (Lindahl et al., 1997). PDGF also plays an 
important role in wound healing in relation to ECM components such as 
collagen and heparin (Sun et al., 2009). 
Amongst the PDGF isoforms, PDGF-D expression is the least characterised, 
although it has been shown to be present in fibroblasts and smooth muscle 
cells. While PDGF-A and –C are expressed in epithelial cells, muscle and 
neuron progenitor cells, PDGF-B is primarily expressed in vascular ECs, 
megakaryocytes and neurons (Andrae et al., 2008). In contrast to PDGF-A, 
PDGF-B can induce proliferation and migration of ECs and tube formation 
(Gacche and Meshram, 2014). Amongst the receptors, PDGFRα is expressed 
in mesenchymal progenitors in lung, skin and intestine, while PDGFRβ is 
particularly expressed in VSMCs and pericytes. Current evidence suggests a 
model such that vascular ECs secrete PDGF-BB, which interact with heparan 
sulphate (HS) at the EC surface or in the periendothelial matrix (Abramsson et 
al., 2003; Lindblom et al., 2003; Abramsson et al., 2007). HS is suggested to 
play two roles at this site: it interacts with and results in local deposits of PDGF-
BB, which are critical for appropriate recruitment of pericytes or VSMCs to the 
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vessel wall, while HS on the EC surface may enhance PDGF-BB mediated 
PDGFRβ signalling in the neighbouring pericytes (Andrae et al., 2008). Thus, 
PDGF promotes maturation of blood vessels through VSMC recruitment, 
consequently supporting the structure of blood vessels especially through the 
PDGF-BB/PDGFRβ pathway and hence playing an important role in 
arteriogenesis (Betsholtz, 2004). 
1.2.6.1 PDGF-BB and vascular development 
All members of the PDGF and PDGFR family display angiogenic activity in vivo 
and are essential for normal vascular development (Figure 1.11B). PDGF-BB 
and its receptor PDGFRβ are the most widely evaluated (Leveen et al., 1994; 
Soriano, 1994), although PDGFRα is also being considered for different types 
of mesenchymal/fibroblast derived pathologies (Andrae et al., 2008). PDGF-BB 
and PDGFRβ are primarily expressed in developing vasculature, where 
quiescent ECs produce PDGF-BB and both perivascular cells and ECs produce 
PDGFRβ. Although initially PDGF-BB is widely expressed by the vascular ECs, 
with time it is restricted to the leading ECs at the sprouting tip, which remain in 
close contact with pericytes or VSMCs, thereby facilitating the release of PDGF-
BB (Gerhardt and Betsholtz, 2003). Stimulation of ECs with PDGF-BB induces 
sprouting, proliferation and tube formation in vitro (Battegay et al., 1994). 
Disruption of this signalling has been shown to result in irregular EC 
proliferation and near complete loss of pericytes, resulting in weakened 
vascular walls, dilated vessels and haemorrhage (Lindahl et al., 1997; Shih and 
Holland, 2006; Andrae et al., 2008), although the loss of pericytes in PDGF-BB 
and PDGFRβ knockouts was less severe in placenta than in kidney (Ohlsson et 
al., 1999). Therefore, while TGFβ is indicated in both recruitment and 
differentiation of VSMCs during angiogenesis, recruitment of pericytes or 
VSMCs appears to be the primary function of PDGF-BB (Lindahl et al., 1999). 
1.2.6.2 PDGF-BB in endometrium 
During the oestrogen dependant proliferative phase of the menstrual cycle, 
PDGF promotes endometrial stromal proliferation via PDGFRβ (Chegini et al., 
1992; Gargett et al., 2008). PDGF also stimulates VEGF, which may play a role 
in vascular growth and remodelling during pregnancy (Taniguchi et al., 2001). 
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Dysregulated PDGF expression has also been implicated in RM (Lash et al., 
2012). Moreover the importance of PDGF-BB in vascular development is further 
highlighted by the fact that dysregulated expression of PDGF is reported in 
tumorigenesis and vascular disorders such as atherosclerosis, restenosis and 
pulmonary hypertension (Andrae et al., 2008; Heldin, 2013; Heldin, 2014). 
Strikingly, although processes such as altered vascular development, EC 
proliferation and VSMC differentiation, shown in heavy menstrual bleeding, are 
directly or indirectly regulated by the PDGF-BB signalling pathway; the role of 
PDGF-BB and its receptors PDGFRα and PDGFRβ remains unknown in this 
context, inviting further research. 
1.2.7 The VEGF family 
The VEGF family of growth factors are potent angiogenic and EC specific 
mitogenic factors critical to regulation of angiogenesis and lymphangiogenesis 
(Figure 1.12). VEGF was first identified as a vascular permeability factor (VPF) 
in the 1980s (Senger et al., 1983) and sequenced later (Leung et al., 1989) 
VEGF is a heparin-binding glycoprotein and in mammals its family comprises 
five homologous factors including VEGF-A (also known as VEGF), VEGF-B, 
VEGF-C, VEGF-D and PIGF (Gacche and Meshram, 2014). In normal tissues, 
VEGF-A is present at highest levels in adult kidney, lung, heart and adrenal 
gland, although lower levels are also detectable in other tissues (Hoeben et al., 
2004). As a result of alternative splicing, VEGF-A has five different isoforms 
including VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206 (Hoeben et al., 
2004; Gacche and Meshram, 2014). VEGF-A binds to its receptors VEGFR1 
and VEGFR2 and is perhaps the most widely studied member with important 
roles in blood vessel development, especially during embryogenesis. Studies in 
mice showed that VEGF-A homozygous as well as heterozygous knockout mice 
are embryonic lethal due to immature blood vessel formation (Carmeliet et al., 
1996; Ferrara et al., 1996). 
In adults, VEGF-B is abundantly expressed in myocardium, skeletal muscle and 
pancreas, while in mouse embryonic tissues VEGF-B is found in the developing 
heart, arterial smooth muscle and in the spinal cord (Hoeben et al., 2004). It has  
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Figure 1.12: The VEGF family. (A) The VEGF family of receptors and ligands and (B) 
co-receptors involved in VEGF pathway. Diagram adapted from Olsson et al. (2006). 
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two isoforms generated through alternative splicing; VEGF-B167 VEGF-B186, 
which are differentially expressed. Both VEGF-B and PIGF act via VEGFR1; 
while VEGF-B has been suggested to play significant roles in stimulation and 
maintenance of the coronary artery system (Aase et al., 2001), PIGF promotes 
angiogenesis and stimulates EC survival (Luttun et al., 2002). VEGF-C is 
predominantly expressed in the adult heart, placenta, ovary, small intestine and 
thyroid gland, and in sprouting lymphatic vessels in embryonic tissues. VEGF-C 
homozygous knockout mice are embryonic lethal due to fluid accumulation from 
dysregulated lymphangiogenesis (Karkkainen et al., 2004). VEGF-C has also 
been shown to regulate differential expression of VEGF-A in cancer by 
promoting angiogenesis (Gacche and Meshram, 2014). It is secreted as a 
precursor and proteolytically processed to an active state, which acts via 
VEGFR3 (Hoeben et al., 2004). Both VEGF-C and VEGF-D play an important 
role in lymphagiogenesis. VEGF-D is present in adult lung, heart, skeletal 
muscle, colon and small intestine, and in the developing lung in the embryo. 
Similar to VEGF-C, VEGF-D is secreted as a precursor, which is proteolytically 
processed for activation and binds to VEGFR3. VEGF-C and VEGF-D may also 
bind to VEGFR2, but with lower affinity than with VEGFR3 (Hoeben et al., 2004; 
Olsson et al., 2006). 
In mammals, the five VEGF ligands bind to three RTKs VEGFR1-3 and co-
receptors such as heparin sulphate proteoglycans (HSPGs) and neuropilins 
(NRP) (Olsson et al., 2006). VEGFR1 binds VEGF-A, VEGF-B and PIGF. The 
VEGF signalling pathway is illustrated in Figure 1.12. VEGFR1 exists either in 
full length or soluble form (sFlt1), both of which bind VEGF-A with greater 
affinity than VEGFR2, and may thus negatively influence VEGFR2-mediated EC 
proliferation function. sFlt1 has been suggested to negatively regulate 
angiogenesis (Koch et al., 2011). Other than ECs, VEGFR1 is expressed on 
monocytes and macrophages, where it regulates migration of these cells in 
response to VEGF-A (Koch et al., 2011). Flt1-/- (Vegfr1-/-) is embryonic lethal 
due to an increase in EC progenitors and formation of vessels without lumens 
(Fong et al., 1995). This may suggest that VEGFR1 plays a negative role in 
angiogenesis, but deletion of VEGFR1 tyrosine kinase domain in mice 
[Vegfr1(TK)-/-] show normal vascular development (Hiratsuka et al., 1998). The 
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primary role of VEGFR1 may therefore be to capture excess VEGF and 
spatially regulate VEGFR2 signalling, rather than as a signalling receptor on 
ECs (Kappas et al., 2008). VEGFR1 contains several tyrosine phosphorylation 
sites, which interact with p85/phosphatidylinositol-3-kinase (PI3K), 
phospholipase C-γ (PLCγ), SHP2, growth-factor-receptor bound 2(Grb2) protein 
and Nck, although downstream signal transduction remains unclear (Olsson et 
al., 2006). 
VEGFR2 is the principal receptor on ECs and is critical both during 
development and in adult physiology and pathology. It is suggested to be the 
main transducer for VEGF-A regulating EC differentiation, proliferation, 
migration and tubule formation (Olsson et al., 2006; Koch et al., 2011). In 
human VEGFR2 is also known as kinase insert domain receptor (KDR) and in 
mouse as fetal liver kinase (Flk1). It binds to proteolytically processed VEGF-C, 
VEGF-D and also VEGF-A with a 10-fold lower affinity than VEGFR1. VEGFR2 
also exits in an alternatively spliced soluble form (sVEGFR2), which binds 
VEGF-C and prevents VEGFR3 binding, thereby inhibiting EC proliferation 
(Koch et al., 2011). VEGFR2 is primarily expressed in vascular ECs or their 
precursors during embryogenesis. Vegfr2-/- mice are embryonic lethal (E8.5-
E9.5) due to abnormal EC development (Shalaby et al., 1995).  
VEGFR3 has a high affinity for VEGF-C and VEGF-D. VEGF-C/VEGFR3 
critically regulates lymphangiogenesis. However, VEGFR3 is also expressed in 
vascular ECs and is upregulated during angiogenesis (Koch et al., 2011). 
Moreover, Vegfr3 gene targeted mice are embryonic lethal due to 
cardiovascular defects. Although later in development VEGF-C/VEGFR3 
expression becomes restricted to lymphatic ECs, ECs at active angiogenesis 
sites such as tumor vasculature and tip cells of angiogenic sprouts in retina 
express VEGFR3 (Tammela et al., 2008). Similar to the other receptors, VEGF-
C and VEGF-D binding to VEGFR3 leads to kinase activation and 
phosphorylation at specific tyrosine sites, which induces association with 
proteins like Shc–Grb2 complex, resulting in activation of downstream pathways 
such as PI3/AKT, which are critical for lymphendothelial cell migration (Koch et 
al., 2011).  
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1.2.7.1 VEGF and vascular development 
VEGFs are crucial regulators of vasculogenesis in the developing embryo as 
well as angiogenesis in the adult (Figure 1.13). Hence, they are key target for 
drug therapy in pathological angiogenesis (Shibuya, 2013; Gacche and 
Meshram, 2014). In adults, most blood vessels remain quiescent, but in the 
presence of a physiological stimulus, vascular ECs can rapidly divide and 
activate angiogenesis under the regulation of VEGFs (Karamysheva, 2008). 
VEGF acts on ECs originating from arteries, veins or lymphatic vessels and 
induces angiogenesis or lymphangiogenesis. VEGF also induces expression of 
Bcl-2 and A1 in ECs, which are antiapoptotic proteins, and it has also been 
shown to act as a survival factor for ECs (Gerber et al., 1998). In new-born 
mice, inhibition of VEGF resulted in extreme apoptotic changes, while mice 
older than four weeks showed no effect, suggesting that only newly formed ECs 
and not mature ECs are VEGF dependant (Karamysheva, 2008). Immature 
vessels lacking periendothelial cells remain dependant on VEGF, which is 
required for maintaining vascular homeostasis in adults (Benjamin et al., 1999; 
Lee et al., 2007). As vessels mature, pericytes or VSMCs are recruited which 
form a layer over the ECs. VEGFs are also involved in regulating vascular 
permeability (Karamysheva, 2008).  
1.2.7.2 VEGF in endometrium 
VEGF is expressed in a variety of tissues, including primate and rodent 
endometrium (Girling and Rogers, 2005). Apart from the ovary, endometrium is 
the only other tissue where physiological angiogenesis takes place in 
adulthood. Given the importance of the VEGF family in angiogenesis, it is 
unsurprising that VEGF is expressed in the normal human endometrium and is 
implicated in pathological states (Charnock-Jones et al., 1993; Shifren et al., 
1996; Donnez et al., 1998; Malik et al., 2006; Girling and Rogers, 2009; Lash et 
al., 2012; Li et al., 2013). Human endometrium expresses VEGF-A isoforms, 
with cyclic variability, although VEGF-A165 is suggested to be the dominant 
isoform (Girling and Rogers, 2009). VEGF-A mRNA was shown to localise to 
the stroma, luminal and glandular epithelium in the proliferative phase, with 
expression remaining in the epithelial cells but not in the stroma in the secretory  
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Figure 1.13: The VEGF regulatory pathway via (A) VEGFR1, (B) VEGFR2 and (C) 
VEGFR3. Diagram adapted from Olsson et al. (2006). 
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phase. Moreover, its expression increases in the secretory phase and is at its 
highest in the menstrual phase (Charnock-Jones et al., 1993; Shifren et al., 
1996; Sharkey et al., 2000). VEGF-C and VEGF-D are also expressed in 
human endometrial stroma, glands and blood vessels (Moller et al., 2002; Lash 
et al., 2012). VEGF-C mRNA has been detected in endometrial biopsies 
throughout the menstrual cycle, with highest levels in glandular epithelial cells, 
vascular endothelium and a population of stromal cells, but there were no 
differences between the stratum functionalis and stratum basalis (Girling and 
Rogers, 2009). VEGF-D has been reported in low or moderate levels in both 
endometrium and myometrium throughout the menstrual cycle, without any 
significant differences between the epithelium, stroma, stratum basalis or 
functionalis or between the phases of the cycle (Girling and Rogers, 2009; Lash 
et al., 2012). 
1.2.8 The angiopoietin family 
Angiopoietins are a family of secreted glycoproteins with major roles in 
regulation of blood vessel development and stability (Figure 1.14). They consist 
of four distinct members: Ang1, Ang2, Ang3 and Ang4, where Ang4 and Ang3 
are human and mouse orthologues respectively (Singh et al., 2011). Ang1 and 
Ang2 are the most widely studied members especially in vascular development. 
Ang1 binds to the RTK Tie2 (Tek) and is expressed in perivascular cells such 
as pericytes and VSMCs, where presence is induced by hypoxia and other 
growth factors such as VEGF and PDGF-B (Park et al., 2003; Nishishita and 
Lin, 2004).  
Ang2 acts as an antagonist to Ang1 and suppresses its effects on vascular 
remodelling and stability (Maisonpierre et al., 1997). It is expressed by ECs and 
expression is transcriptionally regulated by factors such as hypoxia and VEGF 
(Oh et al., 1999). Ang2 is stored within the endothelium in Weibel-Palade 
bodies but can be actively released in response to thrombin, histamine or 
pharmacological activators such as phorbol ester (Fiedler et al., 2004). Similar 
to Ang1, Ang2 also binds to Tie2, although with much lower affinity than Ang1 
and may also act as an antagonist to Ang1, although the mechanism is unclear 
(Singh et al., 2011). Ang3 is expressed in various mouse tissues, while Ang4 is 
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present specifically in human lungs. Ang4 phosphorylates Tie2, and both Ang3 
and Ang4 act as agonists of species specific Tie2 (Fagiani and Christofori, 
2013). 
Angiopoietins primarily bind to endothelial Tie2 and indirectly to Tie1 in 
Tie1/Tie2 heterodimers for downstream signal transduction (Davis et al., 1996). 
Tie1 and Tie2 are expressed by both vascular and lymphatic ECs (Thomas and 
Augustin, 2009). On Ang1 binding, Tie2 receptors cluster to bring their kinase 
domains in close proximity to allow transphosphorylation and receptor 
activation, stimulating intracellular signalling pathways such as PI3K/Akt, 
mitogen activated protein kinase (MAPK) and Dok-R pathways (Singh et al., 
2011). Tie2 has been proposed to be primarily important for vascular EC 
formation rather than proliferation and maintenance (Dumont et al., 1994). ECs 
also express Tie1, and although Tie1 is similar in structure to Tie2, it is unable 
to bind angiopoietins, but instead interacts with Tie2 on ECs (Singh et al., 
2011). The Tie1-Tie2 interaction limits Ang1 signalling through Tie2. However, 
AGFs such as VEGF promote Tie1 cleavage and can therefore regulate Ang1 
responsiveness (Singh et al., 2011). Tie1 null mice are also embryonic lethal, 
due not to perturbed angiogenesis but to loss of vascular integrity, which results 
in oedema and haemorrhage (Puri et al., 1995). Angiopoietins may also bind to 
integrins α2β1, α5β1, ανβ3 and ανβ5, which allow it to transduce signal in non-
endothelial cells lacking Tie2 receptor, such as cardiac and skeletal myocytes 
(Dallabrida et al., 2005). 
1.2.8.1 Angiopoietin and vascular development 
The Ang/Tie signalling pathway is crucial for vascular remodelling and 
maturation by recruitment of perivascular cells during embryogenesis and adult 
vascular homeostasis (Figure 1.14). Transgenic mice with an inactive Tie2 gene 
are embryonic lethal due to defective maturation, stabilisation and the inability 
to transform a primary capillary plexus to a complex branched vascular network 
(Dumont et al., 1994; Karamysheva, 2008). Ang1 mediates vascular 
remodelling, maturation, and perivascular cell association and lowers vascular 
permeability. Ang1 signalling is strictly monitored by regulation of its ability to  
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Figure 1.14: The angiopoietin regulatory pathway. Angiopoietin signaling pathways 
involved in (A) cell proliferation and (B) cell migration, vascular leakage and 
inflammation. Diagram adapted from Thomas and Augustin (2009). 
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bind to its receptor rather than by levels in the tissue microenvironment (Singh 
et al., 2011). In the presence of VEGF, its competitive inhibitor Ang2 regulates 
EC migration, vascular sprouting and growth (Thurston et al., 1999), while in the 
absence of VEGF it contributes to vascular regression (Maisonpierre et al., 
1997; Sheppard, 2005; Karamysheva, 2008). Interestingly, subcellular 
localisation of Tie2 in sparse or confluent ECs is determined by angiopoietins, 
thus affecting the outcome of downstream signalling. ECM bound Ang1 
associates, activates and localises Tie2 to cell-matrix contacts in angiogenic 
ECs, thereby regulating cell migration and matrix adhesion (Fukuhara et al., 
2008; Saharinen et al., 2008). However, in quiescent ECs, Ang1 promotes cell 
survival through association with Tie2 at inter-endothelial cell-cell junctions, 
which mediates further downstream signalling such as Dll/Notch4, which is 
known to regulate vascular quiescence (Zhang et al., 2011). Tie2 is exclusively 
expressed in ECs (stalk cells), which follow the leading ‘tip cells’ during 
angiogenic sprouting where the Ang1/Tie2 pathway induces extracellular 
collagen IV deposition. Ang1/Tie2 may regulate Dll expression in stalk cells, 
thereby affecting vascular maturation in newly formed vessels (Zhang et al., 
2011; Fagiani and Christofori, 2013). Collectively the Ang1/Tie2 system is 
critical for the newly forming vascular network and its stabilisation. 
However, vascular destabilisation occurs when in response to other AGFs, 
Ang2 is released. Increased Ang2 decreases the Ang1/Ang2 ratio, which 
suppresses Ang1 signalling, thereby leading to vascular destabilisation and 
active angiogenesis (Fagiani and Christofori, 2013). Additionally, Tie1 
phosphorylation and heterodimerisation with Tie2 inhibits Tie2 activation and 
clustering, thus acting as another mechanism for regulation of Ang1 (Fagiani 
and Christofori, 2013). Ang1 associates with and activates Tie2 in the absence 
of Tie1 and therefore its action is increased with diminished levels of Tie1. 
Collectively, it is this balance of Ang1 to Ang2 or Tie2 to Tie1, which critically 
regulates and determines the transition between the quiescent and activated 
status of ECs (Fagiani and Christofori, 2013).  
At sites of active angiogenesis, Ang2 promotes pericyte dissociation and 
vascular permeability. This facilitates cytokines and proteases to penetrate into 
the vascular bed preparing it to respond effectively to AGFs (Hammes et al., 
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2004). As a result active angiogenesis by sprouting takes place where VEGF-A 
acts via VEGFR2 to induce Dll-4 expression in tip cells, which then induces 
Notch-1 expression in neighbouring ECs (stalk cells). The tip cells migrate 
towards the VEGF gradient followed by stalk cells (Lobov et al., 2002; Bentley 
et al., 2009), where high levels of Ang2 prevent pericyte recruitment to the 
newly forming vessels, thus helping them to continue elongation and remain in 
an active, unstable state (Fagiani and Christofori, 2013). Proliferation and 
elongation continues until lumen formation in these tubes, which allows blood 
flow (Fagiani and Christofori, 2013). This process of lumen formation and 
pericyte recruitment is repressed by TGFβ1, where Ang2 promotes this 
inhibitory effect, although Ang1 signalling can counteract this (Armulik et al., 
2005; Fagiani and Christofori, 2013). Therefore, again, it is the balance 
between factors such as Ang1-2, VEGF-A, PDGF-B and TGFβ that ultimately 
determines spatio-temporal angiogenesis and the fate of active ECs as 
angiogenic sprouts or mature vessels. 
1.2.8.2 Angiopoietin in endometrium 
Members of the angiopoietin family play an important role in angiogenesis and 
vascular remodelling throughout the body and are expressed in the human 
endometrium, although results vary (Hirchenhain et al., 2003; Rogers and 
Abberton, 2003; Lee et al., 2008; Lash et al., 2012). Nevertheless, Ang1 
immunostaining was observed in the ECs, VSMCs, stroma, luminal and 
glandular epithelium with Ang1 mRNA peaking in the mid secretory phase of the 
menstrual cycle. Ang2 was also detected in the ECs, VSMCs, stroma and 
glandular epithelium, mRNA peaking in the late secretory phase. Tie2 staining 
was also observed in VSMCs, stroma, glandular epithelium, with strongest 
staining on ECs (Akhurst et al., 1990; Hirchenhain et al., 2003; Rogers and 
Abberton, 2003; Girling and Rogers, 2009; Lash et al., 2012). 
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1.3 HEAVY MENSTRUAL BLEEDING DISORDERS 
Abnormalities in menstruation are the leading cause of gynaecological morbidity 
in the USA and UK, constituting 12% of all gynaecological referrals. Although 
abnormal uterine bleeding (AUB) disorders are not life threatening, they can 
have a major impact on woman’s quality of life, posing a crucial health and 
economic problem in the UK and worldwide (Palep-Singh and Prentice, 2007; 
Shankar et al., 2008). 
Until recently, AUB disorders were classified as heavy menstrual bleeding 
(HMB or menorrhagia; blood loss of >80ml per cycle, flooding), metrorrhagia 
(prolonged, irregular periods), polymenorrhoea (frequent periods), 
oligomenorrhoea (scanty and infrequent periods), amenorrhoea (absent 
menstrual periods), intermenstrual bleeding and postcoital bleeding (Palep-
Singh and Prentice, 2007). However, confusion and inconsistency in this 
nomenclature hampered investigation and management of AUB and there is 
now a universally accepted classification and nomenclature (Munro et al., 2011; 
Munro et al., 2012). Consistent with the International Federation of 
Gynaecology and Obstetrics (FIGO), AUB, is defined as any alteration from the 
normal menstrual cycle including variations in the regularity and frequency of 
menses, duration of flow or amount of blood loss (Singh et al., 2013). Table 1.2 
shows the normal limits of menstrual parameters suggested by FIGO, while 
Table 1.3 lists previously used terminologies that are now made redundant. 
Further definitions of terminologies in the FIGO classification of AUB are listed 
in Table 1.4. 
AUB can result from a wide range of conditions such as endometrial or 
endocervical polyps (AUB-P), adenomyosis (AUB-A), leiomyoma (AUB-L) and 
hyperplasia or malignancy (AUB-M) (Munro et al., 2011). AUB due to hormonal 
imbalances affecting the menstrual cycle such as ovulatory dysfunction (AUB-
O), endometrial (AUB-E) or due to acquired or inherited bleeding disorders 
termed ‘coagulopathy’ (AUB-C). However, causes which cannot be 
demonstrated conclusively fall under the ‘not yet classified’ group (AUB-N) 
(Munro et al., 2011; Ray and Ray, 2014). 
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Table 1.2: Normal limits of menstrual parameters (FIGO)  
CLINICAL DIMENSIONS OF 
MENSTRUATION AND MENSTRUAL CYCLE 
DESCRIPTIVE 
TERM 
NORMAL LIMITS 
(90% CI) 
Frequency of menses (d) 
 
Frequent <24 
Normal 24-38 
Infrequent >38 
Regularity of menses: cycle-cycle 
variation over 12 months (d) 
 
Absent No bleeding 
Regular Variation ±2-20 
Irregular Variation>20 
Duration of flow (d) 
 
Prolonged >8.0 
Normal 4.5-8.0 
Shortened <4.5 
Volume of monthly blood loss (ml) 
 
Heavy >80 
Normal 5-80 
Light <5 
d-days; ml-milliliters; Table adapted from Munro et al. (2012). 
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Table 1.3: Discarded terminologies and accepted abbreviations (FIGO) 
DISCARDED TERMINOLOGIES 
ACCEPTED ABBREVIATIONS 
Abbreviation Full terminology 
Dysfunctional uterine bleeding 
Epimenorrhagia  
Epimenorrhea 
Functional uterine bleeding 
Hypermenorrhea 
Hypomenorrhea 
Menometrorrhagia 
Menorrhagia 
Metrorrhagia 
Metropathica hemorrhagica 
Oligomenorrhea 
Polymenorrhagia 
Polymenorrhea  
Uterine hemorrhage 
AUB Abnormal uterine bleeding 
HMB Heavy menstrual bleeding 
HPMB 
Heavy and prolonged 
menstrual bleeding 
IMB Intermenstrual bleeding 
PMB Postmenopausal bleeding 
  
  
  
  
  
Table adapted from Garza-Cavazos and de Mola (2012); Munro et al. (2012).  
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Table 1.4: Definitions of terms for uterine bleeding (FIGO)  
CHARACTERISTICS TERMINOLOGY DESCRIPTION 
Volume Heavy menstrual bleeding 
Excessive menstrual blood loss which 
interferes with the women’s physical, 
emotional, social and material quality of 
life, which can occur alone or in 
combination with other symptoms 
Regularity  
Irregular menstrual 
bleeding 
A range of varying lengths of bleeding-
free intervals exceeding 20 days within 
one 90-day reference period 
Absent menstrual 
bleeding  
No bleeding in a 90-day reference 
period 
Frequency 
Infrequent menstrual 
bleeding 
Bleeding at intervals >38 days apart (1 
or 2 episodes in a 90-day period) 
Frequent menstrual 
bleeding 
Bleeding at intervals <24 days apart 
(>4 episodes in a 90-day period) 
Duration 
Prolonged menstrual 
bleeding 
Menstrual blood loss which exceeds 8 
days in duration 
Shortened menstrual 
bleeding 
Menstrual bleeding less than 3 days in 
duration 
Non-menstrual 
bleeding 
Intermenstrual 
Irregular episodes of bleeding, often 
light and short, occurring between 
otherwise fairly normal menstrual 
periods 
Post-coital Bleeding post-intercourse 
Premenstrual, post-
menstrual spotting 
Bleeding that may occur on a regular 
basis for one or more days before or 
after the recognized menstrual period 
Bleeding outside 
reproductive age 
Post-menstrual 
bleeding 
Bleeding occurring more than one year 
after the acknowledged menopause 
Precocious 
menstruation 
Bleeding occurring before the age of 9 
years 
Acute or chronic 
AUB 
Acute AUB 
An episode of bleeding in a not 
pregnant woman of reproductive age, 
that is of sufficient quantity to require 
immediate intervention to prevent 
further blood loss 
Chronic AUB 
Bleeding that is abnormal in duration, 
volume, and/or frequency and has 
been present for most of the last 6 
months 
Table adapted from Munro et al. (2012); S. Singh et al. (2013). 
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The most common AUB is HMB or menorrhagia. While HMB can be the 
presenting symptom of an underlying bleeding disorder, women with bleeding 
disorders commonly suffer from HMB (Kadir and Davies, 2013). Table 1.5 lists 
the prevalence of bleeding disorders in women with HMB. Therefore menstrual 
history, clinical impression and laboratory tests are utilised often alongside other 
objective questionnaires to differentiate between them (James, 2010). 
Table 1.5: Prevalence of bleeding disorders in women with HMB  
BLEEDING DISORDER PREVALENCE 
von Willebrand disease (vWD)  5-20% (Overall estimate 13%) 
Platelet dysfunction <1-47% 
Factor XI deficiency <1-4% 
Haemophilia carriage <1-4% 
Rare factor deficiencies <1% 
Table adapted from James (2010). 
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1.4 HEAVY MENSTRUAL BLEEDING (MENORRHAGIA) 
HMB can be defined as excessive menstrual blood loss which interferes with 
the woman’s physical, emotional, social and material quality of life, and which 
can occur alone or in combination with other symptoms (NICE, 2007). 30% of 
reproductive age women are affected by HMB, with 1 in 20 women consulting a 
general practitioner (Garside et al., 2004; Collins and Crosignani, 2007). By the 
age of 60 years, 20% of women in the UK have had a hysterectomy, HMB being 
the underlying cause in at least 50-70% (El-Hemaidi et al., 2007). This results in 
an enormous economic burden on the National Health Service (NHS), with 
annual treatment costs of > £65 million in the UK. HMB significantly affects the 
well being of otherwise healthy women with 3.5 million working days lost 
annually (Collins and Crosignani, 2007). While HMB may result from clinical 
conditions (Hapangama and Bulmer, 2015), approximately 50% of cases 
remain unexplained and current treatment options such as oral contraceptives, 
intrauterine systems, endometrial ablation, hysterectomy, etc. affect fertility. 
Studies of the mechanisms that underlie HMB are therefore central not only to 
the understanding of this common condition but also to the possible 
development of new, less invasive and more effective treatments. 
1.4.1 Mechanisms and regulation 
One or more of the following processes may play a role in HMB: elevation in or 
premature breakdown of endometrial tissue and vessels at the beginning of 
menstruation; increased blood flow rate through structurally impaired, aberrant 
blood vessels; and failure of repair at the end of menstruation. Previous studies 
have shown that women with HMB bleed longer but, more critically, exhibit a 
significantly increased (3-4 fold increase) rate of blood loss (flow) (Abberton et 
al., 1999b). Consistent with this Hurskainen et al. (1999) showed that women 
with HMB had a lower uterine artery pulsatility index (PI) than normal, since a 
higher mean velocity of blood flow results in decreased PI. Correlation between 
MBL and PI suggests that abnormal structure and or function of the uterine 
spiral arteries, including inefficient vasodilation or vasoconstriction may 
contribute to HMB.  
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The apparent role of spiral arteries in HMB raises questions regarding the 
underlying mechanisms. Failure of spiral arteries to control the rate of blood 
loss could be due to a failure in normal vasoconstriction, which in turn may be 
explained by abnormal spiral arteriogenesis, together with impaired VSMC 
maturation and function. Further evidence of the crucial role of spiral arterioles 
and VSMCs comes from a report that in women with HMB, VSMC proliferation 
in the spiral and straight arterioles is significantly reduced in the mid and late 
secretory phase (Abberton et al., 1999b). This suggests that the spiral arterioles 
in HMB may have an altered growth pattern, since it is in the secretory phase 
that spiral arterioles grow and gain their distinctive coiled structure. 
Interestingly, the absolute wall thickness and αSMA staining pattern did not 
differ between control and HMB groups. However, it is possible that 
differentiation of VSMCs in the endometrial spiral arterioles is altered in HMB. 
Abberton et al. (1999a) reported that MyHC, which is a later marker for VSMC 
differentiation, was expressed at significantly lower levels in the early secretory 
phase in women with HMB, suggesting that VSMCs mature at different rates in 
the spiral arterioles of HMB endometrium compared with control endometrium. 
It is therefore of interest to determine whether differences in temporal and 
spatial patterns of staining of VSMC differentiation markers underlie HMB.  
Given the vital role of various growth factors in the initiation and formation of 
endothelial tubes, recruitment of cells to the developing vessel and 
differentiation into smooth muscle cells (Smith, 1998; Lash et al., 2012), it is 
probable that they may play a role in HMB. Of particular interest is the TGF-β1 
family and its receptors, which stabilize newly formed vessels and also play a 
role in VSMC differentiation. Additionally, the PDGF family and their receptors 
also play a significant role in vascular maturation. Amongst these growth factors 
which form homo and heterodimers, PDGF-BB is of particular interest since it 
has been shown to have a role in vessel dilation in mice (Lindahl et al., 1997; 
Betsholtz, 2004). In terms of endometrial vessel formation an important 
question in this context is how these factors link to exert an overall effect on 
angiogenesis and how these may be altered in HMB. 
In the endometrium, angiogenesis involves tightly regulated interactions 
between the ECs and VSMCs, an alteration in which may result in HMB. It has 
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been reported that ECs proliferate more in women with HMB than in controls 
and endometrial spiral arterioles remain less covered by VSMCs (Kooy et al., 
1996; Smith, 2001). However, our understanding of the underlying mechanisms 
remains unclear. With the advent of techniques such as live-cell imaging it is 
now possible to study interactions even at a single cell or molecule level. It 
would therefore be of immense significance to study interactions between ECs 
and VSMCs in vitro, and importantly in the presence of factors that may play a 
potential role in vascular maturation or whose absence may have been 
implicated in HMB. For example, how do ECs interact with VSMCs and does 
exposure to proangiogenic factors such as VEGF-C, PDGF-BB or TGFβ1 affect 
their normal interaction? 
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1.5 HYPOTHESES AND AIMS 
1.5.1 Hypotheses 
Given the important role of uterine blood vasculature and the potential effects of 
endometrial leukocytes and angiogenic growth factors in HMB, we hypothesised 
that (illustrated in Figure 1.15): 
1. Endometrial blood vessel structure and development is altered in women 
with HMB  
 
2. Altered endometrial leukocytes and/or staining for angiogenic growth factors 
in the uterine tissue layers may underlie HMB 
 
3. Use of an in vitro assay will aid investigation of the roles of different 
angiogenic growth factors in EC-VSMC association and tubule formation and 
possible future testing of potential interventions 
1.5.2 Aims 
To test the above hypotheses the aim was to: 
1. Determine any impairment in uterine blood vessel development with respect 
to its constituents (ECs, VSMCs and ECM) in women with HMB 
 
2. Determine whether the distribution of endometrial leukocyte populations and 
angiogenic growth factors PDGF-BB and TGF-β1 and their receptors are 
altered in the uterine tissue layers of women with HMB 
 
3. Develop an in vitro assay to investigate endothelial and vascular smooth 
muscle cell association and tubule formation 
 
4. Determine the roles of PDGF-BB and TGF-β1 in endothelial and vascular 
smooth muscle cell association in vitro 
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Figure 1.15: Factors involved in dysregulation of angiogenesis underlying HMB. This 
study aims to investigate the factors highlighted in orange. ESP-early secretory phase; 
MSP-mid secretory phase; LSP-late secretory phase; PI- pulsatility index.  
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2 MATERIALS AND METHODS 
This chapter specifies the general materials and methods used. The detailed 
description of methods for specific studies is discussed in appropriate chapters 
(sections 3.3, 4.3, 5.3, 6.3). 
2.1 MATERIALS 
2.1.1 Tissue materials and clinical data 
2.1.1.1 Ethical considerations 
Tissues and anonymised clinical data used in this study were obtained from 
patients at the Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS 
Foundation Trust, Newcastle upon Tyne or at the Liverpool Women’s Hospital, 
Liverpool with written informed consent (Appendix A1) in compliance with the 
Helsinki Declaration. In Newcastle, research nurses or midwives from the 
Reproductive Health and Childbirth Research team selected eligible patients on 
the gynaecological operating list and obtained their written informed consent. 
Collection of the endometrial samples was approved by Newcastle and North 
Tyneside Research Ethics Committee (Ref:10/H0906/71) and Liverpool Adult 
Ethics committee (Ref:09/H1005/55). 
2.1.1.2 Endometrium for immunohistochemistry or explant culture 
Endometrial biopsies were obtained from 106 women undergoing hysterectomy 
at the Royal Victoria Infirmary, Newcastle upon Tyne or at the Liverpool 
Women’s Hospital, Liverpool. Following surgery the hysterectomy specimen 
was collected from the operating theatre by a member of the research team and 
transported to the Pathology Department. Here, a histopathologist inspected the 
specimen, excluded any suspicion of significant endometrial or cervical 
pathology and excised a block of endometrium or myometrium with overlying 
endometrium measuring approximately 1x1cm. The biopsy was collected in a 
sterile container, transported to the research laboratory and immediately fixed in 
10% neutral buffered formalin or further dissected into smaller sections used for 
explant cultures. For some cases where only a small endometrial research 
sample was obtained, archival paraffin blocks were retrieved and used for the 
  
 
2.1 MATERIALS 
 
  
62
respective immunohistochemical studies. The control group included fertile 
women without any uterine pathology potentially associated with endometrial 
abnormality (e.g. endometriosis, adenomyosis, intramural leiomyomata >2cm, 
any submucosal leiomyomata, history of heavy irregular bleeding or HMB) 
undergoing hysterectomy usually for prolapse, cystocele, rectocele, urinary or 
stress incontinence. The experimental group consisted of women with a history 
of HMB with unknown aetiology, defined as ‘excessive menstrual blood loss 
which interferes with the woman’s physical, emotional, social and material 
quality of life, and which can occur alone or in combination with other 
symptoms’ (NICE, 2007). Any women who had received hormone treatment 
within 3 months prior to the operation were excluded from the study. 
Demographics of patients in the control and HMB groups as obtained from 
sample information form (Appendix A2) are shown in Figure 2.1 and 
medications taken by some patients are detailed in Appendices A3 and A4. 
2.1.1.3 Saphenous veins for in vitro cell association study 
Saphenous veins (SVs) were obtained from 9 patients undergoing coronary 
artery bypass graft surgery at the James Cook University Hospital, 
Middlesbrough. Demographic information obtained on these patients is shown 
in Table 2.1. Following surgery any surplus SVs were collected in a sterile 
container and transported to the research laboratory on ice. They were 
processed for endothelial and vascular smooth muscle cell extraction (section 
2.2.6.7).  
Table 2.1: Demographic details of patients used in the cell association study 
CHARACTERISTICS PATIENT (N=9) 
Age (Years) Mean (±SEM) 67 ±3 
Sex (%) Male: 89 
Female: 11 
Smoking History (%) No: 33 
Yes: 22 
Ex-smoker: 45 
Diabetes (%) No: 78 
Yes: 22 
Hypertension (%) No: 44 
Yes: 56 
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Figure 2.1: Demographic details of control and menorrhagia groups. In A and B the 
stacked bars represent number of patients in each of control and heavy menstrual 
bleeding (HMB) groups, while the different colours represent their ethnic origin or 
smoking history, respectively. In C, D and E the box plots (median indicated with black 
line, within each box) compares the age range, body mass index (BMI) and parity 
between control and HMB groups, respectively. Chi-square test (ethnicity, smoking 
history), Fisher’s test followed by unpaired Student’s t-test (age and BMI) and Mann-
Whitney test (parity) indicated no statistical significance (P>0.05). Variation in patient 
number (N) in (A-E) is due to availability of different information. 
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2.2 METHODS 
2.2.1 General 
All chemicals, reagents, plasticware and glassware used for tissue culture were 
sterile unless stated otherwise. 
2.2.1.1 Sterilization 
Sterilization was carried out in an autoclave (Priorclave, London, UK) with moist 
heat at 121°C for 40 min to sterilize liquid or in a sterilizing oven at 185°C for 90 
min for glassware. 
2.2.1.2 Water 
All tissue culture media and solutions were prepared using double distilled, 
sterilised water. Non tissue culture reagents and solutions were prepared in 
distilled water. PCR reagents were diluted using nuclease-free water (♯AM9932, 
Life Technologies, Paisley, UK). 
2.2.1.3 Surface decontamination 
Work surfaces were decontaminated before and after experiments with 70% 
ethanol or RNaseZap (♯AM9780, Life Technologies, Paisley, UK) and wiped dry 
with paper towel as appropriate.  
2.2.1.4 Incubation 
All cell and tissue culture incubations were carried out in a moisture enhanced 
incubator, supplemented with 5% CO2 at 37°C. 
2.2.2 Human tissue preservation 
Preservation of cells and tissues in their natural state is central to all histological 
techniques. To this end, tissue blocks or sections are immersed in a fixative 
fluid (e.g. formalin), which prevents autolysis, necrosis of the excised tissue and 
makes macromolecules resistant to disintegration by water and other liquids, 
thereby stabilising both intra and inter-cellular structures within the tissue. 
Moreover, fixative fluids act as anti bacterial agents. 
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2.2.2.1 Preparation of formalin fixed paraffin embedded (FFPE) tissue  
Following tissue collection, endometrial or myometrial biopsies were transported 
to the laboratory and immediately fixed in 10% neutral buffered formalin (NBF), 
which is the most common fixative used for histopathology. It fixes tissue by the 
addition of crosslinking methylene bridges to the side chains of basic amino 
acids. This results in low macromolecule permeability, while largely not affecting 
structures of protein molecules. Additionally formaldehyde molecules are small 
in size resulting in faster penetration. This makes it applicable for fixation of 
both small and large tissues. Although NBF penetrates quickly, the cross-linking 
reaction is a slow process. Formalin fixation of tissue was therefore performed 
at room temperature for 24-48 hr following which the tissue was routinely 
processed, embedded in molten paraffin wax and allowed to set in a plastic 
cassette. 3µm tissue sections were cut using a microtome, mounted on APES-
coated glass slides (Appendix B), dried overnight in an oven at 37°C, labelled 
and stored appropriately in a slide storage unit for a short time until use. 
2.2.2.2 Haematoxylin and Eosin (H&E) staining 
Haematoxylin and eosin (H&E) staining is the commonest staining system used 
in the histology laboratory. When haematoxylin dissociates in water, its positive 
ion binds to negatively charged (basophilic) phosphate groups of nucleic acids 
(DNA and RNA) in the nuclei of cells, colouring them blue. On the other hand, 
when eosin dissociates in water, its negative ion combines non-specifically with 
positively charged (acidophilic) proteins in the cell cytoplasm and extracellular 
matrix, colouring them pink.  
H&E staining was used for initial assessment and staging of FFPE endometrial 
or myometrial tissue. FFPE sections on APES-coated glass slides were 
dewaxed in xylene for 5 min, rehydrated through descending concentrations of 
ethanol (99%, 95%, 70%) and washed in running tap water. Slides were then 
immersed in Mayer’s haematoxylin for approximately 90 sec to stain the cell 
nuclei blue and then washed in running tap water. Slides were placed for 1 min 
in Scott’s tap water substitute for further development of the blue stain. After 
washing in running tap water, the slides were placed for 2 min in eosin to stain 
the cytoplasm pink. The slides were washed further in running tap water, 
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dehydrated sequentially through ascending concentrations of ethanol (70%, 
95%, 99%), cleared in xylene and mounted using DPX synthetic mounting resin 
and glass cover slips. Figure 2.2 shows the human endometrium at the different 
stages of the menstrual cycle as observed using H&E staining. 
2.2.2.3 Preparation of frozen tissue samples 
Myometrial tissue to be frozen was placed on small pieces of filter paper. 2-
methylbutane also called Isopentane (♯10093, AnalaR, VWR International) was 
carefully poured into a metal beaker, which was then lowered into a flask 
containing liquid nitrogen for 1-2 min to cool the isopentane. The tissue on filter 
paper was carefully lowered and held in the cooled isopentane for 
approximately 2-3 min, carefully using forceps. The frozen tissue was placed 
into labelled freezer bags or cryotubes (♯377267, Fisher Scientific) and 
immediately stored at -80°C until use. 
2.2.3 Immunohistochemistry 
Immunohistochemistry (IHC), first reported in 1941 (Coons et al., 1941), is a 
technique used to detect antigens or proteins with specific primary or secondary 
antibodies tagged with a visible label. It is an extremely useful technique, which 
allows detection and localisation of cellular components within tissue. In this 
study IHC was performed on FFPE samples as described in section 2.2.2.1. 
Although various labelling and detection systems are used in IHC, the system 
used in this study was the avidin-biotin (ABC) technique as described below. 
2.2.3.1 Avidin-biotin complex (ABC) method 
3µm sections of FFPE tissue mounted on APES-coated glass slides were 
dewaxed for 5 min in xylene, rehydrated sequentially in ethanol (99%, 95%, 
70%) and washed in running tap water. Following this the slides were immersed 
into 1.5% H2O2 in distilled water for 10 min to block any endogenous peroxidase 
activity. 
The slides were further washed in running tap water prior to the antigen retrieval 
process. Antigen retrieval is essential to retrieve epitopes masked by protein 
crosslinking caused by fixation. In this study either an enzyme induced epitope 
retrieval (using Trypsin-CaCl2 working solution, Appendix B) or a Heat-Induced 
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Figure 2.2: Haematoxylin and eosin stained human endometrium (A, C, E, G; 100x 
original magnification) and endometrial glands (B, D, F, H; 400x original magnification). 
Arrows indicate respective changes at the different stages of the menstrual cycle. 
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Epitope Retrieval (HIER) method utilising various sources of heat (pressure 
cooker, microwave) was applied for antigen retrieval. The detailed antigen 
retrieval conditions used in this study are listed in Table 2.2. 
Following antigen retrieval the slides were once again washed in TBS (pH7.6) 
for 5 min. When using fixed frozen samples, antigen retrieval was not required. 
Slides were retrieved from -20°C, brought to room temperature, washed in TBS 
(pH 7.6) and IHC was carried out as for FFPE sections as follows.  
The sections were immunolabelled using an avidin-biotin (ABC) technique. This 
technique depends on secondary antibodies conjugated to biotin, which link 
tissue-bound primary antibody to an avidin-biotin-reporter enzyme complex. 
Avidin forms large complexes containing multiple copies of the biotinylated 
reporter enzyme, horseradish peroxidase (HRP). An HRP substrate is then 
added, which in the presence of H2O2 is converted into a coloured insoluble 
reaction product detectable in the tissue using light microscopy. The principle of 
the streptavidin-biotin complex (ABC) method is outlined in Figure 2.3A. 
The tissue sections were outlined using a hydrophobic barrier pen (♯H-4000, 
Vector Laboratories, Peterborough, UK) and overlaid with blocking serum for 10 
min at room temperature, to block non-specific binding sites in the tissue 
sections. Following this the blocking serum was tipped off and appropriately 
diluted primary antibody was applied. The incubation time and temperature 
used was antibody dependant. Details of the primary antibodies used (dilution, 
incubation times, temperatures) in this study are listed in Table 2.2. The slides 
were washed 2 x 5 min in TBS (pH7.6) on a rocking platform and secondary 
antibody was applied to the sections and incubated at room temperature for 30 
min. Following this the slides were washed 2 x 5 min in TBS (pH7.6) and 
Vectastain ABC reagent was applied and incubated at room temperature for 30 
min. Vectastain Elite secondary antibody and ABC reagents are detailed in 
Table B5 and Table B6. The slides were washed once again 2 x 5 min in TBS 
(pH7.6) and the reaction was developed using 3,3'-Diaminobenzidine (DAB) 
solution (Appendix B) for approximately 1 min. The slides were then washed in 
running tap water, counterstained with Mayer’s haematoxylin for 1 min, followed 
by further development of the blue stain in Scott’s tap water substitute for 30 
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Figure 2.3: (A) The avidin-biotin complex (ABC) method for immunohistochemical 
staining. (B) Formalin fixed paraffin embedded 3µm section of human kidney positively 
stained for collagen-IV using ABC method (200x original magnification). 
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sec. Finally, the slides were dehydrated in ascending concentrations of ethanol 
(70%, 95%, 99%), cleared in xylene and mounted using DPX synthetic 
mounting resin and glass cover slips. Figure 2.3B shows collagen-IV staining in 
human kidney as observed using the ABC immunolabeling technique.  
2.2.3.2 Double immunohistochemical labelling 
Double IHC was performed sequentially using the ABC method and two 
different primary antibodies. Two different combinations of visualization was 
used; either the first immunostain was visualized using DAB solution containing 
0.01% H2O2 (Appendix B) to give a brown reaction product and the second with 
Vector SG substrate kit for peroxidase to give a silver-grey reaction product 
(Appendix B, Table B8), or the first using Vector SG substrate kit for peroxidase 
(Appendix B, Table B8), and the second with Vector NovaRED substrate kit for 
peroxidase (Appendix B, Table B7). Appropriate positive and no primary 
negative controls were performed for each antibody run, including single 
immunohistochemistry labelling with each antibody used. Negative controls 
showed no immunostaining for any of the protocols used. 
2.2.3.3 Optimisation of antibodies 
All antibodies were optimised using appropriate positive and negative controls 
prior to staining the tissue of interest using different combinations of antibody 
dilutions and antigen retrieval methods. The final parameters were selected on 
the basis of strongest specific reactivity with the least background for each 
antibody used. 
2.2.3.4 Quantification of immunohistochemistry 
Immunostained slides were blinded independently before assessment. Tissue 
sections were examined using a Nikon Eclipse 80i microscope with a 20x or 40x 
objective and 10x eyepiece, as appropriate. Depending on the study question, 
images were quantified either by counting positively stained cells, a modified 
quick score method or measurement of the area of positive staining using 
ImageJ (Version 1.46, NIH, Maryland, USA), or NIS Elements Viewer, NIS 
Elements Ar Viewer (NIKON Instruments Inc., Surrey, UK). The modified 
‘Quickscore’ method (Schiessl et al., 2009) took into account both 
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Table 2.2: Primary antibodies used for immunohistochemistry 
ANTIBODY CATALOGUE NO: CLONE HOST ANTIGEN RETRIEVAL DILUTION INCUBATION 
αSMA1 M0851 1A4 Mouse  None 1:200 RT, 60 min 
Caldesmon1 M3557 h-CD Mouse  PC in citrate buffer pH 6.0, 1 min 1:100 RT, 60 min 
Calponin1 M3556 CALP Mouse Trypsin buffer pH7.8, 37°C, 10 min  1:80  RT, 30 min 
CD32 NCL-L-CD3-565 LN10 Mouse  PC in citrate buffer pH 6.0, 1 min 1:100 RT, 60 min 
CD82 NCL-CD8-295 1A5 Mouse  PC in EDTA buffer pH 8.0, 1 min 1:100 RT, 60 min 
CD142 NCL-CD14-223 7 Mouse PC in citrate buffer pH 6.0, 1 min 1:20 RT, 60 min 
CD312 NCL-CD31-1A10 1A10 Mouse PC in citrate buffer pH 6.0, 1 min 1:20 RT, 60 min 
CD341 M7165 QBEnd-10 Mouse PC in citrate buffer pH 6.0, 1 min 1:250 RT, 60 min 
CD562 NCL-CD56-1B6 1B6 Mouse PC in citrate buffer pH 6.0, 1 min 1:50 RT, 60 min 
CD832 NCL-CD83 1H4b Mouse PC in citrate buffer pH 6.0, 1 min 1:40 4°C, ON  
Desmin2 NCL-DES-DERII DE-R-11 Mouse Trypsin buffer pH7.8, 37°C, 10 min 1:50 RT, 60 min 
Collagen-IV2 COLL-IV PHM-12 Mouse Trypsin buffer pH7.8, 37°C, 10 min 1:60 RT, 60 min 
F8RA1 M0616 F8/86 Mouse Trypsin buffer pH7.8, 37°C, 10 min 1:50 RT, 60 min 
Fibronectin2 NCL-FIB 568 Mouse Trypsin buffer pH7.8, 37°C, 10 min 1:100 RT, 60 min 
1Dako Cytomation, Cambridgeshire, UK; 2Leica Laboratories, Newcastle, UK; 3Abcam Cambridgeshire, UK; 4Sigma Chemical Co. Dorset, UK; pd-prediluted, RT-
Room temperature; PC-Pressure cook, ON-overnight, MW-microwave. 
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Table 2.2 (continued): Primary antibodies used for immunohistochemistry 
ANTIBODY CATALOGUE NO: CLONE HOST ANTIGEN RETRIEVAL DILUTION INCUBATION 
FOXP33 ab20034 236A/E7 Mouse PC in EDTA buffer pH 8.0, 1 min 1:50 RT, 60 min 
Ki672 NCL-Ki67-MM1 MM1 Mouse  PC in citrate buffer pH 6.0, 1 min 1:50 RT, 60 min 
Laminin2 NCL-LAMININ LAM-89 Mouse  Trypsin buffer pH7.8, 37°C, 10 min 1:200 RT, 60 min 
Myosin 
heavy chain4 M7786 hSM-V Mouse PC in citrate buffer pH 6.0, 1 min 1:600 RT, 60 min 
Osteopontin3 ab8448 N/A Rabbit None 1:100 RT, 60 min 
PDGF-BB3 ab9704 N/A Rabbit MW in citrate buffer pH 6.0, 2 x 5 min 1:20 RT, 60 min 
PDGFRα3 ab61219 N/A Rabbit PC in citrate buffer pH 6.0, 1 min 1:100 RT, 30 min 
PDGFRβ3 ab15502 N/A Rabbit PC in citrate buffer pH 6.0, 1 min pd RT, 60 min 
Smoothelin3 ab8969 R4A Mouse  PC in citrate buffer pH 6.0, 1 min 1:100 RT, 60 min 
TGFβ13 ab92486 N/A Rabbit PC in citrate buffer pH 6.0, 1 min 1:50 RT, 60 min 
TGFβRI3 ab31013 N/A Rabbit PC in EDTA buffer pH 8.0, 1 min 1:50 RT, 60 min 
TGFβRII3 ab78419 MM0056-4F14 Mouse None 1:75 RT, 60 min 
1Dako Cytomation, Cambridgeshire, UK; 2Leica Laboratories, Newcastle, UK; 3Abcam Cambridgeshire, UK; 4Sigma Chemical Co. Dorset, UK; pd-prediluted, RT-
Room temperature; PC-Pressure cook, ON-overnight, MW-microwave, N/A- not applicable. 
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percentages of vessels stained with a given antibody (1=0-25%, 2>25-50%, 
3>50-75%, 4>75-100%) and the staining intensity for each percentage 
(0=negative, 1=weak, 2=moderate, 3=strong). The percentage and intensity 
scores were then multiplied and summed to give a range of possible scores 
between 0-12. For example: negative staining in 25% of a given cell type (0×
1=0), weak staining in 50% (1×2=2) and moderate staining in 25% (2×1=2), 
would give a total score of (0+2+2)=4.  
2.2.4 Lectin histochemistry 
FFPE sections (3µm) were dewaxed in xylene, rehydrated through descending 
concentrations of alcohol (99%, 90%, 70%) and incubated in 1% H2O2 in water 
for 10 min to block endogenous peroxidase activity. Enzyme induced antigen 
retrieval was carried out at 37°C in Trypsin-CaCl2 working solution for 15 min 
(Appendix B). All washes and incubation were performed in TBS (pH 7.6) at 
room temperature. Sections were treated with rabbit serum (♯PK-6100, 
Vectastain Elite ABC kit; Vector Laboratories) for 10 min to block non-specific 
binding. Following this, the sections were incubated with biotinylated 
Europaeus-Agglutinin I (UEA-I) lectin diluted 1:20 in TBS (pH 7.6) for 60 min 
(♯L8262, Sigma-Aldrich Co.). The sections were further washed and incubated 
for 30 min with streptavidin horseradish peroxidase (HRP) diluted 1:100 in TBS, 
pH7.6 (♯P0397, Dako Cytomation, Cambridgeshire, UK). The sections were 
then washed in TBS (pH7.6) and the reaction was developed using DAB 
solution (Appendix B) for approximately 1 min. The sections were then lightly 
counterstained with Mayer’s haematoxylin for 30 sec, dehydrated in ascending 
concentrations of ethanol (70%, 95%, 99%), cleared in xylene and mounted 
using DPX synthetic mounting resin and glass cover slips. 
2.2.5 Immunofluorescence 
Immunofluorescence (IF), based on the works of Coons and Kaplan (Coons et 
al., 1941; Coons and Kaplan, 1950), is a common laboratory technique used to 
investigate both levels and localisation of proteins within cells or tissue. This 
technique is applicable to both fresh and fixed samples. Immunofluorescent 
labelling can be either direct, where the primary antibody against the molecule 
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of interest is directly conjugated to a fluorescent dye, or indirect, where the 
primary antibody is unlabelled and requires a fluorescently tagged second anti-
immunoglobulin antibody directed towards the primary antibody. Fluorescent 
dyes are molecules with luminescent properties, which absorb and emit light at 
different wavelengths. Commonly used dyes are Fluorescein isothiocyanate 
(FITC), sulforhodamine 101 acid chloride (Texas Red), Tetramethylrhodamin 
(TRITC), 4', 6-diamidino-2-phenylindole (DAPI), etc.  
In this study, indirect IF was used to determine proportion of cells expressing 
different proteins on 8-well BD Falcon chamber slides (♯354108, SLS Ltd., 
Yorkshire, UK) containing vascular smooth muscle cells grown overnight on 
matrigel. Following 24 hr culture, medium from the chamber slides was 
discarded and the cells were washed in PBS (pH7.2), fixed in 99% ethanol for 
10 min at room temperature, washed in PBS (pH7.2), air dried for approximately 
10 min, wrapped in foil and frozen at -20°C until IF was performed. Prior to 
immunolabeling, the slides were removed from the -20°C freezer and brought to 
room temperature. They were washed three times in PBS (pH7.2) for 5 min 
each, overlaid with the diluted primary antibody of interest (Table 2.3) and 
incubated for 30 min at room temperature. Following this the slides were again 
washed three times in PBS (pH7.2) for 5 min each, overlaid with the diluted 
secondary antibody, conjugated with fluorescent dye FITC (♯F1-2000, Vector 
Laboratories) or Texas Red (♯T1-2000, Vector Laboratories) and incubated for 
30 min at room temperature. The slides were washed twice in PBS (pH7.2) for 5 
min, following which the chamber was removed from the slide using the 
chamber removal device provided, washed for a further 5 min in PBS (pH7.2) 
and mounted using Vectashield ultramount aqueous permanent mounting 
medium with DAPI (♯H1200, Vector Laboratories) and glass cover slips. The 
slides were left to dry wrapped in foil at 4°C in the dark, until imaging was 
performed. Figure 2.4 illustrates the basic steps in immunofluorescent staining.  
Table 2.3: Primary antibodies used for immunofluorescence 
 
ANTIBODY CATALOGUE NO: CLONE HOST DILUTION 
1  Caldesmon1 M3557 h-CD Mouse  1:100 
2 Calponin1 M3556 CALP Mouse 1:100 
1Dako Cytomation, Cambridgeshire, UK 
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2.2.6 Tissue and cell culture 
All tissue and cell culture was performed in a BioMAT2 Class-II Microbiological 
Safety Cabinet (CAS, Manchester, UK) using aseptic technique. Cells and 
tissues were cultured under normal growth conditions in a humidified incubator 
at 37°C, supplemented with 5% CO2 (inCu saFe IR Sensor CO2 incubator, 
Panasonic, Leicestershire, UK).  
2.2.6.1 Cell count 
Cell concentration was determined using a Neubauer haemocytometer (VWR 
International, Leicestershire, UK) and an inverted light microscope (Olympus 
CK2, Olympus, Southend-on-Sea, UK) at 200x magnification. Trypsinised cells 
were suspended in 1ml appropriate culture medium. 10µl cell suspension was 
pipetted onto the counting grid of the haemocytometer. The total number of 
cells (α) was counted by adding the number of cells in the outer four squares 
and the centre square. Cell concentration was determined by the following 
equation: 
Cell	concentration	ml =
α
20
× 10 
2.2.6.2 Cell culture 
The routine cell culture method described in this section is applicable to all cells 
used in this study. Cells were seeded into 25cm2 T25 plastic cell culture flasks 
with filtered caps (♯690175, Greiner Bio-One, Gloucestershire, UK) and allowed 
to reach 90% confluence as assessed by an inverted light microscope 
(Olympus CK2, Olympus, Southend-on-Sea, UK) using 10x objective and 10x 
eyepiece. Once confluent, adherent cells in the T25 flasks were washed with 
sterile PBS (pH7.4), followed by a 3-5 min incubation in 1x Trypsin-EDTA 
solution containing 0.5g/l porcine trypsin and 0.2g/l EDTA  (♯T3924, Sigma- 
Aldrich Co.) at 37°C, until cells were detached. The trypsinised cells were 
decanted into a 15ml universal container and cell culture medium was added to 
inactivate the trypsinisation reaction. The cell suspension was centrifuged at 
200g for 5 min (MSE Mistral2000 centrifuge, MSE Ltd., London, UK) to separate 
the cells from suspension. The supernatant was discarded and the cell 
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Figure 2.4: (A) Immunofluorescent staining of 8-well chamber slides. (B) Ethanol fixed, 
frozen human saphenous vein derived vascular smooth muscle cells positively stained 
for αSMA (FITC-green) and nuclei (DAPI-blue), 200x original magnification. 
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pellet was re-suspended in the desired volume of appropriate culture medium 
before being passaged into a 75cm2 T75 plastic cell culture flask with filtered 
caps (♯658175, Greiner Bio-One). Serial passages were carried out when cells 
were 90% confluent and media was replaced every 2-3 days. In order to assess 
the purity of each cell type, cell characterisation (section 2.2.6.3) was performed 
after every two passages. 
2.2.6.3 Cell characterisation 
Primary cell cultures are mortal and therefore can be passaged a finite number 
of times before entering senescence. Moreover, these cells may de-differentiate 
and lose their inherent characteristics during serial passaging. The number of 
times the cells can be passaged depends on various factors such as nutrients, 
culture conditions and manipulation during passaging. Therefore it is key to 
assess the purity of the cells during sequential passaging by cellular 
characterisation. 
Cells to be characterised were added to approximately 4 wells of an 8-well BD 
Falcon chamber slide. They were allowed to settle down for at least 5 hr, 
following which medium from the chamber slides was discarded and the cells 
were fixed in 99% ethanol for 10 min at room temperature, air-dried for 
approximately 10 min, and immunostained using the ABC method (section 
2.2.3.1). 
Endothelial cells were characterised for Factor VIII related antigen (F8RA), 
CD31 and CD34, while vascular smooth muscle cells were characterised for 
alpha-smooth muscle actin (αSMA), h-Caldesmon, and myosin heavy chain. In 
this study, cells were included only if characterisation resulted in >90% positive 
cell population for specific primary markers. Details of primary antibodies and 
dilutions used are listed in Table 2.4. Figure 2.5 demonstrates human SV 
derived ECs and VSMCs were characterised at a specific passage. 
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Table 2.4: Primary antibodies used for immunohistochemistry on fixed frozen 
cells 
ANTIBODY CATALOGUE NO: CLONE HOST 
DILUTIO
N 
αSMA1 M0851 1A4 Mouse  1:200 
Caldesmon1 M3557 h-CD Mouse  1:100 
CD312 NCL-CD31-1A10 1A10 Mouse  1:200 
CD341 M7165 QBEnd-10 Mouse  1:250 
F8RA M0616 F8/86 Mouse  1:800 
Myosin heavy chain3 M7786 hSM-V Mouse  1:600 
1Dako Cytomation, Cambridgeshire, UK; 2Leica Laboratories, Newcastle, UK; 3Sigma Chemical 
Co. Dorset, UK 
2.2.6.4 Cryopreservation of cells 
Endothelial and vascular smooth muscle cells from SVs and cell lines were 
trypsinised using Trypsin-EDTA solution, centrifuged and the cell pellet was re-
suspended in 1ml RPMI 1640 complete medium (Appendix B). The cell 
suspension was added to a cryotube containing 1ml thawed cell freezing 
medium (Appendix B). The cryotube was slowly frozen in a Mr. Frosty freezing 
container (♯5100-0001, Fisher Scientific,) to prevent temperature shock, while 
achieving a very slow and optimal rate of cooling at -1°C/min and maintained for 
24 hr at -80°C. The cryotube was then transferred to a liquid nitrogen container 
for storage. 
Frozen cells were rapidly thawed at room temperature with gentle shaking. The 
cell suspension in freezing medium was added to 2ml appropriate culture 
medium in a 15ml universal container. This suspension was directly seeded into 
a T25 cell culture flask or centrifuged to collect the cell pellet, re-suspended in 
2ml appropriate culture medium and then seeded into a T25 cell culture flask. 
Culture medium was changed after 24 hr and cell culture was carried out as 
described in section 2.2.6.2.  
2.2.6.5 Human aortic endothelial cell line 
The human aortic endothelial cell line (PCS-100-011) was obtained from LGC 
Standards Ltd, Teddington, UK. This primary cell line isolated from human aorta 
has been tested for bacteria, yeast, mycoplasma Hepatitis B, Hepatitis C and 
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Figure 2.5: Characterisation of saphenous vein derived cells. Ethanol fixed, frozen 
human saphenous vein derived endothelial cells (A-D) and vascular smooth muscle 
cells (E-H) characterised for their respective markers at passage 4 (200x original 
magnification). 
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HIV. This cell line demonstrates ≥50% viability when thawed from 
cryopreservation. 
2.2.6.6 Human aortic vascular smooth muscle cell line 
The human aortic vascular smooth muscle cell line (T/G HA-VSMC CRL-1999) 
was obtained from LGC Standards Ltd. This primary cell line isolated from a 
Caucasian female aorta, has been tested for bacteria, yeast, mycoplasma 
Hepatitis B, Hepatitis C and HIV. 
2.2.6.7 Enzymatic disaggregation of human saphenous veins 
Segments from SVs, obtained during coronary bypass operation, were 
transported to the laboratory as described previously in section 2.1.1.3. Vein 
segments that were ≥ 2cm were selected as suitable for endothelial and 
vascular smooth muscle cell extraction. The principle steps used for isolation of 
endothelial and vascular smooth muscle cells are illustrated in Figure 2.6. 
Isolation of endothelial and vascular smooth muscle cells 
Once a vein was assessed as suitable for the study, it was removed from the 
container in a sterile Class II cabinet. The vein was flushed thoroughly three 
times with 500µl sterile PBS (pH 7.4) to remove red blood cells, placed in a petri 
dish (♯639160, Greiner Bio-One, Gloucestershire, UK) and constricted at one 
end using a sterile bulldog clip prior to enzymatic disaggregation.  
Endothelial cells form the inner lining of the veins; hence, the vein segment was 
first filled to slight distension with warmed endothelial cell digestion medium 
(Appendix B), constricted at both ends using sterile bulldog clips and incubated 
for 15 min at 37°C in the incubator. After incubation the bulldog clips were 
removed from the vein and the segment was flushed with 3-4ml sterile PBS (pH 
7.4) and the medium collected in a 15ml universal container. Pellets of 
enzymatically dislodged cells were collected by centrifugation of the flushed 
medium at 200g for 5 min. The supernatant was discarded and the cell pellet 
was re-suspended in 2ml endothelial cell culture medium (Appendix B), plated 
onto one well of a 6-well plate (♯657160, Greiner Bio-One) and cultured at 
37°C. 
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Figure 2.6: Enzymatic disaggregation for ECs or VSMCs from human saphenous 
veins. The incubation and separation and culture and characterisation steps are 
repeated two additional times for collection of VSMCs. 
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Once the vein was flushed with PBS, it was sealed at one end with a bulldog 
clip, filled again with endothelial cell digestion medium, sealed at both ends and 
incubated for a further 40 min at 37°C. The vein was then flushed with 3-4ml 
PBS and the medium was collected in a 15ml universal container. The cell 
pellet was collected by centrifugation at 200g for 5 min, re-suspended in 2ml 
endothelial cell culture medium, plated onto the next well of the 6-well plate and 
cultured at 37°C. 
Finally, the vein segment was sealed at one end with a bulldog clip, filled with 
vascular smooth muscle cell digestion medium (Appendix B), sealed at both 
ends and incubated for 50 min at 37°C in the incubator. The vein was then 
flushed with PBS and medium was collected into a 15ml universal container. 
The cell pellet was collected after centrifugation at 200g for 5 min, re-
suspended in 2ml vascular smooth muscle cell culture medium (Appendix B), 
plated onto the third well of the 6-well plate and cultured at 37°C. 
After 24 hr, medium in each well was replaced with 2ml appropriate EC or 
VSMC medium and incubated at 37°C until 90% confluence was reached. 
EC and VSMC culture and characterisation 
Once the cells were confluent in their individual wells, they were passaged into 
a T25 cell culture flask until confluent and further subculture and 
characterisation were carried out as described in section 2.2.6. 
Preparation of EC and VSMC cell treatments 
The human SV derived endothelial and vascular smooth muscle cells used in 
this study were treated with VEGFC, anti-VEGFC antibody, TGFβ1, anti-
TGFβ1, PDGF-BB or anti-PDGFBB antibody as described in Appendix B. 
Preparation of EC and VSMC cell culture supernatants 
SV derived endothelial and vascular smooth muscle cells were seeded onto 6-
well plates and cultured until confluence at 37°C in the incubator. Once 
confluent, the culture medium in each well was replaced with 2ml VEGFC, anti-
VEGFC, TGFβ1, anti-TGFβ1, PDGF-BB or anti-PDGFBB treatment medium 
and the cells were cultured for a further 24 hr at 37°C. Supernatants from each 
well were then collected into labelled sterile Eppendorf tubes and micro-
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centrifuged at 14.1rcf for 1 min. The supernatant was collected into 100µl 
aliquots, placed into labelled freezer bags and stored at -80°C until required, 
while the cell pellet was discarded.  
2.2.6.8 Endometrium and myometrium explant culture and treatment 
Endometrial biopsies with superficial myometrium obtained from women 
undergoing hysterectomy were transported to the laboratory (section 2.1.1.2). 
The excised tissue was further dissected into 5 approximately equal fragments 
using a scalpel (♯INS4684, Merck Millipore, Nottingham, UK) in a glass petri 
dish in a sterile Class II cabinet. 1-2 ml control medium, TGFβ1, anti-TGFβ1, 
PDGF-BB or anti-PDGFBB tissue treatment medium (Appendix B) was added 
to five separate wells of a 48-well plate (♯677180, Greiner Bio-One). Using a 
pair of forceps the tissue fragments were placed into the 5 wells and cultured for 
72 hr.  Individual treatment media were changed every 24 hr. After 72 hr the 
tissue fragments were removed from the plate, fixed immediately in neutral 
buffered formalin in five separately labelled containers and 3µm FFPE sections 
were prepared for immunohistochemistry (section 2.2.2.1). The basic steps 
used for endometrial explant culture are illustrated in Figure 2.7. 
2.2.7 Polymerase chain reaction 
Polymerase chain reaction (PCR), developed by Kary Mullis in 1986 (Mullis et 
al., 1986), is a revolutionary technique, which allows scientists to create billions 
of copies of a specific segment of DNA of interest (amplicons) in vitro.  
The ingenuity of this method lies in the fact that the key enzyme, DNA 
polymerase, is primer based and that the primers are heat resistant short pieces 
of single stranded DNA, which can be custom built to contain any sequence of 
nucleotides of interest in the laboratory. In a PCR reaction, two primers are 
designed such that they are complementary to the sequence of interest on both 
the coding and complementary DNA strands. The DNA polymerase attaches 
itself near one end of the primer and extends these primers by adding 
complementary nucleotides. 
Essentially a PCR experiment consists of three stages; (i) a denaturation step, 
where heating the reaction denatures double stranded DNA to form single 
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Figure 2.7: Human endometrial explant culture. 
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stranded DNA; (ii) an annealing step, where cooling the reaction leads to 
primers annealing to the single stranded DNA; and finally (iii) an extension or 
elongation step, where heating the reaction once again to a temperature 
optimal to the polymerase enzyme leads to synthesis of a new DNA strand 
complementary to the target sequence. Under optimal conditions, at each 
extension step, the amount of target DNA is doubled, resulting in an exponential 
rate of amplification of the target DNA sequence. 
The most commonly used DNA polymerase in PCR reactions is Taq 
polymerase, which is isolated from a strain of bacterium, Thermus aquaticus. 
The Taq polymerase is thermo stable and works optimally at 72°C. However, 
the Taq polymerase used in the PCR reaction is a modified monoclonal 
antibody attached ‘hot start’ enzyme, which avoids non-specific amplification, by 
inactivating Taq at lower temperatures; only when the amplification temperature 
reaches 95°C, the specific antibody detaches to release Taq polymerase 
leading to amplification with greater specificity. Therefore, an initial step of 
heating the reaction to 95°C is essential to start specific amplification. 
2.2.7.1 Total RNA extraction from cells 
Total RNA was extracted from endothelial and vascular smooth muscle cells 
from cell lines and human SVs using the TRIZOL method, according to the 
manufacturer’s instructions. All RNA work was carried out in a ribonuclease and 
contaminant free surface and apparatus (sections 2.2.1.2, 2.2.1.3).  
Cells grown to confluence on 6-well plates were stored at -80°C until RNA 
isolation. The frozen 6-well plate was brought to room temperature and 500µl 
TRI reagent (♯T9424) was added to each well of the 6-well plate and allowed to 
stand for 5 min at room temperature, prior to RNA isolation. 
The plate was then tilted to one side, the TRI reagent collected using a pipette 
and the cells were scraped from the bottom of the wells by gentle sideways 
movement of the pipette tip, while slowly releasing the reagent back into the 
well. This step was repeated three times for each well and finally the cell 
suspension was collected into six labelled 1.5ml Eppendorf tubes. 100µl 
chloroform was added to each tube and the mixture was shaken vigorously by 
inverting the tubes continuously for 5 sec. The tubes were then left to stand at 
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room temperature for 5 min prior to micro-centrifugation at 14rcf for 15min. 
Centrifugation yielded three distinct visible layers in each tube; (i) upper 
aqueous phase containing isolated RNA, (ii) an interphase containing a high 
amount of DNA and (iii) a lower pink phase. The upper colourless aqueous 
phase was collected into clean tubes and RNA was precipitated by adding 
250µl or an equal volume of isopropanol (♯I9516) and incubating at -20°C 
overnight. 
The following day, the tubes were retrieved and micro-centrifuged at 14rcf for 
10 min. The supernatant was discarded and the RNA pellet in each tube was 
washed in 500µl 75% ethanol. The tubes were further micro-centrifuged at 14rcf 
for 10 min and the RNA pellet was left to air dry for 10-15 min at room 
temperature. Once air dried, the RNA pellet was re-suspended in 30µl nuclease 
free water, left to stand at room temperature for 30 min and stored at -80°C until 
the concentration and quality of the RNA was assessed. 
2.2.7.2 Nucleic acid quantification 
The concentration and quality of total RNA extracted was determined using a 
nanodrop spectrophotometer (ND-1000 V3, Labtech Int., UK). RNA has its 
maximum absorption at 260nm wavelength, such that A260 readout of 1.0 is 
equivalent to approximately 40µg/ml RNA. The purity of RNA is assessed by 
the ratio of absorbance at 260nm and 280nm such that pure RNA has 
A260/A280 ratio of 2.1. Low A260/A280 ratios may indicate the presence of 
phenol, protein or other contaminants, which absorb strongly at around 280nm. 
Therefore, only total RNA extractions with A260/A280 ratio ≥1.8 were used in 
this study. 
2.2.7.3 cDNA synthesis 
Once the concentration and quality of total RNA was assessed, RNA was 
reverse transcribed using Superscript III (♯18080-093). All reagents used for 
cDNA synthesis were obtained from Life Technologies. Up to 5µg RNA was 
diluted with nuclease free water to bring the volume up to 11µl, to which 1µl 
10mM dNTP (♯18427-013) and 1µl 0.5µg/µl Oligo (dT)12-18 (♯18418-012) were 
added. The reaction tubes were placed in an Eppendorf Mastercycler Gradient 
PCR system and run at 65°C for 5 min followed by cooling at 4°C, during which 
  
 
2.2 METHODS 
 
  
87
time a master mix was prepared. The master mix consisted of 5x RT buffer 
(♯18080-093), 0.1M DTT (♯18080-093), RNaseOUT (♯10777-019) and 
Superscript III in a 4:1:1:1 ratio by vol/vol respectively. 7µl master mix was 
added to each of the reaction tubes and run on the PCR system at 50°C for 30-
60 min. The reaction was terminated at 70°C for 20 min and the newly 
synthesised cDNA were stored at -20°C prior to PCR amplification. 
2.2.7.4 Quantitative reverse transcription PCR (qRT-PCR) 
Quantitative reverse transcription PCR is a modified form of the conventional 
PCR, which allows for the detection and quantification of gene expression 
through formation of complimentary strand of DNA (cDNA). In the presence of 
the specific mRNA, reverse transcriptase and primer anneals to the mRNA 
sequence to transcribe a cDNA strand, which is consequently replicated as in 
the conventional PCR in the presence of primers and Taq polymerase (section 
2.2.7). Moreover, while the conventional PCR allows detection of PCR 
amplification only at the final phase or endpoint of the reaction, the qRT-PCR 
allows the reliable detection and measurement of products of PCR 
amplification, which are directly proportional to the amount of the target 
template at the start of the PCR process, as the reaction progresses. This is 
particularly advantageous because a basic PCR consists of three phases; 
exponential, linear and plateau and the exponential phase is the optimal point 
for analysing data. Alongside various other applications, qRT-PCR can be used 
for quantitation of gene expression, when compared with expression of an 
endogenous control. 
In this study real-time RT-PCR was performed on a StepOnePlus™ PCR 
machine (Life Technologies) using TaqMan® primers/probes (with TAMRA™ 
dyes as the quencher) and reagents (Life Technologies). Table 2.5 lists the 
TaqMan® primers/probes used in this study.  
A 20µl base reaction mixture was used containing 2µl sample cDNA, 10µl 
TaqMan® Universal PCR Master Mix (♯4304437), 1µl TaqMan® primers/probes 
and 7µl nuclease free water. Each run included GAPDH housekeeping 
reference gene (for normalisation), decidual cDNA positive control (to verify 
negative amplification) and cDNA negative control (to detect genomic DNA 
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contamination) and reactions were carried out on MicroAmp® Optical 96-well 
plates (♯NB10560) in triplicate. All samples were amplified using the following 
parameters: initial holding for 2 min at 50°C and denaturation at 95°C for 10 
min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing and 
extension at 60°C for 1 min. 
2.2.7.5 TaqMan® chemistry 
TaqMan® real-time PCR probes are fluorogenic-labelled probes, which allow 
detection of specific PCR products as they accumulate during the PCR cycles. 
The TaqMan® oligonucleotide probe consists of a covalently bonded reporter 
fluorescent dye, 6-carboxyfluorescein (FAM) on the 5’ end and a quencher dye 
tetramethylrhodamine (TAMRA) on the 3’ end. As long as the probe is intact, 
due to the proximity of the reporter and quencher, fluorescence emission does 
not occur. During PCR amplification; (i) the probe anneals to the 
complementary target DNA strand, (ii) the Taq polymerase enzyme cleaves the 
5’ end of the probe, separating the fluorescent dye from the quencher resulting 
in an increase in reporter dye signal and (iii) removes the probe from the target 
strand leading to primer extension. With every cycle more reporter dyes are 
cleaved resulting in an increase in fluorescent intensity, which is directly 
proportional to the amount of PCR amplification product. TaqMan® chemistry 
depends on both probe hybridisation and PCR amplification for fluorescence 
emission, reducing false positives and background fluorescence, therefore 
making it highly specific. Figure 2.8 is a schematic representation of the 
principle behind TaqMan® chemistry. 
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Table 2.5: TaqMan® probes used in real-time PCR 
NAME TAQMAN® ASSAY ID AMPLICON SIZE (bp) 
Ang1 (ANGPT1) Hs00919202_m1 86 
Ang2 (ANGPT2) Hs01048043_m1 113 
B-Actin (ACTB) Hs99999903_m1 171 
GAPDH Hs99999905_m1 122 
H-Caldesmon (CALD1) Hs00263998_m1 71 
PDGF-BB (PDGF-B) Hs00234042_m1 80 
PDGF-RA (PDGF-R) Hs00998027_m1 84 
PDGF-RB Hs00387364_m1 100 
Tie2 (TEK) Hs00176096_m1 82 
TGF-B1 Hs00998129_m1 89 
TGF-BR1 Hs00610318_m1 92 
TGF-BR2 Hs00559661_m1 69 
VEGF-A Hs00900057_m1 81 
VEGF-C Hs01099206_m1 93 
VEGF-R1 (FLT1) Hs01052936_m1 72 
VEGF-R2 (KDR) Hs00911705_g1 84 
VEGF-R3 (FLT4) Hs01047677_m1 111 
MYOCD Hs00538071_m1 63 
SRF Hs00182371_m1 67 
CREG1 Hs00355412_m1 84 
CREG2 Hs00944324_m1 75 
CNN1 (Calponin 1) Hs00154543_m1 93 
CNN2 (Calponin 2) Hs00854264_s1 79 
SMTN (Smoothelin) Hs00199489_m1 52 
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Figure 2.8: Principle behind TaqMan® chemistry. During PCR amplification; (i) the 
TaqMan® probe anneals to the complementary target DNA strand, (ii) Taq polymerase 
enzyme cleaves the 5’ end of the probe, separating the fluorescent dye from the 
quencher resulting in an increase in reporter dye signal and (iii) removes the probe 
from the target strand leading to primer extension. 
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2.2.7.6 Relative quantification of gene expression 
Prior to running the PCR reactions, primer efficiency was assessed using serial 
dilutions (1:10 to 1:100000) of decidual cDNA and determining the variation in 
Ct with each dilution. Following this, a standard curve was generated for each 
TaqMan® probe and the slope of the curve were used to determine exponential 
amplification and efficiency of the qPCR reaction by the following reaction 
(Tichopad et al., 2003): 
Efficiency = 10/  
 
Low efficiency can result from poor quality of cDNA or primers or the length of 
the amplicon. Therefore, only primers with ≥98% efficiency were used in the 
study. Fold changes in gene expression from the real-time quantitative PCR 
were measured relative to a normal housekeeping reference gene (HK) GAPDH 
(section 5.4.1) or by utilising a second relative parameter comparing the level of 
expression of the gene of interest (GOI) to a non-treated control (sections 
5.4.1.3, 6.4.2), using the 2!!"# method (Livak and Schmittgen, 2001). 
Briefly, ∆Ct of each sample was calculated by the following equation: 
ΔCt = Ct	of	GOI	in	sample	of	interest − Ct	of	HK	in	each	sample 
  
The ∆∆Ct of each sample was calculated by either of the following equations: 
ΔΔCt = ΔCt	of	GOI	in	sample	of	interest − ΔCt	of	GOI	in	the	normalised	sample 
ΔΔCt = ΔCt	of	GOI	in	sample	of	interest − ΔCt	of	GOI	in	sample	to	be	compared	 
 
The final step involved determining the comparative fold change in expression 
level of the GOI in the sample compared with a normalised sample. This was 
calculated by the following equation: 
Comparative	fold	change	in	level	of	expression = 23345 
2.2.8 Western blotting 
Western blotting or protein immunoblotting, developed in 1979, is a common 
technique (Towbin et al., 1979) for analysis of a specific protein of interest in a 
  
 
2.2 METHODS 
 
  
92
sample, which can be cell lysate or tissue homogenate. Western blotting uses 
gel electrophoresis to separate proteins based on the isoelectric point, 
molecular weight, electric charge or a combination of the three. Following this 
separated protein molecules are transferred onto a suitable membrane such as 
nitrocellulose or polyvinylidene difluoride (PVDF). The membrane transfer 
allows detection of the specific protein of interest either using a primary 
antibody directly conjugated to an enzyme label or using a tagged secondary 
antibody directed towards a primary antibody. An appropriate chemiluminescent 
substrate is added to the membrane for chemiluminescence detection. 
Horseradish peroxidase (HRP) is a common enzyme conjugate, which oxidises 
luminol-based substrates resulting in emission of light. The emitted light is 
captured either by a CCD camera or by exposure to X-ray film.  
In this study western blotting was performed to investigate the effect of 
angiogenic growth factors on the expression of smoothelin, calponin and 
caldesmon in vascular smooth muscle cells (section 6.4.3). 
2.2.8.1 Protein extraction from cell lysate 
Total protein was extracted from vascular smooth muscle cells grown to 
confluence on 6-well plates and stored at -80°C. The 6-well plate was brought 
to room temperature and 200µl 1x protein extraction buffer (Appendix B) was 
added to each well of the 6-well plate, which was then allowed to stand for 5 
min at room temperature prior to protein isolation. 
Following this the plate was tilted to one side, the extraction buffer was 
collected using a pipette and the cells were scraped from the bottom of the 
wells by gentle sideways movement of the pipette tip, while slowly releasing the 
buffer back into the well. This step was repeated three times for each well and 
finally the cell suspension was collected into six labelled 1.5ml Eppendorf tubes. 
The cell suspensions were sonicated (Soniprep 150 sonicator, MSE Ltd., 
London, UK), heated at 100°C for 5 min followed by micro-centrifugation at 
14rcf for 5 min. The supernatant was collected into fresh labelled Eppendorf 
tubes and stored at -80°C until required for protein assay. 
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2.2.8.2 Protein extraction from myometrial tissue homogenate 
Total protein was extracted from myometrial tissue, which was stored at -80°C 
(section 2.2.2.3). Myometrial tissue was removed from the -80°C freezer and 
weighed. Using a pair of forceps up to 200mg of tissue was transferred into one 
2ml Precellys Ceramic Kit tube (♯91-PCS-CKM, VWR International). 1x 
extraction buffer was added to the tube at 10µl/mg of tissue. The 2ml tube was 
placed into the tube holder of a MINILYS benchtop homogeniser (PEQLAB, 
VWR International, Leicestershire, UK) and homogenised at 5000rpm for 25 
sec, followed by 30 sec on ice. This step was repeated five times, following 
which the tube was centrifuged at 14rcf for 10 min at 4°C. Supernatant was 
collected into a fresh labelled Eppendorf tube and stored at -80°C until required 
for protein assay. 
2.2.8.3 Protein quantification  
The total protein concentration of each sample was determined colorimetrically 
using a BioRad DC protein assay (♯500-0112, Hertfordshire, UK) in accordance 
with the manufacturer’s instructions. Essentially the BioRad DC protein assay 
involves two steps: (i) a reaction between copper and protein in an alkaline 
condition and (ii) the reduction of Folin reagent by the copper-treated protein 
(Lowry et al., 1951). The assay is based on the ‘biuret reaction’, where peptides 
containing greater than three amino acid residues form a light blue coloured 
chelate complex with copper ions (Cu2+) in an alkaline condition containing 
copper tartrate, with minimum and maximum absorbance at 405nm and 750nm 
respectively (Peterson, 1979). The extent of blue colouration is proportional to 
the amount of protein present in the sample.  
A bovine serum albumin (BSA) standard curve was prepared by serially diluting 
BSA (♯441555J, VWR International) between 0mg/ml to 10mg/ml in 1x protein 
extraction buffer (Appendix B) and by plating 5µl/well in duplicates into a 96-well 
plate (♯351172, SLS Ltd., Yorkshire, UK). The protein concentration of test 
samples was determined by adding 5µl/well of sample in duplicate into 
appropriate wells of the 96-well plate along with 25µl working reagent A 
(containing 20µl reagent S in 1ml reagent A) and 200µl reagent B. The plate 
was incubated for 15 min at room temperature. Following this absorbance of 
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each well was measured at 750nm on a SpectraMax190 Absorbance Microplate 
Reader (Molecular Devices, CA, U.S.A) and the concentration of test samples 
was determined from the BSA standard curve  (Figure 2.9) using the Softmax® 
Pro (v4.7.1) software package. 
2.2.8.4 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
allows the separation of proteins according to their size. This consists of two 
essential steps: (i) SDS, an anionic detergent, denatures proteins by breaking 
hydrogen bonds and confers negative charge proportional to their length; and 
(ii) the SDS-denatured and reduced proteins are then separated according to 
their sizes by placing them in a polyacrylamide gel and using electricity to pull 
the proteins through the gel. The polyacrylamide gel contains a meshwork of 
pores and the size of the pores is determined by the percentage of acrylamide 
in the gel, such that the higher the percentage, the smaller the pore size and 
the smaller the size of proteins that can be resolved. 
In this project a 10% polyacrylamide gel (Appendix B) was used to separate the 
proteins of interest. To catalyse polymerisation, 60µl ammonium persulphate 
(0.6mg/ml, ♯A3678) and 6µl tetramethylethylenediamine (0.5mg/ml, ♯T9281) 
were added to 10ml of the 10% gel. The gel solution was poured into a Mini-
PROTEAN casting module (♯165-8008, BioRad) and left to polymerise for 30 
min at room temperature after insertion of a 1.5mm thick, 10-well spacer plate 
(♯170-4326, BioRad). Once polymerised, the gel cassette was transferred into a 
Mini-PROTEAN electrophoresis system and the tank was filled with 1x running 
buffer (Appendix B). 100µg protein isolate was combined with 5µl protein 
loading buffer, containing reducing agent (Appendix B) to make up to a 
maximum of 40µl sample per well, which was then heated at 95°C for 5 min. 
The reducing agent β-mercaptoethanol in the protein loading buffer cleaves di-
sulphide bonds, thereby linearising proteins. The reduced samples were loaded 
into respective wells of the gel along with 10µl protein Novex® Sharp Standard 
(♯LC5800, Life Technologies, Paisley, UK) using a Hamilton syringe. The Mini-
PROTEAN electrophoresis system was set to 100V and run for 1-2 hr at room 
temperature for protein separation. 
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Figure 2.9: Representative standard curve to determine protein concentration. The 
standard curve was prepared by serially diluting BSA between 0mg/ml and 10mg/ml. 
The protein concentration in test samples was determined from the standard curve. 
Error bars are representative of mean ± standard deviation (N=2). 
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2.2.8.5 Membrane transfer 
After proteins were separated, they were electrophoretically transferred into a 
0.45µm PVDF membrane (Immobilon-P Membrane, ♯IPVH00010, Merck 
Millipore). PVDF is a hydrophobic membrane, which immobilizes the separated 
proteins and allows for immunodetection of the protein of interest in a sample.  
Following electrophoresis, the gel cassettes were removed and placed in a tray 
with cold transfer buffer (Appendix) for 5 min. Meanwhile, the PVDF membrane 
was placed in 99% methanol for 15 min for activation followed by equilibration 
in cold transfer buffer for 5 min. The transfer electroblotting cassette was 
prepared in cold transfer buffer by placing the protein containing gel and PVDF 
membrane together, with Whatman filter paper and sponges on either side, 
between two electrodes, such that the gel was on the side of the negative 
electrode and the PVDF membrane on the side of the positive electrode. The 
cassette was then suspended into the Mini-PROTEAN electrophoresis system 
and the tank was filled with transfer buffer (Appendix B). Protein transfer was 
performed at 100V for 2 hr on ice.  
2.2.8.6 Immunodetection 
Immunodetection allows both qualitative and quantitative analysis of proteins in 
samples. Following electrophoretic transfer of proteins, the PVDF membrane 
was blocked for 1 hr at room temperature in blocking buffer (Appendix B). The 
membrane was then probed with primary antibody, diluted in blocking buffer, 
overnight on a shaker at 4°C. The primary antibodies used for immunodetection 
in western blotting are listed in Table 2.6. The following day the membrane was 
washed three times in TBST (Appendix B) for 10 min on a shaker at room 
temperature, prior to incubating for 2hrs with an HRP-conjugated rabbit anti 
mouse secondary antibody (♯170-6516, BioRad) diluted 1:3000 in blocking 
buffer. The membrane was again washed three times in TBST for 10 min on a 
shaker at room temperature before chemical detection. 
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Table 2.6: Primary antibodies used for western blotting 
 
ANTIBODY CATALOGUE NO: CLONE HOST DILUTION 
1  Caldesmon1 M3557 h-CD Mouse 1:100 
2 Calponin1 M3556 CALP Mouse 1:1000 
3 Smoothelin2 ab8969 R4A Mouse 1:100 
1Dako Cytomation, Cambridgeshire, UK; 2Abcam Cambridgeshire, UK 
2.2.8.7 Chemical detection of protein and developing signal  
After probing the PVDF membrane with appropriate primary and HRP-
conjugated secondary antibody, peroxidase activity was detected using Pierce 
enhanced chemiluminescent (ECL) substrate (♯32106, Fisher Scientific) for 5 
min or Amersham ECL Select (♯RPN2235, VWR International) for 1-2 min. This 
sensitive detection system is based on the principle of oxidation of luminol 
present in the ECL substrate by the peroxidase activity of the HRP conjugated 
to the secondary antibody resulting in the emission of light, such that the light 
emitted is proportional to the quantity of protein present. This resulting light 
emitted was visualised by the exposure of the PVDF membrane to Kodak® 
BioMax® light film (♯819-4540) using ready to use developer and fixer (Tetenal, 
Leicestershire, UK). Developing times ranged from 2-25 min depending on the 
expression of the protein of interest. Once developed the films were scanned 
using a desktop scanner and the image analysed qualitatively for the presence 
or absence of a band suggesting the presence or absence of a protein, 
respectively, in the sample of interest.  
Equal loading was assessed by washing the PVDF membrane once with TBST 
for 10 min followed by a 25 min incubation in 1% napthol blue solution, 
subsequent washing for 5 min and air-drying at room temperature.  
2.2.9 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme linked immunosorbent assay (ELISA), developed by Perlman, Engvall 
and van Weemen in 1971 (Engvall and Perlmann, 1971; Van Weemen and 
Schuurs, 1971), is an analytical technique, which uses solid-phase enzyme 
immunoassay for the detection and quantification of peptides, proteins, 
antibodies and hormones in a liquid sample. This assay is based on the 
following principal steps: (i) immobilization of an antigen onto a solid surface; 
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followed by (ii) formation of an antibody-antigen complex, where the antibody is 
directly or indirectly linked to an enzyme; and finally (iii) detection and 
quantification by incubation with a substrate to produce a measurable product, 
proportional to the level of antigen present in the sample. The strength of this 
technique lies in the fact that the antigen is immobilised onto a solid surface, 
making it possible to wash away any non-specific binding. HRP is the most 
commonly used enzyme conjugate, which in the presence of an appropriate 
substrate results in a coloured by-product or the emission of light.  
Depending on suitability to the study question, ELISAs can be performed in 
different ways, which are modifications of the basic principle: direct ELISA, 
indirect ELISA, competitive ELISA and capture or sandwich ELISA. While direct 
ELISA utilises a primary antibody directly labelled to an enzyme, in an indirect 
ELISA an enzyme-conjugated secondary antibody is used directed towards the 
unlabelled primary antibody is used for antigen detection and quantification. 
Direct ELISA is quick and minimises cross-reactivity with secondary antibody, 
although labelling primary antibody can be expensive. In comparison, indirect 
ELISA offers the option of a variety of secondary antibodies to be used even 
with the same primary antibody and allows signal amplification through 
utilisation of multiple epitopes on the primary antibody. 
Competitive ELISA involves formation of a primary antibody-antigen of interest 
complex, which is immobilised on a solid surface, pre-coated with the same 
antigen. Following this an enzyme conjugated secondary antibody along with an 
appropriate substrate allows detection and quantification such that the higher 
the sample antigen, the weaker is the eventual signal, rendering this method 
highly specific. Some competitive ELISAs may use an enzyme-linked antigen 
rather than an enzyme linked antibody. 
Sandwich ELISA involves attachment of a ‘capture’ antibody onto a solid 
surface, to which the samples containing the antigen of interest are overlaid. 
Following this an enzyme conjugated secondary antibody is added, which in the 
presence of an appropriate enzyme substrate allows the detection and 
quantification of an antigen of interest in a sample. Since the two antibodies are 
directed towards two different epitopes of the same antigen, this prevents 
binding interference and non-specificity, thus making the sandwich ELISA a 
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highly specific and robust method. The essential steps involved in a sandwich 
ELISA are illustrated in Figure 2.10. 
In this study, the sandwich DuoSet® ELISA development systems (R&D 
Systems Ltd.) for VEGFC (♯DY752B), Ang1 (♯DY923) and TGFβ1 (♯DY240) 
were used to investigate (i) the effect of matrigel on angiogenic growth factor 
expression profile of human SV derived endothelial cells (section 5.4.1) and (ii) 
the effect of PDGF-BB and TGFβ1 on angiogenic growth factor expression 
profile of human SV derived endothelial and vascular smooth muscle cells 
(section 6.4.2). 
2.2.9.1 Sandwich ELISA protocol  
A sandwich ELISA was used to assess supernatants collected as described in 
section 2.2.6.7. The protocol for the sandwich DuoSet® ELISA development 
system was performed in accordance with manufacturer’s instructions. 
The capture antibody was diluted to working concentration in PBS (pH7.6) 
(Appendix B) and 50µl was used to coat an appropriate number of wells of a 96-
well half-area microplate (♯675001, Greiner Bio-One). The plate was sealed 
with an adhesive film (♯AB0558, Fisher Scientific) and incubated at room 
temperature overnight. The following morning, each well was aspirated and 
washed two times with approximately 250µl/well of wash buffer (Appendix B). 
The process was repeated three times, after which any wash buffer was 
thoroughly removed by inverting the plate and blotting against clean paper 
towels. To minimise non-specific binding, the wells were coated with 150µl 
reagent diluent or TGFβ1 blocking solution (Appendix B) and incubated at room 
temperature for 1 hr. Meanwhile, in order to produce a seven point standard 
curve, a two-fold serial dilution was prepared in reagent diluent or TGFβ1 
reagent diluent (Appendix B). The samples along with the standards were first 
plated according to the study design into a u-bottom 96-well plate (♯675180, 
Greiner Bio-One). To activate latent TGFβ1, 10µl TGFβ1 acid activation solution 
(Appendix B) per 50µl sample was added, mixed well and incubated for 10 min 
at room temperature, following which the acidified sample was neutralised by 
adding 10µl TGFβ1 acid neutralisation solution (Appendix B) and mixing well 
prior to the assay. 
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Figure 2.10: Principle behind DuoSet® Sandwich ELISA development system. 
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Following blocking, the 96-well plate was washed and aspirated three times with 
wash buffer as described above. 50µl undiluted or acid activated samples (for 
TGFβ1), along with 100µl serially diluted standards were separately added in 
duplicate to the assay plate, sealed with adhesive film and incubated at room 
temperature for 2 hr. The plate was aspirated, washed three times in wash 
buffer and 50µl appropriately diluted detection antibody was then added to each 
well. The sealed plate was then incubated for 2 hr at room temperature. The 
assay plate was aspirated, washed three times in wash buffer and 50µl diluted 
(1:200 in reagent diluent) streptavidin-HRP conjugate was added to the wells 
before incubating for 20 min in the dark at room temperature. The assay plate 
was again aspirated and washed three times in wash buffer and 50µl substrate 
solution (Appendix B) was added to each well followed by 20 min incubation in 
the dark at room temperature, after which light blue colouration was observed. 
Finally, 25µl stop solution (Appendix B) was added to each well and tapped 
gently to ensure thorough mixing, resulting in a yellow colouration, prior to 
determining optical density of each well. The extent of colouration was 
proportional to the amount of protein of interest present in each sample. 
Absorbance of each well was measured at 450nm (corrected at 540nm) on a 
SpectraMax190 Absorbance Microplate Reader (Molecular Devices, CA, U.S.A) 
and the concentration of growth factor or cytokine in samples was determined 
from the standard curve, using the mean value of the duplicates (Figure 2.11) 
using the Softmax® Pro (v4.7.1) software package. For TGFβ1 the 
concentration read off the standard curve was multiplied by the dilution factor of 
1.4 (as recommended), since the samples were acid diluted and neutralised 
prior to the assay. Table 2.7 details the concentration of the capture antibodies, 
detection antibodies and standards used in the different assays. 
Table 2.7: Concentration details of antibodies and standards used for ELISA 
ASSAY CAPTURE ANTIBODY DETECTION ANTIBODY HIGH STANDARD 
VEGFC  4.0µg/ml 100.0ng/ml 4000.0pg/ml 
Ang1 4.0µg/ml 200.0ng/ml 10000.0pg/ml 
TGFβ1 2.0µg/ml 300.0ng/ml 2000.0pg/ml 
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Figure 2.11: Representative standard curve to determine protein concentration using 
the R&D DuoSet® ELISA kit. The standard curve was prepared for human TGFβ1 
ranging from 0pg/ml-2000pg/ml. Protein concentrations in test samples were 
determined from the standard curve. 
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2.2.10 Quantibody Human Angiogenesis Array 
The Quantibody® human angiogenesis array platform (RayBiotech, Norcross, 
U.S.A) is a multiplexed sandwich ELISA-based technology, which allows 
simultaneous detection and quantification of 10 proteins or cytokines of interest 
with high sensitivity and specificity comparable with traditional ELISAs, but 
combining the high throughput of arrays. The assay follows the basic principles 
of a sandwich ELISA (section 2.2.9.1), except for the final detection step. The 
antigen-antibody complex is visualised with streptavidin labelled Cy3 equivalent 
dye using a laser scanner, such that one array slide spotted with 16 wells of 
identical cytokine antibodies and appropriate positive controls in quadruplicate 
can be processed simultaneously. 
In this study, the Quantibody® human angiogenesis array platform was used to 
investigate (i) the effect of matrigel on the angiogenic growth factor secretion 
profile of human SV derived endothelial cells (section 5.4.1) and (ii) the effect of 
PDGF-BB and TGFβ1 on angiogenic growth factor secretion profile of human 
SV derived endothelial and vascular smooth muscle cells (section 6.4.2). 
Supernatants were collected as described in section 2.2.6.7. 
2.2.10.1 Array protocol  
The protocol was performed in accordance with the manufacturer’s instructions. 
The glass slides were removed from -20°C and equilibrated to room 
temperature inside sealed plastic bags for 20-30 min, after which the plastic bag 
was removed and the slides were air-dried for 2 hr. Meanwhile, a five point 
standard dilution was prepared using lyophilized cytokine standard mix diluted 
in the diluent provided (Appendix B). The serial concentrations for each 
cytokine varied due to the fact that the starting concentration of each cytokine 
was different; details are listed in Table 2.8. In order to minimise non-specific 
binding, the wells were coated with 100µl sample diluent and incubated at room 
temperature for 30 min. Blocking solution was then decanted from each well 
and 50µl undiluted sample or the serially diluted standard cytokines were added 
and incubated overnight at 4°C.  
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Table 2.8: Standard concentrations used for the Quantibody® human array 
(pg/ml) Std1 Std2 Std3 Std4 Std5 
Angiogenin 4000 444 148 49 16 
ANG2 8000 889 296 99 33 
EGF 200 22 7 2 1 
bFGF 8000 889 296 99 33 
HB-EGF 8000 889 296 99 33 
HGF 8000 889 296 99 33 
Leptin 8000 889 296 99 33 
PDGF-BB 2000 222 74 25 8 
PIGF 8000 889 296 99 33 
VEGF 8000 889 296 99 33 
 
The next day, samples and standards were decanted, and the plates were 
washed five times (5 min each) with 150µl 1x wash buffer I (20x wash buffer I 
diluted in distilled water) on a shaker at room temperature with complete 
removal of wash buffer in each step. After washing with wash buffer I, the slides 
were washed twice (5 min each) with 150µl 1x wash buffer II (20x wash buffer II 
diluted in distilled water). 80µl detection antibody cocktail (diluted with 1.4ml 
sample diluent) was added to each well and incubated for 2 hr at room 
temperature. The slides were decanted and washed five times in wash buffer I 
and twice in wash buffer II as described previously. 80µl Cy3 equivalent dye-
conjugated streptavidin (diluted with 1.4ml sample diluent) was added to each 
well and incubated in the dark for 1 hr at room temperature. The slides were 
decanted and washed five times in wash buffer I followed by complete removal 
of the wash buffer. Finally the slides were disassembled and washed in 1x wash 
buffer I in a slide washer on a shaker for 30 min at room temperature followed 
by another 5 min wash in 1x wash buffer II. Wash buffer was completely 
removed by gentle suction with a pipette.  
Integrated density values (IDV) were calculated for each spot (area times 
relative intensity) in each well at 532nm on a GenePix 4000B Microarray 
Scanner (Molecular Devices, CA, U.S.A) and the concentration of each 
cytokine/ growth factor in samples was determined using the mean value of the 
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quadruplicates from the five point standard curves (Figure 2.12) using 
ArrayVision FAST® (v8.0) software package. The maximum possible 
unsaturated reading was obtained for the highest standard for each cytokine. 
2.2.11 Statistical analysis of results 
Data generated in this study were statistically analysed. Data were organised 
and analysed first using Microsoft Office Excel 2011 and statistical analysis was 
carried out in either Prism (GraphPad Software, San Diego, CA, U.S.A) or 
SPSS (IBM, Hampshire, UK) software packages. Quantitative data were 
broadly classified as either count (e.g. quickscore method used for IHC) or 
continuous data (e.g. area of muscle coverage in a tissue, concentration of 
protein, etc.). Analysis of differences between control and experimental groups 
was performed based on whether the data followed a normal distribution. A 
normality test was carried out for continuous data where N≥10 and if normally 
distributed, parametric tests such as Students t-test, analysis of variance 
(ANOVA) were applied for further analysis. However, for count (non-continuous) 
data with N<10, normality could not be reliably tested and therefore non-
parametric tests such as Fisher’s exact test, Mann-Whitney U or Kruskal Wallis 
were applied in association with Bonferroni correction for multiple comparisons, 
where applicable, to derive final conclusions. The significance of the difference 
was calculated as a probability (P value) of ≤0.05 suggesting that the result 
could have only occurred by chance in 1 in 20 cases.  
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Figure 2.12: Representative standard curves to determine protein concentration using 
the Quantibody® human angiogenesis array kit. Protein concentrations in test samples 
were determined from the standard curve. 
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3 HISTOCHEMICAL CHANGES IN THE UTERINE VASCULATURE OF WOMEN 
WITH HEAVY MENSTRUAL BLEEDING 
3.1 INTRODUCTION 
Human menstruation is a highly regulated physiological process involving cross 
communication between the vascular and immune systems, under the control of 
the endocrine system. The endometrial vasculature includes the basal arteries 
supplying the stratum basalis and the spiral arteries supplying the stratum 
functionalis. During the menstrual cycle, angiogenesis is spatially and 
temporally regulated, occurring primarily during three phases: vascular repair in 
stratum basalis in the menstrual phase; support growth in stratum functionalis in 
the proliferative phase, and finally growth and coiling of spiral arterioles in the 
secretory phase (Gargett and Rogers, 2001). The blood vessels comprise 
multiple layers: the innermost EC layer and the radially outward ECM and 
VSMCs. The coiled shape of the spiral arteries and arterioles helps to reduce 
blood pressure and rate of flow along its length, maintaining a steady blood flow 
to the stratum functionalis (Aplin et al., 2008). Studies in the past have 
implicated endometrial vasculature in the pathogenesis of heavy menstrual 
bleeding (Abberton et al., 1999a; Abberton et al., 1999b; Hurskainen et al., 
1999; Rogers and Abberton, 2003; Kawai-Kowase and Owens, 2007). 
VSMCs are a major constituent of the endometrial blood vessels and their stage 
of differentiation contributes to normal blood flow and pressure. Failure of these 
vessels to control the rate of blood loss could be attributed to a failure in normal 
vasoconstriction, which in turn may be explained by abnormal arteriogenesis 
together with impaired VSMC maturation and function. Vascular ECs express 
F8RA, CD34, CD31 and EC specific glycoproteins, which selectively bind the 
lectin UEA-1 and play an important role in the menstrual process. They regulate 
angiogenesis through the production of PDGF-BB and TGFβ1, which aid VSMC 
recruitment and this EC-VSMC signalling is key in maintaining normal blood 
flow through regulation of vascular tone (Feletou, 2011). ECs are also 
associated with degradation of vascular and stromal ECM by protease 
production, thereby allowing for co-ordinated EC migration and proliferation 
(Findlay, 1986; Zetter, 1988; Goodger and Rogers, 1994). Moreover, in a study 
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utilising EC proliferation as a measurement of angiogenesis, patients with HMB 
had high endometrial EC proliferation compared with controls, indicating altered 
blood vessel development (Kooy et al., 1996). Additionally, heterogeneous 
staining between the different EC markers were noted in luteal phase 
endometrium from women suffering recurrent reproductive failure (Quenby et 
al., 2009).  
ECM is a major component of endometrial blood vasculature consisting of 
anchoring fibrils and proteins, including type IV collagen, fibronectin, laminin 
and osteopontin. It plays an integral role in angiogenesis by stabilising tissue 
structure, regulating cell growth and differentiation, and provides mechanical 
properties maintaining vascular tone. Both ECs and synthetic VSMCs are 
capable of synthesizing most of these proteins. Therefore any implication of 
dysregulated vascular structure or function in HMB may also underlie altered 
composition of ECM components. However, while vessel number and 
morphology (Abberton et al., 1999a; Abberton et al., 1999b; Rogers and 
Abberton, 2003) and staining pattern of the different EC and ECM markers in 
endometrium during the menstrual cycle (Aplin et al., 1988; Rees et al., 1993; 
Rogers et al., 1993; Tawia et al., 1993; Kelly et al., 1995; Bilalis et al., 1996; 
Nikitenko et al., 2000; Zhang et al., 2002) have been studied previously, a 
detailed analysis in the different layers of the endometrium and superficial 
myometrium throughout the menstrual cycle and a comparison with HMB has 
not been reported. 
There is evidence for a role of endometrial immune cells in HMB disorders. 
Endometrial macrophages and uNK cells are a key source of angiogenic growth 
factors (Saito et al., 1993; Li et al., 2001; Hanna et al., 2006; Lash et al., 2006; 
Lash et al., 2010) such as vascular endothelial growth factor (VEGF-A) (Ulukus 
et al., 2006) which has been shown to be reduced in women with HMB (Malik et 
al., 2006). Since VEGF-A plays a role in vascular development, its reduction in 
women with HMB may indicate aberrant endometrial vascular development. 
This exemplifies how the endometrial immune response may affect vascular 
development in the endometrium. Additionally it has been suggested that 
macrophages, uNK cells and other migratory leukocytes may directly influence 
vascular permeability (Hickey and Fraser, 2000). Moreover, macrophages and 
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uNK cells are often shown to form aggregates around the spiral 
arteries/arterioles in the stratum functionalis of the late secretory phase 
endometrium (Bulmer et al., 1991) and altered uNK cell numbers have been 
associated with several reproductive disorders such as recurrent implantation 
failure and RM (Clifford et al., 1999; Quenby et al., 1999; Tuckerman et al., 
2007; Lash and Bulmer, 2011). Importantly, advanced development of 
endometrial blood vessels in women with a history of RM was correlated with an 
increased percentage of endometrial stromal uNK cells in the mid secretory 
phase (Quenby et al., 2009). Furthermore prednisolone treatment reduced both 
endometrial uNK cells and angiogenic growth factor expression and vascular 
maturation in these women (Quenby et al., 2005; Lash et al., 2011a). Taken 
together these data suggest a role for uNK cells in advanced blood vessel 
development, although their functional role remains unknown. Recently uNK 
cells have also been shown to regulate endometrial bleeding by maintaining 
arterial stability (Wilkens et al., 2013). Dysregulation of leukocyte cell numbers 
may therefore be linked with abnormal uterine bleeding disorders, although 
these cell populations have not been investigated in the endometrium of women 
with HMB. 
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3.2 HYPOTHESES AND AIMS 
3.2.1 Hypotheses 
Taking into consideration the important roles of uterine blood vasculature, and 
the potential effects of endometrial leukocytes in HMB, we hypothesised that: 
1. Blood vessel structure (VSMC, EC and ECM) is altered in the endometrium 
of women with HMB. 
 
2. Stromal, glandular and vascular proliferation across the phases of the 
menstrual cycle in the normal cycling uterus is spatially altered between the 
layers of the endometrium and superficial myometrium. 
 
3. Endometrial leukocyte numbers are altered in HMB contributing to abnormal 
vascular development. 
3.2.2 Aims 
To test the above hypotheses we aimed to: 
1. Examine the thickness of the blood vessel wall and the differentiation status 
of the VSMCs in endometrium across the menstrual cycle in controls and 
women with HMB. 
 
2. Compare the pattern of various EC markers in the endometrium and 
superficial myometrium across the menstrual cycle in controls and women 
with HMB. Furthermore, we aimed to look at proliferation in vessels 
expressing each of the EC markers across the menstrual cycle in controls. 
 
3. Compare the distribution of ECM components in the endometrium and 
superficial myometrium across the menstrual cycle in controls and women 
with HMB. 
 
4. Assess stromal, glandular and vascular proliferation in the phases of the 
menstrual cycle with the aim of comparing between the layers of the 
endometrium and superficial myometrium. 
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5. Compare endometrial leukocytes across the different phases of the 
menstrual cycle in controls with those in women with HMB. 
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3.3 EXPERIMENTAL DESIGN 
The experimental design has been illustrated in Figure 3.1 and specific 
materials and methods used are described below. 
3.3.1 Human Tissue 
Endometrial biopsies were obtained with informed consent from women 
undergoing hysterectomy as described in section 2.1.1.2. 
3.3.2 Histochemistry and antibodies used 
In general, immunohistochemistry, double-labelling immunohistochemistry and 
lectin histochemistry were performed as described in sections 2.2.3.1, 2.2.3.2 
and 2.2.4, respectively. Details of source, pretreatment, dilution and incubation 
times for all primary antibodies used in immunohistochemistry and double-
labelling immunohistochemistry are provided in Table 2.2. Additionally, details 
of double-labelling immunohistochemistry used to achieve specific aims are 
described below. 
3.3.2.1 Thickness of endometrial blood vessel wall and the differentiation 
status of VSMCs 
Double-labelling immunohistochemistry was used to identify the proportion of 
vessels identified using endothelial cell markers (CD31 or biotinylated UEA-1 
lectin) that were immunopositive for the smooth muscle markers (αSMA, 
smoothelin or calponin). The antibody combinations for double labelling were 
selected based on pre-treatment compatibility as follows: CD31/αSMA, 
calponin/UEA-1 and smoothelin/CD31. The first immunostain was visualized 
using DAB solution containing 0.01% H2O2 (Appendix B) to give a brown 
reaction product and the second with Vector SG substrate kit for peroxidase to 
give a silver reaction product (Appendix B). 
3.3.2.2 Endometrial leukocyte population in the endometrium 
Detection of CD3+ cells in paraffin embedded sections relied on antibodies that 
detect the epsilon (ε) chain of human CD3. Uterine CD56+ NK cells may also 
express cytoplasmic CD3ε and CD3ζ (King et al., 1998b). Therefore double-
labelling immunohistochemistry was used to identify the proportion of CD3+ 
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Figure 3.1: Experimental design to investigate histochemical changes in the uterine vasculature of women with HMB. 
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cells that were CD56+CD3+ double positive. The first immunostain was 
visualised using Vector SG substrate kit for peroxidase (Appendix B) and the 
second with Vector NovaRED substrate kit for peroxidase (Appendix B). 
3.3.3 Quantitative image analysis 
3.3.3.1 Thickness of endometrial blood vessel wall and differentiation status 
of VSMCs 
Sections from endometrial biopsies (N=7) in each of proliferative phase (PP), 
early secretory phase (ESP), mid secretory phase (MSP) and late secretory 
phase (LSP) from both controls and women with HMB were examined. Since 
tissue sections varied in size, in order to standardise the analysis keeping 
sample size consistent between control and HMB, images were captured of 
randomly chosen fields of view, capturing n=25 αSMA positively immunostained 
vessel cross-sections of similar shape (shape factor ≤2e-316) for each tissue 
section. Images were captured of the same fields of view in the corresponding 
serial sections immunostained with different VSMC differentiation markers.  
The thickness of the vessel wall muscle was assessed in sections 
immunostained for αSMA. Measurements were taken of the stained muscular 
area and the inner luminal cross-sectional area using NIS Elements Ar (Nikon 
Instruments Inc.). Vessel muscularity was expressed as the ratio of the outer 
stained muscular area to the total area (stained area + inner luminal area) of the 
vascular cross-section (Figure 3.2). For each individual cross-section, 
measurements were obtained in triplicate and the mean was used for the final 
calculations. The number of vessels expressing αSMA was also quantified as a 
proportion of the total number of vessels as determined by double 
immunostaining with CD31 in the stratum functionalis of the endometrium in 
both controls and women with HMB during the menstrual cycle.  
VSMC differentiation markers were analysed by their absence or presence in 
vascular cross-sections in each field of view, corresponding with the αSMA+ 
vascular cross sections. Vessels expressing smoothelin and calponin were also 
measured as a proportion of total number of vessels as determined by double 
immunostaining with CD31 and UEA-1, respectively, in the stratum functionalis. 
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Figure 3.2: Measurement of endometrial vascular wall thickness. Vessel thickness was 
expressed as the ratio of the outer stained muscular area (x-y) to the total area (x= 
stained area + inner luminal area) of the vascular cross-section. 
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3.3.3.2 Stromal, glandular and vascular proliferation and staining for EC 
marker and ECM component during the menstrual cycle 
Sections were assessed in the entire tissue biopsies (N=3 or N=5 for EC and 
ECM, respectively) in each of PP, ESP, MSP and LSP from controls and 
women with HMB by one observer, who was blinded to the origin of the sample. 
Only muscular vessels with surrounding layer(s) of smooth muscle cells and a 
visible lumen, which were positively stained for MyHC, were included in the 
analysis. Entire full thickness immunostained tissue sections were analysed 
semi-quantitatively for Ki67 using a modified ‘Quickscore’ method (section 
2.2.3.4). The superficial myometrium, stratum basalis (within one 200x field 
adjacent to the myometrium), stratum functionalis and luminal region (within one 
200x field from the surface epithelium) were all scored separately. Proliferative 
vessel numbers were counted manually as the percentage of Ki67+ vessels 
compared with the total number of vessels positively stained for UEA-1, F8RA, 
CD34 or CD31 in 3 randomly selected fields of view (200x original 
magnification) within the luminal region and stratum functionalis in each control 
sample (N=3, in each phase). 
3.3.3.3 Endometrial leukocyte populations 
Sections from endometrial biopsies (N=5), in each of PP, ESP, MSP and LSP 
from both controls and women with HMB were examined. Leukocyte numbers 
were counted using the open-source image analysis software package, ImageJ 
(Version 1.46, NIH, Maryland, USA), in combination with the ‘cell counter’ plugin 
as the percentage of positively stained cells for each leukocyte marker 
compared with the total number of stromal cells in 5 randomly selected fields of 
view (200x magnification) within the stratum functionalis in each sample.  
The proportion of CD3+ cells that were CD3+CD56+ double positive was 
assessed in mid and late secretory phase samples from both control and HMB 
groups (N=3 each group) that were double immunostained for CD3 and CD56. 
Single and double positive cells were counted in 5 randomly selected fields of 
view (x400 magnification) in the stratum functionalis in each sample using 
ImageJ. The number of CD3+CD56+ double positive cells was quantified both 
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as a proportion of the total number of CD3+ cells and as a proportion of the total 
number of CD56+ cells. 
3.3.4 Statistical analysis 
Statistical analyses were performed using either the Prism software package 
(GraphPad Software, San Diego, CA, USA) or Statistical Package for Social 
Sciences version 15.0 (SPSS Inc., Chicago, IL, USA). Data are presented as 
means ± standard error of mean (SEM) and differences are considered 
statistically significant at P≤0.05. Specific tests used are given in the results. 
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3.4 RESULTS 
3.4.1 Altered VSMC differentiation in the endometrial vasculature in HMB 
3.4.1.1 Vascular smooth muscle content remained unchanged during the 
control menstrual cycle and in HMB 
Endometrial samples (N=4 each menstrual cycle phase) were double 
immunostained for αSMA and an endothelial cell marker (CD31) (Figure 3.3A-
H). During the normal menstrual cycle 63% of the CD31-positive vessels in the 
stratum functionalis stained with αSMA in the proliferative phase, increasing to 
81% in the late secretory phase (P=0.002) (Figure 3.3I). During the menstrual 
cycle of women with HMB 63% of vessels in the stratum functionalis stained 
with smooth muscle marker αSMA in proliferative endometrium, increasing to 
79% in the late secretory phase (P=0.02) (Figure 3.3I). There was no difference 
in this percentage between the two groups at any stage of the menstrual cycle. 
Endometrial vascular muscularity was analysed in serial sections from 
endometrial biopsies, collected from both control and HMB groups (N=7 for 
each phase of menstrual cycle) (Figure 3.4A-J). The overall vascular smooth 
muscle cell content (positive αSMA staining) in both groups remained relatively 
stable, accounting for 78%-81% of the total vascular cross-sectional area at all 
cycle phases (Figure 3.4K). There was no difference in the muscle content of 
endometrial vessels between control and HMB groups during the proliferative, 
early, mid or late secretory phases of the menstrual cycle (Figure 3.4K).  
3.4.1.2 Differentiation status of VSMCs in endometrial vasculature is altered 
in HMB compared with controls 
Serial tissue sections were immunostained for the different VSMC differentiation 
markers; H-cal, calponin, MyHC, desmin and smoothelin (Figure 3.5). Tissue 
sections, corresponding with those used for the measurement of thickness 
(αSMA), were imaged in ≥5 fields of views per section. Differentiation markers 
were analysed by means of ‘presence’ or ‘absence’ in the corresponding areas 
of the sections. Desmin immunostaining was absent from all tissues (Figure 
3.5). Amongst the VSMC differentiation markers, MyHC was the most 
commonly present (>84% of all vascular sections) in both control and HMB  
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Figure 3.3: The proportion of vessels stained with αSMA in the control menstrual cycle 
and in heavy menstrual bleeding (HMB). A-H shows representative double 
immunostaining CD31/αSMA (brown/silver grey) of blood vessels in control (A-D) and 
HMB (E-H). The red and black arrows indicate CD31+/αSMA+ (brown/silver) vessels 
and CD31+/αSMA- vessels, respectively. Images were captured at 200x magnification. 
Bar chart with a standard error of mean (SEM) represents the percentage of αSMA+ 
vessels in each phase of the menstrual cycle for control and HMB groups (I). Fisher’s 
test followed by unpaired Student’s t-test was used (denoted by ‘*’). 
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Figure 3.4: Vascular smooth muscle content did not differ between control and heavy 
menstrual bleeding (HMB) endometrium. A-J show vessels (arrowed) immunopositive 
for αSMA in control (A-D) and HMB (F-J) endometrium in the proliferative, early 
secretory, mid secretory and late secretory phases of the menstrual cycle. Images 
were captured at 200x magnification. Bar chart with a standard error of mean (SEM) 
represents the mean muscle content in each phase of the menstrual cycle for both 
control and HMB groups (K). Fisher’s test followed by unpaired multiple Student’s t-
test, with Holm-Sidak correction method to account for multiple comparisons (P>0.05). 
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Figure 3.5: VSMC differentiation markers during the menstrual cycle in heavy 
menstrual bleeding (HMB). Arrows indicate vessels immunopositive for (A-D) H-
Caldesmon, (E-H) calponin, (I-L) MyHC, (M-P) desmin and (Q-T) smoothelin. Images 
were captured at 200x original magnification. 
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tissue (Figure 3.6A). H-cal, was present in >26% of all vascular sections in both 
groups (Figure 3.6B). The staining for MyHC was relatively consistent (85%-
96%) across the four menstrual cycle phases, while that of H-cal varied 
considerably, (26%-50% in control; 35-61% in HMB) during proliferative and 
early secretory phases (Figure 3.6A-B). None of these variations were 
significantly different between control and HMB groups. 
In contrast to MyHC and H-cal, smoothelin and calponin staining differed 
markedly between the control and HMB tissues and also varied between the 
different phases of the menstrual cycle in both groups. In the control group 
calponin was present in 11-18% of vessels in the proliferative and early 
secretory phases, before increasing to be expressed in 37% vessels in the late 
secretory phase. In comparison, in the HMB group, calponin was expressed in 
12% vessels in the proliferative phase, increasing to 32% and 39% in the early 
and mid secretory phases, respectively but was seen in only 11% of αSMA+ 
vessels in the late secretory phase (Figure 3.6C). In the controls, while 
smoothelin was expressed in 36% of the αSMA+ vessels in proliferative 
endometrium, this decreased to 17% in the early secretory phase and 
decreased further to only 5% αSMA+ vessels in the late secretory phase. In 
contrast, in HMB smoothelin remained stable in proliferative (18%), early 
secretory (18%), mid secretory (23%) phases, before increasing to be 
expressed in 47% αSMA+ vessels in the late secretory phase (Figure 3.6D). 
There was an apparent inverse relationship between staining for smoothelin 
and calponin in the αSMA+ vessels in the late secretory phase in both control 
and HMB groups (Figure 3.6C-D). While smoothelin was increased in αSMA+ 
vessels (P=0.03), calponin was decreased (P=0.008) in HMB compared with 
controls. The most marked difference between control and HMB groups in 
calponin and smoothelin staining was in the late secretory phase.  
Double-labelling immunohistochemistry (N=5 samples per subject group) was 
undertaken to investigate smoothelin and calponin stain in conjunction with the 
endothelial cell markers CD31 or UEA-1, respectively, in the stratum 
functionalis of late secretory phase endometrium (Figure 3.6E-I). The proportion 
of vessels identified using EC markers positive for calponin and smoothelin was 
expressed as a percentage of the total number of vessels in the stratum  
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Figure 3.6: Vascular smooth muscle cell (VSMC) differentiation markers in control and 
HMB endometrium across the menstrual cycle. (A-D) Bar charts represent mean 
percentage of vessels immunopositive for different VSMC markers in each phase of 
the menstrual cycle for control and HMB. (E) Bar chart represents mean (±SEM) 
percentage of smoothelin+ or calponin+ vessels respectively in the LSP for both control 
and HMB. Double immunolabeling of endometrial blood vessels in (F, H) control and 
(G, I) HMB. (F, G) Calponin and (H, I) smoothelin are silver/grey and endothelial cells, 
(F, G) UEA-1 and (H, I) CD31 in brown. Black arrows indicate calponin+/UEA-1+ and 
smoothelin+/CD31+ vessels. Images were captured at 200x original magnification. 
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functionalis. This demonstrated that the proportion of vessels expressing 
calponin was significantly decreased (P=0.001) in HMB compared with controls 
(Figure 3.6E). No significant differences were identified using the endothelial 
markers that expressed smoothelin. 
3.4.2 Pattern of stromal, glandular and vascular proliferation during the 
menstrual cycle 
The pattern of stromal, glandular and vascular proliferation in the menstrual 
cycle in control endometrium has been compared spatio-temporally (Figure 
3.7A-C). 
Stromal proliferation: Stromal proliferation was highest in the PP luminal region, 
reducing in ESP (P=0.008), before increasing again in LSP. The stratum 
functionalis followed the same pattern of stromal proliferation as was seen in 
the luminal region. Stromal proliferation was reduced in the stratum basalis; 
LSP showed the maximum proliferation, which was higher than in ESP 
(P=0.001). Finally, superficial myometrium showed negligible stromal 
proliferation which was significantly lower than in the luminal region (MSP 
P=0.005, LSP P=0.007) (Figure 3.7A). 
Glandular proliferation: Glandular proliferation was also highest in the PP in the 
luminal region, gradually decreasing in ESP, MSP to be lowest in LSP (P=0.006 
compared with PP). The stratum functionalis showed the same pattern; 
glandular proliferation was highest in PP and lowest in LSP (P=0.006 compared 
with PP). Although no difference was seen in glandular proliferation between 
the luminal region and the stratum functionalis, the stratum basalis showed 
lower glandular proliferation in PP compared with the luminal region (P=0.02) 
(Figure 3.7B). 
Vascular proliferation: Proliferation in the muscular vessels (MyHC+) differed 
across the menstrual cycle as well as between the layers. Vascular proliferation 
in the luminal region was the highest in PP compared with ESP (P=0.008). In 
the stratum functionalis vascular proliferation reduced from PP to ESP, but 
gradually increased in LSP. Vascular proliferation was negligible in the 
myometrium; compared with the luminal region (P=0.002 in PP) and the stratum 
functionalis (ESP P=0.004, MSP P=0.002, LSP P=0.004) (Figure 3.7C). 
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Figure 3.7: Graphical representation (mean ± SEM) of pattern of immunohistochemical 
staining for proliferation marker Ki67. Ki67 staining between phases (N=3, each phase) 
of the control menstrual cycle (proliferative, early secretory, mid secretory, late 
secretory) and in the different tissue layers (luminal, stratum functionalis, stratum 
basalis, myometrium) for (A) stroma, (B) glands (C) and vessels. Bars labelled with the 
same letter are significantly different from each other. (a-e) represent differences 
between phases within each layer, (A-G) represent differences between layers, within 
each phase. a, eP=0.008, bP=0.001, c, dP=0.006; AP=0.005, BP=0.007, CP=0.015, D, 
FP=0.002, E, GP=0.004. Pairwise Kruskal-Wallis one way ANOVA, with Bonferroni 
correction determined significant difference. 
  
 
3.4 RESULTS 
 
  
127 
3.4.3 Spatio-temporal pattern of vascular staining for different EC markers 
in the menstrual cycle is altered in HMB 
The different EC markers displayed different patterns of staining in the 
endometrium and myometrium (Figure 3.8A-P). 
3.4.3.1 Pattern of vascular staining for each EC marker between the phases 
of the menstrual cycle in the uterine tissue layers  
UEA-1: In the luminal region, UEA-1 reactivity was higher in LSP compared to 
MSP (P=0.006; Figure 3.9A). UEA-1 reactivity in the stratum functionalis was 
lower in MSP compared with ESP (P=0.002). In contrast, in stratum basalis and 
superficial myometrium there were no menstrual cycle differences for UEA-1 
(Figure 3.9A). 
F8RA: In all regions F8RA staining was unchanged from PP to MSP, but was 
reduced in LSP compared with ESP (luminal region P=0.006, stratum 
functionalis P=0.003, stratum basalis P=0.003, and myometrium P=0.002; 
Figure 3.9B).  
CD34: CD34 staining within endometrial layers and superficial myometrium was 
stable across the different phases of the menstrual cycle (Figure 3.9C).  
CD31: CD31 staining remained similar from PP to MSP before increasing in 
LSP compared with PP (Figure 3.9D) in the luminal region (P=0.007) and 
stratum functionalis (P=0.002). In contrast, CD31 staining in the myometrium 
remained similar from PP to MSP before decreasing in LSP compared with PP 
(P=0.003). In stratum basalis, CD31 staining did not vary with menstrual cycle 
phase (Figure 3.9D). 
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Figure 3.8: Staining for endothelial cell (EC) markers in the uterus. Layers of the uterus 
(myometrium, stratum basalis, stratum functionalis, luminal) showing vessels stained 
positive for (A-D) UEA-I, (E-H) F8RA, (I-L) CD34 and (M-P) CD31 during the mid 
secretory phase of the control menstrual cycle. Images were captured at 200x original 
magnification. 
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Figure 3.9: Graphical representation (mean ± SEM) of Quickscore assessment of 
immunohistochemical staining for endothelial cell (EC) marker stainingbetween phases 
(N=5, each phase) of the normal menstrual cycle in the tissue layers (luminal, stratum 
functionalis, stratum basalis, myometrium) for each EC marker (A-D) and between the 
different EC markers (UEA-1, F8RA, CD34, CD31) in the tissue layers for each 
menstrual cycle phase (E-H). Bars labelled with the same letter are significantly 
different from each other. (a-t) represent differences between phases or factors, within 
each layer, (A-J) represent differences between layers, within each phase. a, cP=0.006, 
b, f, h, tP=0.002, d, e, l, j, sP=0.003, gP=0.007, k, l, n, rP=0.001, m, qP<0.001, oP=0.005, 
pP=0.008; A, IP<0.001, B, C, HP=0.001, D, E, G, JP=0.002, FP=0.004. Pairwise Kruskal-Wallis 
one way ANOVA, with Bonferroni correction determined significant difference. 
  
 
3.4 RESULTS 
 
  
130 
3.4.3.2 Pattern of vascular EC marker staining between the uterine tissue 
layers in each phase of the menstrual cycle 
The pattern of staining for different EC markers showed a similar trend of a 
steady increase from the luminal region to the superficial myometrium during 
the menstrual cycle (Figure 3.8A-P). 
Proliferative phase: UEA-1 reactivity and F8RA staining was lower in the luminal 
region compared with myometrium (UEA-1 P<0.001, F8RA P=0.002; Figure 
3.9B). The pattern of CD34 staining differed (Figure 3.9C) with staining being 
lower in the luminal area compared with stratum functionalis (P=0.002). CD31 
staining showed a similar trend with lower staining in the luminal area compared 
with myometrium (P<0.001; Figure 3.9D). 
Early secretory phase: There was increased reactivity for UEA-1 (P=0.001; 
Figure 3.9A), F8RA (P=0.002; Figure 3.9B) and CD31 (P=0.002; Figure 3.9D) 
from the luminal region to myometrium. No difference between the tissue layers 
was observed for CD34 staining (Figure 3.9C). 
Mid-secretory phase: Staining or reactivity of the different EC markers in the 
MSP showed no significant changes between the tissue layers (Figure 3.9A-D). 
Late secretory phase: There was increased reactivity for UEA-1 (P=0.001; 
Figure 3.9A), F8RA (P=0.004; Figure 3.9B) and CD34 (P=0.001; Figure 3.9C) 
from the luminal region to myometrium. In contrast, CD31 staining remained 
unchanged between the endometrial layers and superficial myometrium (Figure 
3.9D). 
3.4.3.3 Comparative pattern of the different EC marker staining in the phases 
of the menstrual cycle in each uterine tissue layer 
Luminal region: CD34 showed highest staining in PP compared with CD31 
(P=0.003; Figure 3.9E) and in ESP compared with UEA-1 reactivity (P=0.001; 
Figure 3.9F). CD31 showed highest staining in MSP compared with UEA-1 
reactivity (P=0.008; Figure 3.9G) and in LSP compared with F8RA (P<0.001; 
Figure 3.9H). F8RA staining was absent in the luminal layer in the LSP.  
Stratum functionalis: CD34 showed highest staining compared with F8RA in PP 
(P=0.001; Figure 3.9E) and ESP (P=0.005; Figure 3.9F). CD31 staining was the 
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higher than F8RA in LSP (P=0.001; Figure 3.9H). Staining for F8RA in LSP was 
scarce. 
Stratum basalis: Staining for CD31 was higher in PP than F8RA (P=0.001; 
Figure 3.9E). The reactivity of the four EC markers was similar in ESP (Figure 
3.9F), MSP (Figure 3.9G) and LSP (Figure 3.9H) apart from F8RA, which 
showed lower staining compared with CD34 in LSP (P=0.003; Figure 3.9H). 
Myometrium: Myometrium showed variation in the reactivity of the EC markers 
with CD31 being higher than F8RA in PP (P<0.001; Figure 3.9E) and UEA-1 
being higher than F8RA in LSP (P=0.002; Figure 3.9H).  
3.4.3.4 Differences between the different vascular EC marker staining 
correlates to the proliferative state of the endometrial vessels 
An immunohistochemical labelling study (N=3 samples in each phase) was 
undertaken to investigate whether differences seen in the pattern of reactivity 
between the four different EC markers correlated to the proliferative state (Ki67+ 
staining, Figure 3.10A-D) of these vessels. In the luminal region, the percentage 
of UEA-I+ and F8RA+ vessels proliferating (Ki67+) was similar within PP/ESP 
and MSP/LSP. Strikingly there was a reduction in the percentage of UEA-1+ 
(P=0.009) and F8RA+ (P=0.04, Figure 3.10E) proliferating vessels (Ki67+) in the 
MSP/LSP compared with PP/ESP. In the luminal region and stratum 
functionalis, UEA-1+ vessels constituted the highest proportion (70%) of 
proliferating vessels in PP reducing to 51% in LSP. This was followed by CD31 
(46% in PP, reducing to 25% in LSP) and CD34 (40% in PP, reducing to 22% in 
LSP). Strikingly, F8RA showed the lowest proportion (34%) of proliferating 
vessels in PP further lowering to 14% in LSP. F8RA was significantly lower in 
both luminal region and stratum functionalis in PP, ESP and LSP (P=0.05 for 
all), compared with UEA-1 (Figure 3.10F-G). 
3.4.3.5 Pattern of vascular EC staining during the menstrual cycle is altered 
in HMB  
The mean Quickscore and standard error in the control and HMB groups are 
shown in Table 3.1. The pattern of reactivity of the different EC markers varied 
considerably in HMB compared with controls. Amongst the EC markers, CD34 
was most differently expressed in HMB, when compared with control samples. 
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Figure 3.10: Staining for vascular Ki67 in the control menstrual cycle. (A-D) Ki67+ 
vessels indicated by the dotted circles in proliferative, early secretory, mid secretory 
and late secretory phase. Images were captured at 200x original magnification. 
Graphical representation (mean ± SEM) of the percentage assessment of 
immunohistochemical staining for proliferation (Ki67, N=3, each phase) in vessels 
expressing UEA-1, F8RA, CD34 and CD31 in the control menstrual cycle in (E, F) 
luminal region and (G) stratum functionalis. (E) Mann-Whitney U test determined 
statistical significance between PP/ESP and MSP/LSP. Pairwise Kruskal-Wallis one 
way ANOVA, with Bonferroni correction determined significant difference between 
factors. (A-G) represent differences between factors, within each phase. 
A,B,C,E,F,GP=0.05, DP=0.046.  
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Interestingly, the majority of differences were detected in the LSP. 
Luminal region: Compared with controls, in HMB ECs showed reduced UEA-1 
reactivity in the PP (P=0.008) and LSP (P=0.008). Similarly, reduced CD31 
staining was observed in HMB in both MSP (P=0.008) and LSP (P=0.008). In 
contrast, compared with controls, staining for F8RA (P=0.008) and CD34 
(P=0.008) in the luminal area was increased in HMB in LSP, although staining 
for F8RA was still low (Table 3.1). 
Stratum functionalis: Staining or reactivity of the four EC markers varied 
between controls and women with HMB, especially in MSP and LSP (Table 
3.1). In particular in HMB ECs were less reactive to UEA-1 in PP (P=0.008) and 
LSP (P=0.008) and also expressed lower CD31 in both MSP (P=0.008) and 
LSP (P=0.008). In contrast, staining for CD34 was increased in MSP (P=0.008) 
in HMB (Table 3.1). 
Stratum basalis: Staining or reactivity of EC markers in stratum basalis also 
differed in HMB but the changes were less extensive and were only seen for 
CD34 and CD31. While CD34 staining was increased in ESP (P=0.008) and 
LSP (P=0.008), CD31 staining was reduced in LSP (P=0.008) (Table 3.1). 
Myometrium: UEA-1 reactivity in myometrium did not differ between control and 
HMB samples. F8RA staining was decreased in ESP (P=0.008) in HMB but 
CD34 staining was increased in all menstrual cycle phases in HMB (PP 
P=0.008, ESP P=0.008, MSP P=0.008, LSP P=0.008). CD31 staining in LSP 
(P=0.008) was also increased in HMB compared with controls (Table 3.1). 
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Table 3.1: Mean immunohistochemical Quickscore (standard error) for EC markers in endometrial vessels in control and HMB  
 
Values represent mean (±SEM); a-tP=0.008, data in bold with same superscript are significantly different from each other, while those without are non-significant. 
HMB-Heavy menstrual bleeding; PP-Proliferative phase; ESP-Early secretory phase; MSP-Mid secretory phase; LSP-Late secretory phase 
 Luminal (N=5) Stratum Functionalis (N=5) Stratum Basalis (N=5) Myometrium (N=5) 
  Control    HMB   Control    HMB   Control    HMB   Control    HMB 
UEA-1 
PP 2.60a (0.24) 1.00a (0.00) 5.00b (0.00) 2.60b (0.40) 6.00 (0.32) 5.00 (0.55) 9.40 (0.40) 9.20 (0.37) 
ESP 2.60 (0.60) 1.80 (0.49) 5.40 (0.40) 3.60 (0.81) 7.00 (0.63) 5.80 (0.49) 9.00 (0.63) 8.60 (0.81) 
MSP 1.20 (0.20) 2.40 (0.40) 3.20 (0.49) 4.20 (0.58) 4.60 (1.29) 5.80 (0.73) 6.40 (1.66) 8.80 (0.58) 
LSP 3.20c (0.20) 1.00c (0.00) 4.60d (0.24) 2.20d (0.20) 6.60 (0.40) 4.20 (0.37) 9.80 (0.73) 6.00 (0.55) 
F8RA 
PP 3.20 (0.20) 4.00 (0.55) 3.80 (0.37) 4.40 (0.40) 5.40 (0.24) 6.20 (0.37) 6.60 (0.24) 7.20 (0.20) 
ESP 4.00 (0.63) 3.00 (0.00) 5.00 (0.55) 2.60 (0.24) 6.60 (0.40) 4.80 (0.20) 8.40e (0.40) 4.80e (0.37) 
MSP 2.00 (0.84) 2.60 (0.24) 3.20 (0.80) 3.80 (0.49) 4.20 (1.07) 4.40 (0.24) 4.80 (1.24) 6.00 (0.32) 
LSP 0.00f (0.00) 1.40f (0.24) 0.60 (0.24) 1.80 (0.20) 3.20 (0.20) 2.00 (0.45) 3.80 (0.49) 2.60 (0.68) 
CD34 
PP 5.80 (0.37) 6.00 (0.63) 8.60 (0.40) 7.40 (0.24) 7.20 (0.20) 8.20 (0.49) 8.00g (0.00) 10.00g (0.45) 
ESP 8.60 (0.40) 7.60 (0.24) 7.80 (0.20) 8.60 (0.24) 7.80h (0.20) 9.00h (0.00) 7.80i (0.20) 10.60i (0.24) 
MSP 5.60 (1.08) 8.00 (0.45) 6.00j (0.63) 8.80j (0.20) 6.60 (1.66) 9.40 (0.24) 6.40k (1.60) 10.60k (0.24) 
LSP 5.80l (0.20) 8.00l (0.32) 6.80 (0.20) 8.60 (0.40) 7.40m (0.24) 9.40m (0.24) 8.40n (0.24) 10.60n (0.24) 
CD31 
PP 2.20 (0.37) 2.80 (0.20) 4.60 (0.40) 5.00 (0.00) 9.00 (0.00) 7.80 (0.80) 11.00 (0.00) 9.80 (0.80) 
ESP 6.20 (0.49) 6.80 (0.20) 7.00 (0.00) 6.80 (0.20) 8.60 (0.40) 8.60 (0.24) 10.20 (0.37) 9.60 (0.24) 
MSP 7.40o(0.24) 2.80o (0.20) 7.00p (0.00) 5.00p (0.00) 6.00 (1.52) 7.60 (0.68) 5.60 (1.40) 9.00 (0.55) 
LSP 7.40q (0.40) 5.00q (0.00) 7.40r (0.40) 5.00r (0.00) 7.20s (0.20) 4.20s (0.49) 5.60t (0.40) 8.80t (0.20) 
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3.4.4 Spatio-temporal pattern of vascular extracellular matrix (ECM) 
staining in normal menstrual cycle is altered in HMB 
The pattern of staining for the ECM components varied both during the different 
menstrual cycle phases and between myometrium and the different endometrial 
layers (Figure 3.11A-L). 
3.4.4.1 Pattern of vascular ECM staining in the phases of the control 
menstrual cycle in each uterine tissue layer 
Stratum functionalis: Osteopontin staining was highest in PP, decreasing in 
MSP (P=0.003; Figure 3.12A). Staining for laminin, fibronectin and collagen IV 
in stratum functionalis remained similar throughout the menstrual cycle (Figure 
3.12B-D). 
Stratum basalis: The stratum basalis showed both lower staining for some ECM 
components and variation compared with stratum functionalis. Osteopontin 
staining remained unchanged during the menstrual cycle phases (Figure 
3.12A). Laminin was scarcely expressed in stratum basalis at all menstrual 
cycle phases (Figure 3.12B). Fibronectin staining was also low and was stable 
apart from a decrease in LSP compared with MSP (P=0.005; Figure 3.12C). 
While collagen IV was absent in PP stratum basalis, it increased in ESP and 
remained stable thereafter in MSP and LSP (Figure 3.12D). 
Myometrium: Myometrial ECM staining did not differ across the menstrual cycle 
with stable staining of osteopontin, laminin, fibronectin and collagen IV (Figure 
3.12A-D). 
3.4.4.2 Pattern of vascular ECM staining between the uterine tissue layers in 
each phase of the normal menstrual cycle 
Vascular staining of the different ECM components differed between stratum 
functionalis, stratum basalis and myometrium (Figure 3.11A-L). 
Proliferative phase: Vascular osteopontin staining was highest in stratum 
functionalis compared with myometrium (P=0.002; Figure 3.12A). Laminin 
staining was low in PP and did not differ between the three layers (Figure 
3.12B). Fibronectin staining did not differ between the three layers 
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Figure 3.11: Staining for extracellular matrix components in the uterus. Uterine layers 
(myometrium, stratum basalis, stratum functionalis), showing vessels immunopositive 
for (A-C) osteopontin, (D-F) laminin, (G-I) fibronectin and (J-L) collagen IV during the 
mid secretory phase of the control menstrual cycle. Arrows indicate vascular 
extracellular matrix components. Images were captured at 200x original magnification. 
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Figure 3.12: Immunohistochemical staining for pattern of staining for vascular 
extracellular matrix (ECM) markers in the control menstrual cycle. Graphical 
representation (mean ± SEM) of Quickscore assessment of ECM markers between 
phases (N=5, each phase) of the control menstrual cycle (proliferative, early secretory, 
mid secretory, late secretory) in the tissue layers (stratum functionalis, stratum basalis, 
myometrium) for each ECM marker (osteopontin, laminin, fibronectin, collagen IV) (A-
D). (a, b) represent differences between phases or factors, within each layer, (A-H) 
represent differences between layers, within each phase. aP=0.003, bP=0.005; 
AP=0.002, BP=0.02, CP=0.005, DP=0.003, EP=0.004, FP=0.001, GP=0.01, HP=0.01. 
Pairwise Kruskal-Wallis one way ANOVA, with Bonferroni correction determined 
significant difference. 
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(Figure 3.12C). Collagen IV was absent from the stratum basalis in PP, with 
higher staining in myometrium (P=0.01; Figure 3.12D). 
Early secretory phase: Osteopontin staining did not differ between the stratum 
functionalis, stratum basalis and myometrium (Figure 3.12A). Vascular laminin 
staining was low throughout but was higher in stratum functionalis compared 
with stratum basalis (P=0.005; Figure 3.12B). Fibronectin staining was also 
higher in stratum functionalis compared with stratum basalis (P=0.003; Figure 
3.12C). Similarly collagen IV showed highest staining in stratum functionalis 
with lowest staining in myometrium (P=0.01; Figure 3.12D). 
Mid secretory phase: Osteopontin staining was higher in myometrium than 
stratum functionalis (P=0.02; Figure 3.12A). Laminin staining was low in MSP 
and did not differ between the layers (Figure 3.12B). Unlike laminin, fibronectin 
was highly present in the stratum functionalis in MSP but was decreased in 
myometrium (P=0.004; Figure 3.12C). In contrast, collagen IV staining in MSP 
was low in both stratum functionalis and myometrium (Figure 3.12D). 
Late secretory phase: There was no variation in staining between the three 
layers for osteopontin, laminin and collagen IV (Figure 3.12A,B,D). However, 
fibronectin staining was higher in stratum functionalis compared with stratum 
basalis (P=0.002; Figure 3.12C). 
3.4.4.3 Pattern of vascular ECM staining during the menstrual cycle is altered 
in HMB 
The Quickscore (mean and standard error) for each ECM component for the 
control and HMB groups are shown in Table 3.2. Differences in ECM 
component staining between HMB and controls were most common in the 
stratum basalis followed by the stratum functionalis and all variations were 
observed in the secretory phases. Amongst the ECM components, collagen IV 
showed most differences in HMB, followed by osteopontin and fibronectin 
(Table 3.2). 
The pattern of vascular laminin staining did not differ between controls and 
women with HMB throughout the menstrual cycle. Compared with controls, 
vascular fibronectin staining was reduced in MSP stratum basalis (P=0.006) in 
HMB (Table 3.2). 
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Compared with controls, in HMB osteopontin staining was increased in the LSP 
(P=0.008) in the stratum functionalis but decreased in the ESP in stratum 
basalis (P=0.008; Table 3.2). The pattern of collagen IV staining differed most 
between HMB and controls and was decreased compared with controls in the 
stratum functionalis in ESP (P=0.008) and in the stratum basalis in ESP 
(P=0.007) and MSP (P=0.002; Table 3.2). In the myometrium, however, 
collagen IV staining remained unaltered compared with controls. 
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Table 3.2: Mean immunohistochemical Quickscore (standard error) for ECM components in endometrial vessels in control and HMB 
 
a,b,dP=0.008, cP=0.006, eP=0.007, fP=0.002; data in bold with same superscript are significantly different from each other, while those without are non-significant. PP-
Proliferative Phase; ESP-Early Secretory Phase; MSP-Mid Secretory Phase; LSP-Late Secretory Phase 
 Stratum Functionalis (N=5) Stratum Basalis (N=5) Myometrium (N=5) 
  Control    HMB   Control    HMB   Control    HMB 
Osteopontin 
PP 11.00 (0.00) 9.20 (0.66) 7.80 (0.49) 7.20 (0.37) 6.80 (0.20) 6.80 (0.58) 
ESP 9.60 (0.60) 8.00 (0.95) 9.40a (0.24) 6.00a (0.84) 8.80 (0.58) 7.20 (0.49) 
MSP 6.40 (0.24) 7.20 (0.97) 7.40 (0.40) 6.40 (1.40) 7.80 (0.20) 5.80 (1.07) 
LSP 7.20b (0.49) 11.20b (0.37) 6.40 (0.75) 7.40 (0.24) 7.00 (0.84) 7.40 (0.51) 
Laminin 
PP 1.40 (0.68) 3.60 (0.81) 0.20 (0.20) 0.40 (0.24) 1.40 (0.40) 1.20 (0.20) 
ESP 2.00 (0.45) 1.60 (0.68) 0.00 (0.00) 0.20 (0.20) 0.40 (0.24) 1.20 (0.37) 
MSP 1.40 (0.40) 5.40 (1.50) 0.60 (0.40) 0.40 (0.24) 1.00 (0.32) 0.40 (0.24) 
LSP 3.20 (1.39) 3.40 (1.47) 0.40 (0.40) 1.60 (0.40) 1.20 (0.20) 1.20 (0.20) 
Fibronectin 
PP 6.60 (1.29) 4.40 (1.47) 1.40 (0.68) 1.20 (0.49) 3.60 (1.21) 2.00 (0.95) 
ESP 8.00 (0.32) 5.40 (1.03) 1.20 (0.20) 1.60 (0.87) 2.20 (0.49) 1.00 (0.55) 
MSP 8.20 (0.80) 4.80 (1.32) 3.20c (0.20) 1.20c (0.49) 2.20 (0.73) 0.60 (0.60) 
LSP 6.20 (0.37) 7.20 (1.32) 0.40 (0.40) 3.40 (1.03) 2.00 (0.00) 3.00 (1.00) 
Collagen IV 
PP 2.40 (0.60) 1.40 (0.68) 0.00 (0.00) 0.00 (0.00) 3.00 (0.63) 3.80 (0.20) 
ESP 7.00d (0.71) 3.40d (0.40) 4.60e (0.60) 1.20e (0.20) 3.60 (0.40) 3.60 (0.60) 
MSP 1.80 (0.37) 4.80 (1.50) 4.60f (0.24) 1.60f (0.98) 2.00 (0.77) 3.20 (1.39) 
LSP 6.20 (1.16) 3.20 (0.73) 3.60 (0.60) 2.80 (0.58) 4.00 (0.32) 6.20 (0.58) 
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3.4.5 Menstrual cycle distribution of leukocytes is altered in HMB 
3.4.5.1 Distribution of leukocytes during the menstrual cycle is altered in 
HMB 
Endometrial samples (N=5 each menstrual cycle phase) were immunostained 
for CD3 (T cells and uNK cells), CD8 (cytotoxic T cells), CD14 (macrophages), 
CD56 (uNK cells), CD83 (dendritic cells) and FOXP3 (regulatory T cells, Tregs) 
(Figure 3.13A-X). During the normal menstrual cycle CD3+ cells accounted for 
5.7% of total stromal cells in the PP, which decreased in the ESP (P=0.01) 
before increasing in the LSP (P=0.01), compared with PP (Figure 3.14). 
Additionally, compared with ESP, the percentage of CD3+ cells was increased 
in both MSP (P=0.001) and LSP (P<0.001). However, no significant variation 
was observed in the percentage of CD8+ cytotoxic T cells and CD14+ 
macrophages throughout the control menstrual cycle, and CD83+ dendritic cells 
and FOXP3+ Tregs remained scarce throughout (Figure 3.14). CD56+ uNK cells 
were least common in PP (2.13 ± 0.31) and ESP (2.09 ± 0.24), but their 
percentage increased in MSP (6.34 ± 0.57, P=0.002) and peaked in LSP (16.95 
± 1.10, P<0.001) compared with PP. Again, compared with ESP, the proportion 
of CD56+ uNK cells was increased in both MSP (P=0.002) and LSP (P<0.001; 
Figure 3.14). 
During the menstrual cycle of women with HMB CD8+ T cells, macrophages, 
dendritic cells and regulatory T cells, showed no difference as a proportion of 
the endometrial stromal cells compared with controls (Figure 3.14B-C, Figure 
3.14E-F). The CD3+ cell population was reduced in the MSP (P=0.01), but 
increased in the LSP (P=0.01) in HMB (Figure 3.14A). The CD56+ uNK cell 
population showed the most alteration in HMB (Figure 3.14D). While the 
percentage of CD56+ cells was increased in both PP (P<0.01) and ESP 
(P<0.02) in HMB compared with controls, in the LSP the proportion of uNK cells 
was reduced in HMB (P<0.01). 
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3.4.5.2 Altered uNK cell staining in HMB is due to an alteration in the 
proportion of CD56+CD3+ cell population 
A double immunohistochemical labelling study (N=3 samples per group for each 
of MSP and LSP) was undertaken to investigate whether the proportion of 
CD56+ positive cells, which express CD3 is altered in HMB (Figure 3.15A-D). 
The percentage of CD56+ cells within the total CD3+ cell population was 
reduced in the stratum functionalis in the LSP in women with HMB, compared 
with controls (P=0.05). Moreover, the proportion of CD3+CD56+ double positive 
cells within the total CD56+ cell population reduced in the stratum functionalis in 
the LSP in women with HMB, compared with controls (P=0.05) (Figure 3.15E-
F). 
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Figure 3.13: Immunohistochemical labeling for leukocytes in the stratum functionalis of 
endometrium in HMB.  Arrows indicate CD3+ cells (A-D), CD8+ T cells (E-H), CD14+ 
macrophages (I-L), CD56+ uNK cells (M-P), CD83+ dendritic cells (Q-T), and FOXP3+ 
regulatory T cells (U-X), during the proliferative, early secretory, mid secretory and late 
secretory phases of the menstrual cycle. Images were captured at 200x original 
magnification. 
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Figure 3.14: Endometrial leukocyte population as a proportion of the total stromal cells 
at each phase of the menstrual cycle in controls and in HMB. Proportion of CD3+ cells 
(A), CD8+ T cells (B), CD14+ macrophages (C), CD56+ uNK cells (D), CD83+ dendritic 
cells (E) and FOXP3+ regulatory T cells (F) in stratum functionalis of the endometrium 
across the phases of the menstrual cycle in controls and in HMB (N=5 in each phase). 
The line graphs show mean ± standard error of mean (SEM) of the percentage 
population of leukocytes as a proportion of total stromal cells at each phase of the 
menstrual cycle. Non-parametric Mann-Whitney U test, with Bonferroni correction for 
multiple comparisons was used to determine significance. 
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Figure 3.15: Double immunolabeling for CD3+ cells and CD56+ uNK cells in the mid 
secretory and late secretory phases in stratum functionalis of control (A, B) and HMB 
samples (C, D). CD3+ cells are red and CD56+ cells are silver. The black arrows 
indicate CD3+CD56+ cells. Images were captured at 400x original magnification. Bar 
chart with a standard error mean (SEM) represents the mean percentage of 
CD3+CD56+ cells as a proportion of all CD3+ cells (E) and that of CD3+CD56+ cells as a 
proportion of all CD56+ cells (F) in control and HMB samples. Mann-Whitney U test 
was used to determine statistical significance. 
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3.5 DISCUSSION 
3.5.1 Vascular smooth muscle content and differentiation during the 
menstrual cycle 
The current study showed that the muscle content of vessels in the stratum 
functionalis measured as a proportion of the vascular cross-sectional area 
increased from the proliferative to the late secretory phase (Figure 3.3). 
However, this pattern did not alter between control and HMB groups (Figure 
3.4). Moreover, vascular calponin staining in relation to both the total number of 
vessels and to αSMA+ vessels was significantly decreased in women with HMB, 
suggesting an alteration in vascular smooth muscle cell differentiation status 
(Figure 3.6). Vascular smooth muscle cells form an integral part of the structure 
and normal functioning of the endometrial spiral arteries and arterioles and 
therefore may play an important role in abnormal bleeding disorders such as 
HMB. Understanding the healthy functioning of the uterus, especially the 
endometrial vasculature may thus provide significant clues to advance the 
development of effective, and less invasive treatments, to improve the quality of 
life for thousands of women suffering from HMB.  
Previous studies have suggested that the structure and/or function of 
endometrial spiral arteries and arterioles may play a role in HMB, but little is 
known about the underlying mechanisms. Abberton et al. (1999b) and 
Hurskainen et al. (1999) reported that menorrhagic women had increased 
volume and rate of blood flow through the endometrial vessels. This increased 
blood flow rate may be explained by either increased vasodilation or poor 
vasoconstriction. If vasodilation is caused by relaxation of the vascular smooth 
muscle cells of the vessel wall, it is possible that differences may lie in the 
vascular muscle content and thickness in HMB endometrium. 
The current study examined whether the thickness of VSMCs differed between 
controls and women with HMB during the different menstrual cycle phases. 
Previous studies have shown no difference in the endometrial microvascular 
density in women with HMB compared with controls (Abberton et al., 1999b). 
This study has extended these findings to demonstrate that, while the 
percentage of muscularised blood vessels increased across the menstrual 
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cycle, there was no difference between controls and women with HMB. In 
addition, in αSMA+ vessels, the proportion of vascular cross-sectional area 
accounted for by VSMCs did not differ between controls and women with HMB 
(Figure 3.3-3.4). This result is partially consistent with that of Abberton et al. 
(1999a) who reported no difference in the muscle thickness of spiral arterioles 
between control and menorrhagic tissue during the menstrual cycle, although 
there was a decrease in muscle thickness in straight arterioles in the late 
secretory phase in HMB. These differences may be explained by the fact that 
our study included both straight and spiral arteries/arterioles, while Abberton et 
al. (1999a) analysed these separately. Furthermore, assessment of vessel 
muscle content by Abberton et al. (1999a) was based on the number of VSMC 
layers surrounding the vessel rather than as a ratio of the total vessel cross 
sectional area, as reported in the current study. Overall, these data suggest that 
the number and muscle content of endometrial blood vessels is not 
substantially altered in HMB and that any underlying vascular abnormalities are 
more subtle.  
VSMCs play a major role in contraction and control of blood flow by monitoring 
vascular tonicity and diameter and consequently in maintenance of blood 
pressure. They express a range of proteins as differentiation markers. αSMA is 
one of the earliest markers of VSMC differentiation, while calponin and h-
Caldesmon are expressed later (Glukhova et al., 1986; Glukhova et al., 1990; 
Frid et al., 1992; Owens, 1995). Myosin heavy chain 1 (MyHC1) is expressed 
prior to MyHC2 (Kocher et al., 1991; Aikawa et al., 1993; Miano et al., 1994; 
Owens, 1995; Owens et al., 2004), whereas smoothelin is expressed in 10-11 
week placental tissue (van der Loop et al., 1997). Combining these a 
chronological pattern of staining for VSMC differentiation markers could be 
deduced as αSMA, h-Caldesmon and calponin, MyHC1, smoothelin and finally 
MyHC2. However, it is not known whether the order of this sequential 
differentiation is similar in endometrial vessels to other vessels; nor is it known 
whether a change in the differentiation status can potentially lead to altered 
vascular function.  
Desmin is the major intermediate filament in smooth muscle and is thought to 
contribute to maintaining mechanical strength and contractility (reviewed by 
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Paulin and Li et al. 2004). However, desmin was not expressed by endometrial 
blood vessels at any stage of the menstrual cycle, perhaps suggesting an 
alternative mechanism of maintaining mechanical integrity and contractile 
function in these vessels. MyHC (both SM1 and SM2 were detected by the 
antibody used) was the most abundantly detected VSMC marker throughout the 
menstrual cycle in both subject groups, while the staining patterns of smoothelin 
and calponin were the most highly variable, both with menstrual cycle phase 
and between control and HMB groups. This difference suggests a change of 
differentiation status of VSMCs in HMB that may reflect altered function, 
particularly in the late secretory phase of the menstrual cycle just prior to 
menstruation. In contrast to our findings, Abberton et al. (1999a) reported 
decreased MyHC staining in spiral arterioles in the early secretory phase in 
HMB (Abberton et al., 1999a). However, as stated, our study included spiral and 
straight arterioles and recorded MyHC staining only in vessels that expressed 
αSMA, while Abberton et al. (1999a) measured MyHC staining independent of 
αSMA using a quick scoring method: integrated optical density x proportional 
area. While both methods have merits, by analysing staining for VSMC 
differentiation markers in relation to all αSMA+ vessels, we hoped to also detect 
differences in the chronological pattern of differentiation in the VSMCs between 
control and HMB samples.  
There was an inverse relationship between smoothelin and calponin staining in 
the late secretory phase; the proportion of αSMA+/smoothelin+ vessels 
increased in the late secretory phase in HMB compared with controls, whereas 
that of αSMA+/calponin+ vessels decreased (Figure 3.3). Double 
immunohistochemical labelling also showed a decrease in the proportion of 
calponin expressing vessels in HMB, compared with the total number of vessels 
detected using endothelial markers. The fact that some of these differentiation 
markers manifest a more restricted distribution than others in endometrial 
vessels raises an important question; do the differences in distribution indicate 
their stage of differentiation or do they reflect functional differences? Further 
future functional studies examining these possibilities are therefore warranted, 
which could in turn indicate potential therapeutic targets. 
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Smoothelin is a major contributor to the contractile properties of VSMCs and 
has two isoforms; smoothelin A, expressed in viscera, and smoothelin B, which 
is specifically present in VSMCs (Rensen et al., 2002; van Eys et al., 2007). 
Rensen et al. (2008)  reported that smoothelin B deficient mice had significantly 
reduced arterial contractility and increased basal mean arterial pressure (MAP), 
which may be attributed to a simultaneous reduction in vasodilation. The rate of 
muscle contraction is determined by acto-myosin cross-bridge cycling and the 
rate of muscle shortening (shortening velocity); the co-operation between these 
acto-myosin cross-bridges in turn depends on proteins such as h-Caldesmon 
and calponin (Butler and Siegman, 1998; Fitzsimons et al., 2001; Morgan and 
Gangopadhyay, 2001). Interestingly, smoothelin B consists of a ‘calponin 
homology domain’, which is capable of binding to αSMA in VSMCs (van Eys et 
al., 2007). In support of this, Schildmeyer et al. (2000) showed that αSMA null 
mice had abnormal vasoconstriction as well as impaired vasodilation. 
Therefore, deficiency or aberrant expression of smoothelin B may result in 
impaired vasodilation (Li and Hui, 2009). Increased smoothelin may facilitate 
contractility and vasodilation leading to increased blood flow. In this study we 
have shown such an increase in smoothelin in the late secretory phase, 
perhaps indicating increased vasocontraction and vasodilation as an underlying 
mechanism for HMB.  
Calponin h1 (or basic calponin) is a smooth muscle specific protein, which binds 
to actin and plays a significant role in regulation of the contractile apparatus in 
VSMCs (Walsh et al., 1993; Lu et al., 1995; Stafford et al., 1995). In aortic 
smooth muscle, shortening velocity is a direct measure of rate of vessel 
contraction and consequently blood flow; increased shortening velocity 
increases the rate of vessel contraction, thereby increasing the rate of blood 
flow per unit time. Takahashi et al. (2000) reported that calponin plays a role in 
regulating cross-bridge cycling and shortening velocity and consolidated 
previous findings that calponin slowed shortening velocity in both tonic and 
phasic smooth muscle (Jaworowski et al., 1995; L-Mezgueldi and Marston, 
1996; Malmqvist et al., 1997; Takahashi et al., 2000). The same group also 
reported that decreased calponin leads to an increase in cross-bridge cycle, i.e. 
increased shortening velocity and therefore increased rate of contraction and 
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blood flow (Fujishige et al., 2002). In the present study there was a significant 
decrease in calponin in the late secretory phase of the menstrual cycle in HMB 
(Figure 3.3). It is possible that reduced calponin leads to increased shortening 
velocity leading to an increased rate of contraction and blood flow in HMB. This 
hypothesis is also in line with our findings on smoothelin; increased smoothelin 
expression may facilitate contractility and vasodilation leading to increased 
blood flow. It should be noted, however, that in contrast with the pump vessels 
investigated in the studies described above, the endometrial vessels are 
thought to be resistance vessels and the mechanism of blood flow in these 
vessels may therefore differ. An alternative explanation for the present results 
could be that the changes in the pattern of expression of the differentiation 
markers may have caused a functional change in the endometrial vasculature, 
such that these vessels operate in a pumping manner similar to those in the 
cardiovascular system. 
Vascular smooth muscle cell differentiation results from the co-ordinated 
transcriptional activation of an array of contractile genes including calponin, 
MyHC, αSMA. Most of these genes carry the transcription binding code, CArG 
box (Minty and Kedes, 1986; Sun et al., 2006). This binds to the serum 
response factor (SRF) transcription factor with differing affinity, thus regulating 
its activation (Miano et al., 2007). However SRF expression is not specific to 
VSMCs; cell specific activation is achieved through the expression of a SMC 
specific co-factor, myocardin (MYCOD) (Wang et al., 2001; Chen et al., 2002). 
In VSMCs, the CArg-SRF-MYCOD acts as the primary transcriptional switch, 
which maintains a physiologically normal functioning SMC phenotype (Long et 
al., 2008). The fact that these contractile genes share a co-ordinated regulation 
may lead to the assumption that their expression pattern (presence or absence) 
may also be co-ordinated. However, our results indicate a decrease of calponin 
without any significant alteration in expression of the other contractile proteins 
between the control and HMB groups. One explanation for this could be 
differences in the CArG positioning between calponin and the other contractile 
protein encoding genes (Miano et al., 2000). Moreover, calponin has another 
layer of complexity such that the positioning of CArG elements must also follow 
a strict positional relationship with other genomic elements (Long et al., 2011). 
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Therefore the specific dysregulation of calponin expression shown in this study 
indicates the possibility of a novel calponin regulatory pathway. 
3.5.2 Stromal, glandular and vascular proliferation during the normal 
menstrual cycle 
The current study showed that proliferation, as marked by Ki67 expression, in 
the stroma, glandular epithelium or vessels, was highest in general in the 
luminal region, closely followed by the stratum functionalis. Strikingly, 
proliferation was lower in the stratum basalis and scarce or negligible in the 
superficial myometrium (Figure 3.7). Although several studies have previously 
compared stromal and glandular proliferation across the phases of the 
menstrual cycle in the context of endometriosis (Jones et al., 1995), 
cyclins/cyclin-dependant kinases (Shiozawa et al., 1996), endometrial 
granulated lymphocytes (Jones et al., 1998), steroid receptors and apoptosis 
(Dahmoun et al., 1999; Mertens et al., 2002), endometrial polyps (Maia et al., 
2004) and out of phase endometrium from infertile and recurrent abortion 
patients (Meresman et al., 2010), comparison of stromal, glandular and vascular 
proliferation has never been done between the layers of the endometrium and 
superficial myometrium. In the current study glandular proliferation across the 
menstrual cycle was in agreement with previous findings (Shiozawa et al., 1996; 
Jones et al., 1998; Dahmoun et al., 1999; Maia et al., 2004). The present study 
showed that stromal proliferation was highest in PP, reducing significantly in 
ESP, before rising back in the LSP (Figure 3.7). This is in line with the 
observations of Shiozawa et al. (1996), but it differs from those observed by 
Jones et al. (1995, 1998) and Dahmoun et al. (1999): in contrast with our 
findings these studies reported no difference between PP and ESP and a 
significant decrease in LSP, followed by an increase in the premenstrual phase. 
These differences may to some extent be explained by differences in the 
methodologies used. Firstly, in these studies samples were grouped as 
proliferative (days 5-13), early secretory (days 14-22) and late secretory (day 23 
onwards), whereas we had four groups separated histologically; proliferative, 
early secretory, mid secretory and late secretory. Secondly, the previous 
studies had counted numbers of cells positively stained for Ki67 as a 
percentage of the total stromal cell population, whereas the current study used 
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a Quickscore method taking into consideration both the percentage of cells 
stained and their staining intensity. Finally the previous studies had examined 
either superficial endometrium or endometrium as a whole, whereas the present 
study assessed endometrium as three separate regions; the luminal region, 
stratum functionalis and stratum basalis. It is of interest to highlight, that the 
current study revealed significant differences between the luminal region and 
stratum functionalis compared with stratum basalis. 
The increase in stromal, glandular and vascular proliferation from superficial 
myometrium towards the surface or luminal region of the endometrium shown in 
the current study, highlights the differences in developmental stage of the 
stroma, glands and vessels between the tissue layers. Moreover it indicates that 
there is minimal growth in the myometrium followed by stratum basalis and 
majority of the stromal, glandular and vascular remodeling takes place in the 
stratum functionalis and the luminal region. Importantly, taken together it 
suggests that at the end of menstruation, when a new layer of stratum 
functionalis regenerates, the stroma, glands and vessels grow outwards and 
that the less mature and more proliferative ends of the vessels, glands or layers 
of stroma remain nearest to the surface. 
3.5.3 Vascular EC staining during the menstrual cycle 
The current study showed that vascular endothelial cell markers were 
differentially expressed across the menstrual cycle and between the different 
endometrial layers and myometrium in controls. Moreover, distinct differences 
were observed in HMB for UEA-1, F8RA, CD34 and CD31 (Figure 3.9).  
ECs in existing blood vessels migrate and form tubules marking the first step in 
blood vessel development and extension (Girling and Rogers, 2005). ECs 
communicate with VSMCs under the action of angiogenic growth factors and 
receptors, which in turn increases their interaction with the ECM and as a result 
stabilises the structure of the blood vessel (Kayisli et al., 2006; Demir et al., 
2010). Importantly, during the menstrual cycle, depending on tissue 
requirements, angiogenesis is spatio-temporally regulated (Gargett and Rogers, 
2001). Therefore, if angiogenesis is tightly regulated during the menstrual cycle, 
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it is possible that there exists a distinct pattern of EC marker staining and that 
any alteration in this pattern may underlie HMB. 
Previous studies in our laboratory had observed differential reactivity/expression 
with UEA-1, F8RA, CD34 and CD31 with variation between different layers of 
the endometrium. In the present study we have shown distinct patterns for 
individual EC markers across the menstrual cycle. CD31 and CD34 were 
expressed at the highest levels (Figure 3.9). CD31 has previously been 
reported to be expressed by both large and small endometrial vessels (Rees et 
al., 1993; Zhang et al., 2002). In contrast, CD34 primarily detected small and 
medium vessels and capillaries, while UEA-1 was reactive with all types of 
vessels (Zhang et al., 2002). F8RA was reported to be expressed only by larger 
vessels (Rees et al., 1993) with weak staining across the menstrual cycle 
(Zhang et al., 2002). Rees et al. (1993) documented no variation in staining for 
CD31, CD34 or F8RA either across the menstrual cycle or between 
endometrium and myometrium. In contrast, in agreement with Zhang et al. 
(2002) we observed menstrual cycle differences in EC staining for each marker 
investigated (Figure 3.9). Differences between our study and that of Zhang et 
al. (2002), are likely to reflect their division of the proliferative phase into early, 
mid and late, while we assessed proliferative phase endometrium as a whole. 
Moreover, we used a modified Quickscore system to analyse the 
immunohistochemical staining, while their analysis was based on a four-point 
scale (absent, weak, moderate and strong). In the present study, UEA-1 
reactivity was present throughout the menstrual cycle and the level of CD34 
staining remained almost unaltered during the menstrual cycle. F8RA was 
weakly expressed in the endometrium and decreased during the secretory 
phase, especially in the luminal region and stratum functionalis in LSP (Figure 
3.9). Although this contrasts with Rees et al. (1993), who found no difference 
between the phases, it agrees with earlier findings by both Zhu and Zhao 
(1988) and Zhang et al. (2002). CD31 staining increased from PP to LSP in the 
luminal region and the stratum functionalis, again in agreement with Zhang et 
al. (2002) but contrasting with Tawia et al., (1993), who did not detect any 
alteration in CD31 staining across the menstrual cycle. Tawia et al. (1993) 
quantified staining intensity in the entire endometrium, whereas the Quickscore 
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method used in the present study assessed both staining intensity and the 
proportion of positively stained vessels separately in the luminal, functional and 
basal regions of endometrium. To summarise, staining for each EC marker 
differed in a spatio-temporal manner; therefore care must be exercised in 
selecting EC markers for studies of endometrial vessels, especially in the 
superficial functional parts of the endometrium. 
UEA-1 reactivity differed from F8RA, CD34 and CD31 staining within the same 
phase of the menstrual cycle specially in the luminal region and stratum 
functionalis (Figure 3.9). To investigate whether these differences reflected 
altered vessel development, Ki67 was used to assess the proportion of 
proliferating vessels separately in the stratum functionalis and luminal region for 
each of the four EC markers. UEA-1 was the best marker of ECs in proliferating 
vessels, whereas F8RA was expressed by the lowest proportion of proliferating 
vessels with decreasing stain from ESP to LSP. The proportion of UEA-1+ and 
F8RA+ proliferating vessels reduced from the proliferative/early secretory phase 
to the mid/late secretory phase, suggesting that developing vessels within the 
endometrial stratum functionalis may not be easily detectable with traditional EC 
markers (Figure 3.10). Combined together, the differences revealed a potential 
vascular developmental stage dependant staining for EC markers in 
endometrial vessels: UEA-1 (most proliferating, least mature vessels) followed 
by CD31/CD34 (less proliferative, medium sized vessels) and finally F8RA 
(least proliferating, most mature, large vessels). 
There were also differences in UEA-1 reactivity and staining for F8RA, CD34 
and CD31 between the layers of the endometrium and superficial myometrium. 
Although CD34 staining was relatively consistent throughout, 
expression/reactivity of other EC markers was highest in myometrium, 
decreasing towards the surface, with least staining in the luminal region (Figure 
3.9). This is in contrast with Rees et al. (1993), who reported no difference in 
staining for CD31, CD34 and F8RA between endometrium and myometrium. 
Differences in the present study were mainly in the luminal region, which was 
not studied separately in the previous study, with no differences between the 
stratum functionalis/stratum basalis compared with the myometrium. The spatial 
difference in staining for EC markers in endometrium at different cycle phases 
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and within different endometrial layers may reflect the vascular developmental 
stage.  Since endometrial blood vessels have been implicated in HMB, could an 
alteration of this staining pattern also underlie HMB? 
While differences were observed in all four markers, vascular staining for CD34, 
a transmembrane glycoprotein, was increased in HMB in both endometrium and 
myometrium. Interestingly, a previous study using double staining for CD34 and 
proliferating cell nuclear antigen (PCNA) reported increased endometrial EC 
proliferation in HMB (Kooy et al., 1996), perhaps highlighting dysregulation of 
CD34+ endometrial vessels in the context of vascular development in HMB. In 
contrast, UEA-1+ and CD31+ ECs were generally reduced in HMB. CD31 has 
been implicated in the binding of leukocytes to ECs as well as in maintaining 
cell-cell contact (Tabibzadeh and Poubouridis, 1990). Since both UEA-1 and 
CD31 may stain small and large vessels, an alteration in CD31+ EC staining 
may indicate dysregulation from an early stage of angiogenesis, possibly giving 
rise to leaky vessels from weaker lumen formation. F8RA was reduced in ESP 
myometrium but increased in LSP in the luminal region in HMB. F8RA enables 
platelet adhesion to injured vessel walls (Sixma and de Groot, 1991); altered 
staining may be indicative of adverse endothelial changes in these superficial 
endometrial vessels in HMB. Combining the results on alteration in staining of 
the different vascular EC markers and the differential staining for EC markers 
according to vascular proliferation it can be speculated that there is 
dysregulation of endometrial vascular endothelium in HMB. This may alter EC-
VSMC signalling, which in turn may affect recruitment and/or differentiation of 
VSMCs ultimately resulting in dysfunctional vascular tone and consequently 
blood flow. 
3.5.4 Vascular ECM staining during the menstrual cycle 
Angiogenesis is regulated both spatially and temporally in the cycling 
endometrium and vascular ECM must also alter to sustain these vascular 
changes, although little is known about the mechanisms underlying ECM 
regulation in the endometrium. In agreement with Kelly et al. (1995), in the 
present study vascular laminin staining was low throughout the menstrual cycle, 
with few spatial or temporal differences. Fibronectin staining was also relatively 
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stable across the phases, with highest staining in the stratum functionalis 
(Figure 3.12). Our results for fibronectin and laminin in the stratum functionalis 
are similar to those of Bilalis et al. (1996), the only difference being their 
complete absence of both at LH+10. Since we examined ESP, MSP and LSP 
endometrium staged using histologic criteria (Noyes et al., 1975) rather than 
endometrium precisely timed from the LH surge, this difference can be 
explained. Osteopontin was expressed at high levels in the stratum functionalis 
with little variation in the secretory phase. In contrast, collagen IV staining 
varied in both stratum functionalis and stratum basalis, with increased levels in 
the secretory phase (Figure 3.12).  
While these results are similar to those of Bilalis et al. (1996), they differ from 
Kelly et al. (1995), who concluded that the number of collagen IV+ vessels 
remained similar across the menstrual cycle. Kelly et al. (1995) examined the 
number of vessels/mm2 in whole endometrium, whereas we assessed the 
proportion and staining intensity of vessels in the entire tissue section and 
separately assessed stratum functionalis and basalis. Another more recent 
study reported increased collagen IV staining in endometrial vessels from the 
proliferative to the secretory phase in whole endometrium (Oefner et al., 2015), 
while we demonstrated increased collagen IV staining in the ESP and LSP in 
stratum functionalis. Furthermore if our data from stratum functionalis and 
basalis are combined we also demonstrate a trend for increased collagen IV 
staining from PP to MSP, although there are many other methodological 
differences between these studies, including antibody specificity, endometrial 
staging and image quantification. The ECM is known to interact with cellular 
receptors determining cell-shape, migration, proliferation and even apoptosis 
(Timpl, 1996). Regulation of normal angiogenesis for the maintenance of normal 
function may result in distinctly separate ECM signature in the stratum 
functionalis, stratum basalis and myometrium. 
A major function of vascular ECM is vascular stability and if ECM component 
staining is tightly regulated in endometrial vasculature any variation in this ECM 
signature could lead to altered vessel stability, which could impact on abnormal 
bleeding in HMB. Laminin and fibronectin staining in stratum functionalis and 
myometrium were comparable in controls and HMB. Both laminin and 
  
 
3.5 DISCUSSION 
 
  
157 
fibronectin staining in the stratum basalis was higher in LSP in HMB, although 
fibronectin was decreased in MSP in HMB, compared with controls; reflecting 
altered vascular structural properties in HMB. Fibronectin is known to promote 
MMP-2 staining resulting in ECM breakdown during menses (Hoffmann et al., 
2006). However, when fibronectin is targeted by MMP-3 and broken into 
proteolytic fragments, it has been shown to induce apoptosis (Fukai et al., 
1995). Therefore, increased fibronectin staining in LSP stratum basalis in HMB 
may reflect increased local ECM breakdown and/or enhanced cellular 
apoptosis. However, the amount of fibronectin remained unaltered in the 
stratum functionalis in HMB. It can be speculated that compared with 
endometrium from control women, in HMB, vessels arising from the stratum 
basalis at the end of menses have altered ECM composition. Finally, this cyclic 
variation of laminin and fibronectin staining is also an indication that their 
production is under the direct or indirect regulation of ovarian steroid hormones, 
oestrogen and progesterone.  
Collagen IV staining was generally decreased in both stratum functionalis and 
stratum basalis in HMB. Collagen IV networks are a major architectural feature 
of the vascular ECM and maintain mechanical stability. Therefore, a decrease in 
collagen IV would suggest a weaker vascular structure in HMB, while the 
increased myometrial collagen IV staining may represent a compensatory 
mechanism to stabilise the vascular bed. 
Previous studies have shown that human endometrial glandular and luminal 
osteopontin staining is elevated in MSP (Apparao et al., 2001). In this study 
vascular osteopontin staining was higher in ESP than in LSP in controls but this 
pattern was reversed in HMB, where osteopontin staining was reduced in ESP 
stratum basalis and increased in LSP stratum functionalis. Osteopontin is 
induced in VSMCs in cardiovascular diseases and increased osteopontin has 
been implicated in renal diseases and linked with the activity of several 
oncogenes (Waller et al., 2010). Activated lymphocytes and macrophages 
synthesize osteopontin, accounting for its elevated staining in traumatised 
tissue (Sodek et al., 2000). Thus, increased osteopontin staining in the LSP 
could reflect increased breakdown of endometrial vascular ECM. A study using 
mice aortic VSMCs has shown that osteopontin down-regulates calponin, 
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through an extracellular signalling pathway (Gao et al., 2012). It can be 
proposed that osteopontin may down-regulate calponin staining in LSP 
endometrium in HMB. The temporal dysregulation may indicate a mechanistic 
basis for osteopontin as a regulator of the endometrial vascular structure-
function relationship, which may underlie HMB. 
3.5.5 Leukocyte distribution during the menstrual cycle 
Menstruation is an immunological process (Finn, 1986; Salamonsen and 
Woolley, 1999; Jones et al., 2004; Berbic and Fraser, 2013) and immune cells 
constitute a significant component of the non-pregnant endometrial stromal and 
epithelial layers (Morris et al., 1985; Bulmer and Earl, 1987; Bulmer et al., 1991; 
Hunt, 1994; Dallenbach-Hellweg, 2012). CD56+ uNK cells, CD14+ macrophages 
and CD3+ T cells form the most prominent leukocyte subsets in the 
endometrium (Morris et al., 1985; Kamat and Isaacson, 1987; Bulmer et al., 
1991; Hunt, 1994; Lachapelle et al., 1996). Leukocyte populations have been 
implicated in remodelling and growth of blood vessels within the endometrium, 
and the endometrial spiral arterioles in turn have been implicated in the 
pathogenesis of HMB in relation to their premature breakdown, failure to repair, 
vascular smooth muscle cell differentiation, vessel number and morphology 
(Abberton et al., 1999a; Abberton et al., 1999b; Hurskainen et al., 1999; Rogers 
and Abberton, 2003; Kawai-Kowase and Owens, 2007; Biswas Shivhare et al., 
2014). The aim of the present study was to compare endometrial leukocyte 
populations during the menstrual cycle in the stratum functionalis of women with 
HMB, compared with controls. The results demonstrated altered leukocyte 
numbers in the endometrium of women with HMB at different phases of the 
menstrual cycle. 
Regulatory T cells (FOXP3+), which play a crucial role in controlling and 
suppressing immune responses, especially to sustain successful implantation 
(Berbic et al., 2010), were rare at all menstrual cycle phases and no dynamic 
alteration was observed in HMB (Figure 3.14). Endometrial macrophages may 
play a role in a wide array of activities important for sustaining fertility; tissue 
degradation during menses, phagocytic activity to clear endometrial debris, 
tissue repair/regeneration, and reconstruction of tissue structure (Aplin et al., 
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2008; Thiruchelvam et al., 2013). As a proportion of all endometrial cells, 
macrophage numbers have been previously reported to increase from 1-2% in 
the proliferative phase to 3-5% in the secretory phase and 6-15% during the 
menstrual phase (Salamonsen and Woolley, 1999; Salamonsen et al., 2002; 
Thiruchelvam et al., 2013). We did not observe any significant change in 
macrophage numbers during the menstrual cycle (Figure 3.14). There are 
several possible explanations for the difference in these results. The previous 
data corresponded to CD68+ macrophages, while we assessed CD14+ 
macrophage numbers; CD68 is a cytoplasmic marker while CD14 is a cell 
surface marker, hence their pattern of staining may not be directly comparable. 
Moreover, the CD68+ macrophage numbers were assessed as a proportion of 
all endometrial cells, while we expressed CD14+ macrophages as a proportion 
of endometrial stromal cells (Salamonsen and Woolley, 1999). Mature CD83+ 
dendritic cells have also been proposed to play a role in remodelling fertile 
cycling endometrium (Bengtsson et al., 2004). Our results are in line with 
previous findings showing that mature dendritic cells are most abundant in the 
late secretory phase (Rieger et al., 2004), but there were no significant 
differences in either macrophages or dendritic cells between control and HMB 
endometrium (Figure 3.14). Taken together these results support our proposal 
that HMB is associated with spatio-temporal dysregulation of blood flow due to 
abnormal vasoconstriction rather than due to failed tissue repair. 
The number of endometrial CD3+ cells was reduced in the mid secretory phase 
and increased in the late secretory phase in HMB compared with controls  
(Figure 3.14). However, CD3+ antibodies for paraffin embedded sections detect 
the epsilon (ε) chain of human CD3, which may also be expressed by a 
proportion of CD56+ uNK cells (King et al., 1998b). Therefore we performed 
double immunohistochemical labelling to differentiate between CD3+ T cells and 
CD56+ uNK cells expressing cytoplasmic CD3ε (Figure 3.15). Double 
immunohistochemical labelling was required to differentiate between CD3+ T 
cells and CD56+ uNK cells expressing cytoplasmic CD3ε. Compared with 
controls, the proportion of CD3+ cells among the total number of CD56+ cells 
was increased and the proportion of single CD56+ cells amongst the total CD3+ 
cells was decreased in the late secretory phase in HMB (Figure 3.15). The 
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increase in CD3+ cells in the late secretory phase in HMB did not therefore 
represent an increase in CD3+ T cells but was accounted for by altered 
expression of CD3ε by the CD56+ cells.  
CD56+ uNK cells are the most prevalent leukocyte population in the stratum 
functionalis during the mid and late secretory phases, although they are present 
in small numbers in proliferative endometrium (Hamperl and Hellweg, 1958; 
Bulmer et al., 1991). In the present study, while uNK cell numbers were 
increased in the proliferative and early secretory phases in HMB their numbers 
did not increase to the same extent in the late secretory phase, resulting in a 
lower proportion of uNK cells compared with controls. Additionally, CD3/CD56 
double-labelling immunohistochemistry confirmed that the uNK cell population 
in the late secretory phase in HMB showed increased staining of CD3 
compared with controls. This may reflect altered uNK cell differentiation in HMB. 
The mechanisms that underlie the dramatic increase in uNK cell numbers in the 
mid and late secretory phases of the menstrual cycle are not fully understood 
and may involve both influx from peripheral blood and local differentiation and 
proliferation (Koopman et al., 2003; Eidukaite et al., 2004; Zhang et al., 2005; 
Lynch et al., 2007). Uterine NK cells have been implicated in a wide range of 
functions; cytokine and angiogenic growth factor secretion, immune function, 
regulation of trophoblast invasion, early stages of spiral artery remodelling and 
regulation of endometrial bleeding (Lash et al., 2006; Smith et al., 2009; Lash et 
al., 2010; Lash and Bulmer, 2011; Wilkens et al., 2013). Importantly, uNK cells 
secrete angiogenic growth factors such as Ang1, Ang2, VEGF-C, PIGF and 
TGF-β1, which play important roles in vascular development (Li et al., 2001; 
Lash et al., 2006).  
Therefore, differences in leukocyte populations and an altered state of uNK cell 
differentiation detected in the present study may reflect altered leukocyte 
recruitment and/or in situ differentiation and proliferation in women with HMB. 
The functional consequences of altered endometrial leukocyte numbers in 
women with HMB may impact on endometrial vascular development and/or the 
way in which the endometrium prepares for menstruation. We have previously 
reported a positive association between uNK cell density and vascular 
maturation in women with RM and recurrent implantation failure (Quenby et al., 
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2009). In the current study, uNK cells were significantly reduced in the late 
secretory phase of the menstrual cycle in HMB, linking to our previous results 
demonstrating reduced vascular development in HMB (Biswas Shivhare et al., 
2014). This study investigated leukocytes in the stratum functionalis of the 
endometrium, on the basis that it is at this site that endometrial leukocytes vary 
during the menstrual cycle. However, future studies investigating their 
expression in the stratum basalis and myometrium with a comparison between 
control women and those with HMB may be beneficial. A further interest will be 
to examine whether uNK cell function such as cytokine production is changed 
between mid and late secretory phases in the non-pregnant endometrium. 
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3.6 CONCLUSION 
In conclusion, endometrial vascular muscle content was unchanged during the 
menstrual cycle in HMB compared with controls. However, there were 
characteristic differences in late secretory phase endometrium in the 
differentiation stage of VSMCs between HMB and control endometrium, with 
smoothelin being increased and calponin staining decreased in muscularised 
vessels in HMB and calponin staining also being reduced in relation to total 
vessel number. This altered VSMC differentiation may lead to altered function, 
which could contribute to abnormal bleeding. These results also indicate 
calponin as a potential therapeutic target, but detailed functional studies are 
required before this can be deduced. The pattern of staining for endometrial 
vascular EC and ECM was also altered during the different phases of the 
control menstrual cycle and in HMB. While laminin and fibronectin did not alter 
to a great extent, osteopontin was generally increased and collagen IV staining 
was decreased in the uterine vessels in HMB. The study suggests that vascular 
ECM is continuously remodelled at the different phases of the menstrual cycle. 
Altered vascular EC and ECM component staining may indicate dysregulated 
development and structural instability of endometrial vessels and consequently 
altered function, which could contribute to abnormal bleeding in HMB. The 
results also highlight a potentially dysregulated osteopontin-calponin pathway 
inviting further functional studies. Moreover temporal differences were observed 
in the leukocyte populations in HMB endometrium, in particular uNK cell 
numbers were significantly reduced in the late secretory phase, perhaps 
implicating reduced/altered vascular maturation at the onset of menstruation 
underlying HMB. 
Collectively, results from these immunohistochemical studies of the uterine 
vasculature revealed key alterations in blood vessel development, crucially 
drawing attention to the significance of VSMC differentiation, the spatio-
temporal pattern of ECs and ECM staining and the uNK cell population and 
differentiation status in the pathogenesis of HMB. In light of the fact that blood 
vessel maturation and development is potentially dysregulated in HMB and that 
development of these vessels is principally regulated by a network of key AGFs 
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and their receptors such as PDGF-BB, PDGFRα, PDGFRβ, TGFβ1, TGFβRI 
and TGFβRII, it is of great interest and significance to consequently investigate 
the pattern of staining for these AGFs and their receptors in the context of HMB 
and potentially their role in VSMC differentiation and vascular ECM staining in 
the endometrium. 
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4 ANGIOGENIC GROWTH FACTORS AND BLOOD VESSEL DEVELOPMENT IN 
WOMEN WITH HEAVY MENSTRUAL BLEEDING 
4.1 INTRODUCTION 
The endometrium, a dynamic tissue with regenerative ability, undergoes 
proliferation, differentiation and breakdown every month during the menstrual 
cycle. The growing endometrium therefore relies heavily on a blood supply from 
newly developing blood vessels or angiogenesis. The endometrium is one of 
the two tissues in women where angiogenesis takes place on a physiological 
basis (Smith, 1998). Abnormal development and flow in these endometrial 
blood vessels has been implicated in various reproductive disorders such as 
RM, recurrent implantation failure, unexplained infertility and HMB (Goswamy et 
al., 1988; Steer et al., 1994; Habara et al., 2002; Quenby et al., 2009). 
Additionally, these studies, discussed in Chapter 3, have highlighted the 
significance of these vessels in HMB especially with respect to VSMC 
differentiation (Biswas Shivhare et al., 2014), EC and ECM component 
expression. 
The carefully timed cyclic angiogenesis and remodelling, which forms the 
backbone of monthly endometrial growth and regression results from a complex 
network of interactions between hormones and pro or anti-angiogenic growth 
factors. Pro-angiogenic factors activate or promote formation of new blood 
vessels, while anti-angiogenic factors inhibit blood vessel formation (Folkman 
and Klagsbrun, 1987). Although oestrogen and progesterone primarily regulate 
endometrial angiogenesis (Iruela-Arispe et al., 1999; Hague et al., 2002), their 
action is indirectly mediated by several growth factors expressed by the diverse 
cell population in the endometrium. Sprouting, pruning and/or intussusception 
during angiogenesis involves proliferation and migration of ECs (Risau, 1997), 
driven by a complex interaction of well-defined families of angiogenic growth 
factors, which include the VEGF family, consisting of VEGF-A (Charnock-Jones 
et al., 1993; Donnez et al., 1998), VEGF-B, and VEGF-C (Mints et al., 2002; 
Moller et al., 2002), VEGF-D, VEGF-E, placental growth factor (PlGF) and the 
receptors VEGF-R1, VEGF-R2 and VEGF-R3 (Smith, 2001; Jain, 2003; Hoeben 
et al., 2004; Tammela et al., 2005; Lash et al., 2012); the fibroblast growth 
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factor (FGF) family (Presta, 1988; Ferriani et al., 1993; Sangha et al., 1997; 
Presta et al., 2005); TGFβ1 and its receptors, TGFβRI and TGFβRII, which 
have been shown to play a role in vascular stabilisation and VSMC 
differentiation (Dickson et al., 1995; Pepper, 1997; Massague et al., 2000; 
Distler et al., 2003). As these new vessels form, a population of leading ECs 
provide directionality and a population of lagging ECs form the lumen of the 
vessel (Kamei et al., 2006). Subsequently, the newly formed vessels undergo 
maturation; capillaries recruit pericytes, whereas larger vessels recruit VSMCs, 
which requires the PDGF family, including PDGF-A, PDGF-B, PDGF-C and 
PDGF-D and their receptors, PDGF-Rα and PDGF-Rβ (Lindahl et al., 1997; 
Betsholtz, 2004). The PDGF signalling pathway plays a critical role in 
recruitment of mesenchymal cells, which differentiate into VSMCs in response 
to TGFβ signalling (ten Dijke and Arthur, 2007). Finally, an extended network of 
vessels is formed which continue to mature and remodel under the influence of 
other cytokines and growth factors, blood flow and tissue specific requirements. 
Amongst other growth factors, which play a role in vascular stabilisation, 
maturation and remodelling are the angiopoietins, consisting of Ang1, and its 
receptor Tie-2 and Ang2, which inhibits Ang1 binding promoting vascular 
breakdown (Maisonpierre et al., 1997; Witzenbichler et al., 1998; Zhang et al., 
2001). The TGFβ, PDGF, VEGF and angiopoietin signalling pathways and their 
specific roles in vascular development have been discussed in detail in section 
1.2.4. 
VEGFs, TGFβs and PDGFs are expressed in the endometrium and their 
expression has been studied previously (Akhurst et al., 1990; Charnock-Jones 
et al., 1993; Shifren et al., 1996; Donnez et al., 1998; Sharkey et al., 2000; von 
Wolff et al., 2000; Aase et al., 2001; Moller et al., 2002; Piestrzeniewicz-
Ulanska et al., 2002; Hirchenhain et al., 2003; Rogers and Abberton, 2003; 
Malik et al., 2006; Lee et al., 2008; Girling and Rogers, 2009; Omwandho et al., 
2010; Lash et al., 2012; Li et al., 2013). Although these AGFs are key to 
angiogenesis and are expressed during the human menstrual cycle, with cyclic 
variation suggesting phase specific role in angiogenesis, the role of these AGFs 
and their expression has not been investigated in HMB. 
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4.2 HYPOTHESES AND AIMS 
4.2.1 Hypotheses 
Taking into consideration the critical roles of both TGFβ1 and its receptors 
TGFβRI and TGFβRII, and PDGF-BB and its receptors PDGFRα and PDGFRβ 
in vascular development, VSMC differentiation and ECM dependant activation 
or spatial diffusion and bioavailability, we hypothesised that: 
1. The spatio-temporal pattern of AGFs in endometrial stroma, glands, ECs and 
VSMCs during the normal menstrual cycle is altered in women with HMB. 
 
2. Abnormal endometrial VSMC differentiation and vascular ECM component 
staining is associated with altered AGF expression. 
4.2.2 Aims 
To test the above hypotheses we aimed to: 
1. Compare the pattern of staining for the AGFs and their receptors in stroma, 
glands, ECs and VSMCs in the endometrium and superficial myometrium, 
across the menstrual cycle in controls and women with HMB. 
 
2. Compare the staining for VSMC differentiation markers and vascular ECM 
components in proliferative endometrium and superficial myometrium in 
controls with those treated with AGFs or their respective neutralising 
antibodies. 
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4.3 EXPERIMENTAL DESIGN 
The experimental design adopted to achieve the specific aims set out in section 
4.2.2, is illustrated in Figure 4.1 and the specific materials and methods used 
have been described below. 
4.3.1 Human tissue 
Biopsies of endometrium with superficial myometrium were obtained with 
informed consent from women undergoing hysterectomy as described in section 
2.1.1.2. Endometrial explant cultures with AGFs and their respective 
neutralising antibodies were carried out as described in section 2.2.6.8. 
4.3.2 Immunohistochemistry and antibodies used 
Immunohistochemistry was performed as described in section 2.2.3.1. Details of 
source, pretreatment, dilution and incubation times for all primary antibodies 
used in immunohistochemistry are provided in Table 2.2. 
4.3.3 Quantitative image analysis 
4.3.3.1 Staining for AGFs in the endometrium and superficial myometrium 
Entire, full thickness immunostained tissue sections (N=5) in each of PP, ESP, 
MSP and LSP from both controls and women with HMB were analysed semi-
quantitatively for the different AGFs in stroma, glands, ECs and VSMCs, using a 
modified ‘Quickscore’ method (section 3.3.3.2) by an observer who was blinded 
to the origin of the sample. Vessels identified by their surrounding layer(s) of 
smooth muscle cells and with a visible lumen were included in the analysis. The 
superficial myometrium, stratum basalis (within one x200 field adjacent to the 
myometrium) and stratum functionalis were scored separately for each cell type.  
4.3.3.2 VSMC differentiation marker and ECM component staining in 
endometrial and superficial myometrial explant cultures 
Staining for VSMC differentiation markers, EC marker (CD31) and ECM 
components in vessels in the entire tissue section of the explant cultures of 
proliferative phase samples from controls (N=3 myometrium, N=2 endometrium) 
was assessed by an observer, who was blinded to the origin of the samples. 
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Figure 4.1: Experimental design to investigate angiogenic growth factors and blood vessel development in women with HMB. 
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Vessels identified by their surrounding layer(s) of smooth muscle cells and with 
a visible lumen were included in the analysis. Expression of VSMC 
differentiation markers and vascular ECM components were assessed using 
open-source ImageJ software package in combination with the ‘cell counter’ 
plugin as the percentage of vessels positively stained for each marker 
compared with the total number of vessels in the entire tissue identified by 
CD31+ staining.  
4.3.4 Statistical analysis 
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc.). Data 
are presented as means ± standard error of mean (SEM) and differences are 
considered statistically significant at P≤0.05. Specific tests used are given in the 
results. 
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4.4 RESULTS 
4.4.1 Spatio-temporal pattern of vascular AGF staining in the control 
menstrual cycle and in HMB 
4.4.1.1 PDGF-BB and its receptors in the menstrual cycle  
PDGF-BB: PDGF-BB staining in stromal cells was minimal throughout the 
menstrual cycle within stratum functionalis, stratum basalis and myometrium 
(Figure 4.2a). Stromal PDGF-BB staining was also low in the myometrium, and 
there were no differences between the menstrual cycle phases (Figure 4.3A). 
PDGF-BB staining in the glandular epithelial cells was minimal in both stratum 
functionalis and stratum basalis and staining did not change during the 
menstrual cycle (Figure 4.2a, Figure 4.3B). 
Vascular ECs showed moderate to high staining for PDGF-BB in both 
endometrium and myometrium (Figure 4.2a). Staining was unchanged during 
the menstrual cycle; although PDGF-BB staining in myometrium was higher 
than in stratum functionalis in PP (P=0.01), and LSP (P=0.009) (Figure 4.3C). 
VSMCs showed low PDGF-BB expression, which remained unchanged during 
the menstrual cycle in both endometrium and myometrium (Figure 4.2a). 
However, PDGF-BB staining in myometrium was higher than in stratum 
functionalis in PP (P=0.004), ESP (P=0.003) and LSP (P=0.004) (Figure 4.3D). 
 
PDGFRα: PDGFRα staining was moderate to high throughout the menstrual 
cycle (Figure 4.2b). Stromal PDGFRα staining was moderate in endometrium 
and myometrium and did not change during the menstrual cycle in myometrium 
and stratum basalis. In stratum functionalis PDGFRα staining was higher in LSP 
than in ESP (P=0.007) and was lower than myometrium in MSP (P=0.007) 
(Figure 4.4A). 
In the glandular epithelial cells, PDGFRα staining was moderate to high 
throughout the menstrual cycle in both stratum functionalis and stratum basalis 
(Figure 4.2b). PDGFRα staining was higher in the PP than MSP in both stratum 
functionalis (P=0.006) and stratum basalis (P=0.007) (Figure 4.4B).  
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Figure 4.2a: Staining for PDGF-BB in the endometrium and myometrium during the 
menstrual cycle. Stromal cells (SC), glandular epithelial cells (GE), VSMCs and ECs 
were stained positive for PDGF-BB (A1-A4, B1-B4). Images were captured at 200x 
original magnification. 
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Figure 4.2b: Staining for PDGFRα in the endometrium and myometrium during the 
menstrual cycle. Stromal cells (SC), glandular epithelial cells (GE), VSMCs and ECs 
were stained positive for PDGFRα (A1-A4, B1-B4). Images were captured at 200x 
original magnification. 
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Figure 4.2c: Staining for PDGFRβ in the endometrium and myometrium during the 
menstrual cycle. Stromal cells (SC), glandular epithelial cells (GE), VSMCs and ECs 
were stained positive for PDGFRβ (A1-A4, B1-B4). Images were captured at 200x 
original magnification 
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Figure 4.3: Graphical representation of immunohistochemical staining for PDGF-BB 
during the menstrual cycle. (A-D) Quickscore assessment (mean ± SEM) of PDGF-BB 
(N=5, each phase, each group) in controls and in HMB for stromal cells (A), glandular 
epithelial cells (B), ECs (C) and VSMCs (D). Bars labelled with the same letter are 
significantly different from each other. (a-e) represent differences between layers, 
within each phase; aP=0.01, bP=0.009, c,eP=0.004, dP=0.003. (A-F) represent 
differences between control and HMB; A-FP=0.008. Pairwise Kruskal-Wallis one way 
ANOVA, with Bonferroni correction determined significant differences between phases 
or layers in control. Mann-Whitney U test, with Bonferroni correction determined 
significant differences between control and HMB. 
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PDGFRα staining in vascular ECs was moderate to high and remained 
unaltered throughout the menstrual cycle in both endometrium and myometrium 
(Figure 4.2b), although staining was higher in the myometrium compared with 
stratum functionalis in both PP (P=0.003) and ESP (P=0.01) (Figure 4.4C). 
VSMCs showed low to moderate PDGFRα staining during the menstrual cycle 
in both endometrium and myometrium (Figure 4.2b). Staining was highest in 
LSP, compared with PP in both stratum functionalis (P=0.006) and myometrium 
(P=0.007). Moreover, PDGFRα staining in myometrium was higher than stratum 
functionalis in PP (P=0.014) (Figure 4.4D).  
 
PDGFRβ: Stromal PDGFRβ staining was moderate throughout the menstrual 
cycle in both endometrium and myometrium (Figure 4.2c). In stratum 
functionalis, PDGFRβ staining was highest in stratum basalis and myometrium 
in LSP compared with PP (P=0.005), although staining remained unchanged 
during the menstrual cycle. PDGFRβ staining was higher in stratum basalis 
compared with stratum functionalis in both PP (P=0.002) and MSP (P=0.011) 
and compared with myometrium in ESP (P=0.003) (Figure 4.5A). 
In the glandular epithelial cells, PDGFRβ was moderately expressed throughout 
the menstrual cycle in both stratum functionalis and stratum basalis (Figure 
4.2c). No changes were observed during menstrual cycle, although staining was 
higher in stratum functionalis compared with stratum basalis in PP (P=0.016) 
(Figure 4.5B). 
PDGFRβ staining was moderate to high in vascular ECs and low to minimal in 
VSMCs in both endometrium and myometrium during the menstrual cycle 
(Figure 4.2c). No differences were observed between menstrual cycle phases 
or tissue layers in either ECs (Figure 4.5C) or VSMCs (Figure 4.5D). 
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Figure 4.4: Graphical representation of immunohistochemical staining for PDGFRα 
during the menstrual cycle. (A-D) Quickscore assessment (mean ± SEM) of PDGFRα 
(N=5, each phase, each group) in controls and in HMB for stromal cells (A), glandular 
epithelial cells (B), ECs (C) and VSMCs (D). ‘P’ values shown in graph represent 
significant differences between phases within each layer. Bars labelled with the same 
letter are significantly different from each other. (a-d) represent differences between 
layers, within each phase; aP=0.007, bP=0.003, cP=0.01, dP=0.014. (A-Q) represent 
differences between control and HMB; A-QP=0.008. Pairwise Kruskal-Wallis one way 
ANOVA, with Bonferroni correction determined significant differences between phases 
or layers in control. Mann-Whitney U test, with Bonferroni correction determined 
significant differences between control and HMB. 
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Figure 4.5: Graphical representation of immunohistochemical staining for PDGFRβ 
during the menstrual cycle. (A-D) Quickscore assessment (mean ± SEM) of PDGFRβ 
staining (N=5, each phase, each group) in controls and in HMB for stromal cells (A), 
glandular epithelial cells (B), ECs (C) and VSMCs (D). ‘P’ value shown in graph 
represents significant difference between phases within each layer. Bars labelled with 
the same letter are significantly different from each other. (a-d) represent differences 
between layers, within each phase; aP=0.002, bP=0.011, cP=0.003, dP=0.016. (A-C) 
represent differences between control and HMB; A-CP=0.008. Pairwise Kruskal-Wallis 
one way ANOVA, with Bonferroni correction determined significant differences 
between phases or layers in control. Mann-Whitney U test, with Bonferroni correction 
determined significant differences between control and HMB. 
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4.4.1.2 TGFβ1 and its receptors in the menstrual cycle  
TGFβ1: TGFβ1 staining in the stromal cells was low throughout the normal 
menstrual cycle in both endometrium and myometrium (Figure 4.6a) and there 
were no differences between either the phases or the tissue layers (Figure 
4.7A). 
In the glandular epithelial cells, TGFβ1 staining was low throughout the 
menstrual cycle (Figure 4.6a) and there were no differences between the 
menstrual cycle phases in both stratum functionalis and stratum basalis. 
However, in ESP, TGFβ1 staining was higher in stratum functionalis compared 
with stratum basalis (P=0.015) (Figure 4.7B). 
TGFβ1 staining was low in the vascular ECs and VSMCs in both endometrium 
and myometrium during the menstrual cycle (Figure 4.6a) and there were no 
differences between phases or tissue layers in ECs (Figure 4.7C).  However, in 
ESP, TGFβ1 staining in VSMCs was lower in stratum functionalis compared 
with myometrium (P=0.010)  (Figure 4.7D). 
 
TGFβRI: TGFβRI staining in the stromal cells was moderate throughout the 
menstrual cycle in endometrium and myometrium (Figure 4.6b). While no 
differences in staining were observed during the menstrual cycle, TGFβRI 
staining was higher in stratum functionalis, compared with stratum basalis in PP 
(P=0.012) and compared with myometrium in LSP (P=0.006) (Figure 4.8A). 
TGFβRI was moderately expressed in the glandular epithelial cells throughout 
the menstrual cycle in stratum functionalis and stratum basalis (Figure 4.6b). 
While no differences in staining were observed between the phases of the 
menstrual cycle, TGFβRI staining was higher in stratum functionalis compared 
with stratum basalis in LSP (P=0.016) (Figure 4.8B). 
TGFβRI was moderately expressed in the vascular ECs and did not alter during 
the menstrual cycle in both endometrium and myometrium (Figure 4.6b). 
However, TGFβRI staining was higher in stratum functionalis compared with 
stratum basalis in PP (P=0.009) and compared with myometrium in LSP 
(P=0.010) (Figure 4.8C). 
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Figure 4.6a: Staining for TGFβ1 in the endometrium and myometrium during the 
menstrual cycle. Stromal cells (SC), glandular epithelial cells (GE), VSMCs and ECs 
were stained positive for TGFβ1 (A1-A4, B1-B4). Images were captured at 200x 
original magnification. 
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Figure 4.6b: Staining for TGFβRI in the endometrium and myometrium during the 
menstrual cycle. Stromal cells (SC), glandular epithelial cells (GE), VSMCs and ECs 
were stained positive for TGFβRI (A1-A4, B1-B4). Images were captured at 200x 
original magnification. 
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Figure 4.6c: Staining for TGFβRII in the endometrium and myometrium during the 
menstrual cycle. Stromal cells (SC), glandular epithelial cells (GE), VSMCs and ECs 
were stained positive for TGFβRII (A1-A4, B1-B4). Images were captured at 200x 
original magnification. 
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Figure 4.7: Graphical representation of immunohistochemical staining for TGFβ1 
during the menstrual cycle. (A-D) Quickscore assessment (mean ± SEM) of TGFβ1 
staining (N=5, each phase, each group) in controls and in HMB for stromal cells (A), 
glandular epithelial cells (B), ECs (C) and VSMCs (D). Bars labelled with the same 
letter are significantly different from each other. (a, b) represent differences between 
layers, within each phase; aP=0.015, bP=0.010. Pairwise Kruskal-Wallis one way 
ANOVA, with Bonferroni correction determined significant differences between phases 
or layers in control. Mann-Whitney U test, with Bonferroni correction determined 
significant differences between control and HMB. 
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VSMCs showed low to moderate staining of TGFβRI during the menstrual cycle 
in both endometrium and myometrium (Figure 4.6b). TGFβRI staining in stratum 
basalis was higher than in stratum functionalis in both PP (P=0.006) and ESP 
(P=0.009) (Figure 4.8D). 
 
TGFβRII: Stromal TGFβRII staining was low to minimal throughout the 
menstrual cycle in endometrium and myometrium (Figure 4.6c) with no 
differences between phases or tissue layers (Figure 4.9A). 
TGFβRII staining in glandular epithelial cells, was low and did not change 
during the menstrual cycle in both stratum functionalis and stratum basalis. No 
alterations were observed between the tissue layers (Figure 4.6c, Figure 4.9B). 
TGFβRII was moderately expressed in vascular ECs, with no differences 
between tissue layers during the menstrual cycle (Figure 4.6c). While in stratum 
functionalis, staining was highest in ESP compared with LSP (P=0.004), no 
such changes were observed in either stratum basalis or myometrium (Figure 
4.9C). 
TGFβRII staining in the VSMCs was moderate to low throughout the menstrual 
cycle in endometrium and myometrium (Figure 4.6c) and no differences were 
observed between phases or tissue layers (Figure 4.9D). 
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Figure 4.8: Graphical representation of immunohistochemical staining for TGFβRI 
during the menstrual cycle. (A-D) Quickscore assessment (mean ± SEM) of TGFβRI 
staining (N=5, each phase, each group) in controls and in HMB for stromal cells (A), 
glandular epithelial cells (B), ECs (C) and VSMCs (D). Bars labelled with the same 
letter are significantly different from each other. (a-g) represent differences between 
layers, within each phase; aP=0.012, b, fP=0.006, cP=0.016, d, gP=0.009, eP=0.010. (A-F) 
represent differences between control and HMB; A-FP=0.008. Pairwise Kruskal-Wallis 
one way ANOVA, with Bonferroni correction determined significant differences 
between phases or layers in control. Mann-Whitney U test, with Bonferroni correction 
determined significant differences between control and HMB. 
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Figure 4.9: Graphical representation of immunohistochemical staining for TGFβRII 
during the menstrual cycle. (A-D) Quickscore assessment (mean ± SEM) of TGFβRII 
staining (N=5, each phase, each group) in controls and in HMB for stromal cells (A), 
glandular epithelial cells (B), ECs (C) and VSMCs (D). ‘P’ value shown in graph 
represents significant difference between phases within each layer. Bars labelled with 
the same letter are significantly different from each other. (A-C) represent differences 
between control and HMB; A-CP=0.008. Pairwise Kruskal-Wallis one way ANOVA, with 
Bonferroni correction determined significant differences between phases or layers in 
control. Mann-Whitney U test, with Bonferroni correction determined significant 
differences between control and HMB. 
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4.4.1.3 Staining for PDGF-BB and its receptors is altered in HMB 
PDGF-BB: Stromal PDGF-BB staining in stratum basalis was lower in ESP in 
HMB, compared with controls (P=0.008) (Figure 4.3A). Glandular epithelial 
staining for PDGF-BB did not differ between HMB and controls (Figure 4.3B). 
PDGF-BB staining in the vascular ECs was reduced in HMB compared with 
controls in stratum functionalis in MSP (P=0.008), in stratum basalis in MSP 
(P=0.008) and LSP (P=0.008) and in myometrium in PP (P=0.008) and LSP 
(P=0.008) (Figure 4.3C). staining of PDGFB-BB in VSMCs was unaltered in 
HMB compared with controls (Figure 4.3D). 
 
PDGFRα: Stromal PDGFRα staining in stratum basalis was lower in LSP in 
HMB, compared with controls (P=0.008). staining in myometrium was lower in 
both ESP (P=0.008) and LSP (P=0.008) in HMB (Figure 4.4A). Glandular 
epithelial staining for PDGFRα in PP and ESP was reduced in HMB compared 
with controls, in both stratum functionalis and stratum basalis (P=0.008 for all) 
(Figure 4.4B). In HMB compared with controls, PDGFRα staining in ECs was 
reduced in stratum functionalis in MSP, in stratum basalis in PP, ESP, MSP and 
LSP and in myometrium in PP, ESP and LSP (P=0.008 for all) (Figure 4.4C). 
While PDGFRα staining in VSMCs in stratum functionalis was unaltered in HMB 
compared with controls, it was reduced in both stratum basalis and myometrium 
in LSP (P=0.008 for all) (Figure 4.4D). 
 
PDGFRβ: While stromal PDGFRβ staining was increased in HMB in PP stratum 
functionalis (P=0.008), it was decreased in PP stratum basalis (P=0.008) 
compared with controls. No differences were observed in myometrium (Figure 
4.5A). Glandular epithelial staining of PDGFRβ did not differ in HMB compared 
with controls (Figure 4.5B). staining of PDGFRβ in ECs was reduced in HMB 
compared with controls in ESP stratum basalis (P=0.008), but no changes were 
observed in stratum functionalis or myometrium (Figure 4.5C). PDGFRβ 
staining in VSMCs did not differ between HMB and controls (Figure 4.5D). 
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4.4.1.4 Staining for TGFβ1and its receptors is altered in HMB 
TGFβ1: TGFβ1 staining in stromal cells, glandular epithelial cells, ECs and 
VSMCs was unaltered in HMB compared with controls (Figure 4.7A-D). 
 
TGFβRI: TGFβRI staining in stroma was unaltered in HMB, compared with 
controls in stratum functionalis and myometrium. However, in stratum basalis, 
stromal TGFβRI staining in PP (P=0.008) was increased in HMB (Figure 4.8A). 
Glandular epithelial staining for TGFβRI was lower in HMB compared with 
controls in LSP stratum functionalis (P=0.008) but no alteration was observed in 
stratum basalis (Figure 4.8B). TGFβRI staining in ECs in MSP stratum 
functionalis was reduced in HMB compared with controls (P=0.008) but no 
alteration was observed in stratum basalis or myometrium (Figure 4.8C). 
TGFβRI staining in VSMCs was unaltered in HMB in stratum functionalis and 
myometrium but was reduced in stratum basalis in PP, ESP and MSP (P=0.008 
for all) (Figure 4.8D). 
 
TGFβRII: TGFβRII staining in stromal cells was reduced in HMB compared with 
controls in PP and ESP stratum functionalis (P=0.008 for all) and in PP 
myometrium (P=0.008) (Figure 4.9A). No alterations in TGFβRII staining were 
observed in the glandular epithelial cells, ECs or VSMCs in HMB compared with 
controls (Figure 4.9B-D). 
4.4.2 Effect of AGFs on endometrial VSMC differentiation 
Preliminary observations from the endometrial and myometrial explants cultured 
for 72 hr with 10ng/ml of PDGF-BB, anti-PDGFBB, TGFβ1 or anti-TGFβ1 
showed patterns of alteration in the various VSMC differentiation markers, but 
none were statistically significant due to the small sample numbers in these 
preliminary studies (Figure 4.10, Figure 4.11A-B). 
h-Caldesmon: Around 30% CD31+ endometrial vessels also expressed h-
Caldesmon in the untreated control group (Figure 4.10, Figure 4.11A). This was 
reduced when treated with either PDGF-BB (~10%) or anti-PDGFBB (~20%) 
(Figure 4.11A). The percentage of CD31+ endometrial vessels expressing h-
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Caldesmon was also reduced when treated with either TGFβ1 (~20%) or anti-
TGFβ1 (~12%) compared with the untreated group (Figure 4.11A). 
In the myometrial explants, around 95% CD31+ vessels also expressed h-
Caldesmon in the untreated control group (Figure 4.10, Figure 4.11B) and this 
was unaltered after treatment with PDGF-BB (100%), anti-PDGFBB (~90%), 
TGFβ1 (~90%) or anti-TGFβ1 (~90%) (Figure 4.11B). 
 
Smoothelin: Around 10% CD31+ endometrial vessels also expressed 
smoothelin in the untreated control group (Figure 4.10, Figure 4.11A); this was 
reduced after treatment with PDGF-BB (<5%), anti-PDGFBB (<5%) TGFβ1 
(<5%) or anti-TGFβ1 (<5%), but none were statistically significant due to the 
small sample numbers in these preliminary studies  (Figure 4.11A). 
In the myometrial explants, around 40% CD31+ vessels also expressed 
smoothelin in the untreated control group (Figure 4.10, Figure 4.11B) and this 
did not change after treatment with PDGF-BB (~30%), anti-PDGFBB (~25%), 
TGFβ1 (~20%) or anti-TGFβ1 (~30%) (Figure 4.11B). 
 
Calponin: Around 15% CD31+ endometrial vessels also expressed calponin 
(Figure 4.10, Figure 4.11A) and this was reduced after treatment with PDGF-BB 
(<5%), anti-PDGFBB (<5%), TGFβ1 (<5%) or anti-TGFβ1 (<5%) (Figure 4.11A). 
Around 60% CD31+ vessels in superficial myometrium also expressed calponin 
in the untreated control group (Figure 4.10, Figure 4.11B), which was unaltered 
after treatment with PDGF-BB (~60%), but was increased after treatment with 
anti-PDGFBB (~80%), TGFβ1 (~80%) or anti-TGFβ1 (~80%) (Figure 4.11B). 
4.4.3 Effect of AGFs on endometrial vascular ECM component expression 
Preliminary observations from endometrial and myometrial explants cultured for 
72 hr with 10ng/ml of PDGF-BB, anti-PDGFBB, TGFβ1 or anti-TGFβ1 showed 
no alteration in vascular ECM component staining (Figure 4.11C-D, Figure 
4.12). 
Collagen IV: In the endometrial and myometrial explants, 100% CD31+ vessels 
expressed collagen IV in the untreated control group (Figure 4.12, Figure 
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4.11C-D) and this remained unaltered in both endometrium and myometrium 
after treatment with PDGF-BB (100%), anti-PDGFBB (100%), TGFβ1 (100%) or 
anti-TGFβ1 (100%) (Figure 4.11C-D). 
 
Osteopontin: Around 100% CD31+ vessels in the endometrium and superficial 
myometrium expressed osteopontin in the untreated control group (Figure 4.12, 
Figure 4.11C-D) and this did not alter after treatment with PDGF-BB (100%), 
anti-PDGFBB (~90% in endometrium, 100% in myometrium), TGFβ1 (100%) or 
anti-TGFβ1 (100%) (Figure 4.11C-D). 
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Figure 4.10: Staining for VSMC differentiation markers h-Caldesmon, smoothelin and 
calponin in endometrial and superficial myometrial explants. Arrows indicate vessels in 
untreated control endometrium and myometrium (A1-A6) or after treatment with 
10ng/ml of PDGF-BB (B1-B6), anti-PDGFBB (C1-C6), TGFβ1 (D1-D6) and anti-TGFβ1 
(E1-E6). Images were captured at 200x original magnification. 
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Figure 4.11: Stacked cluster chart showing % CD31 positive vessels stained for VSMC 
differentiation markers and ECM components in endometrial and superficial myometrial 
explants. h-Caldesmon, smoothelin, calponin (A,B) and collagen IV and osteopontin 
(C,D) in the endometrium (A,C; N=2) and myometrium (B,D; N=3) of untreated control 
or treated for 72 hr with 10ng/ml of each of PDGF-BB, anti-PDGFBB, TGFβ1 and anti-
TGFβ1. Pairwise Kruskal-Wallis one way ANOVA, with Bonferroni correction was used 
to determine significant differences between control and treated groups for 
myometrium; no significant differences were observed. 
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Figure 4.12: Staining for ECM components collagen IV and osteopontin in endometrial 
and superficial myometrial explants. Arrows indicate vessels in untreated control 
endometrium and myometrium (A1-A4) or treated for 72 hr with 10ng/ml of each of 
PDGF-BB (B1-B4), anti-PDGFBB (C1-C4), TGFβ1 (D1-D4) and anti-TGFβ1 (E1-E4). 
Images were captured at 200x original magnification. 
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4.5 DISCUSSION 
4.5.1 Spatio-temporal pattern of vascular AGF staining in normal menstrual 
cycle and in HMB 
Angiogenesis takes place in the endometrium throughout the different phases 
of the menstrual cycle, in accordance with the requirements of this dynamic 
tissue (Girling and Rogers, 2005; Girling and Rogers, 2009). While the process 
of blood vessel growth and development in endometrium remains under the 
master control of steroid hormones, angiogenic growth factors such as PDGF-
BB, TGFβ1 and their corresponding receptors may directly regulate EC 
proliferation and/or apoptosis, interaction with and integrity of ECM 
components, as well as recruitment and maturation of VSMCs, which ultimately 
results in vascular development and maturation (Gold et al., 1994; Dickson et 
al., 1995; Lindahl et al., 1997; Pepper, 1997; Massague et al., 2000; 
Tabibzadeh, 2002; Distler et al., 2003; Betsholtz, 2004). Importantly, previous 
studies as well as those outlined in Chapter 3 have indicated dysregulation of 
endometrial vascular development and maturation in bleeding disorders such 
as HMB (Kooy et al., 1996; Abberton et al., 1999a; Biswas Shivhare et al., 
2014). Although some studies have previously examined the pattern of staining 
for endometrial PDGF-BB, TGFβ1 and their respective receptors in the normal 
menstrual cycle (Chegini et al., 1992; Gold et al., 1994; von Wolff et al., 2000; 
Omwandho et al., 2010; Lash et al., 2012), to our knowledge this has not been 
reported for HMB. 
The current study demonstrated that in controls, PDGF-BB was minimally 
expressed in the stroma, glandular epithelial cells and VSMCs, but was 
moderately expressed in the ECs (Figure 4.3), while both its receptors PDGFRα 
and PDGFRβ were moderately expressed in stroma, glandular epithelial cells 
and ECs but minimally in VSMCs (Figures 4.4-4.5). Although not statistically 
significant, stromal staining for both receptors appeared to increase as the 
menstrual cycle progressed from PP to LSP and PDGFRα staining in VSMCs 
also increased from PP to LSP (Figure 4.4). This phase specific pattern may be 
explained by the fact that PDGF-BB is known to be associated with recruitment 
and maturation of VSMCs; hence as the menstrual cycle progresses and the 
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newly formed vessels require VSMC recruitment, ECs start to express specific 
AGFs and receptors to aid vascular maturation. In contrast, PDGF-BB staining 
in glandular epithelium was unchanged across the menstrual cycle and both 
PDGFRα and PDGFRβ stainings were decreased in the glandular epithelial 
cells from PP to LSP (Figures 4.3-4.5). This is in agreement with Chegini et al. 
(1992), who reported that PDGFRβ staining was highest in PP and decreased 
considerably in the secretory phase. Moreover, the results on staining for 
PDGF-BB, PDGFRα and PDGFRβ across the menstrual cycle are mainly in line 
with those reported by Lash et al. (2012); the only difference between the two 
studies, though not significant, was that the current study observed very low 
PDGF-BB staining in stroma and glands, while Lash et al. (2012) had reported 
no expression. 
In controls, there was low TGFβ1 staining and moderate TGFβRI and TGFβRII 
staining in the endometrial stroma, glandular epithelium and ECs. While TGFβ1 
and TGFβRII staining was minimal in VSMCs, TGFβRI was moderately 
expressed. Although not statistically significant, TGFβ1 staining in stroma 
increased and that in the glandular epithelium decreased from PP to LSP 
(Figure 4.7-4.9). In contrast, Chegini et al. (1994) reported highest TGFβ1 in the 
endometrial tissues from late proliferative and early secretory to late secretory 
phases, while the current study showed highest in the MSP/LSP with levels 
remaining similar to LSP in PP, although the observed differences could be due 
to variation in antibody specificity and/or endometrial staging. On the other 
hand, the current results for TGFβ1, TGFβRI and TGFβRII staining in stratum 
functionalis and stratum basalis collectively are similar to those demonstrated 
by Lash et al. (2012) with some variations in the absolute scores. The phase 
specific pattern of staining for TGFβ1 and its receptors is indicative of their 
steroid hormone dependant regulation, and potentially roles in angiogenesis 
during the menstrual cycle. 
In addition, there was altered AGF staining in HMB. In general compared with 
controls, in HMB, staining for PDGF-BB, PDGFRα, PDGFRβ, TGFβ1, TGFβRI 
and TGFβRII were all decreased across the menstrual cycle in both 
endometrium and myometrium, especially in the stromal cells and ECs, with 
glandular epithelium and VSMCs showing less pronounced changes (Figures 
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4.3-4.5, Figures 4.7-4.9). While PDGF-BB and its receptors are involved mainly 
in VSMC recruitment, TGFβ1 and its receptors regulate both VSMC recruitment 
and differentiation (Massague, 1998; Lindahl et al., 1999; Lebrin et al., 2005). 
Therefore, a reduction in both of these AGF families would point towards 
alteration, not in the activation phase, but in the resolution phase constituting 
vessel stability and VSMC recruitment thereby leading to vascular maturation. 
This in turn may suggest that the alteration/reduction in AGF production by 
these different endometrial cell populations may contribute towards poor 
maturation and consequently dysregulated vascular development in HMB. 
While ECs from Tgfbr2 (or ALK5) deficient mice were found to be defective in 
fibronectin production and migration in culture (Larsson et al., 2001), data from 
the ECM study described in Chapter 3 (section 3.4.4.3) have shown reduced 
fibronectin in endometrium of women with HMB. This is a further indication of 
the potential critical effects of altered levels of AGFs with respect to changes in 
vascular ECM composition, ultimately resulting in altered vascular development, 
which may underlie HMB. Surprisingly, stromal staining for PDGFRβ in PP 
stratum functionalis and that of TGFβRI in PP stratum basalis, were increased 
in HMB compared with controls, indicating an alteration not only in the levels of 
but also in the timing of AGF staining for in the endometrial stromal cells in 
HMB. The current study suggests that reduced AGF expression may contribute 
towards decreased vascular maturation in HMB. Moreover our previous results 
have shown a decrease in the uNK cell population during the LSP (section 
3.4.5) in HMB. Collectively our data suggests that in HMB endometrial vascular 
maturation is reduced alongside the uNK cell population as well as AGF 
expression. Previous studies in the laboratory showed increased endometrial 
vascular maturation in RM alongside both an increased endometrial stromal 
uNK cell population (Quenby et al., 2009) and altered AGF staining (Lash et al., 
2012). In particular staining of vascular TGFβ1, which is the key player in vessel 
maturation, was reported to be increased in RM, while the current study showed 
that there was an overall pattern of a decrease in TGFβ1 staining in HMB 
compared with controls. Although differences exist between the two studies in 
terms of endometrial staging and grouping methodology, the contrasting results 
highlight that while decreased vascular development and maturation with 
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respect to VSMC differentiation may alter vascular function leading to excessive 
blood loss in the form of HMB, increased vascular maturation may also result in 
increased blood flow resulting in increased oxygen at the early implantation site 
proving detrimental to the developing embryo and placenta. Both studies 
showed a decrease in staining for vascular PDGF-BB, PDGFRα, TGFβRI and 
TGFβRII in HMB and RM, compared with controls during mid/late secretory 
phases. This may suggest that the structure and function alterations seen in 
endometrial blood vessels in HMB or RM may share common as well as distinct 
pathways, especially in downstream signalling for differential expression of 
AGFs such as TGFβ1. Therefore further studies are required, especially 
investigating the growth factors, which are differentially expressed between 
HMB and RM and also on the interaction between the different AGFs in the 
endometrium, which may provide crucial clues to elucidating a structure function 
relationship for endometrial blood vessels. 
4.5.2 Effect of AGFs on endometrial VSMC differentiation and ECM staining  
The results in section 4.4.1 and previous studies have indicated an alteration in 
endometrial AGF staining in HMB and reproductive disorders such as RM (von 
Wolff et al., 2000; Lash et al., 2012). Endometrial and myometrial explants were 
used as an in vitro model to study the effects of altered levels of AGFs in 
endometrial vascular development. The effects of PDGF-BB and TGFβ1 on 
VSMC differentiation and ECM component staining in explants of proliferative 
endometrium and superficial myometrium were investigated to assess whether 
the developing vessels of proliferative endometrium undergo altered 
development and maturation on elimination of or exposure to altered levels of 
PDGF-BB and TGFβ1. Preliminary data from the current study showed a 
reduction in h-Caldesmon, smoothelin and calponin staining both on elimination 
of or exposure to different levels of PDGF-BB and TGFβ1 (Figure 4.11). 
Interestingly, the myometrial explant cultures did not reveal such differences for 
h-Caldesmon and smoothelin, although calponin was increased after treatment 
with PDGF-BB, TGFβ1 and anti-TGFβ1 (Figure 4.11). These results, although 
preliminary, may suggest two possibilities; VSMC differentiation with respect to 
h-Caldesmon, smoothelin and calponin staining is regulated by PDGF-BB 
and/or TGFβ1 and that endometrial vessels are more receptive to alterations in 
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PDGF-BB and TGFβ1 levels than those in superficial myometrium. 
Furthermore, vascular development in endometrium is perhaps differently 
regulated than that in myometrium casting doubt on the applicability of 
myometrial explants and myometrial vessels as appropriate models for the 
study of vascular development in endometrial bleeding disorders such as HMB. 
Additionally the current study found no differences in staining for ECM 
components on elimination of or exposure to different levels of PDGF-BB and 
TGFβ1 (Figure 4.11). These preliminary results may suggest either a PDGF-
BB, TGFβ1 independent regulation of endometrial/myometrial ECM component 
expression, or that the levels (10ng/ml) of PDGF-BB and TGFβ1 utilised in the 
current study were not adequate to bring about any alteration. Moreover, 
although treated with increased levels of AGF (physiological concentration 
range between 0.1-4ng/ml), the absolute amount absorbed by the tissue and 
consequently the respective cellular components is uncertain. In summary, the 
results from the explant culture study, although preliminary, have indicated the 
possibility of utilising endometrial explant culture as a method to investigate the 
effects of altered levels of AGFs on vascular development in the endometrium. 
However in future these experiments must be repeated with larger sample size 
prior to drawing any specific conclusions. 
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4.6 CONCLUSION 
In conclusion, PDGF-BB, TGFβ1 and their corresponding receptors are 
differentially stained spatio-temporally in the uterus during the phases of the 
menstrual cycle, highlighting their dependence on steroid hormones and their 
critical role in normal uterine vascular development. Moreover, this distinct 
pattern of AGF staining was altered (principally reduced) in HMB, suggesting 
that reduced levels of AGF may contribute towards reduced or altered vascular 
maturation  and stability underlying HMB. 
Preliminary results from the explant culture study showed that altered levels or 
inhibition of AGF action may affect VSMC differentiation, especially in 
endometrium; although this may not be the case for ECM components. 
Importantly, the results suggested that since the endometrial vessels are 
sensitive to alteration in the levels of AGF, they may be more suited to the 
investigation of vascular development in HMB, compared with those in 
myometrium. These preliminary studies also highlighted the potential of the 
explant culture system for future studies investigating roles of AGFs on 
endometrial vascular development.  
Collectively the results on the role of AGFs in endometrial vascular 
development are in agreement with the results described in Chapter 3, which 
show altered VSMC differentiation, EC, ECM component staining and 
importantly an altered endometrial stromal uNK cell population, all of which 
point towards a dysregulated endometrial vascular development, rather than 
early vascular breakdown underlying HMB. 
The results on the role of AGFs in endometrial vascular development, especially 
vascular maturation and VSMC differentiation, draw attention to the need for 
further study of their effects on EC-VSMC association leading to VSMC 
recruitment and maturation. Although such functional studies are crucial, they 
are not achievable in vivo and due to limited technology currently available, 
have not been investigated in vitro. This highlights the importance of 
development and validation of in vitro assays for angiogenesis, specifically 
suited for visualisation and investigation of the dynamic EC-VSMC association 
and how this may be affected by alterations in the levels of AGFs. 
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5 IN VITRO EC-VSMC ASSOCIATION ASSAY 
5.1 INTRODUCTION 
The human endometrium is one of the very few tissues in the adult human, 
where physiological angiogenesis takes place. During the menstrual cycle, 
following shedding, the endometrium is renewed every 28 days, with 
angiogenesis being central to this process. The complex mechanism of blood 
vessel development includes angiogenesis which involves degradation of ECM, 
EC proliferation, migration and tubule formation, followed by arteriogenesis 
involving recruitment of pericytes or VSMCs, further vascular maturation and 
importantly formation of complex branching networks. Since angiogenesis is 
integral to the normal physiology of the endometrium it is indisputable that it 
may be implicated in endometrial pathologies. The significance of angiogenesis 
in the endometrium and consequently its effects on the menstrual cycle or 
implications in its pathological states have been further discussed in sections 
1.2, 1.4.1 and its role in heavy menstrual bleeding have been investigated 
through immunohistochemical studies in Chapter 3 and Chapter 4. 
Importantly, our studies have implicated dysregulated angiogenesis with a 
possible role of AGFs underlying HMB. Although crucial to the normal 
functioning of the endometrium and consequently for reproduction, 
understanding of the process of endometrial blood vessel development has 
remained limited, due to constraints in availability of animal models or 
technological advancements. Therefore, although current literature outlines the 
interplay of mechanisms which co-ordinate angiogenesis, it also highlights the 
need for further research to understand the molecular regulators of vascular 
patterning and guidance and how any such guidance cues come together to 
develop a new vessel. However, this requires a detailed understanding of the 
complex molecular mechanisms underlying the process, which in turn is 
dependant on in vitro or in vivo assays aiding testing of hypotheses and 
screening of target molecules. The significance of angiogenesis in tumour 
growth and consequently the need for identification of specific anti-angiogenic 
molecules for novel cancer therapy along with the growing need for non-
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invasive technology fuelled advancements in microscopy and bioimaging 
techniques in the context of studying angiogenesis.  
Angiogenesis is a dynamic process and therefore although important, static end 
point assays often offer limited information, such as indication of sustained 
effect or recovery, evidencing a need for development of assays, which may 
permit dynamic imaging of angiogenesis with high spatio-temporal resolution. 
Importantly, in vitro dynamic imaging of angiogenesis has the potential to 
monitor and predict responses to angiogenic factors in real time, thus opening 
doors to identification of candidate molecules and critically determining their 
functions in angiogenesis. Two-dimensional assays are unable to study EC 
activation, the process of invasion, sprouting or branching from parent tubules. 
This has lead to the development of three-dimensional assays utilising collagen 
or fibrin matrices in vitro (Martin and Murray, 2009), which have been shown to 
help retain EC characteristics, thereby responding differently to different stimuli, 
compared with two-dimensional assays. Additionally, these 3D assays were 
further utilised to study spread of vessels formed by ECs and EC invasion in the 
presence of angiogenic stimuli (Martin and Murray, 2009). Although utilising 
these assays helped to investigate EC proliferation, migration, tubule formation 
and proteolysis, to our knowledge no assay has ever been used to study the 
combined effects of EC mediated tubule formation followed by VSMC 
recruitment and how this process may be affected by different AGFs. 
Angiogenesis can be targeted at different levels, such as EC migration, tubule 
formation, VSMC recruitment etc. Therefore an in vitro assay must also be 
sensitive, developed specifically depending on the context of the scientific 
query. The in vitro assay developed in this study aims to investigate the 
following scientific questions; firstly, how do ECs communicate with VSMCs to 
recruit them onto the already formed EC tubules, secondly can this EC-VSMC 
interaction be affected by AGFs and finally, if so could this depend on altered 
AGF secretion, mRNA expression by ECs and VSMCs or VSMC differentiation? 
To be able to study these questions the assay must allow initiation of EC 
mediated tubule formation, be suited for addition of VSMCs, and importantly 
allow continuous imaging over a prolonged period of time allowing dynamic 
visualisation of the EC-VSMC interaction and the effects of AGFs.
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5.2 AIMS 
Understanding the functional role of angiogenesis in the pathogenesis of HMB 
first requires an insight into the basic process of angiogenesis, which is initiated 
through EC proliferation, migration and tubule formation followed by VSMC 
recruitment and differentiation. Investigation of these steps involved in 
angiogenesis requires an appropriate in vitro assay, which is dynamic and thus 
able to quantitatively investigate VSMC recruitment following EC mediate tubule 
formation with high resolution. Therefore, we aimed to: 
1. Develop and optimise an in vitro assay to study EC-VSMC association. 
 
2. Optimise the in vitro assay to study effects of VEGF-C treatments on EC-
VSMC association. 
 
3. Analyse AGF gene expression or secretion profiles of ECs and VSMCs 
cultured on matrigel compared with plastic, as well as differentiation of 
VSMCs cultured on matrigel when treated with VEGF-C. 
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5.3 EXPERIMENTAL DESIGN 
The experimental design is illustrated in Figure 5.1 and specific materials and 
methods used are described below. 
5.3.1 Human aorta cell line 
Human ECs (section 2.2.6.5) and VSMCs (section 2.2.6.6) were cultured 
through sequential passaging as detailed in section 2.2.6. 
5.3.2 Enzymatic disaggregation of human saphenous veins 
Human SVs were enzymatically disaggregated in order to isolate ECs and 
VSMCs. The process of enzymatic disaggregation along with preparation of cell 
culture treatments and supernatants has been described in section 2.2.6.7, 
Figure 2.6. 
5.3.3 Assay description 
The initiation of tubule formation is based on differentiation of ECs on a 
basement membrane matrix such as matrigel (Kubota et al., 1988). ECs 
differentiate and form tubule-like ‘honeycomb’ structures on matrigel but are 
unable to do the same on glass. Therefore we utilised matrigel in our assay, 
making it suitable for EC-mediated honeycomb formation. This required assay 
optimisation on two levels: thickness of the matrigel to achieve uniform coating 
and the seeding density of ECs used. The next step was the addition of 
VSMCs. Again, this step required optimisation to determine the seeding density 
of VSMCs used without disrupting the already formed tubules. Finally, dynamic 
imaging of the assay set-up required optimisation of the imaging parameters 
such as use of the correct objective, time between each frame captured and 
importantly keeping an environment suitable for the cell-culture while imaging is 
being carried out. The principal steps involved in the in vitro assay are outlined 
in Figure 5.2 and the seeding density for ECs to form honeycomb structures on 
matrigel is shown in Figure 5.3. 
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Figure 5.1: Experimental design to develop and optimise an in vitro assay aiding investigation of EC-VSMC association and how this process is 
affected by angiogenic growth factors. 
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Figure 5.2: Principal steps involved in the in vitro tubule formation and EC-VSMC 
association assay. 
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Figure 5.3: Seeding density of saphenous vein derived endothelial cells on glass (A1-
A4) and matrigel (B1-B4). Images were captured at 100x magnification. Arrows 
indicate tubule or honeycomb structure formation. Note that 6x103/well (B4) was 
chosen as optimal. (B5) Higher than optimal number of ECs clustered to disrupt 
efficient tubule formation. 
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5.3.4 Assay optimisation 
5.3.4.1 Matrigel thickness 
Matrigel is a basement membrane matrix extracted from Engelbreth-Holm-
Swarm mouse sarcoma, a tumour rich in ECM proteins such as laminin, 
collagen IV and entactin. The assay used growth factor reduced matrigel that 
contained small amounts of growth factors (Table 5.1), which allowed formation 
of honeycomb structures. The layer of coating played an important role, since 
uneven layer formation due to the hydrophobicity of the chamber slide disrupted 
the EC-honeycomb arrangement, while large amounts affected imaging, by 
increasing the working distance of an objective. Therefore a relatively thin (5-
7µl/ 0.8cm2) even layer was deemed suitable for this assay. 
Table 5.1: Amounts of growth factors in Growth Factor Reduced BD Matrigel 
GROWTH FACTOR CONCENTRATION 
Epidermal growth factor (EGF) < 0.5ng/ml 
Insulin growth factor (IGF-1) 5ng/ml 
Nerve growth factor (NGF) < 0.2ng/ml 
PDGF < 0.5pg/ml 
TGFβ 1.7ng/ml 
VEGF < 1.5ng/ml 
 
5.3.4.2 Seeding density of cells 
The appropriate seeding density of ECs was critical for honeycomb formation as 
well as for quantitative computer aided image analysis, the sensitivity of which 
depended on accuracy in automatic cell counting. Therefore, while less than 
adequate EC seeding density resulted in little tubule formation (Figure 5.3), high 
numbers jeopardised quantitative image analysis. Similarly, seeding density of 
VSMCs had an effect on disruption of EC-honeycomb structures and image 
analysis. While low numbers of VSMC were not sufficient for studying EC-
VSMC interactions, high numbers resulted in collapsing EC-honeycomb 
structures as well as inaccurate image analysis. Therefore, both ECs and 
VSMCs were seeded at 6x 103/well. 
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5.3.5 Vital dyes and confocal time-lapse microscopy 
The ECs and VSMCs were incubated at 37°C, 5% CO2 for 30 min in cell tracker 
CFSE (5mM stock diluted 1:5000 in EC basal medium; Invitrogen ♯C34554) and 
CMRA (10mM stock diluted 1:2000 in VSMC basal medium; Invitrogen 
♯C34551), respectively. The stained cells were washed in PBS (pH 7.4) and left 
to incubate at 37°C, 5% CO2 for ≥ 30 min, before trypsinisation and 
centrifugation (200g for 5 min with brake at 3). The cell pellets were then re-
suspended in the appropriate cell culture media and plated in 8-well chamber 
slides. Prior to cell plating, 4 wells of the 8-well chamber slide were coated with 
matrigel, while the remaining 4 were left uncoated for the control group on 
glass. In the first instance ECs were plated and after 4.5 hr incubation at 37°C, 
VSMCs in cell media or treatment media were added. Following a further 1 hr 
incubation, time-lapse live imaging was performed on a Nikon Eclipse-i laser-
scanning confocal microscope, equipped with 37°C incubator and 5% CO2 
supply, using 20x oil objective, 10x eyepiece and excitation wavelengths of 
492nm (CFSE) and 548nm (CMRA). Live imaging was carried out for up to 10 
hr and images were captured every 15 min. 
5.3.6 Quantitative image analysis 
5.3.6.1 EC-VSMC interaction on glass and matrigel 
The digital time-lapse images were analysed using the NIS Elements Ar 
software package (Nikon Instruments Inc.). In order to study EC-VSMC 
interaction on glass and matrigel, we aimed to analyse: (a) alterations in the 
number and velocity with which an EC or VSMC moved on glass or matrigel 
during the course of the 10 hr assay and (b) the number of other ECs or VSMCs 
which one EC come in contact with in the 10 hr assay.  
The number of ECs or VSMCs in a frame was analysed through automatic 
surface rendering aided by manual threshold adjustment (Figure 5.4A-C, Table 
5.2) so that only ECs or VSMCs were included for analysis, respectively, using 
Imaris 7.3 software (Bitplane AG, Switzerland). The automatic surface rendering 
also allowed for the automatic analysis of average velocity for ECs or VSMCs 
on glass and matrigel over the 10 hr course of the assay. To study EC-VSMC 
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interactions, 10 ECs or VSMCs were randomly chosen from each video and 
tracked to investigate the number of the same cell type (EC-EC, VSMC-VSMC) 
and the other cell type (EC-VSMC) each interacted with during the course of the 
assay. Images were analysed between 2-10 hr, to eliminate any false 
alterations due to stage displacement in the microscope. The same procedure 
was followed for N=3 time-lapse movies. 
Table 5.2: Surface rendering and manual thresholding parameters for IMARIS 
software analysis of EC:VSMC time-lapse recordings  
PARAMETER VALUE (EC) VALUE (VSMC) 
Diameter of largest sphere 
(Background elimination) 
20.00µm 20.00µm 
Manual threshold 
(Signal detection) 
24.18 24.18 
Automatic threshold B 
(Signal detection) 
3619.03 3515.48 
Tracking algorithm 
(EC, VSMC tracking, velocity) 
Autoregressive 
motion 
Autoregressive 
motion 
Tracking maximum distance 
(Maximum distance a cell may travel 
between frames) 
100.00µm 200.00µm 
Tracking maximum gap size 
(Maximum frames a cell may not be 
tracked)   
2 steps 4 steps 
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Figure 5.4: Quantitative image analysis utilised for the in vitro assay. (A-C) show 
surface rendering using IMARIS software package and (D) shows types of 
honeycombs (yellow arrows, dotted lines; D1 shows complete honeycomb, D2 shows 
incomplete honeycomb and D3 shows perimeter of a complete honeycomb. 
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5.3.6.2 Assessment of EC-VSMC interaction on matrigel 
In order to study EC-VSMC interaction on matrigel, the following parameters 
were included: (a) total number of honeycomb (or tubule) structures with ≥3 
arms, (b) the number of complete honeycombs (with an enclosed area), (c) the 
perimeter of the complete honeycombs and finally (d) the percentage of VSMC 
coverage of the complete honeycombs determined as described below. 
The digital time-lapse movies were analysed using the open-source ImageJ 
software package in combination with the ‘cell counter’ plugin to manually count 
the total number of honeycombs, complete honeycombs and measure the 
perimeter of three randomly chosen honeycombs (Figure 5.4) every 2 hr from 
the start of the assay (t=15 min) up to 10 hr. The percentage of VSMC coverage 
was analysed by measuring the total length of one complete honeycomb 
covered with VSMCs with respect to the perimeter of the honeycomb. The 
length of VSMC coverage inside (y) and outside (z) the honeycomb was added 
and a percentage VSMC coverage was obtained out of twice the honeycomb 
perimeter (x), as shown below. 
%789:	;<=>?@A> =
B + D
2E
× 100 
5.3.7 Assay application 
Applications of the in vitro assay include assessment of the effects of treatment 
with AGFs and neutralising antibodies on EC-VSMC interaction and percentage 
VSMC coverage (VSMC recruitment) on the honeycomb structures. 
Functional understanding of the effects of AGF treatment can be achieved 
through analysis of AGF gene expression by ECs and VSMCs, and AGF 
secretion by ECs cultured on plastic compared with matrigel. This can 
potentially help to identify key genes that may play a role in VSMC recruitment 
by ECs. VSMC differentiation is central to EC-VSMC interaction and VSMC 
recruitment. Hence the effect of AGF treatment on VSMC differentiation can be 
assessed by investigating the protein expression for VSMC differentiation 
markers (smoothelin and calponin; section 3.4.1.2) or h-Caldesmon gene 
expression.  
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5.3.7.1 Treatment with AGFs and neutralising antibodies 
In the in vitro assay, SV derived ECs were first plated into the 8-well chamber 
slides in EC culture medium. The chamber was incubated for 4.5 hr at 37°C and 
5%CO2, which allowed ECs to attach to the matrigel layer. Excess EC culture 
medium was carefully discarded using a pipette and VSMCs diluted in VSMC 
culture medium containing VEGF-C or anti-VEGFC neutralising antibodies 
(Appendix B) were added to each well as shown in Figure 5.2. Following this 
the chamber was imaged as described in section 5.3.5 and analysed as 
described in section 5.4.2. 
5.3.7.2 AGF gene expression and secretion  
SV derived ECs and VSMCs (only qRT-PCR) were separately cultured on 6-
well plates with or without matrigel coating. Cells were used to extract RNA for 
qRT-PCR, while supernatants were collected for analysing AGF secretion using 
ELISA/angiogenesis array. SV derived VSMCs were also cultured in 8-well 
chamber slides coated with matrigel in control VSMC culture medium or treated 
with 1ng/ml and 10ng/ml VEGF-C or anti-VEGFC for 10 hr to investigate the 
effect of VEGF-C on VSMC differentiation, in terms of calponin and smoothelin 
expression. 
5.3.7.3 qRT-PCR 
Total RNA was extracted from the ECs and VSMCs that had been grown on 
plastic and matrigel, using the TRIZOL protocol as described in section 2.2.7. 
Real-time RT–PCR was performed using TaqMan Universal PCR MasterMix as 
described in section 2.2.7.4. A list of TaqMan probe/primer sets utilized has 
been listed in Table 2.5. All probe/primer sets were previously validated for use 
with a laboratory standard total RNA extracted from early pregnancy decidua. 
The 2-∆∆CT-method was used to calculate relative fold changes in gene 
expression as described in section 2.2.7.6. 
5.3.7.4 ELISA and Quantibody Human Angiogenesis Array 
Sandwich ELISA and Quantibody Human Angiogenesis Array were used to 
study the effects of matrigel on the profile of secreted AGFs by ECs. Sandwich 
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ELISA was performed as described in section 2.2.9.1 and Quantibody Human 
Angiogenesis Array was performed as described in section 2.2.10. 
5.3.8 Statistical analysis 
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc.). Data 
are presented as means ± standard error of mean (SEM) and differences are 
considered statistically significant at P≤0.05. Specific tests used are given in the 
results.
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5.4 RESULTS 
5.4.1 EC-VSMC association on glass and matrigel 
5.4.1.1 ECs and VSMCs differ in number and velocity when cultured on glass 
and matrigel 
When cultured on glass the number of disconnected (cell not in contact with any 
other cells) SV ECs and VSMCs and their velocity remained unchanged during 
the 10 hr in vitro assay. However, when these cells were cultured on matrigel 
both ECs and VSMCs decreased in number and velocity (Figure 5.5). The 
number of disconnected ECs was halved (P=0.018) and their velocity was also 
reduced (P=0.018). The number and velocity of VSMCs were also reduced 
(P=0.020, P=0.043 respectively; Figure 5.5). 
5.4.1.2 ECs and VSMCs interact more with own cell type than the other 
ECs and VSMCs derived from aorta or SVs were cultured in vitro for 10 hr. ECs 
derived from aorta and SV interacted with other ECs and VSMCs in a similar 
manner (Figure 5.6A, Figure 5.6B). ECs were observed to interact significantly 
more with other ECs than with VSMCs on both glass and matrigel for both the 
aorta cell line (glass P=0.001, matrigel P=0.02; Figure 5.6A) and ECs from SVs 
(glass P=0.01, matrigel P=0.03; Figure 5.6B). VSMCs derived from aorta and 
SV interacted differently with other VSMCs and ECs (Figure 5.6A, Figure 5.6B). 
Aorta VSMCs were observed to interact significantly more with other VSMCs 
than with ECs on both glass and matrigel (glass P<0.001, matrigel P=0.001; 
Figure 5.6A), but no such differences were observed for SV VSMCs on both 
glass and matrigel (Figure 5.6B). Importantly, ECs formed honeycomb 
structures to which VSMCs were recruited only on matrigel and not on glass 
(Figure 5.6C). 
5.4.1.3 ECs and VSMCs from human aorta and saphenous vein differentially 
express AGF genes when cultured on glass and matrigel 
Angiopoietin family and receptor: Ang1, Ang2 and Tie2 mRNA remained 
unaltered when cultured on matrigel compared with plastic in ECs from aorta or 
SV (Figure 5.7A). 
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Figure 5.5: Graphical representation (mean ± SEM) of fold change in number and 
velocity of endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). 
Saphenous vein derived (A) ECs and (B) VSMCs were cultured on glass and matrigel 
(N=3 each group) for up to 10 hr. Mann-Whitney U test determined significant 
difference between glass and matrigel while Pairwise Kruskal-Wallis one way ANOVA 
determined significant difference between different time points. 
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Figure 5.6: Graphical representation (mean ± SEM) of percentage of endothelial cells 
(ECs), which interacted with other ECs or with vascular smooth muscle cells (VSMCs).  
Cellular interaction during the course of a 10 hr assay (N=3 each group) using cells 
from human (A) aorta and (B) saphenous vein. Mann-Whitney U test determined 
significant difference in EC:EC, EC:VSMC, VSMC:EC and VSMC:VSMC interaction 
between glass and matrigel as well as between aorta and saphenous vein. (C) ECs 
(green) form honeycomb structures indicated by arrows, to which VSMCS (red) are 
recruited, only when they are cultured on matrigel (C6-C10), but not on glass (C1-C5). 
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Figure 5.7: Graphical representation (mean ± SEM) of fold change in mRNA 
expression of angiogenic growth factors. (A-D) endothelial cells (ECs) and (E-H) 
vascular smooth muscle cells (VSMCs) from human aorta or saphenous vein cultured 
on matrigel compared with plastic (N=3 each group). Mann-Whitney U test determined 
significant difference in fold change mRNA expression on matrigel compared with 
plastic (indicated by a-k; aP=0.015, b,f,kP=0.05, c,jP=0.016, dP=0.03, eP=0.022, gP=0.006, 
h,iP=0.004, bP=0.05). 
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In aorta VSMCs Ang1, Ang2 and Tie2 mRNA expression remained unaltered 
when cells were cultured on matrigel compared with plastic (Figure 5.7E). In SV 
derived VSMCs, Ang1 and Ang2 mRNA expression remained unaltered, while 
Tie2 was increased over two-fold (P=0.006) when cultured on matrigel 
compared with plastic (Figure 5.7E). 
VEGF family and receptors: VEGF-A, VEGF-C, VEGFR1 and VEGFR2 mRNA 
expression in ECs from aorta or SVs remained unaltered when cultured on 
matrigel compared with plastic (Figure 5.7B). However, VEGFR3 mRNA 
expression was increased over six-fold in aorta ECs (P=0.015) and over three-
fold in SV derived ECs (P=0.05; Figure 5.7B). 
VEGF-C, VEGFR1 and VEGFR2 mRNA expression in VSMCs from aorta or 
SVs remained unaltered when cultured on matrigel compared with plastic 
(Figure 5.7F). VEGF-A increased over two-fold in SV derived VSMCs (P=0.004) 
but remained unaltered for aortic VSMCs, when grown on matrigel compared 
with plastic.  
PDGF-BB and receptors: PDGF-BB mRNA expression in ECs from aorta or 
SVs remained unaltered when cultured on matrigel compared with plastic 
(Figure 5.7C). PDGFRα expression increased over ten-fold in SV derived ECs 
(P=0.016), but was unaltered in aorta ECs when cultured on matrigel compared 
with plastic (Figure 5.7C). PDGFRβ expression increased in ECs from both 
aorta (P=0.030) and SVs (P=0.022; Figure 5.7C). 
PDGF-BB and PDGFRα mRNA expression in VSMCs from aorta or SVs 
remained unaltered when cultured on matrigel compared with plastic (Figure 
5.7G). PDGFRβ was increased in SV derived VSMCs (P=0.004), but remained 
unaltered in aorta VSMCs, when cultured on matrigel compared with plastic 
(Figure 5.7G). 
TGFβ1 and receptors: TGFβRI and TGFβRII mRNA in ECs from aorta or SVs 
remained unaltered when cultured on matrigel compared with plastic (Figure 
5.7D). However, TGFβ1 expression was increased over four-fold in ECs derived 
from SVs (P=0.05) but remained unaltered in aorta ECs, when grown on 
matrigel compared with plastic. 
  
 
5.4 RESULTS 
 
  
220 
TGFβRI mRNA in VSMCs from aorta or SVs remained unaltered when cultured 
on matrigel compared with plastic (Figure 5.7H). VSMCs from SV showed an 
increase in mRNA of TGFβ1 (P=0.016) and TGFβRII (P=0.05) when cultured on 
matrigel compared with plastic (Figure 5.7H).  
5.4.1.4 No alteration in AGF secretion by saphenous vein derived ECs when 
cultured on matrigel, compared with plastic 
In SV derived ECs, fold change in secretion of Angiogenin, Ang1, Ang2, VEGF-
A, VEGF-C, PIGF, PDGF-BB, TGFβ1, bFGF, HGF, leptin, EGF and HB-EGF 
remained unaltered between groups cultured on matrigel compared with those 
cultured on plastic (Figure 5.8A-D). 
5.4.2 Effect of VEGF-C on EC-VSMC association and VSMC differentiation 
in vitro 
5.4.2.1 Effect of VEGF-C on EC-VSMC association 
Number and velocity of ECs and VSMCs: The number of SV derived ECs 
decreased at 10 hr compared with that at 2 hr in all groups (control P=0.018, 
10ng/ml VEGF-C P=0.033, 10ng/ml anti-VEGF-C P=0.018; Figure 5.9A). The 
EC velocity remained unchanged in samples treated with 1ng/ml VEGF-C, 
10ng/ml VEGF-C or 10ng/ml anti-VEGFC, but was decreased in the untreated 
controls (P=0.018; Figure 5.9B). 
The number of SV derived VSMCs decreased at 10 hr compared with that at 2 
hr in the controls (P=0.02) and after treatment with 10ng/ml anti-VEGFC 
(P=0.035; Figure 5.9C). In addition, the number of VSMCs in the anti-VEGFC 
treated group was decreased at 10 hr compared with 4 hr (P=0.02) and at 8 hr 
compared with 2 hr (P=0.044) and 4 hr (P=0.028; Figure 5.9C). VSMC velocity 
decreased in the controls at 8 hr compared with 2 hr (P=0.043) and in the 
10ng/ml VEGF-C treated group at 10 hr compared with 2 hr (P=0.025; Figure 
5.9D). 
Total number of honeycombs: The total number of honeycombs (≥3 arms) was 
reduced at 10 hr compared with 15 min in the untreated control group (P=0.035) 
and after treatment with 10ng/ml VEGF-C (P=0.024; Figure 5.10A-B). 
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Figure 5.8: Graphical representation (mean ± SEM) of fold change in angiogenic 
growth factor secretion in SV derived endothelial cells (ECs). (A-D) Saphenous vein 
derived ECs cultured on matrigel (N=3 each group). Mann-Whitney U test determined 
significant difference between fold changes in AGF secretion on matrigel compared 
with plastic. No significant differences were observed. 
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Figure 5.9: Graphical representation (mean ± SEM) of fold change in number and 
velocity of VEGF-C treated endothelial cells (EC) and vascular smooth muscle cells 
(VSMC) on matrigel. Fold change in saphenous vein derived EC (A) number and (B) 
velocity and VSMC (C) number and (D) velocity (N=3 each group) at different time 
points relative to 2 hr between untreated control or VEGF-C treatments, on matrigel. 
Pairwise Kruskal-Wallis one way ANOVA determined significant difference between 
different time points and between untreated control or VEGF-C treatments. Bars with 
same letters are significantly different from each other; A,CP=0.018, BP=0.033, 
D,FP=0.020, EP=0.035, GP=0.044, HP=0.028, IP=0.043, JP=0.025. 
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Figure 5.10: Graphical representation (mean ± SEM) of fold change in VEGF-C treated 
(EC) honeycombs (HC) and vascular smooth muscle cell (VSMC) coverage. Fold 
change at different time points relative to 15 min in number of (A, B) total HC with 
≥3arms, (A, C) complete honeycomb, (A, D) perimeter of complete honeycomb and (E) 
percentage of VSMC coverage of complete honeycomb by saphenous vein derived 
ECs and VSMCs (N=3 each group). Pairwise Kruskal-Wallis one way ANOVA 
determined significant difference between different time points and between untreated 
control or VEGF-C treatments. Bars with same letters are significantly different from 
each other. ‘P’ values represent differences between different time points; AP=0.035, 
BP=0.024, CP=0.050, DP=0.033, E,FP=0.047. 
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Number of complete honeycombs: The number of complete honeycombs was 
reduced at 10 hr compared with 15 min in the untreated control group (P=0.05) 
but was unaltered in the groups treated with 1ng/ml VEGF-C, 10ng/ml VEGF-C 
and anti-VEGFC (Figure 5.10C). 
Honeycomb perimeter: The perimeter of complete honeycombs increased at 8 
hr compared with 15 min in the control group (P=0.033). The perimeter of 
complete honeycombs was greater after 8 hr (P=0.05) and 10 hr (P=0.05) 
treatment with 10ng/ml VEGF-C compared with 15 min (Figure 5.10D). 
VSMC coverage: The percentage VSMC coverage of honeycombs appeared to 
increase over time, although this was not statistically significant in control or 
VEGF-C treated groups (Figure 5.10E). 
5.4.2.2 Effect of VEGF-C on VSMC differentiation 
Calponin and smoothelin expression: SV derived VSMCs were cultured in 8-
well chamber slides coated with matrigel in control VSMC culture medium, 
1ng/ml VEGF-C, 10ng/ml VEGF-C and anti-VEGFC for up to 10 hr. The number 
of calponin+ or smoothelin+ VSMCs as determined by IHC, remained unaltered 
when treated with different concentrations of VEGF-C or its neutralising 
antibody (Figure 5.11A). 
h-Caldesmon mRNA expression: SV derived VSMCs were cultured overnight in 
6-well dishes coated with matrigel in control VSMC culture medium, 1ng/ml 
VEGF-C, 10ng/ml VEGF-C and anti-VEGFC. h-Caldesmon mRNA (fold change 
compared with untreated controls) as determined by qRT-PCR, remained 
unaltered in VSMCs treated with different concentrations of VEGF-C or its 
neutralising antibody (Figure 5.11B). 
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Figure 5.11: Graphical representation (mean ± SEM) of fold change in calponin+ or 
smoothelin+ in saphenous vein derived vascular smooth muscle cells (VSMCs). Fold 
change compared with untreated control (A) in percentage calponin+ or smoothelin+ 
VSMCs and (B) in H-Cal mRNA in saphenous vein derived VSMCs cultured on 
matrigel (N=3 each group). Pairwise Kruskal-Wallis one way ANOVA.  No significant 
differences were observed. 
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5.5 DISCUSSION 
5.5.1 EC-VSMC association assay 
Angiogenesis is central to the normal menstrual cycle and dysregulated 
angiogenesis has been implicated in HMB. In order to understand the 
mechanisms underlying dysregulated angiogenesis in HMB, it is first necessary 
to study the basic steps in angiogenesis; EC proliferation, migration, tubule 
formation, VSMC recruitment and vascular maturation. ECs and VSMCs are 
present in vascular beds of different tissues and although they have similarities 
with one another such as the cobblestone morphology typical of ECs, tissue-
specific requirements drive them towards distinct heterogeneous cell 
populations, differing at the biochemical, molecular and consequently functional 
levels. This highlights the importance of the source of cells used in an in vitro 
assay, and that the best fit may be from vessels that are perhaps functionally 
the closest match to those in the specific scientific query being investigated. 
ECs mostly remain quiescent in adults until activated by AGFs such as VEGFs, 
following which they undergo proliferation, migration and tubule formation, 
marking the initiation of angiogenesis. ECs have been harvested from large 
vessels such as the aorta, umbilical and saphenous veins through mechanical 
removal or enzymatic disaggregation such as collagenase digestion (Jaffe et 
al., 1973). However, since the endothelium of larger vessels may differ from 
tissue microvasculature, techniques have also been established for isolation of 
ECs from endometrial vasculature for utilisation in in vitro models (Schatz et al., 
2000). Although brain or adipose tissues are suited for microvascular EC 
isolation (Wagner and Matthews, 1975; Dorovini-Zis et al., 1991) due to their 
high vascular density as well as ease of disaggregation, the endometrial 
microvasculature still remains challenging. This is due to the lower density of 
vessels, vascular or branching size and rigidity, the presence of a mixed cell 
population and importantly endometrial tissue availability. 
The other key player in vascular development is the VSMC, whose recruitment 
onto the endothelial tubule leads to vascular maturation and allows blood 
circulation. VSMCs have previously been isolated from umbilical veins or 
arteries (Campbell and Campbell, 1993) and their phenotypic modulation in vitro 
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has also been discussed in detail elsewhere (Campbell and Campbell, 2012). 
The two commonly used techniques used to isolate VSMCs from arteries or 
veins are enzymatic disaggregation of the vessel or tissue explantation and 
subsequent cell isolation. While isolation using the explantation method may 
provide VSMC colonies that may be kept for longer periods, it is not suitable for 
endometrial tissue as explained earlier. 
A number of in vitro assays may be utilised to study angiogenesis; however the 
choice of the most appropriate cell type or assay is ultimately based on the 
combination of a number of factors including tissue, cell, and reagent 
availability, cost of equipment, time taken for an experimental setup and 
importantly the skills required and reproducibility. Taking into consideration the 
above-mentioned factors, the first choice for this study was to utilise the widely 
studied human aorta EC and VSMC cell lines. However, these primary cells 
were often observed to de-differentiate in culture, with loss of characteristics. 
SV derived ECs and VSMCs were the next choice, since SVs are a good 
source of ECs and VSMCs and were relatively easy and sustainable to source. 
Moreover, SV ECs have been reported to retain their characteristics for up to 15 
passages (Scoumanne et al., 2002) and we had also observed that ECs and 
VSMCs isolated from SVs retained their characteristics for longer as determined 
by cell characterisation (section 2.2.6.3); hence SV derived ECs and VSMCs 
were chosen for this assay. 
Finally, while the results from Chapter 3 and Chapter 4 highlighted the 
importance of vascular maturation, VSMC differentiation and AGF expression in 
the endometrium, to our knowledge, no existing in vitro assay was applicable to 
further investigate these processes. Hence this study aimed to developed an 
angiogenesis assay, based on EC differentiation on matrigel to form 
‘honeycomb’ tubular structures, to specifically target vascular maturation 
through EC mediated VSMC recruitment and investigate the effects of AGFs on 
EC-VSMC association and VSMC differentiation. Moreover a comparison of 
ECs and VSMCs, when cultured on plastic and matrigel gave some insight into 
the roles PDGF-BB and TGFβ1 governing the process of vascular maturation. 
Number and velocity of ECs and VSMCs: The current study demonstrated that 
the number and velocity of ECs and VSMCs reduced over time when cultured 
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on matrigel (Figure 5.5). This can be explained by the fact that ECs come in 
contact with other ECs and organise themselves into honeycomb structures, 
which increase in number forming bigger networks with time, leaving fewer 
numbers and space between isolated ECs, resulting in slower movement in 
space. Furthermore, when VSMCs are added to the wells with ECs, with time, 
they are drawn towards the EC honeycomb structures, where they form 
attachments and start to cover the honeycomb structures. Therefore, as more 
and more VSMCs attach to the honeycombs, fewer numbers of isolated VSMCs 
remain present and in addition, with reduced free space (due to EC mediated 
honeycomb structure formation), their average velocity is reduced. 
EC-VSMC interaction: The results showed that ECs and VSMCs are more likely 
to interact with their own cell type than with the other when cultured on both 
glass and matrigel (Figure 5.6). Firstly, this may suggest that ECs and VSMCs 
release mediators in the culture medium, which can be detected by their own 
cell type, therefore reaching and drawing neighbouring cells as well as cells that 
are further away. While ECs are also involved in VSMC recruitment into the 
honeycombs, they may secrete cell specific mediators and therefore 
demonstrate distinct relationships with other ECs or VSMCs. Since this 
interaction remains unaltered when cultured on glass or matrigel, it may indicate 
that this EC mediated cell specific communication in vitro may not be dependent 
on the interaction with extracellular matrix interactions; however EC mediated 
honeycomb structure formation and VSMC recruitment is only observed on 
matrigel. Therefore it may be that although ECs and VSMCs are interacting with 
one another independent of the matrix matrigel, their ability to form stable 
attachments forming honeycombs or VSMC coverage is affected by the 
presence of matrigel; further study is required, which may specifically address 
the role of ECM in EC-VSMC association. 
AGF gene expression: Matrigel was observed to alter ECs and VSMCs in terms 
of their number, velocity and interaction between each other; ECs formed 
honeycomb structures and allowed VSMC coverage only when cultured on 
matrigel. This is perhaps explained by the differences in the pattern of AGF 
mRNA in ECs and VSMCs when cultured with or without matrigel (Figure 5.7). 
PDGFRβ is particularly expressed on VSMCs or pericytes and communicates 
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through PDGF-BB released from ECs; mice lacking PDGF-BB and PDGFRβ 
were shown to be VSMC deficient and died at birth (Lindahl et al., 1997). This 
perhaps suggests that when cultured on matrigel, VSMCs have an increased 
PDGFRβ, which enables them to be more sensitive towards PDGF-BB 
expression on ECs, thereby leading to VSMC coverage on EC honeycombs. 
TGFβ1 and its receptor TGFβRII play important roles in regulating cell 
proliferation, adhesion, differentiation and migration in the activation phase of 
angiogenesis while inhibiting EC migration and proliferation, imparting stability 
at the resolution phase (Goumans et al., 2009). TGFβ1 was increased in both 
ECs and VSMCs when cultured on matrigel, which perhaps reiterates the fact 
that it not only plays a role in mediating EC migration, proliferation and 
honeycomb structure formation, but also later in helping maintain the structure 
after addition of VSMCs. The Ang1-Tie2 signalling pathway is critical for 
vascular development; in particular Tie2 has been proposed to be important for 
EC formation and mice lacking Tie2 die embryonically, due to poor vascular 
organisation and perivascular cell coverage (Dumont et al., 1994; Sato et al., 
1995). This may explain why when cultured on matrigel once ECs have formed 
the honeycomb structures, VSMCs expressing higher Tie-2 are drawn towards 
them resulting in VSMC coverage. 
VEGF-A crucially regulates angiogenesis; homozygous and heterozygous 
VEGF-A knockout mice die embryonically due to immature blood vessel 
formation (Carmeliet et al., 1996; Ferrara et al., 1996). Therefore an increase in 
VEGF-A expression in VSMCs cultured on matrigel may indicate altered 
vascular maturation in vitro. VEGFR3 is expressed in ECs at the tips of 
angiogenic sprouts (Tammela et al., 2008), which may partially explain its 
increase in in vitro culture on matrigel, which is an active site for EC migration 
and honeycomb/tubule formation. Interestingly, VEGFR3 signalling is initiated 
through VEGF-C or VEGF-D binding, although VEGF-D has primarily been 
implicated in lymphangiogenesis. Therefore an increase in VEGFR3 by both 
ECs and VSMCs may also suggest VEGF-C as a potential mediator for tubule 
formation, VSMC recruitment and differentiation, and EC-VSMC association. 
Additionally, both the PDGF-BB receptors and TGFβ1 were also increased, 
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which together with VEGF-C may contribute towards EC-VSMC association, 
highlighting the significance of further investigation into their effects in vitro. 
AGF secretion: Although SV derived ECs, when cultured on matrigel, showed a 
significant increase in VEGFR3, PDGFRα and PDGFRβ and TGFβ1 gene 
expression, matrigel had no effect on AGF secretion by these ECs. This may 
suggest that while matrigel may affect AGF expression in ECs perhaps 
indirectly making them sensitive to paracrine AGF signalling, it is unable to 
directly regulate AGF secretion by ECs thereby not directly affecting EC-EC or 
EC-VSMC communication. This may also be the reason why no alteration in 
EC-EC, EC-VSMC interaction was observed when ECs were cultured with or 
without matrigel. However, these are preliminary results and further 
experiments must be performed before any definite conclusion may be drawn. 
5.5.2 Effect of VEGF-C on EC-VSMC association and VSMC differentiation 
Angiogenic growth factors such as VEGF along with TGFβ and PDGF are some 
of the most important factors in vascular development, homeostasis, 
stabilisation and maturation. Amongst the VEGF family, VEGF-A remains the 
most widely studied member and key to angiogenesis. However, VEGF-C has 
been suggested to regulate VEGF-A expression, thereby promoting 
angiogenesis in cancer (Gacche and Meshram, 2014). VEGF-C binds to 
VEGFR3, but also to VEGF2 with low affinity (Hoeben et al., 2004; Olsson et 
al., 2006). Binding of VEGF-C to sVEGFR2 prevents VEGFR3 binding resulting 
in inhibition of EC proliferation (Koch et al., 2011). Although VEGFR3 is mostly 
restricted to lymphatic ECs in adults, ECs present in tissues or sites of active 
angiogenesis, especially the ‘tip cells’ of angiogenic sprouts express VEGFR3 
(Koch et al., 2011), and presumably initiate signalling via binding of VEGF-C. 
Importantly, Tie2 expressing macrophages localise at vascular branching points 
and induce connection between EC tubule structures by VEGF-C secretion and 
consequently activation of the VEGFR3 signalling pathway in the tip cells 
(Fagiani and Christofori, 2013). Interestingly, an in vivo study using a 
combination of antibodies against VEGFR3 and VEGF-C was shown to be 
efficient in inhibiting VEGFR3 signalling and vascular network formation 
(Tvorogov et al., 2010; P. Saharinen et al., 2011). Again, unpublished data from 
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our laboratory has suggested a role for VEGF-C in tubule formation. The in vitro 
angiogenesis assay described above aided investigation of the effects of 
VEGF-C on EC-VSMC association and VSMC differentiation, governing 
angiogenesis. 
VEGF-C in EC-VSMC association: Results from the in vitro assay showed that 
VEGF-C and anti-VEGFC treatments did not affect the number of disconnected 
ECs or VSMCs compared with untreated controls (Figure 5.9). However, the 
reduction in EC velocity over time in the control group was not observed in any 
of the VEGF-C treated groups. Additionally, the different VEGF-C treatments 
did not affect the number of total and complete honeycombs or the size of their 
perimeter (Figure 5.10). Although this may not suggest any specific role for 
VEGF-C, the results from this study are preliminary and require further 
optimisation in terms of the concentration of VEGF-C treatments and also a 
larger sample size to counteract variability. 
VEGF-C in VSMC differentiation: In order to investigate whether VEGF-C might 
affect EC-VSMC association by regulating VSMC differentiation, VSMCs were 
exposed to different VEGF-C treatments for the same length of time as during 
the in vitro assay. In particular the VSMC differentiation markers calponin and 
smoothelin were implicated in HMB perhaps underlying dysregulated vascular 
maturation. Therefore it was of interest to study whether VEGF-C affected the 
expression of these factors in VSMCs in vitro. However, the number of VSMCs 
expressing calponin and smoothelin remained unaltered in all treatment groups 
compared with untreated controls (Figure 5.11). Although 1ng/ml or 10ng/ml are 
the standard treatment concentrations utilised to study effects of molecules on 
physiological processes, this may need further optimisation, perhaps through a 
dose response assay. These data may not suggest a role for VEGF-C in VSMC 
differentiation in vitro, but the small sample size in this study may have affected 
the results due to variation; therefore inviting further research with a larger 
sample size. 
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5.6 CONCLUSION 
The current study demonstrated that although both aorta and SV derived ECs 
and VSMCs were suitable for tubule formation and the study of EC-VSMC 
association, distinct differences existed in their AGF gene expression and their 
response to VEGF-C treatments. Therefore care should be taken to compare or 
draw conclusions from studies using cells from different sources in relation to 
the process in vivo. While ECs and VSMCs from different tissue vasculature 
may be phenotypically different at the molecular and consequently functional 
level, no gold standard assay or cell type currently exists. Moreover unless an in 
vitro angiogenesis assay utilises ECs and VSMCs from the specific vessels on 
which the scientific query is based on the results may not be directly 
translatable to the in vivo situation. However, as discussed earlier the nature of 
the endometrial vasculature makes it challenging to study and while 
methodology exists for isolation of endometrial EC no such methodology is 
currently available for endometrial VSMCs. Therefore, in the absence of a gold 
standard model and cells derived from the endometrial vasculature, it is only 
possible to develop and optimise an assay with cells from larger vessels such 
as the saphenous vein, keeping in mind factors such as cell characterisation, 
sustainability and reproducibility. Results from the application of the assay, has 
provided us with preliminary results, which would need to be tested with a larger 
sample size and if possible in future compared with cells from the endometrial 
vasculature before any definitive conclusion or direction can be drawn. 
Nonetheless, the assay was successfully optimised along with the development 
of a semi-automated image analysis protocol and shows promise for application 
to further study effects of other AGFs such as PDGF-BB and TGFβ1 on EC-
VSMC association, VSMC recruitment and differentiation. Importantly, further 
research into the development of in vitro angiogenesis assays and utilising the 
quantitative data from these assays will help us to understand the basic 
angiogenic process and open doors to finding candidate molecules with 
potential clinical applications. 
  
CHAPTER 6 
EFFECTS OF ANGIOGENIC GROWTH FACTORS ON EC-VSMC 
ASSOCIATION AND VSMC DIFFERENTIATION IN VITRO 
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6 EFFECTS OF ANGIOGENIC GROWTH FACTORS ON EC-VSMC 
ASSOCIATION AND VSMC DIFFERENTIATION IN VITRO 
6.1 INTRODUCTION 
Angiogenic growth factors such as PDGF-BB and TGFβ1 play significant roles 
in regulation of blood vessel development including initiation of EC proliferation, 
migration, tubule formation, recruitment and differentiation of pericytes or 
VSMCs and vascular stabilisation. PDGF-BB binds to both PDGFRα and 
PDGFRβ; PDGF-BB and PDGFRβ are the most widely studied members of the 
PDGF family. PDGFRα is expressed in mesenchymal cell progenitors in lung, 
skin and intestine and is less well studied, but has been implicated in 
mesenchymal or fibroblast derived pathologies (Andrae et al., 2008). PDGF-BB 
and PDGFRβ are mostly expressed in developing vessels, where quiescent 
ECs, especially the tip cells, express both PDGF-BB and PDGFRβ and 
communicate with perivascular cells, which express PDGFRβ (Gerhardt and 
Betsholtz, 2003). Moreover, in vitro studies have shown that stimulating ECs 
with PDGF-BB induces sprouting, proliferation and tubule formation (Battegay 
et al., 1994), while studies in mice have shown that disruption of the PDGF-
BB/PDGFRβ pathway results in weakened vascular structures and dilated 
vessels, due to irregular proliferation of ECs and loss of pericytes (Andrae et al., 
2008). Consistent with this, increased PDGFRβ expression correlated with 
VEGF-A and VEGFR2 overexpression that resulted in increased sprouting, 
along with increased pericyte recruitment and vascular development 
(Magnusson et al., 2007). Collectively these studies highlight a specific role for 
PDGF-BB in promoting VSMC recruitment and vascular maturation though the 
PDGF-BB/PDGFRβ pathway. 
PDGF-BB plays a role specifically in VSMC recruitment and vascular 
maturation, while TGFβ1 regulates VSMC recruitment as well as differentiation 
(Lebrin et al., 2005). TGFβ1 may bind to and mediate signalling via TGFβRI or 
TGFβRII receptors. TGFβ1 has been shown to stimulate or inhibit angiogenesis 
in vivo and in vitro, depending on the experimental design and the specific 
stage of angiogenesis being studied (Goumans et al., 2009). Furthermore, 
TGFβ1 has been shown to induce, as well as protect against, EC apoptosis; 
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while EC proliferation is an essential step in angiogenesis, especially at the 
activation stage, apoptosis of ECs via TGFβ1 is also crucial, since its inhibition 
leads to abnormal vessel formation (Ferrari et al., 2009). Additionally, both 
TGFβ1 and VEGF have been implicated in increased EC differentiation, EC-
ECM interaction thereby regulating vascular stabilisation, development and 
remodelling (Davis and Senger, 2008; Ferrari et al., 2009; Margadant and 
Sonnenberg, 2010). During the resolution phase of angiogenesis, mesenchymal 
cells undergo differentiation to become pericytes or VSMCs, via EC induced 
TGFβ1 signalling. Consequently, pericytes or VSMCs are recruited onto the EC 
tubules resulting in muscularised and mature vessels (ten Dijke and Arthur, 
2007; Shi and Chen, 2014). The critical role of TGFβ1 in VSMC recruitment is 
further indicated by studies in mice, which showed that the absence of TGFβ 
receptors TGFβRII or ALK5 was embryonically lethal due to vascular defects 
(Jiao et al., 2006). Thus it is evident that TGFβ1 is critical both in the initiation, 
activation as well as later stages of angiogenesis. 
The stage specific reliance of angiogenesis on AGFs highlights that 
dysregulation at any of these stages may give rise to vascular diseases (ten 
Dijke and Arthur, 2007; Demoulin and Essaghir, 2014; Heldin, 2014). Vascular 
dysregulation, including increased EC proliferation is implicated in HMB (Kooy 
et al., 1996; Abberton et al., 1999a; Abberton et al., 1999b; Hurskainen et al., 
1999). In addition, we have shown dysregulated VSMC differentiation in terms 
of altered smoothelin and basic calponin staining (Chapter 3) (Biswas Shivhare 
et al., 2014) and altered (primarily reduced) staining of PDGF-BB, TGFβ1 and 
their respective receptors in the endometrium of women with HMB (Chapter 4). 
AGFs such as PDGF-BB, TGFβ1, EGF and FGF promote VSMC differentiation; 
VSMC differentiation is regulated by the transcriptional activation of genes 
including calponin (CNN), smoothelin (SMTN), MyHC and αSMA through the 
transcription factor SRF and SMC specific co-factor myocardin (Wang et al., 
2001; Chen et al., 2002). A secreted glycoprotein, cellular repressor of E1A-
stimulated genes (CREG), has been shown to play important roles in regulating 
proliferation, migration and differentiation of VSMCs (Han et al., 2009; Han et 
al., 2010; Shi and Chen, 2014). In light of the importance of VSMC 
differentiation in dysregulated angiogenesis underlying HMB and the critical 
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roles of AGFs in angiogenesis, it is of interest to investigate the role of these 
AGFs on VSMC recruitment leading to EC-VSMC association and on 
subsequent VSMC differentiation. The absence of an appropriate in vivo model 
or in vitro assay to study dysregulated angiogenesis underlying HMB 
necessitated the development of the in vitro angiogenesis assay shown in 
Chapter 5. Using this assay we are now able to study the effects of PDGF-BB 
and TGFβ1 on EC-VSMC association, VSMC recruitment and differentiation. 
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6.2 HYPOTHESES AND AIMS 
6.2.1 Hypotheses 
PDGF-BB and TGFβ1 critically regulate angiogenesis; the expression of these 
AGFs and their receptors has been shown to be altered in HMB alongside 
dysregulated angiogenesis and VSMC differentiation. Therefore we 
hypothesised that: 
1. PDGF-BB and TGFβ1 treatment may affect EC-VSMC association. 
 
2. PDGF-BB and TGFβ1 treatment may result in alteration of AGF secretion 
and gene expression by ECs and VSMCs. 
 
3. PDGF-BB and TGFβ1 treatment may affect VSMC differentiation. 
6.2.2 Aims 
To test the above hypotheses we aimed to: 
1. Assess the effect of PDGF-BB and TGFβ1 treatment on EC-VSMC 
association in vitro. 
 
2. Assess the effect of PDGF-BB and TGFβ1 treatment in vitro on AGF mRNA 
expression and protein secretion by both ECs and VSMC. 
 
3. Assess the effect of PDGF-BB and TGFβ1 treatment on in vitro VSMC 
differentiation. 
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6.3 EXPERIMENTAL DESIGN 
The experimental design adopted to achieve the specific aims set out in section 
6.2.2, has been illustrated in Figure 6.1 and the specific materials and methods 
used are described below. 
6.3.1 Enzymatic disaggregation of human saphenous veins 
Human SVs were enzymatically disaggregated in order to isolate ECs and 
VSMCs used in the in vitro assay. The process of enzymatic disaggregation 
along with preparation of cell culture treatments and supernatants has been 
described in section 2.2.6.7, Figure 2.6. 
6.3.2 EC-VSMC association and tubule formation assay 
In vitro EC-VSMC association and tubule formation assay was performed as 
described in sections 5.3.3 and 5.3.4 and Figure 5.2.  
6.3.2.1 Treatment with AGFs and neutralising antibodies 
The method for AGF treatments (PDGF-BB, TGFβ1, neutralising antibodies) 
has been described in section 5.3.7.1 and the constituents of the treatment 
media have been described in Appendix B. 
6.3.2.2 Vital dyes and confocal time-lapse microscopy 
The vital dyes and microscopy parameters used for the in vitro assay have been 
described in section 5.3.5. 
6.3.2.3 Quantitative image analysis 
Quantitative image analysis for EC-VSMC association and tubule formation was 
been carried out as described in section 5.3.6. 
6.3.3 qRT-PCR 
qRT-PCR was used to investigate the effect of AGFs on mRNA of a number of 
genes in ECs and VSMCs. Total RNA was extracted from the ECs and VSMCs, 
treated overnight with PDGF-BB or TGFβ1, using the TRIZOL protocol as 
described in section 2.2.7. Real-time RT–PCR was performed using TaqMan 
Universal PCR MasterMix as described in section 2.2.7.4. A list of TaqMan 
probe/primer sets utilized has been listed in Table 2.5. All probe/primer 
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Figure 6.1: Experimental design to study the effect of PDGF-BB and TGFβ1 on EC-VSMC association and VSMC differentiation in vitro. 
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sets were previously validated for use with a laboratory standard total RNA 
extracted from early pregnancy decidua. The 2-∆∆CT-method was used to 
calculate relative fold changes in gene expression as described in section 
2.2.7.6. 
6.3.4 ELISA and Quantibody Human Angiogenesis Array 
Sandwich ELISA and Quantibody Human Angiogenesis Array were used to 
study the effect of AGF treatment on the profile of secreted AGFs by ECs and 
VSMCs. Sandwich ELISA was performed as described in section 2.2.9.1 and 
Quantibody Human Angiogenesis Array was performed as described in section 
2.2.10. 
6.3.5 Western blotting 
Western Blotting was used to investigate the effects of AGF treatments on 
VSMC differentiation marker (calponin, h-Caldesmon and smoothelin). Western 
blotting was performed as described in section 2.2.8 and the antibodies used 
have been listed in Table 2.6. 
6.3.6 Immunofluorescence, Immunocytochemistry 
Western blotting proved unsuitable to detect calponin, h-Caldesmon and 
smoothelin taking into consideration the amount of starting material available. 
Therefore, immunofluorescence was used next to study the effect of AGF 
treatments on VSMC differentiation markers as described in section 2.2.5. 
However ECs and VSMCs were highly auto-fluorescent; therefore use of 
immunofluorescence could have masked the quantification of any possible 
alterations in the intensity of staining for the VSMC differentiation markers. 
Therefore, immunocytochemistry was performed using an indirect avidin-biotin 
technique to study the effect of AGF treatment on VSMC differentiation 
(calponin, h-Caldesmon and smoothelin) as described in section 2.2.3.1 and the 
antibodies used have been listed in Table 2.2. 
6.3.6.1 Quantitative image analysis 
Immunostained slides were independently blinded prior to assessment. Images 
were quantified as fold change compared with the control group, of percentage 
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of positively stained cells (by count) for calponin or smoothelin in comparison 
with the total number of cells in five randomly selected fields of views within 
each well using the ImageJ software package. 
6.3.7 Statistical analysis 
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc.). Data 
are presented as means ± standard error of mean (SEM) and differences are 
considered statistically significant at P≤0.05. Specific tests used are given in the 
results.
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6.4 RESULTS 
6.4.1 Role of PDGF-BB and TGFβ1 on EC-VSMC association in vitro 
6.4.1.1 Effect of PDGF-BB on EC-VSMC association 
Number and velocity of ECs, VSMCs: The number of ECs remained unaltered 
throughout the 10 hr assay in all PDGF-BB treated and untreated groups 
(Figure 6.2A). EC velocity was unchanged throughout in the control and groups 
treated with 10ng/ml PDGF-BB or 10ng/ml anti-PDGFBB, but was decreased in 
the group treated with 1ng/ml PDGF-BB at 10hr, compared with 2 hr (P=0.035) 
and 4 hr (P=0.022; Figure 6.2B). 
The number of VSMCs remained unaltered throughout the 10 hr assay in all 
PDGF-BB treated and untreated groups (Figure 6.2C). VSMC velocity was 
unchanged throughout for the groups treated with 1ng/ml and 10ng/ml PDGF-
BB, but decreased at 10 hr compared with 2 hr in both the controls (P=0.009) 
and after treatment with 10ng/ml anti-PDGFBB (P=0.006; Figure 6.2D). 
Total number of honeycombs: The total number of honeycombs (≥3 arms) was 
reduced at 10 hr compared with 15 min in the control group (P=0.012) and in 
the groups treated with 1ng/ml PDGF-BB (P=0.021) or 10ng/ml anti-PDGFBB 
(P=0.046; Figure 6.3A). However, the total number of honeycombs remained 
unaltered after treatment with 10ng/ml PDGF-BB. 
Number of complete honeycombs: The number of complete honeycombs 
reduced from 2 hr to 10 hr but was not statistically significant in either control or 
PDGF-BB treated groups (Figure 6.3B). 
Honeycomb perimeter: The perimeter of complete honeycombs in the group 
treated with 10ng/ml anti-PDGFBB increased after 6 hr (P=0.016) and 10 hr 
(P=0.017; Figure 6.3C) compared with 15min. However it remained unaltered 
for the other groups. 
VSMC coverage: The percentage of VSMC coverage of honeycombs appeared 
to increase over time in all groups, although this was not statistically significant 
in either control or PDGF-BB treated groups (Figure 6.3D). 
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Figure 6.2: Graphical representation (mean ± SEM) of fold change in number and 
velocity of PDGF-BB treated endothelial cells (EC) and vascular smooth muscle cells 
(VSMC) on matrigel. Fold change in saphenous vein derived EC (A) number and (B) 
velocity and VSMC (C) number and (D) velocity (N=3 each group) at different time 
points relative to 2 hr between untreated control or PDGF-BB treatments, on matrigel. 
Pairwise Kruskal-Wallis one way ANOVA determined significant difference between 
different time points and between untreated control or PDGF-BB treatments. Bars with 
same letters are significantly different from each other; AP=0.035, BP=0.022, CP=0.009, 
DP=0.006. 
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Figure 6.3: Graphical representation (mean ± SEM) of fold change in PDGF-BB treated 
(EC) honeycombs (HC) and vascular smooth muscle cell (VSMC) coverage. Fold 
change at different time points relative to 15 min in number of (A) total HC with ≥3arms, 
(B) complete HC, (C) perimeter of complete HC and (D) percentage of VSMC coverage 
of complete HC by saphenous vein derived ECs and VSMCs (N=3 each group). 
Pairwise Kruskal-Wallis one way ANOVA determined significant difference between 
different time points and between untreated control or PDGF-BB treatments. Bars with 
same letters are significantly different from each other. ‘a’ represents difference 
between treatments, ‘A-E’ represent difference between time points; aP=0.012, 
AP=0.012, BP=0.021, CP=0.046, DP=0.016, EP=0.017. 
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6.4.1.2 Effect of TGFβ1on EC-VSMC association 
Number and velocity of ECs, VSMCs: The number of ECs decreased at 10 hr 
compared with 2 hr in the control group (P=0.013) and after treatment with 
10ng/ml anti-TGFβ1 (P=0.013; Figure 6.4A). EC velocity remained unaltered 
throughout the 10 hr assay for control and treatment groups (Figure 6.4B). 
The number of VSMCs decreased at 10 hr compared with 2 hr in the group 
treated with 10ng/ml anti-TGFβ1 (P=0.006), but remained unchanged for the 
other groups (Figure 6.4C). VSMC velocity remained unaltered throughout the 
10 hr assay for control, 10ng/ml TGFβ1 and anti-TGFβ1 groups, but decreased 
for the group treated with 1ng/ml TGFβ1 at 10 hr compared with 2 hr  (P=0.005; 
Figure 6.4D). 
Total number of honeycombs: The total number of honeycombs (≥3 arms) was 
reduced at 10 hr compared with 15 min in the control group (P=0.005) and after 
treatment with 1ng/ml TGFβ1 (P=0.001), 10ng/ml TGFβ1 (P=0.006) and 
10ng/ml anti-TGFβ1 (P=0.003; Figure 6.5A). 
Number of complete honeycombs: The number of complete honeycombs was 
reduced at 10 hr compared with 15 min in the control group (P=0.040) and after 
treatment with 1ng/ml TGFβ1 (P=0.022), 10ng/ml TGFβ1 (P=0.028) and 
10ng/ml anti-TGFβ1 (P=0.010; Figure 6.5B). 
Honeycomb perimeter: The perimeter of complete honeycombs increased in the 
control group (8 hr P=0.003; 10 hr P=0.004) and after treatment with 10ng/ml 
anti-TGFβ1 (8 hr P=0.007; 10 hr P=0.002), compared with 15 min (Figure 
6.5C). The perimeter of complete honeycombs remained unaltered in the other 
groups. 
VSMC coverage: The percentage VSMC coverage of honeycombs appeared to 
increase over time, although this was not statistically significant in control or 
TGFβ1 treated groups (Figure 6.5D). 
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Figure 6.4: Graphical representation (mean ± SEM) of fold change in number and 
velocity of TGFβ1 treated endothelial cells (EC) and vascular smooth muscle cells 
(VSMC) on matrigel. Fold change in saphenous vein derived EC (A) number and (B) 
velocity and VSMC (C) number and (D) velocity (N=3 each group) at different time 
points relative to 2 hr between untreated control or PDGF-BB treatments, on matrigel. 
Pairwise Kruskal-Wallis one way ANOVA determined significant difference between 
different time points and between untreated control or TGFβ1 treatments. Bars with 
same letters are significantly different from each other; A,BP=0.013, CP=0.006, 
DP=0.005. 
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Figure 6.5: Graphical representation (mean ± SEM) of fold change in TGFβ1 treated 
(EC) honeycombs (HC) and vascular smooth muscle cell (VSMC) coverage. Fold 
change at different time points relative to 15 min in number of (A) total HC with ≥3arms, 
(B) complete HC, (C) perimeter of complete HC and (D) percentage of VSMC coverage 
of complete HC by saphenous vein derived ECs and VSMCs (N=3 each group). 
Pairwise Kruskal-Wallis one way ANOVA determined significant difference between 
different time points and between untreated control or TGFβ1 treatments. Bars with 
same letters are significantly different from each other. ‘A-L’ represent difference 
between time points; AP=0.005, BP=0.001, CP=0.006, D,IP=0.003, EP=0.040, FP=0.022, 
GP=0.028, HP=0.010, JP=0.004, KP=0.007, LP=0.002. 
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6.4.2 Role of PDGF-BB and TGFβ1 on EC-VSMC gene expression and 
secretion profile in vitro 
6.4.2.1 Effect of PDGF-BB on EC AGF gene expression and secretion 
AGF mRNA (Ang1, Ang2, Tie2, VEGF-A, VEGF-C, VEGFR1-3, PDGF-BB, 
PDGFRα, PDGFRβ, TGFβ1, TGFβRI and TGFβRII) was unaltered in ECs 
treated with different concentrations of PDGF-BB or its neutralising antibody 
compared with controls (Figure 6.6A-D). 
AGF secretion (Angiogenin, Ang1, Ang2, VEGF-A, VEGF-C, PIGF, PDGF-BB, 
TGFβ1, bFGF, HGF, leptin, EGF and HB-EGF) was also unaltered in ECs 
treated with different concentrations of PDGF-BB or its neutralising antibody 
compared with controls (Figure 6.6E-H). 
6.4.2.2 Effect of TGFβ1 on EC AGF gene expression and secretion 
AGF mRNA was unaltered in ECs treated with different concentrations of 
TGFβ1or its neutralising antibody (Figure 6.7A-D), except for PDGF-BB, which 
was increased over two-fold when treated with 10ng/ml TGFβ1, compared with 
controls (P=0.03; Figure 6.7C). 
AGF secretion was unchanged in ECs treated with different concentrations of 
TGFβ1 or its neutralising antibody (Figure 6.7E-H). 
6.4.2.3 Effect of PDGF-BB on VSMC AGF gene expression and secretion 
AGF mRNA (Figure 6.8A-D) and secretion (Figure 6.8E-H) did not alter in 
VSMCs treated with different concentrations of PDGF-BB or its neutralising 
antibody. 
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Figure 6.6: Graphical representation (mean ± SEM) of fold change in (A-D) mRNA and 
(E-H) secretion of angiogenic growth factors by PDGF-BB treated saphenous vein 
derived endothelial cells (N=3 each group) cultured on matrigel. Pairwise Kruskal-
Wallis one way ANOVA determined significant difference in fold change between 
control or PDGF-BB treatments. No significant differences were observed. 
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Figure 6.7: Graphical representation (mean ± SEM) of fold change in (A-D) mRNA and 
(E-H) secretion of angiogenic growth factors by TGFβ1 treated saphenous vein derived 
endothelial cells (N=3 each group) cultured on matrigel. Pairwise Kruskal-Wallis one 
way ANOVA determined significant difference in fold change between control or 
TGFβ1 treatments. ‘a’ represents difference between control and 10ng/ml TGFβ1 
treatment; aP=0.03. 
 
  
 
6.4 RESULTS 
 
  
251 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: Graphical representation (mean ± SEM) of fold change in (A-D) mRNA and 
(E-H) secretion of angiogenic growth factors by PDGF-BB treated saphenous vein 
derived vascular smooth muscle cells (N=3 each group) cultured on matrigel. Pairwise 
Kruskal-Wallis one way ANOVA determined significant difference in fold change 
between control or PDGF-BB treatments. No significant differences were observed. 
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6.4.2.4 Effect of TGFβ1 on VSMC AGF gene expression and secretion 
AGF mRNA was unaltered in VSMCs treated with different concentrations of 
TGFβ1 or its neutralising antibody compared with controls (Figure 6.9A-D). 
AGF secretion did not change in VSMCs treated with different concentrations of 
TGFβ1 or its neutralising antibody (Figure 6.9E-H), except for TGFβ1, which 
was increased over two-fold when treated with 10ng/ml TGFβ1 compared with 
controls (P=0.019; Figure 6.9G). 
6.4.3 Role of PDGF-BB and TGFβ1 on VSMC differentiation in vitro 
Using Western blot analysis calponin and h-Caldesmon was undetectable in 
VSMCs, even though positive control samples gave appropriately sized bands 
(Figure 6.10A2; Figure 6.10B2). Non-specific bands were detected for 
smoothelin in pregnant myometrial tissue extract (10-40µg; Figure 6.10C1), with 
specific bands only detected when 100µg total protein was loaded (Figure 
6.10B2). However 100µg of total protein was unavailable from isolated VSMCs; 
western blotting analysis was therefore unsuitable for investigating the effects of 
PDGF-BB or TGFβ1 on VSMC differentiation. 
The number of calponin+ or smoothelin+ VSMCs, as determined by 
immunocytochemistry, remained unaltered after treatment with different 
concentrations of PDGF-BB or TGFβ1 or their neutralising antibody (Figure 
6.11A-B). 
mRNA of different genes involved in VSMC differentiation; myocardin (Myocd), 
CREG1, CREG2, SRF, CNN1, CNN2 and SMTN remained unaltered in VSMCs 
treated with different concentrations of PDGF-BB or TGFβ1, except for a slight 
increase in SMTN after treatment with 10ng/ml PDGF-BB (P=0.023; Figure 
6.11C-D). 
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Figure 6.9: Graphical representation (mean ± SEM) of fold change in (A-D) mRNA and 
(E-H) secretion of angiogenic growth factors by TGFβ1 treated saphenous vein derived 
vascular smooth muscle cells (N=3 each group) cultured on matrigel. Pairwise Kruskal-
Wallis one way ANOVA determined significant difference in fold change between 
control or TGFβ1 treatments. ‘a’ represents difference between control and 10ng/ml 
TGFβ1 treatment; aP=0.019. 
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Figure 6.10: Western blot analysis for calponin, smoothelin and h-Caldesmon. (A1, B1) 
respectively shows calponin (~29kDa) and h-Caldesmon (~110kDa) in non-pregnant 
(NP1) and pregnant (P1-2) myometrial protein extract (10µg). (C1) shows non-specific 
bands for smoothelin (~110kDa) in pregnant myometrial protein extract (10-40µg). (A2) 
shows undetectable calponin in saphenous vein derived vascular smooth muscle cells 
(VSMCs) (V1-6; 14µg). (B2) shows undetectable h-Caldesmon in aortic VSMCs (10-
40µg). (C2) shows smoothelin specific bands around 110kDa only in P1-2 (100µg 
protein). (A3, B3, C3) shows napthol blue black staining of PVDF membranes 
corresponding to A2, B2 and C2 respectively. 
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Figure 6.11: Graphical representation (mean ± SEM) of fold change in protein and 
mRNA of differentiation markers in saphenous vein derived vascular smooth muscle 
cells (VSMCs) treated with PDGFBB or TGFβ1. Fold change, compared with control in 
(A-B) percentage of calponin+ or smoothelin+ saphenous vein VSMCs and (C-D) 
mRNA of different genes involved in VSMC differentiation; myocardin (Myocd), cellular 
repressor of E1A-stimulated genes (CREG1, CREG2), SRF, calponin (basic-CNN1, 
CNN2), and smoothelin (SMTN) in VSMCs cultured on matrigel (N=3 each group). 
Pairwise Kruskal-Wallis one way ANOVA determined significant difference between 
control or (A-C) PDGFBB, and (B-D) TGFβ1 treatments. ‘a’ represents difference 
between control and 10ng/ml PDGFBB treatment; aP=0.023. 
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6.5 DISCUSSION 
Angiogenesis plays a critical role in the normal menstrual cycle, the 
dysregulation of which is implicated in HMB with altered AGF expression and 
VSMC differentiation (Chapters 3, 4). The importance of studying angiogenesis 
led to the development and optimisation of an in vitro angiogenesis assay 
capable of studying dynamic EC-VSMC associations and the possible effects of 
AGFs on the process of VSMC differentiation and recruitment of VSMCs to EC 
honeycomb structures (Chapter 5). Therefore this chapter utilised the in vitro 
assay to study the potential roles of PDGF-BB and TGFβ1 on EC-VSMC 
association and further investigate if alterations observed in EC-VSMC 
association are due to altered AGF secretion and/or mRNA expression by ECs, 
VSMCs and VSMC differentiation.  
6.5.1 Effect of PDGF-BB and TGFβ1on EC-VSMC association 
PDGF-BB in EC-VSMC association: Results from the in vitro assay did not 
show any effect of PDGF-BB treatment on the number of disconnected ECs and 
VSMCs over time (Figure 6.2). No reduction in numbers of disconnected ECs 
over time i.e. a higher number of isolated ECs in culture may suggest reduced 
honeycomb formation; thereby also reducing VSMC attachment onto the 
honeycombs and consequently leading to a greater number of disconnected 
VSMCs over time. This may be caused primarily by two factors: first PDGF-BB 
treatment and secondly cell seeding density. If unaltered numbers of ECs or 
VSMCs is an effect of PDGF-BB, then the numbers must differ from the control 
group. However there was no alteration in the number of ECs or VSMCs over 
time in the PDGF-BB control group; therefore the unaltered number of ECs or 
VSMCs is not due to an effect of PDGF-BB. On the other hand if there were 
greater number of cells (both ECs and VSMCs) at the start of the experiment, 
even after honeycomb formation and VSMC recruitment, there would be a 
higher number of isolated cells left in the medium, which would remain relatively 
unaltered over time, as suggested by the results; although this is unlikely since 
the seeding density was the same for all in vitro studies. PDGF-BB (1ng/ml) 
was shown to reduce EC velocity while anti-PDGFBB (10ng/ml) reduced VSMC 
velocity at 10hr; this may also be due to higher numbers of cells and 
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consequently a lower amount of space within the culture, however this 
reduction in velocity did not differ significantly from the control group (Figure 
6.2).  
The assay was unable to detect any effect of PDGF-BB on the number of total 
honeycombs, complete honeycombs, perimeter of honeycombs and VSMC 
coverage, compared with those in the control group (Figure 6.3). Interestingly, 
the number of total honeycombs and complete honeycombs in the group 
treated with 10ng/ml PDGF-BB remained stably higher at 10 hr compared with 
the control and other treatment groups, albeit not statistically significant (Figure 
6.3). Since growth factor treatment medium was added after the formation of 
EC honeycombs (4.5 hr after seeding of ECs), this might suggest that PDGF-
BB may help to sustain honeycomb structures i.e. EC-EC attachment in vitro. 
Coincidentally, stimulation of ECs with PDGF-BB has previously been shown to 
induce sprouting, proliferation and tube formation in vitro (Battegay et al., 1994).  
TGFβ1 in EC-VSMC association: The in vitro assay was unable to detect any 
effect of TGFβ1 on the number and velocity of ECs. Anti-TGFβ1 slightly 
reduced the number of VSMCs and 1ng/ml TGFβ1 reduced VSMC velocity at 
10 hr in the assay, although neither of these were different from those seen in 
the control group (Figure 6.4). Additionally, reduction in the number of total 
honeycombs, complete honeycombs and an increase in honeycomb perimeter 
was observed at 10 hr, although these changes were not statistically different to 
those observed in the respective control groups (Figure 6.5). TGFβ1 also had 
no effect on VSMC coverage in vitro. The reduction in the number of 
honeycombs may suggest a disruptive effect of TGFβ1 treatment on EC-EC 
attachment. However a reduction also seen in the anti-TGFβ1 group, may 
suggest otherwise. Interestingly an increase in honeycomb perimeter in the anti-
TGFβ1 group, although not statistically significant, possibly suggested that as 
the perimeter of the honeycombs becomes large, a relatively low number of 
them are sustained over time i.e. the larger the honeycombs the smaller their 
number in culture and vice versa. Interestingly, depending on the experimental 
setup, TGFβ1 has been shown to stimulate or inhibit angiogenesis in vivo and 
in vitro (Goumans et al., 2009). Results from this study are preliminary and may 
not direct any definitive conclusion; future studies with a larger sample size may 
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help to understand possible roles of TGFβ1 on EC-VSMC association. 
Meanwhile, these preliminary results from the in vitro study raise the question of 
further optimisation of the assay to determine its suitability for investigating EC-
VSMC association and VSMC recruitment and the effects of AGFs on this 
process. 
One of the factors which may have affected results of the in vitro assay is the 
AGF treatment concentration. Although the study included the concentrations of 
1ng/ml and 10ng/ml, it is uncertain whether these levels were sufficient to 
induce any effect on EC-VSMC association. Moreover, studies in the past have 
utilised AGFs at concentrations of up to 100ng/ml and neutralising antibodies 
up to 50ng/ml to study their effects on cell migration, proliferation etc., albeit the 
type of cells or tissue of origin of ECs/VSMCs varied. Perhaps absolute 
quantification of the amount of endogenously expressed or secreted AGFs by 
these cells in culture for specific lengths of time could help to determine the 
range of AGF treatment concentrations to use, especially for the neutralising 
antibodies. Therefore this invites further optimisation of the existing assay 
including determination of a dose-response relationship between the 
concentration and length of time for the AGF treatment and its effect on EC-
VSMC association and VSMC recruitment in vitro as assessed through the 
percentage of VSMC coverage. 
Another factor affecting the results could be inter and intra experiment 
variability; this would include differences in the number of honeycombs formed 
and the number of each type of cells at the start of an experiment; although to 
avoid this bias the current study looked at relative change, in future an increase 
in sample size should benefit interpretation of results. Finally in order to 
increase sensitivity of the assay, perhaps an automated image analysis protocol 
may be established such that tubule length (honeycomb arm) rather than 
honeycomb perimeter is determined at each time point throughout the assay 
along with the length of co-localisation between ECs and VSMCs (on the 
tubule) depicting VSMC recruitment. This would not only reduce user variability 
but also increase the accuracy of determination of the percentage of VSMC 
coverage. Collectively, the present assay would not only require optimisation 
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with respect to determining a dose-response relationship for each AGF, but 
would also benefit from a modified fully automated analysis protocol. 
 
6.5.2 Effect of PDGF-BB and TGFβ1 on AGF gene expression and 
secretion by ECs and VSMCs 
Secretion of AGFs and mRNA expression in ECs was minimally affected by 
TGFβ1, while not affected by PDGF-BB. TGFβ1 treatment (10ng/ml) increased 
EC PDGF-BB mRNA expression by two-fold (Figures 6.6-6.7). This suggests 
that TGFβ1 modulates the transcription of PDGF-BB although whether this is 
also translated and/or activated leading to further downstream effects requires 
further investigation. If TGFβ1 mediated alteration in the transcription of PDGF-
BB in ECs in fact leads to further downstream effects, any alteration in EC-
VSMC association shown in the in vitro study using TGFβ1 could possibly be a 
combined result of TGFβ1 and PDGF-BB on ECs. 
Secretion of AGFs and mRNA expression in VSMCs was minimally affected by 
TGFβ1, while not affected by PDGF-BB. TGFβ1 treatment (10ng/ml) led to a 
two-fold increase in TGFβ1 secretion by VSMCs (Figure 6.8-6.9). This TGFβ1 
mediated TGFβ1 secretion by VSMCs may affect VSMC differentiation and 
recruitment by ECs in vitro. Thus any alteration in EC-VSMC association shown 
in the in vitro study using TGFβ1 may be due to its effect on ECs as well as 
VSMCs. 
6.5.3 Effect of PDGF-BB and TGFβ1 on VSMC differentiation 
PDGF-BB treatment (10ng/ml) led to an increase in smoothelin mRNA 
expression in VSMCs in vitro, but this may not have been translated since no 
alteration in smoothelin expression was observed. Additionally, PDGF-BB did 
not alter calponin expression (Figure 6.11). This is striking since PDGF is 
known to promote maturation of blood vessels through VSMC recruitment 
and/or differentiation. Moreover, TGFβ1 treatment had no effect on either 
mRNA or expression of calponin, smoothelin or other genes regulating VSMC 
differentiation (Figure 6.11). This may indicate that alterations seen in the in 
vitro study with respect to EC-VSMC association and consequent VSMC 
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recruitment may not be due to altered VSMC differentiation. Although not 
statistically significant, TGFβ1 treatment appeared to increase while PDGF-BB 
appeared to downregulate mRNA expression for myocardin, which is the SMC 
specific transcriptional co-factor for genes regulating SMC differentiation; 
thereby possibly still directing a role for these AGFs in VSMC differentiation in 
vitro (Figure 6.11). As described previously, one factor that could have affected 
both the protein and gene expression results is the concentration of AGF 
treatments. Moreover, it should be noted that performance of IHC on cells 
grown on matrigel might have resulted in non-specific staining, yielding false 
positively stained cells, which might have masked any alteration in smoothelin 
or calponin expression by PDGF-BB treatment. One possible solution could be 
to recover the AGF treated cells from matrigel using the BD cell recovery 
solution (♯354253, BD Biosciences) followed by immunostaining. Since this 
solution allows for non-enzymatic cell separation, cells should maintain any 
biochemical alteration such as differentiation marker expression, which can then 
be analysed through IHC. It may also be beneficial to culture cells on glass 
bottom culture dishes, instead of the small 8-well chamber slides, which would 
allow a larger number of cells for culture and consequently the option to 
investigate protein expression for several different differentiation markers. 
Additionally supernatants can directly be collected from these cultures for 
further analysis of the AGF secretion profile.  
  
 
6.6 CONCLUSION 
 
  
261 
6.6 CONCLUSION 
The current study suggested that PDGF-BB and TGFβ1 might affect EC-VSMC 
association in vitro through altering EC, VSMC number or velocity. However the 
study did not detect any effect of PDGF-BB and TGFβ1 treatments on 
maintaining EC mediated honeycomb formation; although TGFβ1 might alter 
honeycomb formation in terms of their number and perimeter. The study did not 
demonstrate any effect of PDGF-BB on secretion and mRNA expression of 
AGFs by ECs and VMSCs while it showed that TGFβ1 specifically induced 
PDGF-BB mRNA expression in ECs and TGFβ1 secretion by VSMCs. The 
results revealed minimal effects of PDGF-BB and TGFβ1 on VSMC 
differentiation in vitro, although they did hint at alterations in myocardin and 
smoothelin gene expression. The in vitro studies discussed here and in Chapter 
5 did not allow any definite conclusions to be drawn in terms of the effects of 
VEGF-C, PDGF-BB, and TGFβ1 on EC-VSMC association, VSMC 
differentiation and/or AGF secretion and mRNA expression. Therefore further 
optimisation of methodology and increased sample size is required prior to 
assay validation. It should perhaps also be noted that although the complex 
process of angiogenesis is regulated by each of these factors, their effect on 
angiogenesis is a result of the combination of their specific roles, which are not 
necessarily independent of each other. A possible synergistic role of VEGF-C, 
PDGF-BB and TGFβ1 could perhaps also be taken into account in future 
experiments, possibly incorporating multiple combinations of AGF treatments 
such as PDGFBB-TGFβ1 etc. Nonetheless development and validation of in 
vitro models to study vascular maturation remains vital towards unravelling 
underlying complexities of angiogenesis the dysregulation of which may result 
in diseases such as heavy menstrual bleeding. 
  
CHAPTER 7 
GENERAL DISCUSSION AND FUTURE STUDIES 
 
 
 
 
 
 
 
 
 
 
 
Life can only be understood backwards; 
but it must be lived forwards. 
 
Søren Kierkegaard 
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7 GENERAL DISCUSSION AND FUTURE STUDIES 
7.1 DISCUSSION 
Heavy menstrual bleeding affects 30% of women of reproductive age disturbing 
their quality of life alongside posing a heavy financial burden on the NHS; yet 
not much is known or understood about its underlying mechanisms. A few 
studies in the past had implicated a role of uterine blood vasculature in the 
pathogenesis of HMB (Kooy et al., 1996; Abberton et al., 1999a; Abberton et 
al., 1999b; Hurskainen et al., 1999). Considering the importance of blood vessel 
development in menstrual bleeding it is unsurprising that dysregulated 
angiogenesis may underlie menstrual bleeding disorders such as HMB. On the 
basis of the key findings the current study set out to investigate two principal 
queries: 
1. To what extent is the uterine blood vessel development impaired in women 
with HMB? 
2. How is this vascular impairment affected by angiogenic growth factors?  
7.1.1 Impaired blood vessel development in women with heavy menstrual 
bleeding 
Blood vessels are primarily made up of ECs, VSMCs and the ECM; the 
development of which heavily relies on the tissue specific composition of the 
vascular bed i.e. the endometrial or myometrial stroma. Since the menstrual 
cycle involves active tissue breakdown and repair and is considered to be an 
inflammatory process, an important regulator of endometrial angiogenesis is its 
stromal leukocyte population. Additionally while VSMCs and ECs have been 
implicated in HMB (Kooy et al., 1996; Abberton et al., 1999a; Abberton et al., 
1999b), uNK cells have been associated with reproductive disorders; 
particularly blood vessel development in the endometrium of women with RM 
(Quenby et al., 2005; Lash et al., 2011a) and have been shown to regulate 
endometrial bleeding by maintaining arterial stability (Wilkens et al., 2013).  
The current study showed for the first time that ECs in the uterine blood 
vasculature of women with HMB show altered pattern of staining (Table 3.1), 
which were associated with their proliferative state (Figure 3.10). This may be 
  
 
7.1 DISCUSSION 
 
  
264 
suggestive of an altered vascular endothelium, which in turn may affect EC-
VSMC association and subsequently VSMC differentiation; this may result in 
immature, weaker or leaky vessels or altered vascular tone affecting the rate of 
blood flow underlying HMB. In line with this theory, the study demonstrated for 
the first time an altered state of VSMC differentiation, especially in terms of 
smoothelin and calponin expression (Figure 3.6). Interestingly decreased 
calponin had been shown to result in an increase in cross-bridge cycle, i.e. 
increased shortening velocity and therefore an increased rate of contraction and 
blood flow (Fujishige et al., 2002). Therefore the reduction in vascular calponin 
staining shown in the current study may also suggest an increased rate of 
contraction and blood flow in HMB, while an increase in smoothelin staining 
may facilitate contractility and vasodilation, again, leading to increased blood 
flow in HMB. However, endometrial vessels are thought to be resistance 
vessels and the mechanism of blood flow in these vessels may differ from those 
in the cardiovascular system; although changes shown in the current study may 
well indicate an underlying functional change in the endometrial vessels 
causing them to operate similar to those in the cardiovascular system. 
A key finding of the present study is that the reduction in calponin in the late 
secretory phase of the menstrual cycle was also shown to associate with 
increased osteopontin expression (Figure 3.12). Osteopontin, an ECM 
component is induced in VSMCs in cardiovascular diseases and is elevated in 
traumatised tissue (Sodek et al., 2000; Waller et al., 2010). But importantly it 
has been shown to downregulate calponin expression (Gao et al., 2012); thus 
suggesting osteopontin as a regulator of endometrial vascular structure-function 
relationship, possibly underlying HMB. Additionally the increased osteopontin 
could also be indicative of increased vascular breakdown in HMB, which along 
with decreased collagen IV staining may again suggest weaker vasculature in 
HMB. Along with alterations observed in the structure of the endometrial blood 
vessels, the current study also revealed an altered endometrial uNK cell 
population during the menstrual cycle and critically the alteration in the late 
secretory phase in HMB showed altered staining of CD3 by the uNK cells 
(Figures 3.14-3.15). Since uNK cells are implicated in a wide range of functions; 
cytokine and growth factor secretion (Ang1, Ang2, VEGF-C, PIGF and TGF-β1), 
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immune function, regulation of trophoblast invasion and also in the initial stages 
of spiral artery remodelling, the results from our study may suggest altered 
AGFs in the endometrial stroma further affecting endometrial angiogenesis. 
Importantly uNK cells are positively correlated with vascular maturation. 
Therefore a decrease in uNK cell number in the late secretory phase of HMB 
may indicate reduced vascular maturation at the onset of menstruation 
underlying HMB. 
7.1.2 Role of AGFs in dysregulated angiogenesis underlying heavy 
menstrual bleeding 
7.1.2.1 Altered AGF staining in uterine tissue layers in women with heavy 
menstrual bleeding 
Blood vessel development is a complex multistep process under the strict 
regulation of AGFs. Additionally our previous studies suggested that altered 
AGF staining in the uterine tissue layers may underlie the dysregulated 
angiogenesis observed in HMB. Investigation of AGFs in fact showed distinct 
alterations in AGF staining with respect to the stroma, glands and the blood 
vessels. In HMB, staining for PDGF-BB (Figure 4.3), PDGFRα (Figure 4.4), 
PDGFRβ (Figure 4.5), TGFβ1 (Figure 4.7), TGFβRI (Figure 4.8) and TGFβRII 
(Figure 4.9) were all decreased across the menstrual cycle in both endometrium 
and myometrium, especially in the stromal cells and ECs followed by the 
glandular epithelium and VSMCs. Critically the reduction in both the PDGF and 
TGFβ family of AGFs suggested that the dysregulation in angiogenesis in HMB 
may not be during the activation phase of angiogenesis; instead it is perhaps 
during the resolution phase thereby affecting vessel stability, VSMC 
differentiation and consequently vascular maturation. Moreover, altered AGF 
expression also affects ECM production by ECs in culture, which may add to 
the significance of these findings and also support the results from our studies 
on altered vascular ECM composition in HMB. Rather than an early breakdown, 
collectively the results from the IHC studies in HMB distinctly highlight that 
altered AGF staining associated with dysregulated vascular maturation in terms 
of EC-VSMC interaction and subsequent VSMC differentiation underlies HMB.  
  
 
7.1 DISCUSSION 
 
  
266 
7.1.2.2 In vitro model to study EC-VSMC association 
An alteration in AGFs and a role of altered vascular maturation indicated by our 
previous studies fuelled the need for investigation of the roles of AGFs in 
angiogenesis, especially on EC-VSMC association, VSMC recruitment and 
VSMC differentiation. Although existing angiogenesis assays have studied EC 
migration, proliferation and mediated tubule formation, to our knowledge, no 
assay has ever been optimised to look at the dynamic EC-VSMC interaction 
and VSMC recruitment following EC tubule formation. Therefore for the first 
time in this present study we have established an in vitro assay together with a 
semi-automated quantitative image analysis protocol, for studying EC-VSMC 
interaction, with possible applications including the study of effects of AGFs on 
angiogenesis (Figure 5.2). 
7.1.2.3 Effect of AGFs on EC-VSMC association and VSMC differentiation in 
vitro 
The final aim of the current study was utilisation of the in vitro angiogenesis 
assay to study the effects of AGFs on EC-VSMC association, VSMC 
recruitment and critically VSMC differentiation. The primary purpose of this 
assay is justified by the previous studies, which revealed an altered state of 
VSMC differentiation in association with altered AGF staining suggesting 
dysregulated angiogenesis underlying HMB. The results from the angiogenesis 
assay were inconclusive, in part due to small sample size, in terms of the 
specific effects of VEGF-C (Figures 5.9-5.10), PDGF-BB (Figures 6.2-6.3) and 
TGFβ1 (Figures 6.4-6.5) on EC-VSMC association and VSMC recruitment; 
although they may hint at a disruptive role of TGFβ1 on EC mediated 
honeycomb formation. In order to further validate any findings from the in vitro 
assay, the study investigated the effects of these AGFs on mRNA and secretion 
of AGFs by ECs and VSMCs; these revealed that TGFβ1 increased PDGF-BB 
mRNA in ECs and TGFβ1 secretion by VSMCs while PDGF-BB had no effect 
on either mRNA or secretion of AGFs. This suggests that TGFβ1 may alter AGF 
gene expression and secretion in vitro, which may in turn affect EC-VSMC 
interaction. However, these preliminary results from the in vitro study must be 
repeated with further functional studies prior to drawing definitive conclusions. 
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7.2 LIMITATIONS AND FUTURE STUDIES 
7.2.1 Immunohistochemical study of the uterine vasculature 
Immunohistochemical studies utilising endometrial biopsies from women 
undergoing hysterectomy provided us with important insights into the extent of 
endometrial vascular impairment along with implications of the role of 
endometrial leukocyte populations and AGF expression in women with HMB. In 
this context it must be noted that the current study included both straight and 
spiral arterioles within the endometrium, a further distinction of which, as 
performed by Abberton et al. (1999a), could possibly reveal any distinctions 
underlying HMB.  
The endometrial biopsies utilised in the present study showed inter-patient 
variability; it would therefore be ideal if material from the same patient could 
have been used throughout the different phases of the menstrual cycle possibly 
through endometrial pipelle biopsies. However since pipelle biopsies may often 
only retrieve superficial endometrium, this would limit the study to investigating 
the endometrium as a whole rather than examining specific differences in the 
stratum basalis and stratum functionalis as indicated by the present study. 
Moreover acquiring endometrial samples from the same patient would be more 
difficult with respect to obtaining consents as well as proving time consuming. 
This study demonstrated altered VSMC differentiation in the endometrial 
vessels in HMB; in future these results could be validated, utilising laser capture 
microdissection. Following microdissection mRNA or protein may be extracted 
from these cells to further investigate any alteration in the levels of different 
genes or proteins regulating VSMC differentiation respectively. Moreover the 
importance of microRNAs (miRs) in functional regulation of EC as well as 
VSMC may suggest further studies investigating their alterations would be 
worthwhile, perhaps also utilising laser capture microdissection in isolating 
endometrial vessels. Since vascular maturation and VSMC differentiation was 
the central aim of this thesis, the current study investigated alterations in 
staining for PDGF-BB and TGFβ1 and their receptors in HMB. However both 
VEGF-A and VEGF-C have also been suggested to regulate angiogenesis. 
Therefore in future studying the pattern of staining for these AGFs along with 
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their respective receptors may also provide further insights into the roles of 
AGFs in vascular impairment in HMB. 
7.2.2 EC-VSMC association and VSMC differentiation in vitro 
The in vitro assay developed in this study, utilised cells isolated from SVs from 
patients undergoing cardiac bypass surgery. The choice of these cells 
depended on factors such as sample availability, ease of isolation and cost, but 
most importantly the observation that SV derived ECs and VSMCs retained 
their characteristics longer than the commonly used human aorta cell lines. 
However whether these cells are the best representatives for the endometrial 
vascular ECs and VSMCs could perhaps be investigated further. At present 
there are three major sources of ECs and VSMCS; human aorta, SVs and 
umbilical cord. In future a direct comparison could be made between ECs and 
VSMCs from these with respect to expression of characteristic proteins further 
validated through western blotting or mRNA expression and finally a secretion 
profile using angiogenesis arrays or ELISAs. Moreover since both ECs and 
VSMCs from aorta cell lines de-differentiated much earlier than those from SVs, 
again, the above profiles could perhaps be repeated between passages, which 
would give a more detailed analysis of the de-differentiation timeline for cells 
from each of these sources. Not considering time or cost, if possible this could 
be taken a step further; the above protein and gene expression profile of ECs 
and VSMCs could also be studied after treatments with different AGFs which 
may in turn give insight into differences in sensitivity to AGF signalling amongst 
cells from the different sources. While these studies may prove time consuming 
they may help to draw some conclusions on the suitability of each of these cell 
types for specific angiogenesis assays, where due to practical limitations cells 
cannot be isolated from the tissue specific vessels. 
Results from the in vitro assay provided some insights into the effects of 
matrigel on ECs and VSMCs; while the study investigated the AGF secretion 
profiles of ECs cultured on matrigel compared with plastic, due to sample 
unavailability this was not done for VSMCs. Although matrigel had a more 
observable effect on ECs marked by distinct honeycomb structure formation, 
future studies could investigate its role on VSMCs. Additionally the results from 
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the study of EC-VSMC interactions and VSMC recruitment and the role of AGFs 
in vitro must be repeated with larger sample size. Again, the current study only 
examined the effects of PDGF-BB and TGFβ1 on mRNA and secretion of AGFs 
by ECs and VSMCs; this could perhaps also be repeated utilising VEGF-C to 
further validate the effects of VEGF-C on EC-VSMC association and VSMC 
recruitment and differentiation. Moreover apart from the AGFs studied in vitro, 
the assay can be used in future to study the effects of other key growth factors 
such as VEGF-A. Finally, possible synergistic roles of AGFs on angiogenesis 
may suggest further studies utilising combinations of AGF treatments in addition 
to treating with individual AGFs. Importantly the in vitro assay must be further 
optimised in terms of the concentration and length of time for the AGF 
treatments along with a possible fully automated image analysis protocol prior 
to any future applications. 
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7.3 SUMMARY 
The primary aim of this exploratory study was to investigate vascular 
impairment in HMB and investigate the role of AGFs in dysregulated 
angiogenesis. This has been achieved and the study represents a significant 
move forward for understanding the mechanisms underlying this condition. The 
study has identified VSMC differentiation with respect to dysregulated calponin-
osteopontin pathway as key to dysregulated angiogenesis in HMB, in 
association with altered EC-VSMC association, AGF distribution and leukocyte 
populations (Figure 7.1). Furthermore an in vitro angiogenesis assay has been 
developed to investigate dynamic effects of AGFs on EC-VSMC association, 
key to VSMC recruitment and differentiation; ultimately directing vascular 
maturation, which in turn has been implicated in HMB. Findings from this study 
along with development of the in vitro assay has provided key directions 
towards future investigations which may ultimately lead to treatment advances, 
promising a better quality of life for women with HMB. 
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Figure 7.1: Key outcomes from the investigation of uterine blood vessel development in 
heavy menstrual bleeding. 
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Appendix A1: Patient information sheet and consent form 
 
 
 
 
 
Patient information sheet 
Tissue samples for research into pregnancy complications to be stored in the 
Newcastle Uteroplacental Tissue Bank. 
 
Introduction. 
Most women have a straightforward pregnancy and deliver a healthy baby around their expected date. 
Unfortunately some women miscarry. Others go into labour and deliver early (preterm birth) or develop 
problems with the placenta (afterbirth) resulting in high blood pressure or small babies. These later 
problems can have a major impact on the health of the mother and/or her baby.  
Our research involves studying cells from the uterus (womb), cervix and placenta (afterbirth) in order to 
better understand how these cells work, what controls or regulates them and why sometimes these control 
mechanisms go wrong. Researchers at Newcastle University are coordinating a local collection of tissue 
samples from the uterus and placenta for use in research projects so we can provide better care to women 
in the future. We would like to ask your permission to donate tissue samples to the collection. It is important 
for you to understand why the research is being done and what it will involve before you decide whether to 
take part.  Please take time to read the following information carefully and discuss it with others if you wish.  
Ask us if there is anything that is not clear. 
The research work will not directly benefit you, but may help patients with pregnancy problems in the 
future. You do not have to give permission for your samples to be stored. If you decline it will not affect your 
medical care in any way. 
Any research we do requires the approval of a Research Ethics Committee. We occasionally send samples to 
other UK research teams but only if their projects have been approved by a Research Ethics Committee. No 
personal details which could be used to identify you will be available to any researcher. 
What will happen to me if I take part? 
We are asking you to take part because you are having a hysterectomy.  If you do decide to take part you 
will be asked to sign a consent form. A copy of your consent and this information sheet will be given to you 
to keep.  
In order to undertake this study we need 3 or 4 small samples, each about the size of a pea, from the muscle 
layer and neck of the uterus (cervix). These are collected after the uterus (womb) has been removed and will 
not interfere with the detailed pathological examination.  
In order to make the best use of these important samples, more than one laboratory study may be 
undertaken on each sample. Samples may be stored prior to study and will represent a gift to the research 
team.  
What will happen to my specimens? 
Samples will be stored in the Newcastle Uteroplacental Tissue Bank. Samples may be stored for many years 
before they are used. The samples may be used to extract DNA (the genetic information inside a cell) which 
would also be stored. Samples are stored with a code number, and the only link between the sample code 
and your identity details is stored in a secure file. 
PIS Non Pregnant v4 Oct 2012 
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 Researchers will have some information about your health but will have no personal details which could 
identify you. 
 Similarly, any results from each research project will not be traceable back to you. All information on your 
samples will be kept at the Newcastle Uteroplacental Tissue Bank in accordance with national guidelines 
(The Data Protection Act and Caldicott guidelines) 
What processes are in place to approve use of the donated specimen? 
Before the start of any research work, written approval is required from the Tissue Bank Manager 
ProfessorRobson.  He will be advised by Tissue Bank Governance Committee, chaired by Professor Davison. 
The Governance Committee will assess requests to use samples from the Newcastle Uteroplacental Tissue 
Bank. Voting members of the committee will include an independent non-consultant clinical assessor, an 
independent scientist and a clinical obstetrician from outside the research team. The governance committee 
will be responsible for ensuring that projects are scientifically sound, worthwhile and adequately funded. 
What will happen to the results of the research study? 
We anticipate the results will be published in medical journals. You will not be identified in any report or 
publication.  
What are the benefits and risks of taking part? 
You will not directly benefit from taking part in the study but the knowledge gained will help patients in the 
future. As the uterus (womb) has already been removed there are no risks involved in taking the samples. 
The research samples are very small compared to the rest of the uterus which will examined as part of your 
routine care. If evidence of disease with immediate clinical relevance were found in the research samples it 
is extremely unlikely that the same problem would not have been seen in the larger clinical sample but we 
would always make sure your clinical team were aware so they could advise the most appropriate 
management.  
Do I have to take part? 
No. Your participation is entirely voluntary. Whether or not you decide to allow your specimens to be stored 
for research purposes will not affect you being given the best possible treatment. If at any time in the future 
you change your mind and do not wish the specimens to be used for research, then as soon as you have told 
your doctor, any samples remaining will be disposed of, usually by incineration, but we will use the 
information collected up to the time of your withdrawal. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do 
their best to answer your questions. If you remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure (or Private Institution). Details can be obtained from the hospital.   
Further information 
If you have any questions about the study please contact: Dr. M. Smith or Professor S. Robson  (Tel: 0191 
2824132)  
Thank you for reading this information sheet 
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Consent NP v4 Oct 2012 
 
CONSENT FOR GIFTING OF CLINICAL SAMPLES 
Title of Project: Tissue samples for research into pregnancy complications 
to be stored in the Newcastle Uteroplacental Tissue Bank 
Name of Researcher:  Professor S. Robson, Newcastle Uteroplacental Tissue Bank 
 
I agree to donate the following samples for research (initial appropriate boxes) 
Myometrial biopsies   Cervix   Vaginal swab 
 
I understand that relevant sections of my medical notes and data collected during  
the study, may be looked at by researchers, from regulatory authorities or from the      YES / NO 
NHS Trust, where it is relevant to my taking part in this research. I give permission  
for these individuals to have access to my records 
 
If YES, please initial each of the following statements: 
• I have read and understood the relevant patient information sheet/s.  
 (Please take a copy home with you to keep) 
• I have had an opportunity to discuss the Tissue Bank and ask any questions  
 
• I understand that I am free to withdraw consent for use of my tissue at any time without 
having to give a reason and without affecting my  medical care  
 
• I agree to donate small samples specifically for research purposes and for these to be stored 
for future use in approved research projects 
• I understand that I will not be told the results of any tests carried out on my sample.  
   
• I give permission for my medical information to be stored 
  
• I agree for my anonymised medical information to be used analysis of the study results 
 
 
Name + MRN of Patient   Date    Signature 
 
Name of Person taking consent Date Signature 
 
1 form for patient; 1 form to be kept with hospital notes; 1 form for Biobank 
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Appendix A2: Sample information form 
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Appendix A3: Patient medications in the control group 
 
 
 
 
 
Drug Function 
Fluoxetine Fluoxetine (also known by the tradenames Prozac, Sarafem, and Fontex, among others) 
is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class, used to 
treat premenstrual dysphoric disorder. 
Salbutamol Salbutamol (INN) or albuterol (USAN) is a short-acting β2-adrenergic receptor agonist 
used for the relief of bronchospasm in conditions such as asthma and chronic 
obstructive pulmonary disease. 
Tramadol is a centrally acting synthetic opioid analgesic used to treat moderate to moderately 
severe pain. 
Amitriptyline Amitriptyline (Tryptomer, Elavil, Tryptizol, Laroxyl, Saroten, Sarotex, Lentizol, Endep) is 
a tricyclic antidepressant (TCA). It is the most widely used TCA and may be efficacious 
for the treatment of depression.These types of tricyclics have been used historically for 
the treatment of migraines, tension headaches, anxiety, psychosis, aggression and 
violent behavior.  
Paracetamol Paracetamol is classified as a mild analgesic. It is commonly used for the relief of 
headaches and other minor aches and pains and is a major ingredient in numerous cold 
and flu remedies. 
Fentanyl Fentanyl is a potent, synthetic opioid analgesic with a rapid onset and short duration of 
action. 
Oramorph Oramorph oral solution contains the active ingredient morphine sulphate, which is a 
type of medicine called an opioid painkiller. 
Mesalazine Mesalazine (INN, BAN), also known as mesalamine (USAN) or 5-aminosalicylic acid (5-
ASA), is an anti-inflammatory drug used to treat inflammatory bowel disease, such as 
ulcerative colitis and mild-to-moderate Crohn's disease.[2] Mesalazine is a bowel-
specific aminosalicylate drug that acts locally in the gut and has its predominant 
actions there, thereby having few systemic side effects. 
Lansoprazole Lansoprazole reduces the amount of acid produced in the stomach. The common side 
effects are digestive system discomfort (feeling sick, stomach ache, diarrhoea) and 
headache. These effects are mild and do not last long 
Dihydrocodeine Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for pain, severe 
dyspnea, or as an antitussive, either alone or compounded with aspirin or paracetamol, 
as in co-dydramol. 
Ferrous 
sulphate 
This medicine is used to treat and prevent iron deficiency anaemia. It belongs to a 
group of medicines called iron supplements. 
Omeprazole Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer 
disease (PUD), gastroesophageal reflux disease (GORD/GERD), laryngopharyngeal 
reflux (LPR) and Zollinger–Ellison syndrome. 
Levothyroxine It is also used to treat thyroid hormone deficiency, and occasionally to prevent the 
recurrence of thyroid cancer. 
Citalopram Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor 
(SSRI) class. It has U.S. Food and Drug Administration (FDA) approval to treat major 
depression. 
Mefenamic acid Mefenamic acid is a non-steroidal anti-inflammatory drug used to treat pain, including 
menstrual pain. It is typically prescribed for oral administration. 
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Appendix A4: Patient medications in the HMB group 
 
 
 
Drug Function 
Nurofen Nurofen is the brand name of a range of pain-relief medication. There are 11 
variants of Nurofen, all of which contain the analgesic ibuprofen as the active 
ingredient 
Co-codamol Co-codamol (BAN) is a compound analgesic consisting of a combination of 
codeine phosphate and paracetamol (acetaminophen). Co-codamol tablets are 
used for the relief of mild to moderate pain 
Thyroxine Thyroxine is the main hormone produced by the thyroid gland. It plays an 
important role in regulating many of the body’s metabolic functions. 
Penicilin Penicillin is a group of antibiotics derived from Penicillium fungi. Penicillin 
antibiotics are the first drugs that were effective against syphilis, and 
infections caused by staphylococci and streptococci. 
Mefanemic acid Mefenamic acid is a non-steroidal anti-inflammatory drug used to treat pain, 
including menstrual pain. It is typically prescribed for oral administration. 
Salbutamol Salbutamol (INN) or albuterol (USAN) is a short-acting β2-adrenergic receptor 
agonist used for the relief of bronchospasm in conditions such as asthma and 
chronic obstructive pulmonary disease. 
Paracetamol Paracetamol is classified as a mild analgesic. It is commonly used for the relief 
of headaches and other minor aches and pains and is a major ingredient in 
numerous cold and flu remedies. 
Fluiticasone Fluticasone is used to treat symptoms of allergic rhinitis and perennial 
nonallergic rhinitis. These symptoms include sneezing and stuffy, runny, or 
itchy nose. It works by preventing and decreasing inflammation (swelling that 
can cause other symptoms) in the nose. 
Citalopram Citalopram is an antidepressant drug of the selective serotonin reuptake 
inhibitor (SSRI) class. It has U.S. Food and Drug Administration (FDA) approval 
to treat major depression. 
Omeprazole Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia, 
peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD), 
laryngopharyngeal reflux (LPR) and Zollinger–Ellison syndrome. 
Fluoxetine Fluoxetine (also known by the tradenames Prozac, Sarafem, and Fontex, 
among others) is an antidepressant of the selective serotonin reuptake 
inhibitor (SSRI) class, used to treat premenstrual dysphoric disorder. 
Ferrous fumarate This medicine is used to treat and prevent iron deficiency anaemia. It belongs 
to a group of medicines called iron supplements. 
Fludrocortisone Fludrocortisone, a corticosteroid, is used to help control the amount of sodium 
and fluids in your body. It is used to treat Addison's disease and syndromes 
where excessive amounts of sodium are lost in the urine. It works by 
decreasing the amount of sodium that is lost (excreted) in your urine. 
 
Bendroflumethiazide Bendroflumethiazide belongs to a group of medicines called thiazide diuretics. 
A diuretic is a medicine, which increases the amount of urine that you pass out 
from your kidneys. They are also used to clear excess fluid from your body in 
conditions where your body retains more than it needs, called oedema. 
Ramipril Ramipril is an angiotensin-converting enzyme (ACE) inhibitor, used to treat 
high blood pressure and congestive heart failure. 
Propranolol Propranolol (INN) is a sympatholytic non-selective beta-blocker. 
Sympatholytics are used to treat anxiety and panic. 
Levothyroxine It is also used to treat thyroid hormone deficiency, and occasionally to prevent 
the recurrence of thyroid cancer. 
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Appendix B: Reagents and solutions 
Most chemicals and reagents, used in the study were obtained from Sigma-
Aldrich Co., Dorset, UK, unless stated otherwise. 
Mayer’s Haematoxylin: 
Mayer’s Haematoxylin solution was prepared by adding the ingredients listed in 
Table B1 to 2L distilled water. 
Table B1: Preparation of Mayer’s Haematoxylin 
 
Scott’s tap water substitute: 
Scott’s tap water substitute solution was prepared, by adding the reagents listed 
in Table B2 to 5L distilled water at room temperature. 
Table B2: Preparation of Scott’s tap water substitute 
 
 
 
REAGENT (SOURCE) QUANTITY 
Haematoxylin (♯261103G, BDH, Poole UK) 2.0g 
Potassium alum (♯237086) 100.0g 
Sodium iodite (♯S4007) 0.4g 
The above chemicals were dissolved in 2L distilled water at room 
temperature overnight and then the following were added. 
Chloral Hydrate (♯C8383) 100.0g 
Citric acid (♯C7129) 2.0g 
The above solution was brought to the boil, left overnight and filtered prior to 
use. 
REAGENT (SOURCE) QUANTITY 
Sodium bicarbonate (♯S5761) 17.5g 
Magnesium sulphate (♯M7506) 100.0g 
The above chemicals were dissolved in 2L distilled water at room 
temperature. 
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DPX Mounting medium: 
DPX synthetic mounting medium (♯SEA-0304-00A) was obtained from CellPath 
Ltd., Newtown, UK). 
Eosin: 
Eosin (♯HT110316) was obtained from Raymond A Lamb, London, now under 
Fisher Scientific, Loughborough, UK. 
Ethanol: 
Ethanol (99%) (♯E/0650DF/17), was obtained from Fisher Scientific. 95% and 
70% alcohol solutions were prepared by diluting the above with distilled water 
appropriately.  
3-Aminopropyltriethoxysilane (APES) coated glass slides:  
Glass microscope slides (♯MAF-0102-03A, CellPath, Ltd.) were washed in 
diluted detergent and rinsed several times with water. The slides were then 
immersed in distilled water and washed in 99% methanol (♯M/4000/17, Fisher 
Scientific). Following this they were air dried prior to coating with APES solution. 
The slides were then immersed sequentially into acetone only, acetone and 
APES solution (196ml acetone ♯154598, 4ml APES solution ♯A3648), acetone 
only and distilled water. Finally slides were air dried overnight at room 
temperature and stored at 4°C until required. 
Citrate buffer (pH6.0): 
Citrate buffer solution was prepared by adding the ingredients listed in Table B3 
to 10L distilled water at room temperature. 
Table B3: Recipe for preparation of citrate buffer solution 
 
 
INGREDIENT (SOURCE) QUANTITY 
Citric acid (♯C7129) 21.0g 
2M Sodium hydroxide (♯S8045) 130.0ml 
The above chemicals were dissolved in 10L distilled water overnight at room 
temperature. The solution was adjusted to pH6.0 before use. 
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p-Xylene: 
p-Xylene (♯134449) was obtained from Sigma-Aldrich Co. 
3,3’- Diaminobenzidine tetrachloride (DAB) solution: 
One DAB tablet (♯D5905) was added to 0.2ml 1% aqueous H2O2 (♯31642) in 
10ml TBS pH7.6 and left to dissolve. This was filtered using 5-13µm qualitative 
filter paper (♯516-0815, VWR International, Leicestershire, UK) prior to applying 
to the slides. 
Ethylenediaminetetraacetic acid (EDTA) buffer (pH8.0): 
Ethylenediaminetetraacetic acid (EDTA) buffer solution was prepared by 
dissolving 2.26g EDTA (♯10093, VWR International) in 5L distilled water 
overnight at room temperature. The solution was adjusted to pH8.0 before use. 
Phosphate buffered saline (PBS): 
Phosphate buffered saline (PBS) solution was prepared by dissolving five PBS 
tablets (♯P4417) in 1L distilled water at room temperature. Depending on the 
type of application the solution was adjusted to pH7.2, pH7.5, pH7.4 or pH7.6 
and if required sterile filtered through a 0.2µm syringe filter (♯190-2520, 
Nalgene Fisher Scientific), autoclaved and stored at 4°C. 
Calcium chloride stock solution: 
Calcium chloride (CaCl2) stock solution (4%) was prepared, by dissolving 4g 
calcium chloride (♯C3306) in 100ml distilled water at room temperature. 5ml 
aliquots were stored at -20°C, until required. 
Trypsin stock solution: 
Trypsin stock solution (4%) was prepared by dissolving 4g trypsin (♯215240, BD 
Biosciences, Oxford, UK) in 100ml distilled water at room temperature. 5ml 
aliquots were stored at -20°C, until required. 
Tris buffered saline (TBS): 
Tris buffered saline (TBS; 0.1M Tris, 0.5M saline) solution (pH7.6) was 
prepared by adding the reagents listed in Table B4 to 10L distilled water at 
room temperature. 
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Table B4: Preparation of tris buffered saline solution 
 
Trypsin-CaCl2 working solution: 
One aliquot (5ml) each of the trypsin and CaCl2 stock solutions was diluted in 
200ml distilled water and the working solution was adjusted to pH7.8. 
Hydrogen peroxide: 
Hydrogen peroxide (H2O2) (♯31642) was obtained from Sigma-Aldrich Co., 
Dorset, UK. 
Vectastain Elite mouse IgG ABC kit: 
The Vectastain Elite mouse IgG ABC kit (♯PK-6102) was used as per 
manufacturer’s instructions (Table B5) 
Table B5: User instructions for Vectastain Elite mouse IgG ABC kit 
 
Vectastain Elite rabbit IgG ABC kit: 
The Vectastain Elite rabbit IgG ABC kit (♯PK-6101) was used as per 
manufacturer’s instructions (Table B6) 
REAGENT (SOURCE) QUANTITY 
Sodium chloride (♯S3014) 80.0g 
Tris (♯252859) 6.05g 
1N HCl (♯H1758) 38.0ml 
The above chemicals were dissolved in 10L distilled water overnight at room 
temperature. The solution was adjusted to pH7.6 before use. 
REAGENT QUANTITY 
Blocking serum Vectastain normal horse serum (15µl) diluted in 1ml TBS 
Secondary 
antibody 
Vectastain normal horse serum (15µl) and Vectastain 
Biotinylated anti-mouse IgG antibody (5ul) diluted in 1ml 
TBS 
Tertiary 
antibody 
Vectastain reagent A (20µl) and Vectastain reagent B 
(20µl) diluted in 1ml TBS 
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Table B6: User instructions for Vectastain Elite rabbit IgG ABC kit 
 
Vector NovaRED peroxidase (HRP) substrate kit: 
Vector NovaRED peroxidase (HRP) substrate kit (♯SK-4800) was used as per 
manufacturer’s instructions (Table B7) 
Table B7: User instructions for Vector NovaRED peroxidase substrate kit 
 
Vector SG peroxidase (HRP) substrate kit: 
Vector SG peroxidase (HRP) substrate kit (♯SK-4700) was used as per 
manufacturer’s instructions (Table B8) 
Table B8: User instructions for Vector SG peroxidase substrate kit 
 
 
REAGENT QUANTITY 
Blocking serum Vectastain normal goat serum (15µl) diluted in 1ml TBS 
Secondary 
antibody 
Vectastain normal goat serum (15µl) and Vectastain 
Biotinylated anti-rabbit IgG antibody (5ul) diluted in 1ml 
TBS 
Tertiary 
antibody 
Vectastain reagent A (20µl) and Vectastain reagent B 
(20µl) diluted in 1ml TBS 
REAGENT QUANTITY 
Reagent 1 2 drops, mixed well 
Reagent 2 1 drops, mixed well 
Reagent 3 1 drops, mixed well 
Hydrogen peroxide 1 drops, mixed well 
The above reagents were added to 5ml distilled water, and the final solution 
was applied to the slides. 
REAGENT QUANTITY 
SG chromogen 3 drops, mixed well 
Hydrogen peroxide 3 drops, mixed well 
The above reagents were added to 5ml PBS (pH7.5), and the final solution 
was applied to the slides. 
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Ultramount aqueous permanent mounting medium: 
Ultramount aqueous permanent mounting medium (♯S1964) was obtained from 
Dako, Cambridgeshire, UK. 
Endothelial cell culture medium: 
Endothelial cell culture medium was prepared by adding reagents from the 
Endothelial Cell Growth Kit-BBE (♯PCS-100-040, LGC Standards Ltd, 
Teddington, UK) listed in Table B9 to 475ml Vascular Cell Basal Medium 
(♯PCS-100-030, LGC Standards Ltd). 
Table B9: Preparation of endothelial cell culture medium 
 
Vascular smooth muscle cell culture medium: 
Vascular smooth muscle cell culture medium was prepared by adding the 
reagents listed in Table B10 to 450ml Ham's F-12K (Kaighn's) Medium (♯30-
2004, LGC Standards Ltd).
 
 
REAGENT QUANTITY FINAL CONCENTRATION 
Bovine brain extract (BBE) 1.0ml 0.2% 
rh EGF 0.5ml 5ng/ml 
L-glutamine 25.0ml 10mM 
Heparin sulphate 0.5ml 0.75Units/ml 
Hydrocortisone hemisuccinate 0.5ml 1µg/ml 
Fetal bovine serum (FBS) 10.0ml 2% 
Ascorbic acid 0.5ml 50µg/ml 
The above reagents were added to 475ml Vascular Cell Basal Medium and 
stored at 4°C for use. 
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Table B10: Preparation of vascular smooth muscle cell culture medium 
 
RPMI 1640 incomplete medium: 
RPMI 1640 incomplete medium was prepared by adding the reagents listed in 
Table B11 to 200ml RPMI 1640 medium (♯R0883). 
Table B11: Preparation of RPMI incomplete medium 
 
RPMI 1640 Complete medium: 
RPMI 1640 complete medium was prepared by adding 10% vol/vol heat 
inactivated fetal bovine serum (♯F7524) to the RPMI Incomplete medium 
described above.  
DMEM-F12 Complete medium: 
Dulbecco’s modified eagle (DMEM) complete medium was prepared by adding 
the reagents listed in Table B12 to 200ml DMEM medium (♯D6421). 
REAGENT 
(SOURCE) QUANTITY 
FINAL 
CONCENTRATION 
Fetal bovine serum (FBS) (♯F7524) 50.0ml 10% 
Endothelial cell growth supplement (♯E0760) 15.0mg 30µg/ml 
Ascorbic acid (♯A4403) 25.0mg 50µg/ml 
HEPES (♯H0887) 5.0ml 1% 
TES (♯T5691) 1.15g 2.3mg/ml 
Insulin-transferrin-sodium selenite (ITS; ♯I1884) 5.0ml 1% 
Amphotericin (♯A2942) 5.0ml 1% 
Penicillin Streptomycin (♯P0781) 5.0ml 1% 
The above reagents were added to 450ml Ham's F-12K (Kaighn's) medium 
and stored at 4°C for use. 
REAGENT 
(SOURCE) QUANTITY 
FINAL 
CONCENTRATION 
L-glutamine (♯G7513) 2.0ml 0.4mM/ml 
Penicillin Streptomycin (♯P0781) 2.0ml 1% 
The above reagents were added to 200ml RPMI 1640 medium and stored at 
4°C for use. 
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Table B12: Preparation of DMEM complete medium 
 
Cell freezing medium: 
Cell freezing medium was prepared by adding 20% vol/vol DMSO (♯D2650) to 
FBS solution (♯F7524). 1ml aliquots were stored at -20°C, until required. 
Citric acid solution: 
Citric acid solution was prepared by dissolving 21mg (10mM) or 42mg (20mM) 
citric acid (♯C7129) in 10ml distilled water. The solution was adjusted to pH3.0, 
filtered through a sterile 0.2µm syringe filter (♯190-2520, Nalgene Fisher 
Scientific) and stored at 4°C. 
TGFβ1 tissue or cell treatment medium: 
TGFβ1 (♯100-21, Peprotech EC Ltd., London, UK) and anti TGFβ1 (♯ab92486, 
Abcam, Cambridgeshire, UK) were individually diluted with DMEM-F12 
complete medium (for tissue) or endothelial cell culture medium or vascular cell 
culture medium to prepare 1ng/ml, 10ng/ml final concentration of treatment 
media. Since TGFβ1 stock solution (10µg/ml) was diluted in acid and PBS, to 
prepare culture medium for the control group, 10mM citric acid was first diluted 
to 2mM in sterile PBS (pH7.4), which was further diluted to a final concentration 
of 2µM with DMEM-F12 complete medium (for tissue) or endothelial cell culture 
medium or vascular cell culture medium for the respective control groups.  
PDGF-BB tissue or cell treatment medium: 
PDGF-BB (♯130-094-630, Miltenyi Biotec Ltd., Surrey, UK) and anti PDGF-BB 
(♯ab9704, Abcam) was individually diluted with DMEM-F12 complete medium 
REAGENT 
(SOURCE) QUANTITY 
FINAL 
CONCENTRATION 
Ham's F-12K (Kaighn's) Medium 
(♯30-2004, LGC Standards Ltd). 200.0ml 
1:1, ratio by 
volume 
Fetal bovine serum, heat inactivated (♯F7524) 20.0ml 10% 
L-glutamine (♯G7513) 2.0ml 0.4mM/ml 
Penicillin Streptomycin (♯P0781) 2.0ml 1% 
The above reagents were added to 200ml DMEM and stored at 4°C for use. 
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(for tissue) or endothelial cell culture medium or vascular cell culture medium to 
prepare 1ng/ml, 10ng/ml final concentration of treatment media. Since PDGF-
BB stock solution (10µg/ml) and was diluted in acid, to prepare culture medium 
for the control group, 20mM citric acid was diluted to a final concentration of 
20µM with DMEM-F12 complete medium (for tissue) or endothelial cell culture 
medium or vascular cell culture medium for the respective control groups. 
Endothelial cell digestion medium: 
Endothelial cell digestion medium was prepared by adding Type I collagenase 
(♯C2674), 0.1% volume, to 10ml sterile PBS (pH7.4). 500µl aliquots were stored 
at -20°C. 
Vascular smooth muscle cell digestion medium: 
Vascular smooth muscle cell digestion medium was prepared by adding (i) 
0.1% vol/vol of type I collagenase, (ii) 0.02% vol/vol of elastase (♯E7885) and 
(iii) 0.02% vol/vol of DNase (♯D5025) to 10ml sterile PBS (pH7.4). 500µl 
aliquots were stored at -20°C. 
BD Matrigel Basement Membrane Matrix: 
Matrigel Basement Membrane Matrix (♯354234) for the in vitro cell association 
and tubule formation assay was obtained from BD Biosciences, Bedford, UK. 
100µl aliquots were prepared and stored at -20°C, until required. 
VEGF-C cell treatment medium: 
VEGF-C (♯2179-VC, R&D Systems Ltd., Abingdon, UK) and anti VEGF-C (♯sc-
9047, Santa Cruz Biotechnology, Heidelberg, Germany) were individually 
diluted with endothelial cell culture medium or vascular smooth muscle cell 
culture medium as required to prepare 1ng/ml and 10ng/ml final concentrations 
of cell treatment media. Endothelial cell culture medium or vascular smooth 
muscle cell culture medium was used as culture medium for the control group 
respectively.  
Amresco 10% gel: 
Amresco 10% gel (♯M256) was obtained from VWR International, 
Leicestershire, UK. 
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Protein extraction buffer (3X): 
Protein extraction buffer (3X) was prepared by adding the reagents listed in 
Table B13 to 100ml distilled water. 
Table B13: Preparation of protein extraction buffer (3X) 
 
Protein extraction buffer (1X): 
Protein extraction buffer (1X) was prepared by diluting protein extraction buffer 
(3X) in distilled water and adding 1% vol/vol protease inhibitor (♯P8340) and 
0.5% vol/vol phosphatase inhibitor (♯P5726). 
Protein loading buffer: 
Protein loading buffer was prepared by combining the reagents listed in Table 
B14. 
Table B14: Preparation of protein loading buffer 
 
 
 
REAGENT 
(SOURCE) QUANTITY 
FINAL 
CONCENTRATION 
Tris-HCl (♯73253) 2.27g 62.5mM 
SDS (♯L3771) 6.0g 2% 
Sucrose (♯84097) 30.0g 10% 
The above reagents were added to 100ml distilled water to make up 3X 
protein extraction buffer. The solution was adjusted to pH6.8 before use. 
REAGENT 
(SOURCE) QUANTITY 
FINAL 
CONCENTRATION 
Tris (♯252859) 2.0ml 0.5M 
SDS (♯L3771) 4ml 10% 
Bromophenol blue (♯B0126) 2.0ml 1% 
99% Glycerol (♯G5516) 2.0ml 20% 
The above reagents were combined and the final volume was brought up to 
10ml by addition of distilled water, if required. 
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Protein loading buffer (reducing): 
Protein loading buffer (reducing) was prepared by adding 5% vol/vol 
mercaptoethanol (♯161-0710, BioRad, Hertfordshire, UK) to the protein loading 
buffer described above. 
Running buffer: 
Running buffer (20X) (♯M256) was obtained from VWR International. Running 
buffer (1X) was prepared by diluting running buffer (20X) in distilled water. 
Transfer buffer: 
Transfer buffer was prepared by adding the reagents listed in Table B15 to 2L 
distilled water. 
Table B15: Preparation of transfer buffer 
 
Tris buffered saline with Tween20 (TBST): 
Tris buffered saline with Tween20 (TBST) was prepared by adding 0.05% 
vol/vol Tween20 to TBS pH7.6.  
Blocking buffer (5%): 
Blocking buffer (5%) was prepared by dissolving 5g non-fat dry powdered milk 
in 20ml TBST. 
Wash buffer (0.05% PBS with Tween20): 
Wash buffer was prepared by adding 0.05% vol/vol Tween20 (500µl) to 1L of 
PBS (pH7.6). 
REAGENT 
(SOURCE) QUANTITY 
FINAL 
CONCENTRATION 
Tris (♯252859) 11.62g 5.81g/L 
Glycine (♯G8898) 5.86g 2.93g/L 
SDS (♯L3771) 0.75g 0.38g/L 
99% Methanol (♯M/4000/17, Fisher Scientific) 400.0ml 200ml/L 
The above reagents were added to 2L distilled water and the final solution 
was stored at 4°C till use. 
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Reagent diluent: 
Reagent diluent was prepared by adding 10g BSA (1% final concentration) 
(♯441555J, VWR International) to 1L PBS (pH7.6). 
Substrate solution: 
Substrate solution was prepared by combining 1:1 ratio vol/vol colour Reagent 
A (H2O2, ♯895000; R&D Systems Ltd., Abingdon, UK) and Reagent B 
(Tetramethylbenzidine, ♯895001; R&D Systems Ltd.). 
Stop solution (2N Sulphuric acid): 
Stop solution (2N Sulphuric acid) ♯339741, was obtained from Sigma-Aldrich. 
TGFβ1 blocking solution (5% PBST): 
TGFβ1 blocking solution was prepared by adding 5% vol/vol Tween 20 to PBS 
(pH7.4) and sterile filtered using a 0.2µm syringe filter (♯190-2520, Nalgene 
Fisher Scientific). 
TGFβ1 Reagent diluent: 
TGFβ1 reagent diluent consisted of 5% charcoal stripped FBS (♯F7524) sterile 
filtered using a 0.2µm syringe filter (♯190-2520, Nalgene Fisher Scientific). 
TGFβ1 acid activation solution (1N HCl): 
TGFβ1 acid activation solution was prepared by diluting 8.33ml 12N (36%) 
concentrated HCl (♯H1758), in 91.67ml deionised water. 
TGFβ1 acid neutralisation solution (1.2N NaOH/ 0.5M HEPES): 
TGFβ1 acid neutralisation solution was prepared by adding (i) 12ml 10N NaOH 
(♯S8045), (ii) 11.9g HEPES (♯H0887), to 75ml deionised water and bringing the 
final volume up to 100ml. 
Quantibody® Human Angiogenesis Array 1: 
The Quantibody® Human Angiogenesis Array 1 (♯QAH-ANG-1) was obtained 
from RayBiotech, Norcross, U.S.A). Components of this array detect 
Angiopoietin-2 (Ang2), Epidermal growth factor (EGF), basic Fibroblast growth 
factor (bFGF), Heparin binding Fibroblast growth factor (HB-FGF), Hepatocyte 
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growth factor (HGF), Leptin, Platelet-derived growth factor (PDGF-BB), 
Placental growth factor (PIGF) and Vascular endothelial growth factor (VEGF) 
(Table B16). 
Table B16: Components of Quantibody Human Angiogenesis Array 1 
 
 
 
 
 
ITEM DESCRIPTION 
1 Quantibody array glass chip 
2 Sample diluent 
3 20X Wash Buffer I 
4 20X Wash Buffer II 
5 Lyophilized cytokine standard mix 
5 Detection antibody cocktail 
6 Cy3 equivalent dye-conjugated streptavidin 
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